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Abstract 
Background: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are two 
distinct forms of chronic auto-immunity; understanding the transcriptomic 
profiles of key leukocyte subsets implicated in these arthritides could improve 
the diagnosis and treatment of patients. Current microarray analyses of samples 
derived from RA and PsA patients have examined the genetic profiles of whole 
blood or diseased tissue which, although informative, can mask the genetic 
contributions of individual cell types. Monocytes and macrophages are a cellular 
subset known to play a major role in PsA and RA through the production of pro-
inflammatory chemokines, cytokines and destructive proteinases.  
Aim: To define the transcriptome in CD14+ cells separated from the blood and 
synovial fluid of PsA and RA patients, and to then compare and contrast that 
signature in health and disease. Thereafter to define the relevant activities of 
selected novel moieties described in the foregoing analysis.  
Methods & Results: The transcriptomic profiles of healthy, RA and PsA CD14+ 
blood cells were remarkably similar - few genes could distinguish diseased from 
healthy CD14+ cells. Comparison of the genetic signature of the RA and PsA 
synovial fluid CD14+ cells revealed that just over 50% of the differentially 
expressed genes were shared between the two disease groups. Furthermore, 
analysing the canonical pathways in the synovial fluid cells compared to the 
matched peripheral blood of both patient groups surprisingly revealed Liver X 
receptor (LXR) activation pathway as the most significantly upregulated 
pathway: this pathway has been previously shown by our group to play a pro-
inflammatory role in arthritis.  
Examination of specific upregulated mRNAs in the synovial fluid CD14+ cells from 
both disease types revealed two novel genes that had not previously been 
associated with arthritis, the lysosomal enzyme legumain and the cell surface 
molecule plexin A1. Legumain was demonstrated to be present in RA and PsA 
CD14+ cells by RNA and protein analysis and was physiologically active. 
Incubation of CD14+ cells with patient synovial fluid under hypoxic conditions 
also potentiated legumain expression. Plexin A1 was confirmed to be expressed 
at the mRNA level within RA synovium. siRNA knockdown of plexin A1 suggested 
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that it may play a pro-inflammatory role within macrophages since subsequent 
treatment of these macrophages with LPS resulted in decreased TNFα 
production. However, investigations into the identity of the specific ligands for 
plexin A1 in arthritis, known as semaphorins, were inconclusive.  
I finally generated microarray data to evaluate the transcriptome of 
macrophages activated via cel contact with activated T cells. Such cells shared 
only a small percentage of genes with those dysregulated in the RA and PsA 
synovial fluid derived CD14+ cells suggesting that this model at the time points 
chosen may not be an appropriate in vitro representation of articular 
macrophages. An imaging system of this in vitro model was also established to 
visualise the dynamic nature of the T cell – macrophage interactions and 
demonstrated that variables such as duration or method of T cell activation 
could alter the number and duration of interactions between the two cell types.  
Conclusions: These studies demonstrate that the CD14+ cells isolated from the 
blood are similar transcriptomically between healthy controls and RA and PsA 
patients. The synovial fluid CD14+ cells from RA and PsA patients exhibit 
substantial overlap in terms of their genetic profile. Two novel molecules 
expressed by diseased patients namely plexin A1 and legumain have been 
identified and their preliminary characteristics in the context of synovitis have 
been defined.  
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VASH1  Vasohibin 1 
VEGF   Vascular endothelial growth factor 
ZIA   Zymogen induced arthritis 
 
Chapter 1 Introduction  
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1.1 Inflammatory Arthritis: Rheumatoid Arthritis and 
Psoriatic Arthritis 
The inflammatory arthritides compose a heterogeneous group of chronic 
inflammatory rheumatic diseases. The progressive joint inflammation and 
immune cell infiltration typically seen in these diseases leads to progressive and 
irreversible destruction of the cartilage and bone. Arthritis affects 1-3% of the 
general population and is projected to affect 67 million people by 2020 in the 
United States alone [1]. This disease is not only associated with significant 
healthcare costs but also severe physical limitations and disability within the 
individual [2]. Rheumatoid arthritis affects 0.5-1.1% of the population [3]. 
Psoriatic arthritis is another common inflammatory arthritis affecting 2-3% of the 
general population and occurring in 7-26% of psoriasis sufferers [4]. 
1.1.1 Definition and Classification 
Rheumatoid arthritis (RA) is a chronic symmetric polyarticular arthritis which 
primarily affects the small joints of the hands and feet [5]. It is characterised by 
inflammation of the joint lining and cellular infiltration into the joint, which 
subsequently causes damage and destruction of bone and cartilage. RA sufferers 
have a life expectancy decrease of 3 to 10 years compared to the general 
population [3]. The current accepted criteria for the classification of RA have 
been defined by the 1987 American College of Rheumatology (ACR) criteria 
outlined in Table 1.1 [6]. 
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Table 1.1 ACR classification criteria for rheumatoid arthritis 
 
A patient is diagnosed as having RA if they present with at least 4 of the 7 
criteria with the first four criteria being present for at least 6 weeks: 
1. Morning stiffness 
2. Soft tissue swelling in 3 or more joint areas 
3. Arthritic swelling of the hand joints 
4. Symmetrical presentation of arthritis 
5. Rheumatoid nodules  
6. Serum rheumatoid factor (RF) positive 
7. Radiographic changes including erosions or bony decalcifications. 
 
Psoriatic arthritis (PsA) is a (predominantly) seronegative inflammatory disease 
of joints, entheses and periarticular connective tissue in association with 
psoriasis [7]. Rheumatoid factor and anti-cyclic citrullinated proteins (anti-CCP) 
antibodies are seen in 4.7% and 7.6% of cases respectively [8]. PsA constitutes a 
subset within the spondyloarthropathy (SpA) group due to it sharing common 
clinical features with the other SpA diseases. Clinical, radiologic and familial 
evidence has indicated PsA as a distinct disease entity however basic research 
within this disease has been confounded by the absence of widely agreed-upon, 
validated disease criteria. Several classification criteria have been proposed by 
Moll and Wright [9], Vasey and Espinoza [10] and the European 
Spondyloarthropathy Study Group (ESSG) [11]. A large international study group 
identified as the classification criteria for psoriatic arthritis or CASPAR study 
group has since been used to construct new classification criteria [8] (see Table 
1.2). 
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Table 1.2 Classification criteria for psoriatic arthritis (CASPAR) 
 
To meet the CASPAR criteria a patient must have inflammatory articular disease 
(joint, spine or entheseal) with ≥ 3 points from the following categories (1 point 
each): 
1. Psoriasis (skin, scalp) 
2. Psoriasis in patient‘s history 
3. Psoriasis in family history 
4. Psoriatic nail involvement (now) 
5. Rheumatoid factor negative (determined by ELISA) 
6. Dactylitis (inflammation of an entire digit) (now) 
7. Dactylitis in patient‘s history 
8. Radiological signs of new bone formation adjacent to the joints  
 
1.1.2 Epidemiology 
Numerous population based studies have been performed on the incidence and 
prevalence of RA and indicate large differences between various communities. 
Studies performed in North America and Northern Europe have found the 
prevalence of RA to be 0.5-1.1% with an annual incidence of 29-38 per 100,000 
whereas lower prevalence of 0.3-0.7% were demonstrated in Southern Europe 
which had an annual incidence of 16.5 per 100,000 inhabitants [3]. In the UK the 
prevalence of RA is estimated to be 0.8% [12] with an incidence of 36 per 
100,000 in women and 14 per 100,000 in men [13]. There have been few 
prevalence studies in developing countries but those that have taken place 
suggest a significantly lower prevalence of RA than in North America and 
Northern Europe, of 0.1-0.5% [14].  
In comparison, fewer epidemiological studies have been performed on PsA 
possibly due to a previous lack of a widely accepted classification or diagnostic 
criteria. Prevalence is estimated at 0.1-1% [15] which increases in patients with 
psoriasis to 7-26% [4] but has been reported up to 30% in a Swedish study [16]. 
Few population based incidence studies have been undertaken on PsA however, 
the various incidence rates have been reported as 6 in 100,000 individuals in 
Finland [17], 6.59 in 100,000 in the USA [18] and 8 in 100,000 in Sweden [19]. In 
a study performed in Minnesota the age- and sex-adjusted incidence increased 
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from 3.6 (1970-1979) to 9.8 (1990-2000), reasons for this increased are unknown 
but may be due to better classification and diagnosis of the disease [20]. 
1.1.3 Clinical Features 
RA and PsA often present similar overlapping features of disease, as outlined in 
Table 1.3, such as the presence of rheumatoid factor which occurs in 80% of RA 
patients but also 4.7% of PsA patients [8]. Secondly, although PsA classically 
presents with an asymmetric distribution, symmetry has been detected in up to 
33% of patients with polyarticular disease [21].  The pattern of joint involvement 
is not fixed and in a 2 year follow up study of early PsA patients initially 
classified as polyarticular, 49% were subsequently classified as oligoarticular 
[22]. In addition psoriasis, which is a defining feature of PsA, develops after the 
rheumatological manifestations in 20% of patients or does not develop at all 
[23]. However, there are several differential features between the two diseases 
that aid in differential diagnosis: PsA shares features in common with the 
spondyloarthropathies such as HLA-B27 association which are not observed in RA 
[24-26]; also the involvement of the distal joints, spine involvement and the 
presence of enthesis are all typical clinical features specific to PsA [15]. 
Consequently, several factors must therefore be taken into account when 
distinguishing PsA from RA. 
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Table 1.3 Comparison of clinical features of RA and PsA 
 
Finding     RA    PsA 
Morning stiffness >1 hour    +++    + 
Standard mortality ratio   1.27 [27]   1.62 [28] 
Rheumatoid Factor    ++ (80%) [6]   +/- (4.7%) [8] 
Articular Features 
Symmetrical Arthritis   +++    +/- [21] 
Dactlylitis     -    +++ 
New bone formation near joints  -    +++ 
Affection of distal finger/toe joints -    +++ 
 
Extra-articular features  
Rheumatoid arthritis: 
Skin (Rheumatoid nodules, Vasculitis); Cardiac (ischemic heart disease) [29]; 
Respiratory (interstitial lung disease) [30]; Haematological (anaemia) [31] 
 
Psoriatic Arthritis: 
Skin (psoriasis, nail lesions 87% [32]); Ocular (uveitis [33]); Back pain [21]. 
 
 
 
1.1.4  Risk Factors 
The precise cause of RA or PsA is currently unknown, but it is believed to be a 
combination of numerous risk factors as well as disregulated inflammatory 
processes. 
1.1.4.1 Genetic Factors  
There is overwhelming evidence that the risk of developing RA or PsA is 
associated with genetic factors. 
1.1.4.1.1 First-degree relatives and twin studies 
A well established approach to assess and quantify the possible role of genetic 
factors and disease risk is to measure the concordance of diseases between 
related individuals. A highly heritable disease will have an increased prevalence 
in individuals related to the arthritis sufferer compared to the general 
population. A parameter used to measure this is the λR which is the ratio of the 
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prevalence of a disease among first-degree relatives compared to the general 
population. The λR for RA is 2-17 [34] which is a modest value compared to a 
highly penetrant diseases such as cystic fibrosis which can have a λR value of 500 
[35]. A recent study in Sweden demonstrated an increased relative risk (the 
probability of the disease occurring) of RA in siblings of affected individuals as 
4.6 and in children as 3.0 [36]. The λR for PsA was determined to be 30.8 in a 
first-degree relative study of 100 PsA patients in Canada [37] and 47 in a similar 
study conducted in the UK [38]. A 2009 Icelandic study also demonstrated that 
first-degree relatives had a 40-fold increased risk of developing PsA whilst 
second-degree relatives had a 12-fold increased risk [39]. Overall these studies 
indicate that PsA a more heritable disease in first- and second-degree relatives 
compared to RA. 
Twin studies are a powerful tool to understand the genetics of a disease. An 
increased incidence of disease amongst monozygotic (identical) twins compared 
to dizygotic twins offers evidence that inherited factors predispose to disease 
[35]. In RA two major twin studies have been undertaken using a Finnish [40] 
cohort and a British cohort [41] and the combined data from these studies 
suggests that RA is approximately 65% heritable [42]. Unlike RA there are no 
large twin cohorts available for PsA and the one twin study reported could not 
demonstrate a genetic effect on PsA as it was underpowered [43] however the 
results from the first-degree relative studies have demonstrated that PsA is a 
highly heritable disease. 
1.1.4.1.2 HLA associations 
The largest genetic contribution to RA susceptibility is a combination of a group 
of alleles within the HLA-DRB1 gene found within the major histocompatibility 
complex (MHC) region in chromosome 6p21. These alleles are collectively known 
as the shared epitope since they encompass a conserved sequence of amino 
acids in the third hypervariable region of the class II DRβ1 chain (70Q/R-K/R-R-A-
A74) [44]. Many studies have demonstrated that HLA-DRB1 alleles are consistently 
linked and associated with RA in every population [45, 46] and have been shown 
to interact with environmental factors such as smoking [47]. Despite being the 
largest genetic contribution to RA a large UK based study found no PsA 
susceptibility association with the HLA-DRB1 alleles [48]. 
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There have been far fewer genetic mapping studies performed on PsA compared 
to psoriasis which was first found to be associated with HLA class 1 antigens in 
the 1970s [49], however subsequent studies have since identified the same 
psoriasis risk alleles to be associated with PsA. For example, the HLA-Cw*0602 
which comprises the largest genetic contribution to psoriasis is also associated 
with PsA patients who have psoriasis [48]. HLA-B27 is another molecule 
containing PsA associated variants [24-26], it is considered indicative of the 
association of PsA to the spondyloarthropathies and could also be a predictive 
marker for clinical features such as joint deformity [50]. PsA has also been 
associated with polymorphisms in the MHC class 1 chain-related gene A (MICA), 
which was not associated with psoriasis alone [51]. MICA molecules are 
considered markers of stress and are expressed by epithelial cells [52], they are 
recognised by the receptor NKG2D found on CD8 αβ T cells, γδ T cells and 
natural killer (NK) cells and therefore polymorphisms within this molecule may 
subsequently affect the innate immune response. 
1.1.4.1.3 Other genetic associations 
Despite the MHC locus contributing the single strongest genetic risk to RA, it is 
estimated to explain only 30% of total genetic component of susceptibility 
indicating that other genes may also be involved in disease predisposition. 
Genome wide linkage scans have subsequently identified a number of non-HLA 
genes associated with disease risk.  
PTPN22 
A variant within the PTPN22 gene is the second largest genetic risk to the 
development of RA after the shared epitope. This variant has been associated 
with RA in numerous studies [53, 54] but has been found to be very rare in Asian 
populations and is not associated with RA in these populations [55]. PTPN22 
codes for a lymphoid-specific phosphatase (Lyp), which is an intracellular 
protein tyrosine phosphatase (PTP) involved in T cell receptor (TCR) signalling. 
Following engagement of the TCR complex, protein tyrosine kinases become 
activated and then phosphorylate immunoreceptor tyrosine-based activation 
motifs (ITAMs) in the cytoplasmic tail of the TCR-CD3 chains. Phosphatases 
dampen this response thereby providing a means of turning the signalling on and 
off. The genetic variant within the PTPN22 gene associated with RA is a 
nucleotide change causing an amino acid substitution. This results in a gain of 
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function for Lyp by increasing its enzymatic activity and causes an overall defect 
in T cell response to antigen stimulation. It has been proposed that this variant 
could predispose to RA by suppressing T cell receptor signalling during thymic 
development resulting in the survival of autoreactive T cells [56]. 
Despite the PTPN22 variant predisposing to RA and many other autoimmune 
diseases such as systemic lupus erythematosus (SLE) [54] and systemic sclerosis 
(SSc) [57] there has been no consistent evidence for an association with PsA [58, 
59]. However, different variants within the same gene locus have been 
associated with psoriasis [60, 61]. 
STAT4 
Signal transducer and activator of transcription 4 (STAT4) is an important 
transcription factor in the regulation of the immune response. STAT4 is involved 
in the signalling pathways of IL-12, IL-23 and type 1 interferons in T cells and 
monocytes leading to a T helper type 1 (Th1) and Th17 differentiation and 
monocyte activation [62]. A fine-mapping study first identified an RA 
susceptibility locus within the STAT4 gene in a US population [63] and this 
association has since been confirmed in other populations of European and Asian 
descent [64, 65]. Analysis of STAT4 deficient mice have underlined the 
importance of this transcription factor in RA since these mice lack Th1 responses 
and do not develop experimental arthritis [66]. However, further studies are 
required to determine the role of the susceptibility variants in RA. There has 
been no reported PsA susceptibility locus in STAT4 however, as has been found 
with PTPN22, a gene polymorphism in STAT4 is associated with psoriasis [67]. 
IL12B and IL23R 
IL12B and IL23R are both proteins which are known to be important in T cell 
development. Genetic variants within these genes have been identified as 
psoriasis genetic susceptibility loci and subsequent studies have also identified 
association with PsA but not RA [68]. 
1.1.4.2 Gender 
Despite PsA showing no gender bias, RA is far more common in women than men 
with the female to male ratio being 3:1 [3]. Gender differences may also play a 
role in the disease activity as women with RA have been found to have worse 
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disease activity compared to men with RA [69]. The higher incidence of RA in 
women had led many studies to analyse whether or not there is a hormonal 
influence on disease risk. Studies on hormone levels are often difficult as 
treatment for the disease or often the disease itself can affect hormone levels 
and reports on pre-disease hormone levels are not often available. One study 
found that serum testosterone levels were lower in males with RA compared to 
healthy controls which is supportive of the hypothesis that male sex hormones 
could protect against RA [70]. RA frequently goes into remission in women during 
pregnancy [71] but will flare up again during breastfeeding [72] which is thought 
to be due to the major hormonal fluctuations taking place. Further studies into 
the use of the oral contraceptive pill (OCP) in women has found that current or 
ever-use of OCP has a protective effect against RA development although it has 
not been determined whether OCP postpones rather than prevents the onset of 
RA [73]. 
1.1.4.3 Environmental and lifestyle factors  
Both environmental and lifestyle factors are influences that have long been 
considered as potential triggers for the pathogenesis of RA and PsA. 
1.1.4.3.1 Infectious agents 
A potential involvement of infectious agents in the occurrence of RA and PsA has 
been speculated as it is thought that such agents could trigger the development 
of disease in a genetically susceptible host. The identification of bacterial DNA 
in the RA synovium has fuelled this hypothesis as investigations have 
demonstrated the presence of Mycobacterium [74] and mycoplasma [75] DNA. 
However, the bacterial species identified frequently have an equal occurrence in 
control populations therefore the pathogenic role for these bacteria remain to 
be identified. 
Bacterial infections have also been suggested to have a pathogenic role in PsA as 
there have been reports of increased immunoreactivity in the sera of PsA 
patients to some streptococcal antigens which is not seen in RA patients or 
psoriasis patients without arthritis [76]. However, it is difficult to prove a solely 
pathogenic role for such antigens since secondary infections of psoriatic plaques 
are common. Anti-enterobacterial antibodies have also been detected in the 
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sera of PsA patients at a significantly higher level compared to psoriatic patients 
or healthy controls [77] although the significance of this is yet to be established. 
Interest into the role of viral infection in the initiation and propagation of 
inflammation in inflammatory arthritis has been stimulated through several 
observations such as acute viral infections are occasionally followed by the 
development of an acute polyarthritis similar to early RA. Proposed viral triggers 
associated with RA include parovirus B19, retroviruses, and herpes viruses 
including Epstein-Barr virus (EBV) [78]. EBV was initially proposed as a potential 
factor involved in arthritis by the presence of anti-EBV antibodies in the sera of 
affected patients [78]. Subsequent research has since aimed to address the 
possible role of EBV in RA, Takeda et al found evidence of EBV infection in 47% 
of RA synovial samples but none of the 30 OA controls [79]. However, two 
following studies by Blaschke et al [80] and Niedobitek et al [81] did not find 
such a high proportion of EBV within the RA synovium (8% and 18% respectively). 
Consequently, since its expression is highly variable in RA synovium it is unlikely 
that EBV plays a primary role in this disease. Hepatitis C infection has been put 
forward as a trigger for PsA since levels of the virus are found at significantly 
higher levels in the sera of PsA patients compared to that of healthy controls 
[82] but once again the role of this virus within disease pathogenesis is unknown.  
Consequently, there has been no conclusive evidence to date which has clearly 
defined the role of any infectious agent in RA or PsA. The persistent expression 
in joint tissue of any one particular pathogen has not been demonstrated but 
interestingly a study analysing the synovial tissue of a variety of inflammatory 
arthritis patients demonstrated that several samples were positive for two or 
more viral species at the same time [83]. Therefore, multiple different 
infections may be needed in order to drive arthritis pathogenesis. 
1.1.4.3.2 Smoking 
Cigarette smoking has been demonstrated to significantly increase the risk, 
severity and outcome of RA in men and women [84, 85]. Smoking is associated 
with a thirteen fold increase in the incidence of the disease and can induce long 
term susceptibility as individuals who have ceased smoking for greater than ten 
years remain twice as likely to develop RA as the general population [86]. 
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Cigarette smoking supports the process of citrullination which is the post-
translational modification of the amino acid arginine within a protein to the 
amino acid citrulline. This process is catalysed by the enzyme peptidylarginine 
deaminase 4 (PADI4). Citrullinated proteins such as fibronectin, fibrin, α-
enolase, fibronectin and type-II collagen have been detected in the RA synovium 
and have been demonstrated to be targets of the autoantibody response [87, 
88]. These anti-citrullinated protein antibodies (ACPAs) have been identified in 
over 90% of RA patients and correlate with disease activity [89]. Citrullinated 
proteins have been suggested to play a pathogenic role by modifying self peptide 
which may then drive an immune response [90]. There is a strong association  
between smoking and the generation of ACPAs in patients with HLA-DRB1 alleles 
demonstrating how genetic and environmental factors may interact to drive RA 
pathology [47]. 
1.1.5 Histopathology 
The normal synovium covers the inner surface of the joints and is relatively 
acellular consisting of 0.5-5 mm thickness. It comprises of a thin intimal layer of 
predominantly fibroblasts and macrophages and a thicker sublining layer 
connective tissue layer. Within the joint, a protective smooth layer of cartilage 
acts as a shock absorber and provides a low friction surface to allow the bones to 
gently move over each other. This is lubricated by synovial fluid which within a 
non-diseased joint is relatively acellular with mean counts of 35 cells/μl [91]. 
The synovial fluid also provides nutrients to the chrondrocyte cells within the 
joint cartilage as the cartilage lacks blood vessels.  
During the progression of chronic arthritis, the synovium evolves from a 
protective structure to an invasive tissue that is characterised by inflammatory 
cell infiltration into the synovial membrane (synovitis) which drives the typical 
symptoms of joint pain and stiffness. In RA, the intimal lining layer thickens to 
over 8 cells deep and in PsA this thickening is 2-3 cells deep [92]. In addition, 
the synovial fluid expands abnormally acquiring between 10-1000 cell/µl [93] 
consisting of polymorphonuclear cells as well as monocytes, T cells, DCs, B cells 
and NK cells. 
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Radiographic examinations reveal a loss of joint space and the destruction of 
underlying cartilage and bone which is caused, in part, by the release of 
proteolytic enzymes from macrophages and fibroblasts. MMP-1, MMP-3 and TIMP-
1 mRNA have been detected at similar levels in the synovium of both RA and PsA 
[94]. Moreover, the activation of bone-resorbing osteoclasts by M-CSF and RANK-
L, both of which are up-regulated by IL-1 and TNFα, is a critical event for 
progression of bone damage in RA and PsA and levels of both osteoclast 
activating factors are found in both the synovium and peripheral blood of RA and 
PsA patients [95, 96]. In PsA, bony erosions are less common and often appear at 
a slower rate than in RA and consistent with these findings the levels of 
aggrecans, which are components of the cartilage structure and an indicator of 
damage, are lower in PsA synovial fluid compared to RA synovial fluid [97]. 
This articular destruction is accompanied by pannus formation (intrusion of the 
bone and cartilage by the proliferating synovial membrane) and the infiltration 
of inflammatory cells. The influx of these cells can promote synovial 
inflammation and damage through the production of chemokines, cytokines and 
proteases which can in turn promote a state of hypoxia and hence pronounced 
angiogenesis. Angiogenesis is a prominent feature of synovitis and is 
fundamental to disease pathology by transmitting oxygen and nutrients to the 
synovium in addition to being a means through which inflammatory cells are 
recruited to different areas of the diseased tissue. In both RA and PsA pro-
angiogenic factors, such as angiopoetin-1 and -2 and VEGF, are detectable at 
early stages of disease [98, 99] however levels have been found to be higher in 
PsA than RA which may be explained by the significantly increased number of 
blood vessels found in PsA compared to RA [92]. See Figure 1.1 for a comparision 
of an arthritic and normal synovium. 
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Figure 1.1 Comparison of a normal and arthritic synovium 
This illustration demonstrates the presence of inflammatory cell infiltrates characterised by 
macrophages, B cells, T cells and DCs; synovial membrane hyperplasia and cartilage and bone 
destruction. 
 
1.1.6 Immunopathology 
RA and PsA are both characterised by an inflammatory cell influx into the 
diseased joints which drives tissue destruction and inflammation. Consequently, 
in order to elucidate the mechanisms which drive synovitis it is important to 
identify which cells are present within the synovium and how they may be 
contributing to the perpetual inflammatory response.  
See Figure 1.2 for a summary of the interactions between the inflammatory cells 
found within the arthritic joint. 
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1.1.6.1 The monocyte/macrophage lineage 
Monocytes and macrophages are found at high levels within the synovium of both 
RA and PsA. Circulating monocytes of the peripheral blood also demonstrate an 
increased level of activation compared to healthy controls. The variety of 
cytokines, chemokines, growth factors and enzymes that are secreted by this 
cell type ensure that they play a central role in the pathogenesis of arthritis. 
Due to this cell type being the focus of this thesis; a full and detailed discussion 
of monocytes and macrophages will take place in section 1.2 of this 
introduction.  
1.1.6.2 Dendritic cells 
Dendritic cells (DCs) arise from myeloid progenitor cells and are a highly 
phagocytic cell type. DCs are professional antigen presenting cells (APCs) that 
are critical to the cross talk between the innate and adaptive immune response. 
DCs are found in tissues in a inactive form and upon immune activation by TLR 
ligation or antigen uptake they downregulate their phagocytic activity and 
upregluate their ability to process and present antigen and are subsequently 
directed to lymph nodes via a CCR7 dependent pathway in order to induce to T 
cell activation [100]. There have been two major subsets of DCs identified, 
myeloid DCs (mDC) and plasmacytoid DCs (pDC). mDCs have a primary function 
of antigen capture and presentation and are capable of producing a wide variety 
of cytokines such as IL-23, IL-18, IL-12p70, IL-15 and TNFα and therefore are 
able to polarise T helper cells depending on the cytokines they secrete. pDCs 
tend to be present in the circulation at a lower frequency than mDCs and upon 
viral infection are a major source of type I interferon synthesis. In RA and PsA 
the levels of circulating pDCs are significantly reduced compared to healthy 
controls and the levels of mDCs are significantly reduced in RA patients however 
both mDCs and pDCs are found to be present in the SF of both RA and PsA 
patients [101]. Depletion of pDCs in a murine model of arthritis has been shown 
to enhance the severity of articular pathology suggesting that they may mediate 
an anti-inflammatory function [102] whereas mDC numbers have been 
demonstrated in RA patients to inversely correlate with disease activity 
suggesting that they may contribute to RA activity [103]. 
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1.1.6.3 T cells  
T cells can be divided into two subgroups, CD4+ and CD8+. CD4+ effector T cells 
can be divided into distinct subgroups depending on their cytokine secretion 
profile. Th1 cells are classified according to the secretion of the cytokines IL-2 
and IFNγ whilst Th2 cells are known to secrete the cytokines IL-4, IL-5 and IL-13. 
In addition another subset of T cells designated Th17 has recently been 
described due to their secretion of IL-17A in addition to IL-17F and IL-22. There 
is strong evidence which implicates a role for T cells within the pathogenesis of 
RA and PsA, first CD4+ T cells contribute a large proportion of infiltrating cells 
into the synovium and synovial fluid of RA and PsA. The number of T cells within 
the synovial fluid are similar in both groups of patients [92]. Secondly, the strong 
association of HLA genes to aggressive pathology in RA and PsA may reveal the 
presentation of arthritogenic peptide to autoreactive T cell clones especially 
since T cells can be detected co-localised to MHC II expressing APCs in RA and 
PsA synovium. In addition, T cells have been demonstrated to play a primary role 
in several murine models of arthritis including CIA [104]. 
RA and PsA were thought to be Th1 mediated diseases due to the predominance 
of Th1 cytokines such as IFNγ and IL-12 within the synovium and the detection of 
Th1 CD4+ IFNγ+ cells at an elevated ratio compared to Th2 cells [105]. However, 
more recently, studies in animal models have favoured a mechanism which 
implicates Th17 cells. IL-6 is known to induce the differentiation of Th17 cells 
and studies have demonstrated that IL6-/- mice are resistant to the development 
of CIA [106]. In addition, the inhibition or overexpression of IL-17 within the 
murine joints suppresses or increases joint inflammation respectively [104, 105]. 
At present it is not known how well these murine models represent human 
disease as although IL-17 is detected within RA synovial fluid [106] Th17 cells are 
present in low numbers within the RA synovium and may only be induced to 
produce IL-17 following cell contact with activated macrophages [107]. Other 
studies have also demonstrated that the frequency of Th17 within the synovium 
is low compared to the frequency in patient blood and Th1 cells are the 
predominant T cell subtype within the diseased joint [108]. Additionally, IL-17 is 
now known to be secreted by non-CD4+ T cells such as γδ T cells, NK cells, CD8 
cells, macrophages, neutrophils and most recently mast cells [109-112] therefore 
it is unlikely that the observed phenotype upon IL-17 deletion is solely 
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attributable to Th17 cells but may be a combination of different cellular 
sources. IL-17 can induce the secretion of numerous effector molecules, 
including TNFα, IL-23, IL-6, MCP-1 and RANKL from macrophages, fibroblasts and 
chrondrocytes indicating that blockade of IL-17 may be a beneficial therapeutic 
target for RA and PsA [113]. 
CD4+,CD25+ regulatory T cells (Tregs) have become a focus of arthritis research 
due to their participation in controlling effector CD4+ cell function and their 
ability to regulate the autoimmune response through the production of IL-10 and 
TGFβ [114] and via direct cell contact. Treg cells have been identified within the 
peripheral blood and synovial tissue of RA patients but they have been found to 
have a decreased ability to suppress TNFα and IFNγ from effector CD4+ cells or 
monocytes [115]. Interestingly, this ability to suppress cytokine secretion from 
effector CD4+ cells was demonstrated to be mediated through TNFα, since 
treatment with the anti-TNFα antibody infliximab was able to restore the Treg 
suppressive capacity.  
In contrast to CD4+ T cells, CD8+ T cells or cytotoxic T cells mediate effector 
function by MHC I directed antigen specific killing of target cells and through 
cytokine production, in particular IFNγ and TNFα. Populations of CD8+ T cells 
have been identified in both RA and PsA synovium [116, 117]. Of interest, 
studies have reported a greater CD8+ T cell enrichment in PsA synovial fluid 
compared to RA synovial fluid which may be reflecting a more important role for 
CD8+ T cells in the former compared to the latter [118] however the role of CD8+ 
T cells in either disease are at present unclear. 
1.1.6.4 B cells 
B cells mediate adaptive immunity through the secretion of antigen-specific 
antibodies which promote pathogen elimination, but are also able to present 
antigen. Upon activation by antigen presentation, B cells will migrate to the 
lymph nodes or spleen where they will differentiate into antibody secreting 
plasma cells. The production of auto-antibodies can subsequently induce 
inflammatory cell activation through the binding of the antibodies to the Fc 
receptors expressed on leukocytes. 
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There is a wealth of evidence which points to a key role of B cells within 
arthritis pathology including the presence of germinal centres within the 
synovium of both RA and PsA [119, 120]. These germinal centres are in an 
environment surrounded by pro-inflammatory cytokines and self antigens and 
therefore provide an ideal location for antigen presentation, plasma cell 
differentiation and auto-antibody production. In addition, the use of the anti-
CD20 monoclonal antibody therapy rituximab has shown clinical benefits in both 
RA and PsA [121, 122]. Of particular importance, it is recognised that B cells may 
be critical in the initiation of RA since autoantibodies against self citrullinated 
proteins, type II collagen and rheumatoid factor are present in the serum of 
patients up to 10 years before the clinical manifestation of disease [123]. A 
similar finding has yet to be shown in PsA. 
1.1.6.5 Other inflammatory cell types 
Neutrophils and Mast cells 
Neutrophils are found at a high concentration within the synovial fluid and 
synovium of RA and PsA with an increased number being detected in the latter 
disease [124]. At present their primary role within disease pathogenesis is not 
known. However, neutrophils are activated by complement components and 
cytokines to release a variety of proinflammatory cytokines such as TNFα, BAFF, 
IL-6 and IL-18 and therefore may generally contribute to the pro-inflammatory 
milieu found within the synovium. Mast cells are also detected in the synovial 
fluid of both RA and PsA [125, 126]. Animal models of arthritis have been 
contradictory in determining the role that mast cells play within the disease 
[127, 128]. However, as mentioned above, a recent study has demonstrated that 
mast cells within the synovium of RA patients express the proinflammatory 
cytokine IL-17A [109] and therefore may be playing a pathogenic role within the 
disease by secreting cytokines into the synovium which will activate other 
inflammatory cells resulting in a positive feedback loop of inflammation. 
Fibroblasts 
Synovial fibroblasts together with synovial macrophages are the two leading cell 
types within the hyperplastic synovial tissue that invades and degrades adjacent 
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cartilage and bone. Fibroblasts are well established effectors of inflammation 
within arthritis as they are known to produce a wide variety of inflammatory 
mediators such as IL-1, IL-6, TNFα, MCP-1, IL-8 and M-CSF which in turn can 
potentiate the influx, survival and activation of several leukocyte subtypes 
[129]. Synovial fibroblasts are also an important source of MMPs and cathepsins 
which are enzymes that drive the destruction of articular cartilage and bone. In 
addition, these cells produce high levels of RANKL in both RA and PsA and 
therefore can drive articular destruction indirectly through the induction of 
osteoclasts and hence osteoclastogenesis [130, 131]. 
Osteoclasts and Chrondrocytes 
The articular structure in healthy individuals is maintained in stable equilibrium 
through maintaining a balance of both bone resorption and deposition and 
collagen deposition. Within the diseased synovium this balance is skewed in 
favour of bone resorption and collagen removal which leads to articular 
degradation, furthermore in PsA patients aberrant bone formation may also 
occur. Osteoclasts are multinucleated cells which mediate bone resorption 
through the secretion of acid and MMPs, and are differentiated from monocyte 
precursors in the presence of RANKL and M-CSF [132]. Other cytokines within the 
inflammatory milieu can drive osteoclast formation such as TNFα, IL-1β and IL-17 
which induce RANKL expression.  
Chrondrocytes are cells which, under normal conditions, maintain a stable 
equilibrium between the synthesis and degradation of matrix components such 
as collagen. However, in arthritis the chrondrocyte cell participates in the 
destruction of its own matrix by releasing a variety of MMPs in response to the 
proinflammatory cytokines present within the synovium such as IL-1 and TNFα. 
The chrondroytes themselves can also release pro-inflammatory mediators in 
response to cytokine activation which can further perpetuate the chronic 
cartilage destruction in a paracrine and autocrine fashion [133]. Consequently, it 
is evident that the synovial environment within RA and PsA can promote 
articular destruction through several mechanisms.  
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Figure 1.2 Inflammatrory cell types within the synovium 
An overview of the cellular communication between immune cells within the RA and PsA inflamed 
joint. Adapted from [132]. 
 
1.1.7 Mechanisms of inflammation 
The numerous inflammatory cells infiltrating the synovial compartment release 
soluble factors including cytokines, chemokines and MMPs that are directly 
responsible for the disease pathology by activating and promoting recruitment of 
further inflammatory cells. A full explanation of the cytokines and chemokines 
expressed by monocytes and macrophages in RA and PsA are discussed fully in 
section 1.2.4 and 1.2.5. 
1.1.7.1 Cytokines 
Cytokines are small (5 to 50 kDa) proteins or glycoproteins that serve as 
chemical messengers between cells and thus are of significant importance in 
almost all aspects of innate and adaptive immunity. Cytokine levels are 
significantly upregulated in RA and PsA where they regulate the chronic 
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inflammatory response. Within the synovium cytokines can work in an autocrine 
fashion and due to the close proximity of cells they can also work in a paracrine 
(neighbouring cell activation) and juxtacrine (cell-to-cell contact) manner. 
In both RA and PsA numerous pro-inflammatory cytokines including TNFα IL-6, IL-
1α/β, IL-17, IL-18, BAFF and IL-23 are elevated in the serum, synovial fluid and 
synovium [132] (see Table 1.4). The critical role of cytokines within the 
pathogenesis of both RA and PsA is exemplified by the success of specific 
cytokine targeted therapies such as anti-TNFα and anti-IL-6R [134, 135]. Of note, 
anti-inflammatory cytokines such as IL-10, IL-1Ra and soluble TNF-receptor 
(sTNFR) are also detectable in the inflamed synovial compartment. However, the 
levels of these are thought to be too low to be biologically active thus providing 
a disequilibrium of pro- and anti-inflammatory cytokines. 
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Table 1.4 Major cytokines with a role in inflammatory arthritis 
 
Cytokine Principle Source   Primary Biological Activity 
 
TNFα  Monocytes, macrophages  activates macrophages and  
  Fibroblasts, T cells, DC,  endothelial cells; induces  
  Neutrophils    neutrophil apoptosis; increases 
       ICAM-1, VCAM-1 and E selectin 
       expression 
 
IL-1α/β Monocytes, macrophages  induces cytokine secretion from 
  DC, B cell, fibroblasts  monocytes and fibroblasts;  
       increase endothelial adhesion  
       molecule expression; osteoclast 
       activation 
 
IL-1Ra  Monocytes    antagonize effects of IL-1α and 
       IL-1β 
 
IL-18  Monocytes, DC, neutrophils T cell differentiation; NK cell  
activation; activation of 
monocytes and macrophages 
 
IL-6  Fibroblasts, monocytes,  B cell proliferation and antibody 
  macrophages, T cells,  production; T cell proliferation;  
B cells    acute phase response;  
     thrombopoiesis 
 
IL-10  Monocytes, T cells,   decrease DC activation and  
  B cells, DC, epithelial  cytokine release; decrease  
  cells     synovial fibroblast cytokine and 
       MMP release 
 
Type I IFN Widespread    antiviral response; macrophage 
       activation; lymphocyte activation 
       and survival 
 
IL-17  T cells, macrophages,  induces proinflammatory cytokine 
  DC and γδ T cells   release from macrophages;  
       fibroblasts and endothelial cells 
 
IL-15  T cells, monocytes,   increased T cell and NK cell  
  macrophages, DC   recruitment, B cell 
differentiation, synovial 
fibroblast and macrophage  
activation 
 
IL-23  monocytes, DC,   Th17 cell proliferation 
  macrophages 
 
RANKL  stromal cells, osteoblasts,  stimulates osteoclast mediated 
  T cells    bone resorption 
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Table 1.4 continued 
 
APRIL  monocytes, macrophages,  promotes T and B cell survival 
  lymphocytes    and proliferation 
 
BAFF  T cells, monocytes,   Promotes B cell survival and 
  macrophages, DC   maturation 
 
GM-CSF Monocytes, fibroblasts,  Stimulates the differentiation 
  T cells, osteoclasts   and survival of macrophages 
       and neutrophils 
 
M-CSF  Lymphocytes, fibroblasts,  regulator of monocyte 
  monocytes and osteoclasts differentiation and proliferation 
       and of macrophage survival 
 
 
1.1.7.2 Chemokines 
The influx of inflammatory cells into the synovium is mediated by chemokines 
which are small molecular weight (8-12 kDa) chemoattractant proteins that 
primarily promote leukocyte recruitment and activation. Over 50 distinct 
chemokines have been identified and can be classified into four sub-families: 1) 
CXC which can promote angiogenesis, 2) CC which act primarily on monocytes 
and T cells, 3) C and 4) CX3C which consists of the chemokine fractalkine 
(CX3CL1) [136]. A number of pro-inflammatory chemokines have been detected 
at elevated levels in both RA and PsA (see Table 1.5). 
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Table 1.5 Chemokines with a role in inflammatory arthritis 
 
Chemokine ligand Receptor (s) Primary source  Physiological  
         Feature 
 
CC Family 
CCL2 (MCP-1)  CCR2  Fibroblasts, macrophages, Inflammation, 
Osteoclasts osteoclast 
differentiation 
 
CCL3 (MIP-1α)  CCR1, CCR5 Macrophages, fibroblasts Inflammation 
 
CCL4 (MIP-1β)  CCR5  Monocytes, DCs  Inflammation 
 
CCL5 (RANTES) CCR3, CCR5 T cells, macrophages, Inflammation 
   CCR1  Fibroblasts 
 
CCL19 (ECL)  CCR7  Macrophages,    Homeostatic,  
     neutrophils   Inflammatory 
 
CCL20 (MIP-3-α) CCR6  macrophages,   Inflammation, 
     Fibroblasts   bone resorption 
 
CCL21 (SLC)  CCR7  endothelial cells  Inflammation, 
         Lymphoid neogenesis 
 
C Family 
XCL1 (lymphotactin) XCR1  mast cells, activated  Inflammation, 
     CD8+, NK cells   stimulates T cell  
Accumulation 
 
CXC Family 
CXCL1 (gro-alpha) CXC2R, Fibroblasts   Inflammation,  
CXCR1      synovial angiogenesis 
 
CXCL5 (ENA-78) CXCR2  Fibroblasts   Inflammation 
 
CXCL8 (IL-8)  CXCR1, Macrophages,   Inflammation, 
   CXCR2  fibroblasts, epithelial  synovial angiogenesis 
     cells 
 
CXCL9 (Mig)  CXCR3  macrophages,   Inflammation, 
     Neutrophils   angiostatic 
 
CXCL10 (IP-10) CXCR3  Fibroblasts, monocytes, Inflammation, 
     DCs, epithelial cells,  agiostatic 
     Endothelial cells 
 
CX3C Family 
CXC3CL1 (fractalkine) CXC3CR1 Monocytes, fibroblasts, Inflammation 
     Macrophages, DC 
     Endothelial cells 
 
MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; RANTES, 
regulated on activation normal T cell expressed and secreted; ECL, Epstein-Barr virus-induced 
receptor ligand; SLC, secondary lymphoid  tissue chemokine; ENA, epithelial-derived neutrophil-
activating peptide; MIG, monokine induced by gamma interferon; IP-10, interferon gamma-
induced protein 10kDa. 
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1.1.8 Current therapies in RA and PsA 
Advances in the knowledge of the mechanisms driving RA and PsA pathology have 
enabled the discovery of new therapeutics. In recent years the purpose of new 
therapeutics has altered from that of simply inhibiting disease progression to the 
ability to prevent the initial onset of disease. 
1.1.8.1 DMARDS 
Disease modifying anti-rheumatic drugs (DMARDs) particularly methotrexate 
have been widely used for the treatment of RA and PsA for decades. Despite 
reports of methotrexate treatment reducing the synovial sublining layer within 
PsA patients [137] it has been increasingly recognised that methotrexate only 
partially inhibits the progression of structural damage in RA [138]. In addition, a 
2-year retrospective study of matched PsA patients either on or off 
methotrexate therapy did not show any difference in radiologic progression 
scores between the two groups [139]. Furthermore, up to 60% of RA patients 
have reported adverse reactions to methotrexate including nausea, diarrhoea, 
headaches, hepatitis and leukopenia which have only resolved with 
discontinuation of therapy [140]. As a result methotrexate does not exert 
therapeutic benefits in a large proportion of patients and may only delay the 
progression of disease. Other DMARDs in use are sulfasalazine, cyclosporine, 
leflunomide and hydroxychloroquine which all demonstrate some clinical benefit 
in a percentage of patients but as with methotrexate are often associated with 
toxicitiy and restricted duration of effectiveness. 
1.1.8.2 Anti-TNFα 
TNFα is a potent pro-inflammatory cytokine that is known to play a critical role 
in chronic inflammatory diseases such as RA and PsA [141]. Soluble TNFα is 
produced as a precursor form called transmembrane TNFα (tmTNFα) which is a 
cell surface protein found on activated macrophages and lymphocytes [142]. This 
tmTNFα is cleaved and processed by TNFα-converting enzyme (TACE) to release 
a soluble 17 kDa molecule. The combination of three of these 17 kDa molecules 
as a homotrimer forms soluble TNFα, which mediates its pro-inflammatory 
properties through type 1 and 2 TNF receptors (TNFR1 and TNFR2) [143]. 
Numerous studies have indicated that both soluble TNFα and its precursor form 
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tmTNFα are involved in the inflammatory response through binding to TNFR1 or 
TNFR2. Soluble TNFα can act at sites distant from the TNFα-producing cells 
whereas tmTNFα can exert its function on other cells through direct cell contact 
[144]. 
At present there are three anti-TNFα agents, infliximab, etanercept and 
adalimumab, which are approved worldwide for the treatment of various 
inflammatory conditions including RA, PsA, psoriasis, Crohn‘s disease and AS 
[135]. In addition, other anti-TNFα agents, certolizumab pegol and golimumab, 
have just been approved for clinical use. Infliximab, adalimumab and golimumab 
are monoclonal antibodies against human TNFα and etanercept is engineered 
from human TNF receptors. Adalimumab, infliximab and entanercept all bind to 
soluble or tmTNFα with a similar affinity [145].  
Adalimumab has been demonstrated to have a high level of tissue penetration in 
RA patients as radioscintography demonstrated that labelled adalimumab rapidly 
(within minutes) localised to the inflamed joints after intravenous administration 
[146] and tissue concentrations of the antibody in the synovial fluid range from 
31% to 96% of those in the serum [147]. Greater than two thirds of RA patients 
respond favourably to TNFα inhibitors and administration of adalimumab to RA 
patients has been shown to significantly slow the radiological progression after 
one year [148]. PsA patients treated with adalimumab over 48 weeks show 
reduced radiographic progression, reduced disability and improved skin and joint 
manifestations [149] therefore this anti-TNFα treatment have proved to be a 
highly effective treatment for the management of inflammatory arthritis. The 
antibody‘s mechanisms of action within the diseased patients include binding 
and hence neutralising soluble TNFα. 
Infliximab is a similar therapy to adalimumab as it is a monoclonal antibody 
against human TNFα. A phase III study of infliximab in 200 PsA patients showed 
significant benefit since at week 14, 58% of patients achieved an ACR20 
response. The presence of dactylitis and enthesitis decreased significantly and 
quality of life measures also significantly improved [150]. Within RA patients 
infliximab has proven to be highly efficacious with ACR20 and ACR50 responses 
of up to 80% and 60% respectively [151]. Etanercept is a soluble receptor for 
TNFα and has been demonstrated to be successful in the treatment of PsA and 
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RA. In a phase III trial of 205 PsA patients an ACR20 response was achieved by 
59% of etanercept treated patients and psoriatic skin involvement significantly 
decreased after 24 weeks of treatment [152]. Furthermore, the successful 
response of patients to treatment from any of these three anti-TNFα therapies 
are significantly increased when administered in combination with methotrexate 
with which it has synergistic benefits [151, 153, 154]. 
Since TNFα can act independently, additively or synergistically within the 
arthritic joint its neutralisation can reduce the production of other pro-
inflammatory molecules such as IL-6, IL-1β and MCP-1 from immune cells as well 
as reducing the expression of ICAM-1 and VCAM-1 adhesion molecules which can 
prevent cell trafficking into the joint and is the reason for the reduced 
cellularity seen the inflamed tissue after anti-TNFα therapy [135]. 
1.1.8.3 Rituximab and B cell targeted therapies 
Rituximab is a chimeric human/mouse monoclonal antibody directed at the CD20 
antigen expressed by mature B cells and pre-B cells but not on other cells 
including plasma cells. It was first used as a treatment for non-Hodgkin‘s 
lymphoma but has since been approved for treatment of RA. Although several 
studies have suggested that CD20 may function as a calcium channel or a cell 
surface signalling receptor, its function and the mechanisms of action in RA 
remains unclear [155]. In the phase III REFLEX trial rituximab was administered 
to 309 RA patients whilst 209 patients received placebo, and it was found that 
rituximab efficacy versus placebo was evident from 8 weeks onwards and the 
retardation of joint damage was significantly different from placebo after 56 
weeks [122]. Rituximab therapy has also been successful in the treatment of PsA 
[121]. 
Several mechanisms for the observed improvements have been suggested such as 
reduced antibody production; reduced secretion of B cell derived pro-
inflammatory cytokines or reduced antigen presentation. Due to the success of 
rituximab considerable effort has been expended into developing biologics 
against BLyS (B-lymphocyte stimulator) also known as BAFF (B-cell-activating 
factor of the TNF family) and APRIL (a proliferation induced ligand) which are 
TNF superfamily members and promote B cell survival, differentiation and 
44 
activation. Belimumab is a fully human monoclonal antibody that specifically 
targets BLyS, the reports of a phase II study of this antibody in RA demonstrated 
a reduction in B cells and rheumatoid factor however the ACR responses were 
low in comparison to those seen with rituximab as only 29% of patients achieved 
an ACR20 response [156]. 
1.1.8.4 Anti IL-6 receptor 
Since anti-TNFα therapy is ineffective in a proportion of patients, other 
therapies are required to treat such non-responder patients. Tocilizumab, a 
human monoclonal antibody against the IL-6 receptor, has provided encouraging 
results in patients who have previously failed anti-TNFα therapy [134]. In 
addition, as has been observed with anti-TNFα therapy, the optimal clinical 
responses are seen when tocilizumab is administered in combination with 
methotrexate [157]. At present there have been no trials investigating the 
efficacy of tocilizumab in psoriatic arthritis. 
1.1.8.5 Abatacept 
Abatacept is a recombinant human fusion protein of the extracellular domain of 
the cytotoxic T lymphocyte-associated antigen 4 (CTLA4) linked to the Fc portion 
of human IgG1. Abatacept functions to block T cell activation by binding to the 
CD80/86 receptor on an antigen presenting cell thus blocking the second signal 
activation of the CD28 receptor on the T cell. During clinical trials of RA patients 
abatacept treatment resulted in a high ACR response and it is now approved in 
Europe for treatment of RA [158]. A recent trial has also found that abatacept is 
an efficacious therapy for PsA resulting in significant improvements in patients 
compared to placebo controls [159]. 
1.1.8.6 Other therapies 
Ustekinumab is an IL12/23 inhibitor and its administration has demonstrated 
significant efficacy in psoriasis since IL-12 and IL-23 are over expressed in 
psoriasis plaques. This inhibitor has also shown efficacy in preliminary PsA 
studies by reducing the signs and symptoms of arthritis [160]. 
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1.2  Monocytes and Macrophages  
1.2.1  Monocyte and macrophage origin 
Leukocytes are a diverse group of cells types which mediate the body‘s immune 
response. They have a shared origin of hematopoietic stem cells (HSC) and 
develop along divergent differentiation pathways in response to internal and 
external cues. The mononuclear phagocyte system represents a population of 
leukocytes originating as bone marrow derived myeloid cells [161] and comprises 
of bone marrow monoblasts and promonocytes, peripheral blood monocytes, 
tissue macrophages and dendritic cells (DCs). 
Current models propose that blood monocytes originate in vivo from HSC derived 
progenitors with myeloid restricted differentiation potential. Successive 
commitment steps include common myeloid progenitors (CMPs) and 
macrophage/DC progenitors (MDPs). Each of these differentiation steps involves 
cell fate decisions which subsequently restrict cell development potential [162]. 
MDPs are a subset of proliferating cells in the bone marrow that differentiate 
into both monocytes, which give rise to the macrophage subsets, and common 
DC precursors (CDPs), which give rise to the DC subsets [161]. See Figure 1.3 for 
an overview of monocyte and macrophage differentiation. 
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Figure 1.3 Differentiation of the macrophage/DC progenitor and origin of macrophage and 
DC subsets 
Differentiation of monocytes and macrophages in humans. Hematopetic stem cells (HSC) give rise 
to common myeloid progenitors (CMPs) which can differentiate into macrophage/DC progenitors 
(MDPs) within the bone marrow. The MDPs will then give rise to monocytes which will then 
differentiate into tissue macrophages, alternatively the MDPs will differentiate into common DC 
precursors (CDPs) within the blood. The CDPs will then differentiate into classical DCs (cDC) or 
plasmacytoid DCs (pDC). 
 
1.2.2 Monocytes 
Circulating blood monocytes supply peripheral tissues with macrophage and DC 
precursors and within the setting of infection contribute to immune defense 
against microbial pathogens. Newly formed monocytes are thought to remain in 
the bone marrow for less than 24 hours before entering into the peripheral 
blood. In humans and mice, monocytes contribute 4-10% of all circulating 
leukocytes [163] and share some typical morphological features such as irregular 
cell shape, cytoplasmic vesicles and high cytoplasm to nucleus ratio.  
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1.2.2.1 Monocyte subsets 
In humans, circulating monocytes are not a homeogenous population and can be 
divided into two distinct subsets on the basis of the expression of CD14, a 
component of the LPS receptor complex, and CD16 the FcγRIII immunoglobulin 
receptor [164]. These subsets are designated CD14+CD16-, otherwise known as 
CD14+ monocytes, and CD14lowCD16+, otherwise called CD16+ cells [165]. These 
two monocyte subsets express distinct chemokine, immunoglobulin, adhesion 
and scavenger receptors and have varying levels of cytokine production, antigen 
presentation and transendothelial migration [166]. See Table 1.6 for the 
characteristics of these two monocyte subtypes. 
CD14+ monocytes are large ~18 μm in diameter and represent 80-90% of 
circulating monocytes, in contrast CD16+ monocytes are smaller ~14 μm in 
diameter and constitute ~10% of circulating monocytes [166]. CD14+ cells express 
high levels of the chemokine CCR2 and low levels of CX3CR1; consequently, their 
phenotype resembles that of mouse Ly6c+ (Gr1+) monocytes [161, 165] whereas 
CD16+ cells resemble the phenotype of mouse Ly6clo(Gr1lo) monocytes. TLR4 
stimulation of both CD14+ and CD16+ monocytes with LPS induced similar levels 
of TNFα mRNA within the two cell types whilst the IL-10 mRNA was low to absent 
in CD16+ monocytes [167]. In addition, intracellular cytokine staining of CD14+ 
and CD16+ monocytes demonstrated a higher level of TNF protein within the 
CD16+ in response to TLR4 and TLR2 stimulation [168]. This combination of low 
IL-10 levels and high TNF levels meant that CD16+ monocytes became known as 
pro-inflammatory monocytes. 
Despite monocytes being far less efficient than DCs at MHC class II antigen 
presentation to CD4+ T cells [169], both CD14+ and CD16+ monocytes 
demonstrated the ability to present tetanus toxin antigen to T cells [170]. 
However, CD16+ monocytes have demonstrated a higher level of HLA-DR 
expression compared to CD14+ monocytes [164] and have been shown to 
preferentially develop into DCs with high antigen presentation capacity in 
response to TLR stimulation [171] suggesting that this monocyte subset and their 
DC progeny may be superior antigen presenting cells. 
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A third human monocyte subset has been recently reported that is defined by 
the expression of CD14+ CD16+ and CD64+ (FcγR-I) [172]. These cells combine 
characteristics of macrophages and DCs as they have high expression of CD68 
and HLA-DR and high T cell stimulatory activity. In comparison to CD14+ 
monocytes, CD14+CD16+CD64+ monocytes have a similarly high phagocytic 
activity and produce large amounts of cytokines such as TNFα and IL-6. But they 
also share characteristics with CD16+ monocytes such as a greater stimulatory 
activity in mixed leukocyte reactions (MLR) compared to CD14+ cells [173]. At 
present the origins of this subset are not know but they are speculated to be an 
intermediate phenotype between monocytes and DCs [172]. 
49 
Table 1.6 Characteristics of human monocyte subsets 
 
    CD14+ (CD14+CD16-)   CD16+ (CD14lowCD16+) 
 
Monocyte markers 
CD14     ++     +/— 
CD16     —     + 
CD11b     +     + 
 
Chemokine receptors 
CCR1     +     — 
CCR2     +     — 
CCR4     +/—     — 
CX3CR1    +/—     ++ 
CXCR4     +/—     + 
 
Adhesion molecule 
CD62L     +     — 
 
 
1.2.2.2 Monocyte diapedesis  
A central component of monocyte trafficking is the continuous transition from 
the blood circulation into the tissue and vice versa, as this process enables the 
monocyte cells to differentiate and develop into functional macrophages. The 
endothelium within the vasculature represents the interface between these two 
compartments and acts as a barrier to leukocyte trafficking whilst also 
instructing leukocyte adhesion and transmigration. Egress of the monocytes from 
the bone marrow into the circulation or from the circulation into the tissue 
requires migration across the monolayer of endothelial cells which line the 
vascular circulatory system, known as diapedesis. 
Extravasation of monocytes can be divided into several steps and the process 
begins when monocytes accumulate on the luminal side of the endothelium and 
undergo transient rolling interactions mediated by selectins [163], which 
facilitates sensing of chemokines presented on the endothelial surface and 
enables the monocytes to respond to them. This triggers the interaction of 
monocyte integrin receptors with their endothelial ligands which results in cell 
arrest, these molecules include junctional adhesion molecule-like (JAML) which 
has been demonstrated to contribute to monocyte adhesion and transmigration 
in vitro [174]. Once the cells have arrested on the endothelium they undergo 
actin polarisation and integrin-dependent lateral migration. This process is to 
allow the monocytes to search for sites permissive for endothelial barrier 
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penetration [175] and once a site has been found the monocytes breach and 
transmigrate across the endothelium. The movement across the endothelium 
may either be paracellular where the monocytes move in between two 
endothelial cells or transcellular where the monocytes pass directly through an 
individual endothelial cell through the formation of a transcellular pore [176]. 
As mentioned previously, CD14+ cells preferentially express the chemokine CCR2 
which allows monocyte intravasation into the circulation from the bone marrow 
through interaction with its ligands CCL2 (otherwise known as MCP-1) and CCL7 
[177]. This finding is further exemplified in CCR2-/- mice which express a 
diminished number of Ly6C+ mouse monocytes in the circulation under 
homeostatic conditions [178] demonstrating that the exit of CD14+ or Ly6C+ 
monocytes from the bone marrow is mediated in part by CCR2. Inflammation is 
associated with an increase in CCL2 within the circulation therefore in the 
presence of a local inflammatory stimulus, circulating CD14+ monocytes 
extravasate into the affected non-lymphoid areas in a CCR2-CCL2 dependent 
manner where they differentiate into macrophage or DC subsets [179]. These 
and many other studies has resulted in the human CD14+ cells and the equivalent 
mouse Ly6C+ cells becoming known as the ―inflammatory‖ subset. 
In contrast, CD16+ monocytes lack CCR2 expression and undergo transendothelial 
migration through the expression of CX3CR1, which is the fractalkine receptor, 
and CCR5 which is the receptor for CCL3 (otherwise known as MIP1α) [163]. 
Studies performed by Auffray et al have demonstrated that the Ly6C- subset of 
murine monocytes, which are equivalent to the CD16+ human monocytes, 
continuously migrate over the luminal surface of dermal and mesenteric 
microvascular endothelium where they are thought to be patrolling for signs of 
infection or tissue damage [180]. This patrolling behaviour was dependent on the 
integrin ICAM-1 and the chemokine receptor CX3XR1 and is responsible for this 
cell subset becoming known as ―resident‖ monocytes. Upon tissue damage such 
as exposure to irritants, aseptic wounding or peritoneal infection these 
patrolling resident monocytes extravasated rapidly within 1 hour and invaded 
the surrounding tissue where they were the main producers of the pro-
inflammatory cytokines TNFα and IL-1 and were shown to differentiate into 
macrophages. The Ly6C+ cells were shown to enter the immune site at a later 
time and differentiated into inflammatory DCs. These results elegantly 
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demonstrated the functions of the two monocyte subsets within an immune 
response [180]. Since human CD16+ monocytes share a phenotype similar to the 
resident Ly6C- mouse monocytes these cells could have a similar patrolling 
function within human immune system surveillance. 
1.2.2.3 Monocyte function in immune defense  
Monocytes were previously considered to be merely a developmental 
intermediate between bone marrow precursors and tissue macrophages. 
However, it is now clear that monocytes can carry out specific effector functions 
during inflammation. Monocytes have been demonstrated to be crucial for host 
defense again a wide variety of pathogens such as Listeria monocytogenes, 
Mycobacterium tuberculosis, toxoplasma gondii and various fungi. CCR2-/- mice 
are susceptible to infections caused by all of the above bacteria/fungi indicating 
that CCR2 mediated recruitment of Ly6C+ monocytes is crucial for host immune 
defense [166]. This result is verified by experiments performed in MCP-1-/- mice 
which are also more susceptible to bacterial infections such as L. monocytogens 
infection, MCP-1 is a ligand for CCR2 and is released during infection [181] and 
therefore plays a role in monocyte trafficking. Once at the site of infection it 
has been shown that monocytes produce reactive nitrogen intermediates (RNIs) 
and reactive oxygen intermediates (ROIs) and increase the production of 
phagolysosomal enzymes in order to destroy the bacteria and bring the infection 
to an end [182]. 
1.2.3  Macrophages 
The term ―macrophage‖ was first used over 100 years ago by Elie Metchnikoff to 
describe the large mononuclear phagocytic cells he observed in tissues [183]. 
Since this first observation an enormous amount of research to establish the 
function and importance of this cell type has taken place. It is now known that 
macrophages, along with DCs, form networks of phagocytic cells throughout 
most tissues where they play major roles in host development, inflammation, 
scavenging and antipathogen defences. Most macrophages in the tissue of an 
adult are derived from circulating monocytes which replenish these populations 
and there is substantial debate about whether specific monocyte populations 
develop into specific tissue macrophage subsets [184]. In addition, some 
macrophages such as those found within the lung and brain, undergo self-
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renewal and proliferation and do not need circulating precursor monocytes to 
maintain their population [185].  
1.2.3.1 Macrophage heterogeneity 
Macrophages are distributed constitutively throughout the body and known to 
have a very high degree of heterogeneity which reflects the specialized 
functions adopted by these cells in different tissue localisations. Apart from the 
inflammatory monocyte derived macrophages which will be discussed in detail in 
section 1.2.3.3 there are several other macrophage types that have been 
identified. Examples of these cell types include: Langerhan cells which are a 
self-renewing subset found within the epidermis [186]; the bone re-modelling 
osteoclasts which require M-CSF and RANKL for development [187, 188]; 
microglia and choroid-plexus macrophages which reside within the CNS; and 
Kupffer cells which are the resident macrophages of the liver and are involved in 
the clearance of particulate and soluble substances. 
1.2.3.2 Macrophage function 
The heterogeneous nature of the macrophage, its diverse distribution and 
numerous cell subsets indicate that it has several physiological functions. 
However, there are two main function shared by most macrophage subsets; 
phagocytosis and antigen presentation. 
1.2.3.2.1 Phagocytosis  
Macrophages represent a major defense against invasion of the host by a wide 
variety of microorganisms including bacteria, viruses, fungi and protozoa. 
Macrophages also play a role in the clearance of apoptotic cells and the process 
by which they carry out these two important functions is phagocytosis. Apoptosis 
is a feature that is conserved through all eukaryotic cells and constitutes a series 
of cellular events through which the cells orchestrate their own demise. A 
critical feature of apoptosis is the ability of the apoptotic cell to be recognised 
by the innate immune system and phagocytes. One of the most studied apoptotic 
signals is the change in the plasma membrane phospholipid distribution on the 
apoptotic cell, especially the exposure of the phospholipid phosphatidylserine 
(PS). PS is normally found in the inner leaflet of the plasma membrane of viable 
cells. However during apoptosis PS is exposed on the outer membrane of the cell 
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and is a marking of an apoptotic cell. It has been proposed that PS exposure is a 
sufficient signal for macrophage-mediated phagocytosis [189]. Macrophages 
appear to use several receptors in the recognition and phagocytosis of apoptotic 
cells such as PS-R, CD36 and CD14 [190] which is thought to maintain the 
efficient clearance of apoptotic bodies as different receptors may engage with 
different phases of apoptosis. CD14-dependent clearance of apoptotic cells by 
macrophages has been demonstrated in both murine and human systems [190, 
191] and it has been shown to interact specifically with ICAM-3, a glycosylated 
leukocyte protein, during the clearance of apoptotic leukocytes [192].  
Macrophages also have specialised surface receptors that detect the presence of 
microorganisms before phagocytosis takes place. These receptors can directly 
interact with the microorganism through the recognition of pathogen associated 
molecules such as surface carbohydrates, peptidoglycans or lipoproteins. The 
macrophage can also recognise the pathogen through opsonins. Opsonins are 
host factors such as IgG and components of the complement cascade that attach 
to the pathogen surface. These opsonins are then recognised by receptors on the 
macrophage such as Fcγ receptors (FcγR) and complement receptor 3 (CR3) 
[193].  
Once the macrophage has recognised the apoptotic cell or the microorganism it 
will engulf the cell or pathogen by advancing pseudopodia over the regions of 
the cell/microorganism that are linked to the cell surface receptors. This 
internalisation requires reorganisation of the macrophage cyotoskeleton as well 
as delivery of membrane to accompany the increased surface area of the 
phagocytic cup which engulfs and surrounds the apoptotic cell/microorganism. A 
process called phagosome maturation then takes place inside the phagocytic 
macrophage by which the phagosome undergoes sequential fusion with early 
endosomes, late endosomes and lysosomes which are increasingly acidified 
membrane bound structures [194]. The fusion of these structures to the 
phagosome eventually leads to degradation of the phagocytosed pathogens or 
cells. Although most pathogens are phagocytosed and destroyed with ease by the 
macrophages, certain pathogens have developed mechanisms through which they 
avoid phagocytosis such as M. Tuberculosis which inhibits phagosomal 
maturation and L.pneumophila which can redirect the phagosomal maturation 
pathway in order to allow bacterial replication [193]. 
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1.2.3.2.2 Antigen processing and presentation 
Macrophages are one of several antigen presenting cells (APCs) which present 
antigen to T cells or to B cells within follicles of the lymph node [195]. Indeed 
one of the important functions of the macrophage is to assist in initiating and 
facilitating cell-mediated immune responses against pathogens through the 
processes of secreting cytokines and inflammatory mediators as well as antigen 
presentation. As professional phagocytes, macrophages express a variety of 
receptors that participate in the phagocytic uptake of antigens including those 
which recognise complement activation products or Ig Fc fragments. 
Macrophages express both MHC class I and class II molecules and therefore are 
able to present antigen derived from cytosolic or extracellular proteins for 
recognition by the appropriate CD8+ (MHC class II expressing) or CD4+ (MHC class 
I expressing) restricted antigen specific T cells. In addition macrophages can 
deliver the second co-stimulation signal required by the T cell to enhance 
cellular adhesion and signalling and promote maximal cross-talk between the 
macrophage and the T cell. These signals include CD80/86 and CD40 which 
interact with CD28 and CD154 respectively on the T cells [196]. The process of 
antigen presentation amplifies the inflammatory signal through subsequent T 
cell cytokine production and clonal expansion. 
1.2.3.3 Macrophage activation  
Macrophages are an extremely heterogenous cell type and as a result have 
demonstrated remarkable plasticity which allows them to respond to 
environmental cues and change their phenotype. These stimuli can be exogenous 
or endogenous and can be produced by innate immune cells, antigen-specific 
cells or the macrophages themselves. This extensive network of potential stimuli 
can give rise to diverse populations of macrophages with distinct physiology and 
much work has been devoted to phenotyping and understanding these 
macrophage populations. 
One of the first populations of activated macrophages to be described were the 
classically activated macrophages which designates the effector macrophage 
population that are produced during the process of cell-mediated immune 
responses [197]. The first description of a classically activated macrophage was 
the result of research performed in the 1960s by Mackaness et al which 
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demonstrated that the infection of mice with Mycobacterium bovis bacillus 
Calmette-Guerin (BCG) or Listeria monocytogenes enhanced the antimicrobial 
ability of macrophages in a stimulus dependent but antigen independent manner 
[198]. Since this first observation, several studies have shown that classical 
macrophage activation depends on the pro-inflammatory cytokines produced by 
T helper 1 (Th1) cells and NK cells, in particular TNFα and IFNγ, and microbial 
products [199]. The combination of these two signals resulted in a macrophage 
population which had enhanced microbicidal activity and secreted high levels of 
pro-inflammatory cytokines [200].  
IFNγ can be produced by both innate and adaptive immune cells. NK cells are an 
early source of this cytokine as they produce IFNγ in response to stress and 
infection. This cytokine can prime macrophages to secrete pro-inflammatory 
cytokines and produce oxygen and nitrogen radicals to increase their killing 
ability [201]. However this production of IFNγ by NK cells is transient and cannot 
maintain a population of macrophages. Therefore an adaptive immune response 
is normally needed to sustain the activated macrophages and sustain host 
defense against intracellular pathogens. In this situation IFNγ can also be 
provided by Th1 cells which are antigen specific however the microbicidal 
macrophages that the IFNγ induces can kill and phagocytose randomly. 
Other mechanisms of classical macrophage activation include TLR ligation by 
bacterial pathogens which, acting in a MyD88-dependent manner, induces the 
transcription of TNFα which will then assist IFNγ and activate the macrophage 
population in an autocrine manner. In addition to this mechanism of activation, 
TLR ligands can also activate TIR-domain-containing adaptor protein inducing 
IFNβ (TRIF)-dependent pathways, which signal through IRN-regulatory factor 3 
(IRF3) and result in IFNβ production [202], this IFNβ can induce classical 
macrophage activation in place of IFNγ indicating that TLR agonists can 
overcome the IFNγ dependent classical macrophage activation. 
The role of classically activated macrophages in the host defense to intracellular 
pathogens has been well established. Studies have shown that mice lacking in 
IFNγ expression are more susceptible to various bacterial or viral infections and 
treating macrophages with IFNγ and TNFα before infection with Leishmania 
parasites results in a population of macrophages which can kill the parasite. 
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However the complex combination of genes and cytokines that are expressed 
and produced as a result of classical activation require both the IFNγ receptor 
ligation and either TNFα receptor ligation or TLR ligation. Since stimulation of 
macrophages with IFNγ alone resulted in macrophages that could not clear the 
Leishmania parasite effectively but exogenous treatment with TNFα or a TLR 
ligand restored the macrophage ability to clear the parasite completely [197]. 
In conclusion, classically activated macrophages can be produced by innate 
stimuli following a pathogenic infection and cell-mediated immune response. 
This activation usually requires two stimuli consisting of IFNγ and TNF or TLR 
ligation but this can be overcome by certain TLR agonists that can induce TNF 
and IFNβ production from the macrophages which acts in an autocrine manner. 
The resultant macrophages have increased microbicidal activity and can produce 
high levels of pro-inflammatory cytokines. The pro-inflammatory cytokines 
produced by classically activated macrophages, such as IL-1, IL-6 and IL-23, are 
known to induce the development and expansion of Th17 cells [197, 203] which 
can contribute to numerous inflammatory autoimmune pathologies. Therefore 
although classically activated macrophages are a fundamental constituent of 
host defense, their regulation must be tightly controlled to avoid extensive host 
damage. 
Since the identification of classically activated macrophages numerous 
investigations have demonstrated that macrophages can also be activated by 
other stimuli which results in the upregulation of cell surface markers and 
phenotypic changes that are distinct from those induced by IFNγ. These studies 
analysing different subset of activated macrophages came after reports of the 
macrophage mannose receptor, which is expressed on resident macrophages, 
being specifically downregulated by IFNγ but upregulated by the cytokine IL-4 
[204, 205]. It was proposed that IL-4 induced an ―alternative‖ form of 
macrophage activation compared to the classical activation and subsequently 
other workers introduced the term M1 and M2 for classically and alternatively 
activated macrophages respectively to emulate the T helper cell polarisation 
literature [206]. Further work has demonstrated that IL-13 can also induce 
alternative macrophage activation [207] by upregulating the mannose receptor 
which is dependent on IL4Rα1 which is the common IL-4 and IL-13 receptor alpha 
chain [208]. 
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Alternatively activated macrophages are similar to classically activated 
macrophages as they can develop in response to innate or adaptive signals. IL-4 
is thought to be one of the first cytokines released during tissue injury [209] 
where one of the main sources of this cytokine are basophils and mast cells. 
However, as has been demonstrated with classically activated macrophages, the 
transient secretion of activating cytokines by innate cells is not sufficient to 
maintain the sustained macrophage activation therefore the adaptive immune 
response is necessary to develop and maintain an alternatively activated 
macrophage population. In contrast to the classically activated macrophages 
which require a Th1 immune response to produce the cytokines needed for 
activation the alternatively activated macrophages require a Th2 immune 
response. Th2 immune responses are primarily induced in response to 
disturbance at mucosal surfaces such as the intestine or the lung but can also be 
induced at non-mucosal surfaces such as in response to helmith infections [210]. 
The main cytokines which are produced by Th2 cells are IL-4 and IL-13 which 
directly induce the alternative activation of macrophages, however other 
cytokines have also been demonstrated to indirectly induce alternative 
macrophage activation through Th2 cells. IL-33 is one such cytokine and binds to 
it receptor ST2 on Th2 cells which therefore amplifies Th2 cytokine production 
and hence alternative macrophage activation [211]. 
Alternatively activated macrophages act upon inflammatory and immune 
processes and their main role is to counteract pro-inflammatory and cellular 
immune mechanisms through regulatory and inhibitory functions. Treating 
macrophages in vitro with IL-4 and IL-13 induces macrophages that fail to 
present antigen to T cells, produce minimal levels of pro-inflammatory cytokines 
and are much less efficient at producing oxygen and nitrogen radicals and killing 
intracellular pathogens compared to classically activated macrophages [212]. IL-
4 can also stimulate arginase activity in these macrophages which allows them to 
convert arginine to ornithine, since ornithine is a precursor of collagen these 
cells can therefore contribute to the production of extracellular matrix. 
Consequently, alternatively activated macrophages are often referred to as 
wound healing macrophages [197].  
Alternatively activated macrophages also have a role in parasitic infections 
where they contribute to the clearance of helmiths by aiding in the expulsion of 
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the worms in an arginase-dependent manner [213]. Recent reports have 
suggested that this protective effect mediated by alternatively activated 
macrophages may be due to these macrophages controlling the underlying Th-1 
responses during the helmith infections which if left unregulated would 
contribute to pathogenesis of the infection [210]. Alternatively activated 
macrophages can also secrete the chemokine CCL22 which induces the 
recruitment of Th2 cells into affected tissue to aid in the removal of parasitic 
infection [214]. This macrophage subgroup has also been identified in the lungs 
of mice with experimental asthma and also in those of humans with asthma 
where they are thought to play a role in the recruitment of inflammatory cells 
into the lung through their secretion of the chemokines CCL24 and CCL17. These 
chemokines recruit several cell types into the lung including basophils, 
eosinophils, mast cells and Th2 cells which may lead to excessive type 2 
inflammation and airway hyperreactivity and therefore contribute to the clinical 
disease pathogenesis [211, 215].  
Previously, during the investigations into the phenotypes and subsets of 
macrophages the term ―alternative activation‖ was used to describe all forms of 
non-classical activation of macrophages. This loose definition obscured the 
phenotypic differences observed in macrophages which were activated by 
cytokines or factors other than IFNγ in a non-classical manner. Consequently, 
three subsets of the M2 alternative activation were proposed:  M2a are 
macrophages activated by IL-4 and IL-13; M2b are macrophages that are induced 
by agonists of TLRs or IL-1 receptors; and M2c macrophages are induced by IL-10 
and glucocorticoid hormones [216]. However, a recent review by David Mosser 
and Justin Edwards proposed a different grouping of macrophage subsets and 
propositioned a new population of macrophages called regulatory macrophages 
[197]. These regulatory macrophages would appear to be most like the M2c 
subset as they are induced by glucocorticoids, IL-10, apoptotic cells and immune 
complexes and have anti-inflammatory activity. Glucocorticoids are naturally 
produced hormones which are released by the adrenal gland in response to stress 
and can inhibit macrophage mediated host defense by preventing the 
transcription of genes coding for pro-inflammatory cytokines such as IL-1β and 
TNFα [217]. Glucocorticoids can exert both direct and indirect effects on 
immune responses as glucocorticoid treated APCs either fail to present antigen 
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to T cells or induce the development of regulatory T cells which can inhibit 
immune responses [218] therefore the macrophages induced by glucocorticoids 
are primarily anti-inflammatory.  
The first report of regulatory macrophages was by Gerber and Mosser in 2001 
who demonstrated that following in vitro stimulation with immune complexes 
and the TLR4 agonist LPS, the subsequent macrophage population produced high 
levels of the anti-inflammatory cytokine IL-10 [219]. Following studies 
demonstrated that the same IL-10 producing regulatory macrophages could be 
obtained by activating macrophages with various stimuli including IL-10 and 
apoptotic cells [197, 220]. Similar to the induction of classically activated 
macrophages, regulatory macrophages require two signals to induce their anti-
inflammatory activity. The first signal of glutocorticoids, immune complexes or 
apoptotic cells for example will generally have little stimulatory function on the 
macrophage however when combined with a second signal, such as a TLR ligand, 
these two signals will induce the macrophages to produce IL-10 which is the 
most reliable characteristic of regulatory macrophages. In addition, regulatory 
macrophages also downregulate IL-12 production [219] therefore the ratio of IL-
10 to IL-12 can be used to define regulatory macrophage populations. Due to the 
ability of IL-10 to downregulate the production of pro-inflammatory, regulatory 
macrophages are effective inhibitors of inflammation although they do maintain 
their ability to produce pro-inflammatory cytokines [197]. Regulatory 
macrophages are unable to contribute to the extracellular matrix which is seen 
in alternatively activated macrophages however they do express high levels of 
the co-stimulatory molecules CD80 and CD86 and as a result can still present 
antigens to T cells [212]. 
In summary, the regulatory macrophages represent a newly defined subset of 
activated macrophages that have a predominantly anti-inflammatory function 
through the production of IL-10. However several studies have demonstrated 
that incorrect regulation of these macrophage can have deleterious effects on 
the host and regulatory macrophages have been found to play a role in the 
neoplastic growth of tumours [197]. Tumour associated macrophages have been 
found to have a regulatory phenotype and produce high levels of IL-10 and can 
also contribute to angiogenesis and tumour growth [221]. However, the function 
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and exact role that these regulatory macrophages play in tumour progression is 
still to be elucidated. 
To conclude, the plasticity of macrophages has made classification of activated 
populations very difficult and there is controversy regarding the phenotype of 
these populations as research groups denote different identifications of the 
macrophage subsets. As demonstrated above the classification of macrophages is 
more complex that an M1 or M2 macrophage because unlike T cells, which 
undergo major epigenetic modifications during differentiation, macrophages will 
maintain their plasticity and continue to respond to environmental cues [222]. 
Therefore rather than being strict phenotypic characteristics the three subsets 
of macrophages discussed here represent a spectrum of activation and these 
macrophages will have the ability to change from one subset to another and may 
even display attributes of two subsets depending on the host environment. See 
Figure 1.4 for a cartoon representation of the three macrophage population 
which arise as a result of different mechanisms of activation. 
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Figure 1.4 Innate and acquired immune activation of macrophages 
Classically activated macrophages develop in response to the cytokines IFNγ, which can be 
produced during an adaptive immune response by Th1 cells or during an innate immune response 
by NK cells, and TNFα which can be produced by NK cells, Th1 cells or APCs. Alternatively, 
classical macrophage activation can develop as a result of TLR ligation by microbial products. 
Alternatively activated macrophages arise in response to IL-4 and IL-13 which are produced during 
a Th2 adaptive response or during a granulocyte innate response. IL-33 can activate Th2 cells and 
amplify their cytokine production and therefore alternative macrophage activation. Regulatory 
macrophages develop in response to various stimuli including IL-10, apoptotic cells, immune 
complexes and glucocorticoids. Each of these macrophage populations has a different phenotype 
and role within host defense, classically activated macrophages have microbicidal activity whereas 
alternatively activated macrophages have a role in tissue repair and parasite expulsion and 
regulatory macrophages produce high levels of IL-10 to dampen the immune response. The 
development of the macrophage populations shown here are not permanent changes to the cells 
and due to remarkable plasticity of macrophage cells they retain the ability to change from one 
subset to another depending on the environmental stimuli. Adapted from [197]. 
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1.2.4 Monocytes and macrophages in inflammatory arthritis 
Autoimmune disorders such as PsA and RA are characterised by the obliteration 
of self-tolerance and the appearance of self-reactive lymphocytes. Monocytes 
and macrophages are one of the cell types implicated in the perpetuation of 
arthritic disease and are found in dense populations within the diseased synovial 
membrane. 
1.2.4.1 Blood monocytes in RA and PsA 
Within healthy individuals the circulating blood monocyte population will consist 
of approximately 90% CD14+CD16- cells and 10% CD14lowCD16+ cells [166]. In 
comparison to the CD14+CD16- monocytes, CD14+CD16- (CD16+) monocytes have 
shown distinct patterns of additional surface molecules such as MHC class II, 
ICAM-1 and LFA-1 [164, 223] and are thought to bear resemblance to tissue 
macrophages. CD16+ monocytes are thought to be of pathological significance 
since they are expanded in inflammatory conditions such as asthma [224] and 
sepsis [225] and have been discovered to be at a higher ratio in the blood of RA 
patients. The percentage of CD16+ monocytes is significantly increased in RA 
blood (11-15%) compared to healthy blood (9-9.5%) [226-229] and the RA 
diseased blood monocytes also had increased levels of surface TLR2 compared to 
the healthy controls [227]. CD16+ cells produce larger amounts of TNFα in 
response to TLR2-specific ligands compared to CD16- cells [168] suggesting that 
the RA blood monocytes may be more proinflammatory and have higher levels of 
activation compared to those of the healthy controls. 
The expression of CD16 on blood monocytes in RA patients has also been shown 
to be correlated to the disease activity of the patients which also substantiates 
the hypothesis that CD14+CD16+ monocytes in RA contribute to the disease 
pathogenesis [226, 228, 229]. In addition, the plasma concentrations of 
cytokines which are known to induce CD16+ expression such as M-CSF, TGFβ1 and 
IL-10 are increased in RA patients. In addition, to being at an increased level in 
the blood of RA patients, CD16+ monocytes are also overrepresented in the 
synovium of patients where they again correlate with disease activity and the 
degree of joint destruction [229]. Moreover, circulating CD16+ monocytes as well 
as the lining layer in the synovial tissue of RA patients show increased expression 
of CX3CR1 which is the receptor for fractalkine (CX3CL1). CX3CR1 is capable of 
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mediating leukocyte migration and firm adhesion, and high levels of fractalkine 
have been detected in the serum and synovial fluid of RA patients indicating that 
this receptor – ligand complex may be mediating the migration and recruitment 
of CD16+ monocytes from the blood into the synovium [230]. 
In addition to the work performed on CD16+ overexpression within the blood of 
RA patients other studies investigating the function of monocytes in RA have 
further demonstrated their pathogenic role within the disease. For example, RA 
CD14+ monocytes have been shown to inhibit synovial T cell glucocorticoid –
mediated apoptosis though the release of soluble factors rather than via direct 
cell contact. Therefore RA monocytes could provide a mechanism for the 
increased survival of synovial T cells within the disease and may be a mechanism 
for the differences in response to glucocorticoid treatment for RA [231]. 
In comparison to the RA literature there has been little research into the 
presence of an elevated CD16+ monocyte population in PsA patients. However, a 
very recent study by Chiu et al noted that there was an increased frequency of 
circulating CD14+CD16+ monocytes in PsA patients compared to healthy controls 
(0.91% versus 0.46% respectively) [232]. It had been previously demonstrated 
that circulating monocytes in PsA were able to mature into osteoclasts, which 
are cells that directly absorb bone, without any exogenous stimuli [233]. The 
results of the current study demonstrate that the osteoclast cells were mainly 
derived from the CD14+CD16+ cells in PsA and increased CD16 expression was 
associated with increased bone erosion in PsA [232]. However, this result is in 
direct contrast to those of Komano et al who isolated monocytes from the blood 
of RA patients and illustrated that the CD16- monocyte subset but not the CD16+ 
population were able to differentiate into osteoclasts by stimulation of the cells 
with RANKL in combination with M-CSF. In contrast, the CD16+ monocytes 
expressed larger amounts of TNFα and IL-6 which were enhanced by RANKL 
stimulation therefore this would suggest that the RA blood monocytes consist of 
two functionally distinct subsets which respond in alternative ways to RANKL 
stimulation [234]. The difference demonstrated between the ability of CD16+ 
cells to form osteoclasts in PsA but not in RA is at present inexplicable but may 
be due to differences in the monocyte subsets between the two diseases. 
 
64 
1.2.4.1.1 Chemokine receptor expression on diseased monocytes 
The majority of cells which form the infiltrate in RA and PsA synovial tissue are 
derived from the circulation and the synovial inflammation seen in both diseases 
is dependent on the infiltration and retention of these inflammatory cells within 
the joint. Chemokines and their receptors play a crucial role within these 
processes as they allow the immune cells to chemotax from the blood to the 
synovium and the upregulated expression of chemokine receptors is a 
characteristic of diseased monocytes. The chemokine network represents a large 
group of chemotatic proteins which are structurally related. To date there are 
around 50 chemokines signalling through 20 different receptors which can be 
constitutively expressed on cells or be up- or down-regulated dependent on cell 
activation.  
Arthritic blood monocytes have previously been demonstrated to express 
chemokine receptors at a significantly increased level compared to normal blood 
monocytes. As mentioned previously fractalkine (CX3CL1) is expressed at a 
higher level on RA CD16+ monocytes which is thought to mediate the migration 
of these cells into the diseased joint [230]. An additional study has also found 
that RA PB monocytes express both CCR1, which will bind a variety of ligands 
including CCL3 and CCL5, and CCR2, which binds with CCL2, while RA SF 
macrophages have upregulated levels of CCR5 and CCR3. This differential 
chemokine receptor expression would suggest that CCR1 and CCR2 may be 
involved in monocyte recruitment from the blood and CCR3 and CCR5 may be 
involved in retention of the monocytes within the synovium [235]. In addition, a 
recent paper had revealed the expression of the chemokine receptor CCR9 on RA 
PB monocytes as well as RA synovia, the expression of CCR9‘s only known ligand 
CCL25 was also detected in RA synovia co-localised with CD14+ monocytes and 
CD68+ macrophages. CCL25 induced strong chemotaxis of PB monocytes and also 
the differentiation of monocytes into macrophages and therefore this receptor-
ligand complex may play a dual role in the pathogenesis of monocytes in RA by 
inducing their movement into the synovium and promoting their differentiation 
into a destructive macrophage phenotype [236]. 
The RA and PsA synovium also contains high levels of monocyte chemotactic 
chemokines including the ligands for the chemokines receptors mentioned above 
which are expressed on PB monocytes such as CCL5 and CCL3 [237, 238] which 
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will enable the migration of blood monocytes into the synovium in order to 
differentiate into pathogenic macrophages and maintain their continual 
pathogenic secretion of pro-inflammatory cytokines and chemokines.  
A recent interesting imaging study which investigated the migration of RA 
monocytes, isolated CD14+ monocytes from patients and labelled them with a 
radioactive tracer before re-infusing these monocytes back into the patients. 
The patients were imaged and the results determined that a small number of the 
monocytes had migrated into the diseased joints after 1 hour and had a 
continuous movement into the joint [239]. These results demonstrate the short 
migration time of monocytes from the blood into the synovial compartment and 
reveal the strong migratory potential of these monocytes possibly led in part by 
the high levels of chemotactic proteins expressed within both the patient 
synovium and serum and the upregulation of adhesion molecules on the surface 
of the cells [230, 240].  
The proinflammatory milieu within the serum of arthritis patients can also 
induce blood monocytes to produce chemokines and pro-inflammatory cytokines 
therefore the blood monocytes are not only the precursors for the inflammatory 
macrophages seen in the synovium but can also contribute to the inflammatory 
environment themselves. For example, a recent study demonstrated that the 
pro-inflammatory molecule osteopontin which is found at increased levels in the 
serum of RA patients induced the expression of the chemokines CCL2 and CCL4 
in CD14+ monocytes [241]. Monocytes have also been shown to secrete TNFα in 
response to immune complexes found in the serum of arthritis patients [242] 
indicating that these cells play a role in the elevated serum chemokine and 
cytokine levels observed in RA and PsA.  
1.2.5 Macrophages in RA and PsA 
Once the peripheral blood monocytes have entered the arthritic synovium they 
will mature and develop into macrophages which express broad pro-
inflammatory, remodelling and destructive potential and contribute significantly 
to the inflammation and joint destruction observed in RA and PsA. Similar 
numbers of CD68+ macrophage populations are found within the lining and 
sublining of the synovium in RA and PsA [243] and upregulated levels of 
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monocytes and macrophages have been found in the synovial fluid of RA and PsA 
patients [244]. The importance of macrophages for the pathogenesis of 
inflammatory arthritis has been demonstrated by several studies such as those 
performed by Tak et al who illustrated that the number of synovial macrophages 
correlate with the scores for knee pain and also the levels of TNFα and IL-6 
expression [245]. In addition, the radiographic progression of joint destruction in 
RA has been found to correlate with the degree of synovial macrophage 
infiltration [246] which underscores the important role the macrophage plays in 
synovial inflammation. Furthermore, an ex vivo cellular model of rheumatoid 
arthritis which was set up using cultures of synovial tissue from RA patients 
revealed that the spontaneous reconstruction of inflammatory tissue which was 
visualised after 4 weeks of culture could be inhibited by depleting CD14+ cells  
from the synovial tissue. They suggested that these results imply a critical role 
of CD14+ monocytes and macrophages in the development of the destructive 
pannus tissue observed in RA [247]. Studies in animal models have also revealed 
the importance of macrophages in arthritis as op/op mice which are deficient in 
the macrophage differentiation cytokine M-CSF fail to develop collagen induced 
arthritis [248]. 
1.2.5.1 Stimulation of macrophage activation in RA and PsA 
The differentiation and activation of infiltrating monocytes into pathogenic 
macrophages underlies the systemic inflammation observed in both RA and PsA 
and is a complex interaction of paracrine mechanisms through cell-cell 
interaction as well as the result of soluble stimuli and autocrine mechanisms. 
1.2.5.1.1 Cell-cell interaction 
A considerable part of macrophage effector responses is mediated by cell 
contact dependent signalling with different inflammatory or mesenchymal cells. 
Due to the large numbers of fibroblasts and macrophages within synovial tissue 
the interaction of these cell types is essential for the resulting tissue damage 
and inflammation. The direct cell contact of these two cell types elicits the 
production of IL-6, GM-CSF and IL-8 which can be enhanced by the addition of 
other pro-inflammatory cytokines or inhibited by the addition of regulatory 
cytokines or by neutralising CD14 [249].  
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The interaction between monocytes and endothelial cells in arthritis is necessary 
for the sustained influx of cells into the synovium through the interaction of 
selectin/intergrin pairs on the surface of the two cell types. The synovial 
cytokine environment upregulates the expression of these ligand pairs and leads 
to the further influx and activation of peripheral blood monocytes [250]. In 
addition, cell contact between macrophages and monokine-activated NK cells 
induces TNFα production from the macrophages demonstrating a further 
mechanism for macrophage activation [251]. 
A substantial amount of work has been dedicated to analysing the cell contact 
dependent activation of macrophages by T cells which will be discussed in detail 
in section 1.2.5.3. This cell contact activation occurs in the absence of antigen 
but there have also been reports of macrophages acting as APCs within the joint 
and presenting autoantigens such as collagen to T cells [252]. 
1.2.5.1.2 Soluble stimuli 
There are numerous soluble stimuli present in the arthritic joint which are able 
to activate macrophages of these the most notable stimuli are cytokines. Many 
of the cytokines present have a pro-inflammatory effect on the macrophages and 
several of them, such as TNFα, IL-1 and IL-15, are produced by macrophages 
themselves and therefore will activate the macrophages in an autocrine fashion 
and result in a subset of perpetually activated macrophages. T cells within the 
joint can also produce inflammatory cytokines that will affect the macrophage 
population such as IL-17 which has pro-inflammatory and amplifying effects on 
macrophages in RA [113]. In addition to their inflammatory effects, there are 
also cytokine stimuli within the joint which have a regulatory effect on the 
synovial macrophages such as IL-4 and IL-13 which are produced by T cells and 
are involved in the alternative activation of macrophages as discussed previously 
and also IL-10 which is produced by macrophages themselves and may be a 
mechanism of autocrine regulation in order to try and reduce the chronic 
inflammation taking place. 
An interesting study undertaken by Vandooren et al demonstrated that the 
synovial fluid from SpA patients which included a subset of PsA patients was able 
to induce the preferential expression of the M2 (alternative activation) markers 
CD163 and CD200R on peripheral blood monocytes in comparison to synovial fluid 
68 
from RA patients [253]. Previous studies had also shown an increased number of 
CD163 expressing macrophages in the synovium of SpA patients [254, 255], these 
studies demonstrate that the local inflammatory synovial environment is 
different in SpA compared to RA and could be preferentially inducing a more 
wound healing alternative macrophage phenotype which may be contributing 
towards maintaining tissue integrity although at present no differences in the 
subsequent destructive processes in SpA and RA have been identified. 
1.2.5.2 Macrophage effector molecules in RA and PsA 
Once the blood monocytes have been differentiated and fully activated into 
synovial macrophages they start to produce a number of pro-inflammatory 
effector molecules that contribute to the continual inflammation and joint 
destruction seen within the arthritic joint. Subsets of these molecules are 
outlined below. 
1.2.5.2.1  Chemokines  
As discussed previously chemokine receptor expression play a significant role in 
the infiltration of blood monocytes into the synovium. Once in the arthritic joint 
the differentiated macrophage will upregulate a different profile of chemokine 
receptors such as CCR3 and CCR5 which may be involved in their retention 
within the synovium [235] and in addition will also secrete chemokines in 
response to the pro-inflammatory environment. Synovial macrophages have been 
shown to produce a range of CXC and CC chemokines and will often produce the 
ligands for the chemokine receptors expressed on the diseased blood monocytes 
in order to increase the number of infiltrating monocytes entering the synovium. 
One such chemokine is CXCL16 which is the sole ligand for CXCR6 and is found in 
the RA synovial tissue lining and interstitial macrophage cells. CXCL16 is involved 
in monocyte recruitment into the RA synovial tissue [256]. 
In addition to secreting monocyte chemotactic chemokines synovial macrophages 
also produce chemokines such as CXCL8 (IL-8), CXCL1 (Groα), CXCL7 (CTAP-III) 
and CCL18 (PARC) which are chemotactic for other inflammatory cells such as 
neutrophils and T cells [257, 258]. CCL22 is also secreted by macrophages in RA 
and PsA synovium and is thought to be involved in the migration of CCR4 
expressing memory T cells to the joint [259]. These secreted chemokines can 
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become part of autocrine loops of macrophage activation as their cognate 
receptors are often found on the surface of the macrophages themselves. 
Furthermore, some of the macrophage-expressed chemokines such as IL-8 are 
powerful promoters of angiogenesis and thus provide a link between macrophage 
activation and the prominent neo-vascularisation of the RA and PsA synovium 
[136]. 
1.2.5.2.2 Cytokines, proteinases and growth factors 
 
TNFα 
In RA and PsA, TNFα is mostly produced by macrophages at the cartilage pannus 
junction and in the synovial membrane [250], this cytokine can induce the 
production of adhesion molecules, collagenase and collagen from synovial cells 
and can also act on macrophages in an autocrine manner to produce numerous 
products including IL-6, IL-8, MCP-1 and MIP-1α [258]. Due to its significant pro-
inflammatory capabilities TNFα is of critical importance in the pathogenesis of 
RA and PsA and neutralisation of the cytokine through the use of anti-TNFα 
antibodies is now used as a therapy for both diseases [135, 148, 149]. 
IL-1 
IL-1 is another pro-inflammatory cytokine found within the synovial joint that is 
predominantly secreted by CD14+ macrophages [260], and synovial fluid levels of 
this cytokine have been found to correlate with joint inflammation [261]. IL-1 
influences proteoglycan synthesis and degradation and hence articular damage 
underscoring the pathogenic effect macrophages and their products can have on 
the chronic nature of arthritis. In addition, the IL-1 type 1 receptor (IL-1R1), 
which mediates IL-1-induced cell activation, is found on numerous cells within 
the synovium of RA patients [262] indicating the pro-inflammatory capacity of IL-
1 within the synovium. The type II receptor (IL-1R2) which does not induce 
cellular activation and is therefore anti-inflammatory is found at low levels in 
the arthritic synovium [263]. However, IL-1 receptor antagonist (IL-1RA) which 
blocks the action of IL-1 by binding to IL-1R1 is constitutively expressed by 
differentiated macrophages and is produced at increased levels by the 
mononuclear cells of RA patients compared to healthy controls [264]. In 
addition, IL-1RA levels in the sera of PsA patients correlate with the number of 
swollen joints [265]. These findings may help to explain why therapeutic 
application of IL-1RA (anakinra) appears to be only modestly effective in RA 
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[266] and PsA [267] despite being an effective therapeutic for several hereditary 
autoimmune diseases.  
IL-15 
IL-15 is an IL-2 family member cytokine that has chemoattractant properties for 
memory T cells, it is produced by lining layer cells including macrophages and is 
increased in the synovial fluid of RA patients [268]. Peripheral or synovial T cells 
stimulated with this cytokine can induce macrophages to produce IL-1β, TNFα, 
MCP-1 and IL-8 but not the anti-inflammatory IL-10 [269]. Since IL-15 is produced 
by the macrophages themselves, this may re-stimulate the T cells and result in a 
self-perpetuating pro-inflammatory loop [268].  
IL-6 
IL-6 has also been shown to be produced by synovial macrophages in addition to 
synovial fibroblasts, it is elevated in the synovial fluid of RA and inflammatory 
arthritis during the acute phase of disease and has been shown to have phase 
dependent effects as it protects the cartilage in acute disease but promotes 
excessive bone formation during chronic disease [250]. However, despite these 
opposing effects of IL-6 within the disease setting clinical trials of an anti-IL-6 
receptor antibody suggest it may be used as an effective treatment for RA [134, 
157] although at present no trials have investigated the use of such antibodies in 
PsA. 
IL-18 
IL-18 is a member of the IL-1 family of cytokines and its expression is up-
regulated within the synovial membrane as well as the serum and synovial fluids 
of RA and PsA patients [270, 271]. It is expressed by CD68+ macrophages 
contained within lymphoid aggregates as well as by fibroblast-like synoviocytes 
and RA synovial fluid CD14+ macrophages also express the IL-18 receptor (IL-18R) 
[272]. Several lines of investigation have demonstrated the pro-inflammatory 
role of IL-18 in arthritis: (a) IL-18 deficient mice exhibit reduced incidence and 
severity of disease in the CIA and ZIA mouse models of arthritis [273-275] (b) 
anti-IL-18 antibodies can effectively reduce development and established 
arthritis in both streptococcal cell wall induced arthritis (a strongly macrophage-
dependent model) and CIA [276, 277] (c) treatment with low doses of IL-18 prior 
to induction of CIA was able to increase the severity and incidence of disease 
[278] and (d) IL-18 is selectively overexpressed in the bone marrow of patients 
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with juvenile idiopathic arthritis and macrophage activation syndrome [279]. IL-
18 has also been demonstrated to correlate with CRP levels in arthritis patients 
and their levels decrease in parallel in synovial tissue and serum following 
effective treatment with DMARDs [271]. A recent study performed by Ruth et al 
engrafted human synovial tissue into SCID mice and investigated whether the 
injection of IL-18 into these grafts could induce the migration of human PB 
monocytes which were administered to the mice. They found that IL-18 could 
indeed induce monocyte recruitment to the synovial tissue and in addition IL-18 
gene knockout mice showed pronounced reductions in joint inflammation during 
ZIA model of arthritis once again indicating the dominant role of IL-18 within 
arthritis and its ability to act in an autocrine manner and induce monocyte 
migration to sites of inflammation [275]. 
MIF 
Macrophage migration inhibitory factor (MIF) is an early-response cytokine 
abundantly released by macrophages. This cytokine can stimulate macrophage 
functions in an autocrine manner such as the release of TNF-α and phagocytosis. 
MIF can also confer resistance to apoptosis in both macrophages and synovial 
fibroblasts within the synovial joint [250]. In RA, MIF is overexpressed in the 
serum and synovial fluid of patients and correlates with disease activity and 
arthritis severity is significantly reduced in MIF-/- mice in comparison to wild 
type mice and is associated with reduced T cell activation [280]. 
Proteinases 
Matrix metalloproteinases (MMPs) are enzymes involved in extracellular matrix 
degradation that is a central part of the joint destruction seen in arthritis. There 
are around 30 known MMPs and of these mainly MMP-1 (collagenase), MMP-2 
(gelatinase A) and MMP-9 (gelatinase B) are released by RA synovial macrophages 
[258, 281]. MMP-1 and MMP-3 (stromelysin) mRNA has also been detected in the 
synovium of PsA patients [94]. Synovial macrophages also produce tissue 
inhibitors of MMPs such as TIMP-1 and TIMP-2 that anatagonise the effects of 
MMPs. 
Growth factors 
Growth factors are involved in the synovial angiogenesis, inflammation and 
fibrosis occurring in the arthritic joint.  Synovial macrophages are known to 
secrete several such factors including platelet-derived growth factor (PDGF) and 
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vascular endothelial growth factor (VEGF) [258]. PDGF-C and PDGF-D are the two 
isoforms expressed by synovial tissue macrophages and the latter isoform has 
been previously shown to increase the production of the enzyme MMP-1 within 
the synovium [282]. VEGF levels are significantly increased in the sera of PsA and 
RA patients and correlate with disease activity [98, 283]. The VEGF receptor 
(VEGFR-1/Flt-1) has previously been implicated in macrophage activation and 
angiogenesis in RA [284]. VEGFR-1 deficient mice were shown to obtain 
diminished clinical symptoms of induced arthritis compared to wild type mice 
and this VEGFR-1 deficiency was associated with reduced macrophage 
differentiation and function including a decrease in the secretion of pro-
inflammatory mediators [284]. 
1.2.5.2.3 Anti-inflammatory cytokines 
In addition to producing a large variety of pro-inflammatory mediators in the 
synovial joint macrophages also produce anti-inflammatory cytokines, namely IL-
1RA as mentioned previously and IL-10. IL-10 is a macrophage and Th2 derived 
cytokine which reduces antigen presentation by macrophages and prevents the 
production of pro-inflammatory cytokines by synovial macrophages [250]. The ex 
vivo production of IL-10 by RA PBMCs is negatively correlated with radiographic 
joint damage suggesting that IL-10 is protective however several studies have 
found a deficiency of IL-10 in the synovial compartments [285] which proposes 
that the synovial macrophages may be reducing their regulatory cytokine output 
in favour of a highly pro-inflammatory profile. 
An outline of the characteristics and pro-inflammatory potential of inflammatory 
arthritis monocytes and macrophages are shown in Figure 1.5. 
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Figure 1.5 Phenotypic overview of RA and PsA monocytes and macrophages 
An overview of the functional differences between healthy monocytes and RA or PsA diseased 
monocytes in the blood (A) and the arthritic joint (B). This figure demonstrates the inflammatory 
phenotype of these cellular subtypes and the mechanisms of their activation in RA and PsA. 
 
1.2.5.3 In vitro model of inflammatory arthritis 
The use of in vitro model systems within the investigation of chronic arthritis is 
valuable for the detailed analysis of patient cells to fully understand how they 
activate and interact with other cells. One such in vitro model has been 
established to investigate the contact-dependent, antigen independent 
interactions occurring in the synovial joint between macrophages and stimulated 
T cells. Since histologically, T cells are often found within close contact with 
macrophages within RA synovial tissue [286]. In addition, T cell cytokines such as 
IL-4, IL-10, TGF-β and IL-13 have predominantly anti-inflammatory effects and 
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IFN-γ alone displays weak activation capacity in terms of IL-1β and TNF-α 
induction which suggests that the soluble factors produced by T cells are not 
pathological mediators. Therefore it was hypothesised that within the synovium, 
one method through which T cells could exert a pathological effect would be 
through direct cellular contact with macrophages to induce cytokine and 
chemokine secretion from the latter cell type. 
The history of contact mediated activation of macrophages by stimulated T cells 
began in the mid-eighties when it was observed that the expression of 
membrane- associated IL-1 (IL-1α) in mouse macrophages was mediated by both 
soluble mediators and direct cell contact with T cells [287]. The same group 
subsequently demonstrated that this T cell contact mediated IL-1 induction in 
monocytes took place with both Th1 and Th2 cells in the absence of lymphokine 
release [288]. Following this result a similar experiment was setup with human 
cells and it was demonstrated that the production of IL-1β by human monocytes 
also required direct cell contact with anti-CD3 stimulated cells [289]. 
Accordingly, other investigators have shown that the induction of macrophage 
effector functions mediated through T lymphocytes in living cell co-cultures 
involved signals from cell-cell contact in addition to IFNγ [290]. Furthermore, by 
using isolated plasma membranes from T cells stimulated with PHA/PMA Vey et 
al demonstrated that this contact activation was sufficient for the activation of 
the human monocytic cell line THP-1 and their subsequent secretion of IL-6, 
TNFα and IL-1β in the absence of T cell derived cytokines. This cytokine release 
did not occur when the cells were physically separated by a permeable 
membrane [291].  
Antigen independent, direct contact mediated activation of monocytes and 
macrophages by stimulated T cells was found to be as potent as LPS in inducing 
cytokine production in monocytes and monocytic cell lines [291-293]. However, 
besides PHA/PMA various stimuli for the T cells were found to activate 
monocytes by direct cellular contact such as cross-linking CD3 by anti-CD3 mAb 
and the addition of cytokines to the T cells. In addition, depending on the T cell 
type and the stimulus, direct cell-cell contact between stimulated T cells and 
monocytes/macrophages induced different patterns of products secreted from 
the latter cell type (see Table 1.7).  
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Table 1.7 Depending on T cell stimulus, various products are induced in the 
monocyes/macrophages upon direct cell contact 
 
Stimulus   T cell   Monocyte  Products  
 
PHA/PMA  PB T cells,  PB mo, THP-1 TNFα, IL-1β, IL-6, 
   Synovial, Jurkat,    IL-8, IL-1α, MMP-1, 
   Th1 and Th2,    MMP-9, TIMP-1 
HUT-78     [291, 293-295] 
 
PdBu/ionomycine PB T cells  PB mo   IL-10, TNFα [296] 
 
Anti-CD3  PB and synovial  PB mo, THP-1 IL-10, IL-1β, TNFα, 
   T cells     MMP-1 [296-299] 
 
Anti-CD3  PB T cells  PMA/IFNγ treated IL-10, IL-12, TNFα, 
      U937    IL-4 [300] 
 
IL-15 or IL-2  PB T cells,  U937, PB mo, TNFα, IL-1β, IL-10  
   Synovial T cells, THP-1, synovial [301, 302] 
   Th1 and Th2  mo 
 
IL-2, IL-6, TNFα PB T cells,   PB mo   TNFα, MCP-1, 
   Synovial T cells    MCP-1, MIP-1α, 
MIP-1β, RANTES,  
IL-8, GROα, IP-10,  
IL-1β [269, 298] 
 
 
The observations outlined in Table 1.7 suggested that multiple ligands and 
counter-ligands are involved in the contact mediated activation. It was 
hypothesised that membrane associated cytokines or soluble cytokines may play 
a role however the Dayer group consistently demonstrated that neither soluble 
TNFα receptors or IL-1Ra blocked T cell mediated signalling of the monocyte. 
Additionally neutralisation of TNFα, IL-1, IL-2, GM-CSF and IFNγ all failed to 
affect monocyte activation by membranes from stimulated T cells [291, 293, 
297]. In addition to membrane-associated cytokines other surface molecules 
were investigated for their ability to activate macrophages upon contact with 
stimulated T cells. The CD40/CD40L interaction was shown to be involved in the 
contact activation of both human and mouse macrophages by T cells stimulated 
for 6 hours [303] but T cells isolated from a CD40L knockout mouse were also 
able to trigger macrophage activation although this activation was less than that 
seen from wild type murine T cells [304]. Furthermore, blocking antibodies to 
CD40L or soluble CD40 failed to inhibit contact-induced activation of 
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macrophages by 48 hour activated T cells. HUT-78 cells, which are able to 
induce cytokine production from macrophages, do not express CD40L mRNA in 
the resting or activated state [305]. Finally, Th1 but not Th2 clones stimulated 
with IL-15 were able to induce IL-1β production from monocytes, in the former 
system blockade of the CD40/CD40L interaction resulted in inhibition of IL-1β 
production despite similar levels of CD40L expression in the Th1 and Th2 cells 
indicating the selective requirement of CD40 engagement upon monocyte 
activation by Th1 clones [301]. Other groups have also demonstrated the 
presence of surface molecules such as CD69, LFA-1 and ICAM-1 on simulated T 
cells play a role in macrophage activation through the use of blocking antibodies 
which effectively inhibited macrophage activation [291, 302, 306]. 
Histological studies of the RA synovium have indicated that this tissue is very 
cellular and that several different cell types including macrophages and T cells 
are in close proximity [286]. This could therefore suggest that direct contact 
between macrophages and T cells could be important in vivo in modulating 
synovial macrophage function. It was first reported in 1994 that a cocktail of 
cytokines, namely IL-2, IL-6 and TNFα, could activated T cells in the absence of 
antigen which in turn stimulated B cells [307]. Since the RA synovial joint is a 
highly pro-inflammatory environment containing a milieu of pro-inflammatory 
cytokines it was hypothesised that these cytokines could activate the T cells 
contained within the joint which would subsequently activate the synovial 
macrophages by direct cell contact and be a mechanism for the increased 
production of pro-inflammatory mediators.  
In 1997, McInnes et al demonstrated that IL-15 alone, which is a cytokine found 
within RA synovium [268], could activate T cells isolated from the PB or SF of RA 
patients; these fixed T cells were then able to activate U937 cells or matched RA 
PB or SF monocytes to produce TNFα. This monocyte activation was cell contact 
dependent since the TNFα production was abrogated in the presence of a semi 
permeable membrane. Furthermore, it was demonstrated that the T cell surface 
molecules CD69, LFA-1 and ICAM-1 were involved in this activation since 
antibodies against these molecules prevented the secretion of TNFα from the 
monocyte [302]. In the same year Brennan and Feldmann used the cytokine 
cocktail IL-2, IL-6 and TNFα to stimulate PB T cells and demonstrated that the 
manner in which the T cells were activated influenced the profile of cytokines 
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secreted by the monocytes. Thus, if blood T cells were activated with cross-
linked anti-CD3 this induced the production of TNFα and IL-10 from monocytes 
[296]. However, if the T cells were stimulated with the cocktail of cytokines for 
8 days, the monocytes produced TNFα production but not IL-10 [269]. Such 
observations suggested that these cytokine stimulated T cells, designated Tcks, 
could be similar to the T cells found in the synovial tissue of RA patients since 
they induce an unbalanced pro-inflammatory cytokine response from monocytes.  
Consequently, further work performed by the Brennan and Feldmann group set 
out to investigate fully these Tck cells and their relevance to RA. This group 
demonstrated that the TNFα production in RA synovium was T cell dependent as 
the removal of CD3-positive T cells from RA synovial mononuclear cells resulted 
in the significant reduction of macrophage TNFα, in addition this TNFα output 
was abrogated if physical contact between the two cell types was blocked [298]. 
It was also shown that Tck cells but not T cell receptor dependent stimulated T 
cells induced TNFα production in monocytes in an NF-κB dependent manner. 
Conversely, phosphatidylinositol 3-kinase (PI3K) inhibitors were found to block T 
cell receptor stimulated T cell activation of monocytes but did not affect Tck 
mediated monocyte activation indicating the different signalling mechanisms 
employed by the two differentially activated T cells [298]. Interestingly, RA 
synovial T cells were also found to employ the same signalling mechanisms as 
Tcks since the induction of TNFα in resting PB monocytes by synovial T cells was 
NF-κB dependent and were superinduced if PI3K was blocked [298]. These 
results provided evidence that the IL-2, IL-6, TNFα activated Tcks were similar 
to the synovial T cells found in RA and provided a basis for an in vitro model of 
inflammatory arthritis.  
Subsequent investigations have also substantiated this finding and provided 
evidence for the Tck cell contact activated macrophages as a model of arthritis. 
For example, the chemokines produced by M-CSF differentiated macrophages 
after contact with fixed Tck cells have been analysed and it was revealed that 
they produce several CC and CXC chemokines such as MCP-1, MIP-1α, MIP-1β, 
RANTES, IL-8, GROα and IP-10. Interestingly, blockade of NF-κB signalling 
through IκBα overexpression inhibits Tck and synovial T cell induced macrophage 
secretion of CXC but not CC chemokines, suggesting that RA synovial T cells 
share similarities in their effector function to Tck cells [308]. Subsequent 
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phenotyping of this Tck cell subset has revealed that they are a 
CD4+CD45RO+CCR7- CD49dhigh population of T cells. After IL-2, IL-6 and TNFα 
stimulation in culture these Tcks acquire an activated phenotype that resembles 
the phenotype of RA synovial T cells including the selective upregulation of 
adhesion molecules and integrins such as very late antigen 4(VLA-4) [309]. In 
summary, these investigations established the functional and phenotypic 
similarities between in vitro cytokine activated T cells (Tck) and RA synovial T 
cells and demonstrated the importance of the cell contact mediated activation 
of monocytes/macrophages as a surrogate model of RA. 
The modulation of T cell induced signalling in monocytes may be an important 
concept as it would maintain a low level of monocyte activation within the blood 
stream. Apolipoprotein (apo) A-I has been identified as a specific inhibitor of 
contact-mediated activation of monocytes [310]. Apo A-I is known as a negative 
acute phase protein and is one of the main proteins of high density lipoprotein 
(HDL). There have been several reports of variations of apo A-I concentration in 
inflammatory diseases [311] and in RA the levels of circulating apo A-I and HDL-
cholesterol in untreated patients were lower than in healthy controls [312]. 
Conversely, apo A-I levels were enhanced in the synovial fluid of RA patients 
[313]. 
This possible regulatory mechanism within the synovium may be overcome by a 
positive acute-phase protein which can displace apo A-I from HDL, known as 
serum amyloid A (SAA) [314]. SAA is produced in the liver but has also been 
detected in the RA synovium, HDL-associated SAA is a pro-inflammatory 
molecule and the expression of SAA can be increased by cytokines such as TNFα 
and IL-1β. This could therefore lead to a positive feedback loop of inflammation 
within the synovium as the cell contact dependent activation of synovial 
macrophages will induce the production of pro-inflammatory cytokines which 
will therefore increase the levels of SAA and consequently decrease the levels of 
Apo A-I. The decreased level of Apo A-I, which is an inhibitor of contact 
mediated monocyte activation, will thereby result in higher levels of monocyte 
activation and increased levels of pro-inflammatory molecules thus increasing 
the chronic synovial inflammation [314]. To try to further understand the role of 
HDL within T cell contact activation of monocytes Gruaz et al performed a 
microarray analysis of monocytes activated by the plasma membranes of fixed 
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PHA/PMA stimulated T cells in the presence or absence of HDL. The results of 
this study demonstrated that T cell activation of monocytes induced the 
upregluation of 437 probe sets in the monocytes including genes associated with 
the inflammatory response and inflammatory diseases. It was also shown that 
the addition of HDL to the monocytes at the time of T cell membrane activation 
was able to inhibit the expression of 164 (38%) of these probe sets which 
included probe sets specific for TNFα, IL-6, IL-1β, CCL4 and CCL3. Consequently 
this study substantiated the previous reports of the pro-inflammatory nature of T 
cell contact activation of human monocytes and the subsequent anti-
inflammatory capacity of HDL upon this cell contact model [315]. 
In summary, these studies have demonstrated that stimulated T cells have the 
ability to active monocytes and macrophages in an antigen independent but cell 
contact dependent manner. The method through which the T cells are 
stimulated can vary (see Table 1.7) and this variation can affect the products 
secreted by the monocytic cell. However it has been demonstrated that a 
particular stimulus consisting of a cocktail of cytokines can induce a T cell 
phenotype and activation pattern similar to that of RA synovial T cells. Due to 
the close proximity of T cells and macrophages within the RA synovium and the 
predominantly anti-inflammatory effect of T cell secreted cytokines the T cell – 
macrophage cell contact activation has been postulated to be a mechanism of 
increasing the pro-inflammatory cytokine and chemokine levels within the 
synovium. Therefore the cytokine cocktail method of T cell stimulation within 
the cell contact model has become an established in vitro method of 
investigating the role T cell – macrophage activation within arthritis.  
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1.3  Gene expression analyses in inflammatory 
arthritis 
As described in 1.1.1, the rheumatic diseases are a heterogenous group of 
disorders with a wide clinical spectrum and considerable variability in secondary 
organ involvement. Every aspect of this heterogenous disease phenotype should 
be represented in the pattern of genes and proteins which are expressed by the 
patient. This molecular signature will represent the contribution of the 
interactions between specific molecules and the individual cell types that are 
associated with disease characteristics and subtypes and thus will determine the 
samples‘ unique molecular biology. A powerful way to gain insight into the 
molecular signature contained within the cells and tissues of rheumatic diseases 
has arisen with the advent of DNA microarray technology, which can 
comprehensively identify the subset of genes which are differentially expressed 
among patients with clinically defined disease. There were initially several 
problems in the use of such technology, which requires highly standardised 
conditions, such as the lack of consistent methods for blood and tissue handling 
or preparation or the use of different platforms and standardisation procedures. 
However, after a decade of technical improvement the technology and 
standardisation procedures have been shown to be robust and allow comparison 
between properly designed and controlled experiments [316] thereby helping to 
unravel information that may aid in allowing clinicians to optimise treatment for 
and understanding further the complexity of rheumatic diseases. 
The resultant findings of microarray analyses performed in RA and PsA are 
summarised in Table 1.8. 
1.3.1.1 Rheumatoid arthritis 
1.3.1.1.1 Genetic analysis of affected tissues  
One of the first gene expression profiling studies for RA was conducted on biopsy 
tissue using high density cDNA arrays [317]. This report identified an increased 
expression of inflammation associated genes, such as HLA-DR, in the RA 
synovium compared to normal synovium. However, due to the investigators using 
pooled samples from three patients with RA and three healthy controls it was 
impossible to study the individual genetic profiles of the patients or the 
heterogeneity between samples. In contrast, a study set up by van der Pouw 
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Kraan analysing the genetic expression of the synovial tissue from RA (n=21) and 
OA (n=9) patients found the RA patients to be highly heterogenous in their 
genetic signatures [318, 319]. Interestingly, they identified two molecularly 
distinct forms of RA; the synovial tissue from one group of patients had an 
abundant expression of clusters of genes indicative of ongoing inflammation and 
involvement in the adaptive immune response. This subgroup was referred to as 
the RA high inflammation group. The second group, known as the low 
inflammation subgroup, contained expression profiles of tissue remodelling 
genes such as increased expression of MMP-11 and MMP-13 and low levels of 
inflammatory genes which was similar to the patterns seen in the OA tissue 
[318]. Analysis of the genes in the RA high inflammation subgroup indicated a 
prominent role of genes involved in activated IFN and the signal transducer and 
activator of transcription (STAT)-1 pathway [318]. It was determined by 
histological analysis that the difference obtained in the two subgroups of RA 
patients were related to differences in cell distribution, as tissues which 
contained germinal centre-like structures were those found in the high 
inflammation subgroup. 
A further study performed by Devauchelle et al analysed the differences in gene 
expression between the synovial tissue of RA (n=5) and OA (n=10) patients [320]. 
A set of 63 genes were identified based on their over- or under-expression in RA 
tissue compared to the OA tissue, 15 of these genes had unknown function but 
the expression of the remaining 48 genes allowed the correct classification of 
additional RA or OA patients therefore the authors proposed that such 
information could aid in the diagnosis of RA. Of interest, 16 genes from this 
study overlapped between the microarray performed by van der Pouw Krann and 
seven of these genes including the type I IFN regulated GBP1 and CTSL had 
comparable gene expression profiles indicating the ability to reproduce genetic 
results between different patient samples and different groups of investigators.  
Additional studies have also demonstrated that RA patients have significant 
tissue heterogeneity both between and within patient samples. A study 
performed by Tsubaki and colleagues [321] showed that early RA patients were a 
heterogenous group in comparison to patients with longstanding RA as the early 
RA patients could be subdivided into at least two different subgroups depending 
on their gene expression profiles. A similar study was performed in 2009 [322], 
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the synovium from 4 early RA patients, 4 treated longstanding RA patients and 7 
controls was analysed by microarray and it was found that distinct molecular 
signatures were expressed during early or longstanding RA suggesting that 
increased understanding regarding the main biological processes and pathways 
involved at each stage of the disease may help to decide the most appropriate 
therapy for the patients. An interesting study by Lindberg et al [323] 
investigated the variability in synovial gene expression at the biopsy site, 
between different sites and between patients. Multiple biopsy samples were 
taken from 13 patients; 7 by orthopaedic surgery and 6 by rheumatic arthroscopy 
and it was found that the number of differentially expressed genes between 
pairs of biopsies from the same knee ranged from 6 to 2,133 indicating the 
considerable level of heterogeneity between biopsy samples. The methods by 
which these samples were taken had a significant effect on the results since the 
number of differentially expressed genes between biopsies from the same 
patient was three times higher when the biopsies were taken by the orthopaedic 
method compared to the arthroscopic method which was thought to be due to 
sampling of non-inflamed tissue. Upon removal of biopsies which contained non-
inflamed tissue the remaining gene expression signatures were found to be 
unique to each patient but also contained groups of genes which belonged to 
gene ontology categories such as cell communication and immune response.  
Since the arrival of microarray studies which have analysed the diseased 
synovium of RA patients there has also been an increase in the number of studies 
which analyse the gene expression changes of the synovium in response to 
patient treatment. Lindberg and colleagues recently investigated the 
transcriptional profile of the synovium of RA patients treated with the anti-TNFα 
therapy infliximab in order to determine biomarkers which could be predictive 
of response to treatment [324]. This study found that within the 62 patients 
analysed no significant differences in genes expression could be detected 
between responders and non-responders to the infliximab treatment which 
therefore does not support the idea that microarray analysis of whole synovium 
biopsy specimens can be used to identify non-responders before the initiation of 
treatment.  
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1.3.1.1.2 Genetic analysis of blood derived cells  
Although the gene expression analysis of tissue samples of affected target organs 
offer insight into the genes principally involved in disease progression and 
activity, it may not be viable to use this approach to study all patients especially 
large cohorts. Consequently, several groups began to analyse the gene 
expression profiles of whole blood or peripheral blood mononuclear cells (PBMCs) 
to obtain disease related gene expression profiles since the systemic nature of 
RA allows the communication between systemic and organ specific 
compartments within the disease. In addition, understanding the gene 
expression of blood cells may allow the use of such profiles for biomarker studies 
and could also improve diagnosis and personalised therapy. 
One of the first microarrays analysing RA PBMCs took place in 2004 by Bovin and 
colleagues who examined the PBMCs from eight RF-positive RA patients, six RF-
negative patients and seven healthy controls [325]. No significant differences 
between RF-positive and RF-negative patients were detected. However, 
comparison of the gene expression pattern from all fourteen patients and the 
healthy controls identified a subset of 25 discriminative genes which included 
genes associated with the inflammatory response such as defensin alpha and 
CD14 antigen as well as the calcium binding proteins S100A8 and S100A12. 
Batliwalla and colleagues investigated the gene expression differences between 
PBMCs from RA patients (n=29) and those from healthy donors (n=21) [326]. 
Using cluster analysis they identified a significant alteration in the expression of 
81 genes in the PBMCs of RA patients compared to controls. A large number of 
these genes correlated with differences in the monocyte counts between the 
two study populations as many of the genes were known to be expressed at high 
levels in monocytes such as CD14 antigen. A logistic regression analysis revealed 
that of the remaining genes IL-1RA, S100A12, glutaminyl cyclase and Grb2-
associated binding protein (GAB2) were the top discriminator genes in 
categorising RA patients from controls.  
A further study performed by Edwards and colleagues analysing the RNA from 
the PBMCs of nine RA patients and thirteen healthy controls found 330 genes 
differentially expressed in RA [327]. These differentially expressed genes 
belonged to diverse functional classes and included genes involved in several 
biological groups such as transcription, signal transduction, extracellular matrix, 
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cytokines, enzymes and proteases. Interestingly, ten genes which had an 
increased expression in RA PBMCs compared to healthy controls mapped to an RA 
susceptibility locus, 6p21.3 which the investigators hypothesised could be a 
mechanism contributing to the etiology of the disease through the coordinated 
transcription of specific regions of a chromosome in response to stress or 
inflammation. A study performed by Junta et al evaluated the differential gene 
expression profile of PBMCs of RA patients and their association with the HLA 
shared epitope (HLA-SE), anti-CCP antibody levels, DAS-28 score and disease 
treatment [328]. This research demonstrated that thirteen genes were 
exclusively associated with the presence of HLA-SE alleles whose major functions 
were related signal transduction, apoptosis and signal transduction. One hundred 
and one genes were associated with the presence of anti-CCP antibodies, 91 
genes were associated with disease activity including genes involved in DNA 
damage, signal transduction and response to stress and finally 28 genes were 
associated with TNF blockade treatment which included genes involved in 
protein transport and intracellular signalling.  
In 2007, van der Pouw Krann and colleagues published a paper investigating the 
gene expression profiles of whole blood from RA patients (n=35) and healthy 
controls (n=15) [329]. The microarray data confirmed previous observations of 
increased expression of genes such as the S100A8 and S100A12 calcium-binding 
proteins. Pathway analysis software identified the increased expression within 
RA patients of immune defense genes including the type I IFN response genes 
indicating that this pathway is activated systemically in RA. A separate study 
comparing RA PBMCs to those of controls identified a spectrum of genes involved 
in immunity and defense to be upregulated in the RA patients once again 
demonstrating that such immune pathways are upregulated systemically in RA 
[330]. 
In addition to microarray analyses being performed on synovial biopsies from 
patients before and after therapeutic intervention there have also been a 
number of recent studies evaluating the effect of different treatments on the 
gene profile of PBMCs. Since a significant percentage of patients fail to show a 
clinical response to treatment, designated non-responders, the main focus of 
such microarray studies has been to determine molecular discriminators of 
response in patients. One study which obtained blood from patients before 
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starting the TNFα blockade therapy infliximab identified an eight-gene 
expression profile that was able to predict the patient response to the treatment 
as either a responder or non-responder [331]. This profile, which included the 
genes HLA-DRB3 and TLR5, was able to predict response of an independent 
validation set of RA patients with 85.7% accuracy. Another study looking at 
molecular discriminators of response to the anti-TNFα therapy etanercept found 
certain genes which when expressed in groups of two or three could have 89-95% 
prediction accuracy [332]. Finally, a microarray analysis of PBMCs taken from 
patients before the commencement of the IL-1Ra therapy anakinra identified 52 
genes which were expressed as a response to treatment [333]. Seven of these 
transcripts, as assessed by quantitative RT-PCR, were able to predict 15 of 18 
independent responder and non-responder patients with an accuracy of 87.5%. In 
conclusion, the emergence of such modelling systems could aid the clinician in 
the selection of the optimal treatment strategy for RA patients and has strong 
application potential within the clinical setting.  
1.3.1.1.3 Gene analysis within cell subsets 
The analysis of synovial biopsies and PBMCs from RA patients has been extremely 
useful in identifying patterns of gene expression within the disease and the 
response of patient tissues to treatment. However, it has been suggested that 
some of the genetic signatures identified in such studies may be attributable to 
differences in the relative abundance of individual cell populations within the 
sample. In addition cell-specific changes may be missed when analysing a mixed 
population of cells. Consequently, several groups set out to investigate the 
genetic signatures of individual cell populations within RA patients.  
Fibroblast-like synoviocytes (FLS) are considered to play a major role in joint 
destruction in RA and also contribute to leukocyte migration into the joint. One 
of the first gene expression profiles of RA FLS revealed the over-expression of 
genes responsible for tumour like growth of rheumatoid synovium [334]. This 
study used a cDNA array containing 588 cDNA-fragments of known cancer related 
genes to compare the gene expression of FLS from five RA patients and five 
traumatic control patients and found the increased expression of such cancer-
related genes in the RA FLS. An additional study analysing the genetic expression 
of 19 RA FLS samples correlated the genetic data to that of paired synovial 
tissue samples and found that the heterogeneity at the synovial tissue level was 
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associated with a specific FLS phenotype [335]. The high inflammation tissues 
were associated with an FLS subtype that exhibits similarity with a fibroblast cell 
called myofibroblasts. The myofibroblast cells are specialised cells that have a 
key role in connective tissue remodelling and cell infiltration. Addition studies in 
oncology have demonstrated that these cells play a crucial role in angiogenesis 
through the production of growth factors and extracellular matrix proteins. 
Therefore these myofibroblast-like FLS in RA synovium are thought to contribute 
to the tissue destruction and angiogenesis which is often seen in this disease.   
Szodoray and colleagues used a genome scale microarray to identify 
differentially regulated genes in peripheral blood B cells from eight RA patients 
with early disease compared to eight healthy controls [336]. They discovered 
that 305 genes were overexpressed in RA B cells and 231 genes were 
underexpressed compared to controls. Clusters of functionally associated 
networks were analysed and five biological classes were defined: autoimmunity; 
cytokines; cell activation and apoptosis; neuro-immune regulation and 
angiogenesis. A microarray analysis has also been performed on isolated CD4+ T 
cells, the study by Li et al analysed the microRNA (miRNA) profile of CD4+ T cells 
isolated from the synovial fluid of RA patients compared to CD4+ T cells isolated 
from healthy controls [337]. Analysis of the results demonstrated that miR-146a 
was upregulated in SF CD4+ T cells whilst miR-363 and miR-498 were 
downregulated. Subsequent studies indicated that miR-146a overexpression 
suppressed T cell apoptosis since one of the genes it regulated was Fas 
associated factor 1 (FAF1) and therefore the upregulation of this miR could 
promote the long-term survival of the pathogenic T cells.  
There is also one microarray gene expression study that has been performed 
specifically on monocytes from RA patients, Stuhlmüller et al compared 
monocytes from the first leukapheresis pool (activated cells) and third 
leukapheresis pool (nonactivated cells) of 26 RA patients undergoing 
leukapheresis treatment to identify known and novel genes in the activated 
monocytes [338]. This analysis identified 482 differentially expressed genes 
between the first and third pools, the activated monocytes were found to 
express inflammatory genes such as IL-1β, IL-6 and TNFα whilst the nonactivated 
monocytes expressed differentiation and transcription genes such as PU.1. 
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Despite the enormous advances in the field of transcriptomics and microarray 
analyses there appears to be very few studies investigating the genetic signature 
of individual cell types within arthritis which could be masked in a full scale 
microarray of whole blood or synovium. Since individual cell types are known to 
play diverse roles in the pathogenesis of arthritis understanding the genetic 
signal of the different activated cell types may aid in unravelling the causes and 
different treatment mechanisms of this disease. 
1.3.1.2 Psoriatic arthritis  
In comparison to the vast amount of microarray analysis that has been 
performed on RA patients there has been a paucity of research into the genetic 
signature of PsA. In addition, there has been a great deal of progress into 
identifying the genetic phenotype of psoriasis but very few studies analysing the 
arthritis that will often accompany or follow this condition have been 
performed. One of the few microarray studies analysing PsA took place in 2002, 
Gu and colleagues investigated the genetic profiles of PBMCs from RA patients 
(n=6), spondyloarthropathy (SpA) patients (n=7) and PsA patients (n=6) compared 
to healthy controls (n=7). They established an upregulation of several genes in 
the three types of arthritis in comparison to healthy controls including those 
coding for chemokine receptors (CCR1 and CXCR4), cytokines (IL-1β) and the 
signalling molecules JAK3 and MAP kinase p38 [339]. They also found an 
upregluation of the chemokine receptor CXCR4 in the three arthritis groups, the 
ligand for CXCR4 is SDF-1 and levels of this chemokine were detected in the SF 
of the SpA and RA patients. Since SDF-1 is a chemokine for lymphocytes and 
monocytes it was suggested to be potentially important pro-inflammatory 
mediator within the pathogenesis of RA, SpA and PsA. 
Despite the interesting observations of the above study, due to the method by 
which they grouped the microarray results together for all three different 
arthritis subsets it proved difficult to discriminate the specific gene profile of 
the PsA patients. However, two subsequent studies used microarray technology 
to compare the PBMCs of PsA patients to those of healthy controls. The first 
study performed by Batliwalla and colleagues analysed the gene expression 
signature of peripheral blood cells from 19 PsA patients compared to that of age 
and sex matched healthy donors [340]. They found that 257 genes were 
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expressed at a lower level in PsA patients and 56 genes were expressed at a 
higher level in comparison to controls. The genes that were downregulated in 
the PsA patients were found to be involved in the suppression of innate and 
acquired immune mechanisms suggesting that these cells favoured a pro-
inflammatory response. Pro-inflammatory genes such as S100A8 and S100A12 
demonstrated increased expression in the PsA samples. In addition, using a 
dataset of RA samples for comparison it was found that the combination of two 
genes MAP3K3 and CACNA1S could correctly classify the RA patients and PsA 
patients. Therefore this gene expression profiling was able to differentiate PsA 
from control subjects and PsA from RA patients indicating that PsA has a 
distinctive blood cell gene expression pattern. Stoeckman et al also performed a 
similar microarray analysis comparing the PBMCs of PsA patients to those of age 
and sex matched healthy controls and discovered that 310 genes were 
differentially expressed with the majority being upregulated in PsA [341]. It was 
also found that this differential gene expression profile did not overlap with 
those of RA or SLE patients and that individual genes, such as ZNF395, had high 
discriminatory potential for disease diagnosis indicating that PsA patients had a 
unique gene expression profile which could reveal novel disease markers. 
At present these three microarray analyses are the only studies to be performed 
investigating the gene expression pattern of PsA. There have been no studies 
into the gene expression of synovial tissue or individual cell subsets and the 
effect of different drug therapies on the genetic signatures of diseased cells, 
which has been very informative in the field of RA, have not been performed. As 
a result very little is known about the transcriptomics of PsA and therefore more 
investigation is required in this field in order to gain more information into the 
pathogenesis of this disease and to aid clinicians in deciding the optimal therapy 
for the patients. 
See Table 1.8 for a summary of the gene expression studies performed in RA and 
PsA. 
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 Table 1.8 Genomic studies in RA and PsA 
Disease Tissue  Number of   Approx number Comparison   Results    Ref. 
    samples  of genes on array 
 
RA  Synovium 21 RA and 9 OA 11,500 and 18,000 Within RA and versus  Evidence for the existence of [318, 319] 
          OA    multiple pathways for tissue 
              destruction 
                
RA  Synovium  5 RA and 10 OA  5,760  RA versus OA   Differentially expressed genes  [320] 
              between RA and OA  
 
RA   Synovium  12 early and 4 late  23,040  Early versus longstanding Early RA fell into two groups  [321]  
          RA    dependent on the expression  
              of genes critical for proliferate 
              inflammation 
 
RA  Synovium 4 early untreated,  10,000  Early RA versus LS RA, Early and LS RA have separate [322] 
    4 treated     early RA versus healthy, molecular signatures with distinct 
    longstanding, 7     LS RA versus healthy  biological processes participating  
    controls         during the course of disease 
 
RA  Synovium 13 RA. 7 biopsies   46,000  Biopsies from the same There is a substantial level of [323]   
    obtained by     patient compared,   heterogeneity between pairs of  
    orthopaedic sampling,   orthopaedic versus  patient samples. Orthopaedic 
    6 by arthroscopy    arthroscopy   biopsies are unsuitable for gene 
expression analysis 
 
RA   Synovium 62 patients before  17,927  Treatment responders No difference between responders [324]  
infliximab treatment    versus non-responders and non-responders was detected therefore  
synovial biopsy samples may not be  
appropriate to identify non-responders to 
infliximab treatment 
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Table 1.8 continued               
 
RA  PBMCs  8 RF+, 6 RF-, 7   10,000  RF+ versus RF- and  No differentially expressed genes  [325] 
    healthy controls    versus healthy control between RF+ and RF- patients.  
              Increased expression of  
immunoinflammatory response 
              genes in RA 
 
RA  PBMCs  29 RA and 21   12,626  RA versus HC   Monocyte associated gene  [326] 
    healthy controls        signature increased in RA 
 
RA  PBMCs  9 RA and 13    6937  RA versus HC   Diverse functional subsets of  [327]  
    healthy controls        genes were differentially expressed  
              between RA and HC samples. Ten  
              genes with increased expression in  
RA PBMCs mapped to RA susceptibility  
locus 6p21.3 
 
RA  PBMCs  23 RA    4500  Comparison between  Different numbers of genes were [328] 
          patients according to  exclusively associated with each 
          anti-CCP level, DAS-28, disease variable  
          HLA-shared epitope  
          presence and treatment 
          type 
 
RA  Whole blood 35 RA and 12   18,000  within RA and versus HC Assignment of a type I IFN   [329] 
    healthy controls        signature in a subpopulation 
              of patients 
 
RA  PBMCs  18 RA and 15   48,701  RA versus HC   Elevated expression of genes  [330] 
    healthy controls        associated with immunity and 
              defense in RA patients 
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RA  Whole blood 44 RA before   47,000  treatment responders An 8-gene expression profile  [331] 
    infliximab treatment    versus non-responders was able to predict treatment response 
 
RA  PBMCs  19 RA    18,500  Before versus 72 hours Gene pairs and triplets predictive  [332] 
          after etanercept  for response to treatment at an 
              early stage of treatment 
 
RA  PBMCs  32 RA before   12,000  treatment responders A 52-gene expression profile  [333] 
    anakinra treatment    versus non-responders was demonstrated to predict 
              treatment response  
 
RA  FLS  5 RA and 5 HC   588  RA versus HC   Increased expression of genes  [334] 
              responsible for tumour-like growth 
              in RA FLS 
 
RA   FLS  19 RA    18,000  Within RA   The heterogeneity between   [335]  
              synovial tissue is reflected in the FLS 
 
RA  B cells  8 RA and 8 HC   21,329  RA versus HC   B cell biology in RA is disregulated [336] 
              due to the differential expression of 
              multiple biological pathways 
 
RA  CD4 T cells 2 RA and 1 HC   47,000  RA SF versus   RA CD4+ cells overexpress  [337] 
          HC PB CD4+ cells  micro-RNA‘s which help promote the 
              long term survival of the T cells 
 
RA  Monocytes  29 RA    482  Monocytes from first  Activated monocytes from first  [338] 
          leukapheresis compared leukapheresis pool had and increased 
          to monocytes from third expression of pro-inflammatory genes 
          leukapheresis pool 
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PsA  PBMCs  6 RA, 7 SpA,   588  Three forms of arthritis The three forms of arthritis similarly [339] 
    6 PsA, 7 HC     versus HC   upregulate pro-inflammatory 
              molecules in comparsion to HC 
 
 
PsA  PBCs  19 PsA, 19 HC   22,215  PsA versus healthy  Downregulated genes in PsA   [340]  
              compared to HC consisted of genes 
associated with suppression of 
              immune mechanisms 
               
PsA  PBMCs  16 PsA, 15 HC   54,000  PsA versus healthy  PsA genetic profiles showed no  [341] 
              overlap with RA or SLE profiles 
              and were distinct from control profiles 
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2.1 Patients and controls 
RA and PsA patients who fulfilled the American College of Rheumatology criteria 
for RA [6] or met diagnostic criteria for PsA [8] were identified from the 
Rheumatology Clinics in Glasgow Royal Infirmary (GRI) and Glasgow Gartnavel 
Hospital (GGH) and were invited to take part in the study. All patients and 
healthy donors gave informed consent and the study protocol was approved by 
the Ethical Committee, Glasgow Royal Infirmary, Scotland. 
2.2  Cell Culture 
2.2.1 Primary Human Cell Culture 
All tissue culture work was performed in laminar flow hoods and all cells were 
cultured at 37oC, 5% CO2 in RPMI-1640 medium (Invitrogen) containing L-
glutamine (2 mM), penicillin (100 IU/ml), streptomycin (100 μg/ml) and 10% 
foetal calf serum (complete medium). 
2.2.2 Purification of mononuclear cells from buffy coats and 
peripheral blood 
Peripheral blood mononuclear cells (PBMC) were purified by standard density 
gradient centrifugation. Briefly, blood was obtained from either single donor 
plateletpheresis residues donated by Gartnavel blood bank or from healthy 
donors. The blood was then diluted 1:1 in phosphate buffered saline (PBS) 
(Invitrogen) and 10 mls were overlaid on 4 mls Histopaque®-1077 (Sigma) in 15 
ml centrifuge tubes. Tubes were centrifuged at 350 g for 20 minutes at room 
temperature. The mononuclear cells were then harvested from each tube and 
washed three times at 200 g for 5 minutes in ice cold PBS containing 2 mM 
ethylene diamine tetra-acetic acid (EDTA) and 0.5% human serum albumin, (PEA) 
before cell purification. 
2.2.3 Purification of mononuclear cells from synovial fluid  
Before the mononuclear cells were isolated from patient synovial fluid (SF) the 
fluid was centrifuged for at 350 g for 20 minutes in order to pellet the cells. The 
cell free synovial fluid was collected and stored at -700C. The pellet of cells 
from the synovial fluid was resuspended in PEA before being overlaid on 4 mls 
Histopaque®-1077 and centrifuged at 350 g for 20 minutes. The mononuclear 
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cells were then harvested and washed three times in PEA before cell 
purification. 
2.2.4 Isolation of CD3+ T cells and CD14+ monocytes 
CD3+ T cells and CD14+ monocytes were purified by positive selection from 
mononuclear cell suspension by autoMACS, according to the manufacturer‘s 
instructions. Briefly, mononuclear cells were incubated in 90 μl/107 cells PBS/2 
mM EDTA/0.5% human serum albumin (PEA) containing 10 μl/107 cells anti-CD3-
conjugated magnetic microbeads (Miltenyi Biotec), or 10 μl/107 cells anti-CD14-
conjugated magnetic microbeads (Miltenyi Biotec) for 15 minutes at 4oC. After 
washing in ice cold PEA by centrifugation at 200 g for 5 minutes CD3+ T cells or 
CD14+ monocytes were isolated by positive selection using the possel programme 
on the autoMACS machine. The positive cell fraction was put through the 
machine twice on possel programme to ensure a higher purity. Purity was 
assessed by flow cytometry and routinely >95%. 
2.2.5 CD3+ T cell and CD14+ monocyte stimulation 
CD3+ T cells were purified by positive selection from peripheral blood and 
activated for 6 days in complete medium containing IL-2 (25 ng/ml), IL-6 (100 
ng/ml) and TNF-α (25 ng/ml) (all from Biosource), in order to produce an 
activated phenotype similar to that displayed in the synovium [309]. CD14+ cells 
were purified by positive selection from the same peripheral blood and cultured 
in 96, 24 or 12 well plates depending on the experiment at 5x105 cells/ml in 
complete medium supplemented with 50 ng/ml M-CSF (Biosource). These cells 
were then incubated for 6 days at 370C. 
2.2.6  T cell / macrophage cell contact 
After 6 days in culture the cytokine activated T cells (Tcks) were washed three 
times in PEA and either fixed in PBS/2% paraformaldehyde on ice for 2 hours, or 
not (as indicated), and added back to the macrophage culture at a ratio of 4:1. 
This culture was incubated at 370C for between 1 to 24 hours depending on the 
experiment. 
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2.3 Flow cytometry 
2.3.1 Assessment of cell purity 
All samples which were isolated on the autoMACS were analysed for purity by 
Flow cytometry. After positive selection cells were washed in PEA and 
resuspended at a concentration of 1 x 106 cells/ml. 100 μl of cells was added to 
two clean FACS tubes, one for the isotype control and one for the antibody 
staining. For purity checks the following antibodies were used (all from BD 
biosciences): 
Tube 1. Isotype IgG FITC, IgG APC 
Tube 2. CD14 FITC, CD3 APC 
5 μl of each antibody was added to the tube and the cells were incubated at 
room temperature for 15 minutes in the dark. The cells were then washed with 
PEA and the supernatant discarded. If the cells were to be analysed immediately 
they were resuspended in 200 μl PEA or if they were to be analysed the following 
day they were resuspended in 200 μl FACS FIX (2% paraformaldehyde in PBS). The 
cells were analysed on a FACS Calibur (BD Biosciences) using Cell Quest 
software™. When assessing the purity of the samples, an analysis gate was set to 
ensure that within the isotype control sample <2.5% of the cells were positive 
for FITC or APC staining. 
2.3.2 Semaphorin 6D staining 
Surface and intracellular semaphorin 6D staining was assessed on Tck cells and 
CD3/CD28 activated cells after 0, 3 and 6 days of activation. 
T cells were obtained from donor blood packs as described in 2.2.4 and half of 
the T cells were stimulated with IL-2, IL-6 and TNF-α as described in 2.2.5 for 3 
and 6 days to produce Tcks. The remainder of the T cells were stimulated with T 
cell activation expansion kit cytostim beads (Miltenyi Biotec) according to the 
protocol. Briefly, the MACSibead particles were loaded by pipetting 100 μl each 
of CD2-biotin, CD3-biotin and CD28-Biotin into a 1.5 ml eppindorf and mixing. 
500 μl of Anti-biotin MACSibead particles (1 x 108 Anti-biotin MACSibead 
Particles) were added to the antibody mix with 200 μl of PEA and the mixture 
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was incubated for 2 hours at 40C under constant, gentle rotation. Once the Anti-
Biotin MACSibead particles were loaded they were stored at 40C until required. 
To activate the T cells with the Anti-Biotin MACSibead particles 25 μl of beads 
per 5 x 106 T cells were resuspended in 100 μl complete culture medium and 
centrifuged at 300 g for 5 minutes after which time the beads were resuspended 
in 100 μl complete medium. The T cells were resuspended at a density of 5 x 106 
cells per 900 μl of complete medium and the 100 μl of beads were added. The 
cells were cultured in 24 well plates at a concentration of 2.5 x 106 cells per 
well for 3 and 6 days. In order to remove the beads before the FACS staining 
commenced the T cells were extracted from the plate and washed before being 
resuspended in PEA and vortexed thoroughly. The cells were then placed in an 
easystep magnet (Stemcell) for 2 minutes and the supernatant containing the 
activated T cells was removed and the process was repeated again. Once all the 
beads had been removed from the cells they were washed twice in PEA buffer 
and stained for semaphorin 6D.  
The following protocol for intracellular and surface staining of semaphorin 6D 
was used to stain unactivated T cells at day 0 and the Tcks and CD3/CD28 Anti-
biotin MACSibead after 3 and 6 days of activation. 
2.3.2.1 Surface staining Semaphorin 6D 
T cells were washed and approximately 1 x 106 cells were put into each FACS 
tube. 10 μl of Fc block (Miltenyi Biotec) was added to each tube and the cells 
incubated for 5 minutes at 40C. The cells were washed in PEA at 200 g for 5 
minutes and 5 μg of semaphorin 6D antibody (MAB2095, R&D) or 5 μg of 
irrelevant antibody (CD68 mouse anti human DAKO) was added to the tubes 
before being incubated for 20 minutes at 40C. The cells were washed in PEA and 
6 μl of goat F(ab‘)2 anti-mouse IgG APC secondary antibody (F0101B, R&D) was 
added to the cells for 10 minutes at 40C before being washed again. CD4 FITC or 
isotype FITC (BD bioscences) was added to the relevant FACS tubes for 15 
minutes at 40C and the cells were washed a final time before being resuspended 
in 300 μl PEA and analysed on the FACS Calibur. 
2.3.2.2 Intracellular staining of semaphorin 6D 
T cells were washed and approximately 1 x 106 cells were put into each FACS 
tube. 10 μl of Fc block (Miltenyi Biotec) was added to each tube and the cells 
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incubated for 5 minutes at 40C. The cells were washed in PEA at 200 g and 100 μl 
of cytoperm (BD biosciences) was added for 20 minutes at 40C, after this time 50 
μl of permwash (BD Biosciences) was added to the cells which were then spun at 
200 g for 5 minutes. The cells were then resuspended in 100 μl of 2% goat 
serum/perm wash and incubated at 40C for 20 minutes; 5 μg of semaphorin 6D, 
CD68 or mouse IgG1 was added directly to the cells in 2% goat serum/perm wash 
and incubated at 40C for 20 minutes. After this time 500 μl of permwash was 
added to the cells which were then spun at 200 g for 5 minutes. The cells were 
resuspended in 100 μl of permwash and 5 μl of goat anti-mouse APC (Invitrogen) 
was added before the cells were incubated at 40C for 10 minutes. For the final 
step the cells were washed in permwash and resuspended in 200 μl permwash 
before being analysed on the FACS Calibur. 
2.4 Enzyme-linked-immunosorbent assay (ELISA)  
ELISA was used to measure concentration of human IL-6 and TNFα in cell culture 
supernatants. The concentrations of antibodies and buffers used for each ELISA 
are shown in Table 2.1. 
96 well plates (Thermo Labsystems) were coated with detection antibody in PBS 
and incubated overnight at 40C. The plates were then washed with 0.05% 
PBS/Tween followed by the addition of blocking buffer (0.5% BSA/PBS) to block 
non-specific binding and incubated at 370C for 1 hour. An eight point standard 
curve was made using recombinant human cytokine dissolved in complete media 
at a top standard of 2000 pg/ml and serially diluted 1:2. 100 μl of each standard 
was added in duplicate to the plate along with two wells containing only 
complete media. Samples were then diluted 1:2-4 with complete media (donor 
dependant) and 100 μl transferred to each well. The plates were covered and 
incubated for 2 hours at room temperature. The plates were washed several 
times in 0.05% PBS/Tween followed by addition of secondary antibody and 
incubated at 370C for 1 hour. After incubation the plates were washed and 100 μl 
TMB chromagen (Biosource) was added to each well. The reaction was stopped 
by addition of 100 μl stop solution (Biosource) and the intensity of the signal was 
read at 450 nm on a microplate reader (Dynex Technology). 
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Cytokine Concentration 
of primary 
antibody 
Concentration 
of secondary 
antibody 
Streptavidin 
HRP dilution 
Kit supplier 
TNFα 
 
IL-6 
2 μg/ml (100 
μl/well) 
2 μg/ml (100 
μl/well) 
1.5 μg/ml 
(100 μl/well) 
1.5 μg/ml 
(100 μl/well) 
1:1250 
 
1:1250 
Invitrogen 
 
Invitrogen 
Table 2.1 Cytokine analysis by ELISA 
 
2.5 Microarray  
2.5.1 Collecting and preparing samples for microarray 
All CD14+ blood and synovial fluid samples were collected by density gradient 
centrifugation and magnetic bead positive selection as described in 2.2.2 and 
2.2.3. An aliquot of each sample was taken to check for cell purity and the 
sample was lysed in trizol (Invitrogen) (2x106 cells/ml trizol) and stored at -700C.  
2.5.2 Isolating cells using the FACS ARIA 
For the cell contact activated macrophages the following protocol was used. 
Cytokine activated T cells (Tcks) were washed three times in PEA, CFSE 
(Invitrogen) dye was made up in Hank‘s buffered salt solution (HBSS) media 
(Invitrogen) at a concentration of 10 μM and 1 ml was added to the Tcks before 
incubating for 10 minutes at 370C. Tcks were washed three times in PEA and 
then fixed in PBS/2% paraformaldehyde on ice for two hours. After washing 
three times in PEA the fixed CFSE stained Tcks were added to macrophages in a 
24 well plate at a 4:1 ratio and left in cell contact for 2 hours. Following the 2 
hour cell contact the supernatant was collected and retained for cytokine 
analysis by ELISA and 0.5 ml cell dissociation solution (Sigma) was added to each 
well. The plate was incubated for 15 minutes at 370C to remove the adherent 
macrophage cells. Any remaining cells that were seen to be still adhering to the 
plate on inspection under a brightfield microscope were incubated with 
additional cell dissociation solution. All of the cell suspensions were washed in 
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PEA and pooled together for isolating on the FACS ARIA. The two cell fractions of 
macrophages and fixed CFSE stained Tcks were separated on the basis of FITC 
positive and FITC negative therefore all the FITC negative cells were believed to 
be macrophages. Cells were counted as they were being separated on the FACS 
ARIA and cell fractions were lysed in Trizol (2 x 106 cells/ml Trizol) and stored at 
-700C. 
A small aliquot of each cell fraction was taken for cytospins to ensure we had 
collected the correct cell type in each fraction.  
2.5.2.1 Cytospins 
An aliquot of cells isolated from the FACS ARIA were resuspended at a 
concentration of 0.5 x 106 cell/ml in PEA. Glass slides were labelled and placed 
into the metal holders with a piece of filter paper and a cuvette, 200 μl of the 
cell suspension was loaded into the cuvette and the cells were spun at 350 rpm 
for 6 minutes. The slides were then removed and the cuvette was carefully 
detached to avoid damaging the smear of cells. The cells were immediately 
stained with RAPI-DIFF reagents (Ready reagents). The slides were placed in a 
Coplin jar containing solution A for 15 seconds and then placed in a Coplin jar 
containing solution B for 15 seconds finally the slides were washed twice in 
Phosphate buffer pH 6.8 for 10 seconds and then left to dry before being imaged 
on a light microscope. 
2.5.3 Manual RNA Isolation from Trizol 
The cells isolated from the cell contact experiments and patient samples were 
stored in Trizol and transferred to GlaxoSmithKline (GSK) in Stevenage for mRNA 
extraction. QIAgen mini columns were used for the RNA clean-up with an 
incorporated on column DNAse step. Briefly, 200 μl of chloroform was added to 
each epindorff of cells containing 1 ml of Trizol and centrifuged at 12,000 g for 3 
minutes. The aqueous supernatant was removed to a clean epindorff and an 
equal volume of 70% ethanol added. This solution was applied to a QIAgen 
RNeasy mini-column and the protocol supplied with the QIAgen kit was followed 
to extract the RNA. Briefly, the RNeasy column was centrifuged at 13,000 g for 
30 seconds at room temperature and the flow through discarded. The sample 
was then washed by adding 700 µl of solution RWT and the column was spun at 
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13,000 g for 1 minute at room temperature and the flow through was discarded. 
A DNase-1 stock solution (Qiagen) was prepared in 550 µl RNase-free water and 
10 µl of this solution was added to 70 µl buffer RDD. 80 µl of DNase-1/RDD buffer 
was pipetted onto each column and incubated at room temperature for 15 
minutes. Following this step 500 µl of buffer RW1 was added to each column 
which was subsequently spun at 12,000 g for 1 minute. The sample was then 
washed twice by adding 500 µl of solution RPE and spinning the column at 13,000 
g for 1 minute. The column was then transferred to an RNase-free microfuge 
tube and 35 µl of RNase-free water was added to the column making sure the 
liquid was centred on the membrane. The sample was allowed to stand for 1 
minute to allow the RNA to dissolve into the water and the microfige tube was 
spun for 1 minute at 13,000 g. The RNA sample was then re-pipetted onto the 
column membrane and allowed to stand for 1 minute in order to increase RNA 
yield before being centrifuged at 13,000 g for 1 minute. All RNA samples were 
subsequently stored at -70ºC. 
The concentration of each RNA sample was measured on a nanodrop 
spectrophotometer and the quality of the RNA was analysed on an Agilent 2100 
bioanlyser using the agilent RNA 6000 pico kit (Agilent Technologies). When using 
the Agilent bioanalyser the sample RNA was diluted to 5 ng/ml in deionised 
water before being put on the pico chip for analysis.  
RNA was then diluted to 10 ng/μl using water on a Beckman Coulter Biomek FX 
machine. 5 μl of this RNA was transferred to a 96 well cone plate (Greiner) for 
amplification. 
2.5.4 Single strand cDNA amplification 
Single strand amplification was performed using NuGEN RNA amplification 
system V2. 
2.5.4.1 First strand cDNA synthesis 
For the primer annealing stage 2.5 μl of A1 primer was added to each 5 μl RNA 
sample and the 96 well plate was placed in a thermal cycler for 5 minutes at 65 
ºC. After this time the samples were removed and snapcooled by placing them 
on ice. 
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The first strand master mix was prepared as follows (volumes listed are for a 
single sample) 
First strand buffer mix   12 μl 
First strand enzyme mix   1 μl 
Total Volume    13 μl 
 
13 μl of the first stand master mix was added to each sample and the samples 
placed in a thermal cycler programmed to run as follows: 
Incubate at 48ºC for 60 minutes 
Heat at 70ºC for 15 minutes 
Cool to 4ºC  
Once the temperature had reached 4ºC the plate was removed from the thermal 
cycler and spun in a centrifuge to collect condensation before being placed on 
ice. 
2.5.4.2 Second strand cDNA synthesis 
The second strand mastermix was prepared as follows (volumes listed are for a 
single sample) 
Second strand buffer mix (B1)   18 μl 
Second strand enzyme mix (B2)  2 μl 
Total Volume     20 μl 
 
A multichannel pipette was used to add 20 μl of second strand master mix to 
each well containing the first strand reaction mixture in the 96 well plate. The 
plate was briefly centrifuged for 2 seconds to remove air bubbles before being 
placed in a pre-warmed thermal cycler set to the following programme: 
Incubate at 37ºC for 30 minutes 
Continue heating at 75ºC for 15 minutes 
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Cool to 4ºC 
Once the programme had completed the plate was removed from the thermal 
cycler and spun briefly before being placed on ice. 
2.5.5 SPIA™ amplification 
The SPIA mastermix was prepared as follows (volumes are listed for a single 
sample): 
SPIA buffer mix (C2)  72 μl  
SPIA primer mix (C1)   2 μl 
Water      4 μl 
SPIA enzyme mix (C3)  40 μl 
Total Volume    118 μl 
 
A multichannel pipette was used to add 118 μl of the SPIA mastermix to each 
well of the 96 well plate containing the second strand reaction mixture. The 
plate was briefly centrifuged before being placed in a thermal cycler 
programmed to incubate the samples at 48ºC for 30 minutes. After this time a 
further 6 μl of SPIA primer mix (C1) was added to each well of the 96 well plate 
containing the SPIA reaction mixture. The 96 well plate was centrifuged for 2 
seconds and placed back into the thermal cycler to run on the following 
programme: 
Incubate 48ºC for 30 minutes 
Continue heating at 95ºC for 5 minutes 
Cool to 4ºC 
The plate was removed from the thermal cycler and centrifuged for 2 seconds 
before being placed on ice. 
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2.5.6 Purification of amplified cDNA 
Purification of the amplified cDNA is required if it is intended for fragmentation, 
labelling and GeneChip array analysis. All amplified cDNA was purified according 
to the Agencourt RNAClean magnetic beads protocol. 
The magnetic beads were resuspended by gently agitating the RNAClean bottle 
before being dispensed into a clean reagent reservoir. 288 μl of beads were 
added to one matrix tube per sample. The amplified cDNA sample (160 μl) was 
then pipetted into a matrix tube and incubated at room temperature for 10 
minutes to allow the cDNA to bind to the magnetic beads.  
A round bottomed 96 well plate was placed onto the plate magnet and for each 
sample half of the bead/cDNA mixture (220 μl) was added into each well and 
incubated for 10 minutes at room temperature. After this time the supernatant 
was carefully removed and discarded using a multichannel pipette.  
The remaining 220 μl of bead/cDNA mixture was added to the same wells and 
again the plate was incubated for 10 minutes at room temperature before 
removing the supernatant from the wells.  
Each sample was washed by dispensing 200 μl of 80% ethanol to each well for 30 
seconds after which time the ethanol was removed and discarded. This step was 
repeated ensuring that all ethanol was removed before leaving the samples to 
air dry for 2 minutes.  
34 μl of water was added to each sample on the plate and the plate was left 
undisturbed for 5 minutes, after this time the plate was tapped gently to mix 
and left for another 5 minutes. The plate was then placed onto the magnet and 
incubated for 10 minutes.  
The cDNA concentration of each sample was measured on a nanodrop 
spectrophotometer and the quality of the cDNA was analysed on an Agilent 2100 
bioanlyser using the agilent RNA 6000 pico kit. When using the Agilent 
bioanalyser the sample cDNA was diluted to 5 ng/ml in deionised water before 
being put on the pico chip for analysis. 
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2.5.7 Fragmenting and biotin labelling of the amplified cDNA 
For fragmenting and labelling, 5 μg of cDNA in a total volume of 25 μl was used. 
Fragmenting and labelling was performed using the FL-Ovation™ cDNA Biotin 
Module V2 kit from Nugen. 
2.5.7.1 Fragmentation 
The fragmentation master mix was prepared as follows (volumes listed are for a 
single sample) 
FL1   5 μl 
FL2   2 μl 
Total Volume 7 μl 
 
7 μl of master mix was added to each cDNA sample in a 96 well plate and mixed 
by pipetting the sample several times. The plate was centrifuged briefly to 
remove any air bubbles and then was placed into a thermal cycler set to the 
following programme: 
Incubate 370C for 30 minutes 
Incubate 950C for 2 minutes 
Cool to 40C. 
The plate was centrifuged briefly and placed on ice before proceeding with the 
labelling step. 
2.5.7.2 Labelling 
The labelling buffer mix (FL3), labelling reagent (FL4) and labelling enzyme 
(FL5) were obtained from the product box stored at -200C 15 minutes prior to 
completion of the fragmentation reaction to allow the products to thaw to room 
temperature.  
The labelling master mix was prepared as follows (volumes listed are for a single 
sample): 
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FL3   15 μl 
FL4   1.5 μl 
FL5   1.5 μl 
Total Volume 18 μl 
 
18 μl of master mix was added to each cDNA sample in a 96 well plate and mixed 
by pipetting the sample several times. The plate was centrifuged briefly to 
remove any air bubbles and was then placed into a thermal cycler set to the 
following programme: 
Incubate 370C for 60 minutes 
Incubate 700C for 10 minutes 
Cool to 40C  
After completion of the programme the plate was removed from the thermal 
cycler and centrifuged briefly before continuing with the hybridization step. 
2.5.8 Array hybridization 
Array hybridization was performed using the GeneChip Hybridization Control Kit 
(Affymetrix). The biotin-labelled cDNA was hybridized onto Human genome U133 
Plus 2.0 array cartridges (Affymetrix).  
The Affymetrix cartridges were removed from the refrigerator one hour before 
use to allow them to equilibrate to room temperature. 
The hybridization cocktail was prepared as follows (volumes listed are for a 
single sample): 
2x hybridization buffer  110 μl 
Affymetrix B2   3.7 μl 
Affymetrix 20X controls  11 μl 
Invitrogen BSA   2.2 μl 
Invitrogen herring sperm DNA  2.2 μl 
DMSO     22 μl 
Water     19 μl 
Total volume    170.1 μl 
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170 μl of hybridization cocktail was added to a 96 well plate (one well per 
sample) into which 50 μl of fragmented and labelled cDNA was added. After 
pipetting several times to mix the sample the 96 well plate was placed in a 
thermal cycler set to the following programme: 
Incubate 950C for 3 minutes 
Incubate 450C for 5 minutes 
Cool to 40C 
The plate was removed from the thermal cycler and centrifuged at 350 g for 5 
minutes. 
For each sample 200 μl of sample/hybridization cocktail was removed from the 
96 well plate and dispensed into an Affymetrix chip. The chips were secured in a 
450C hybridization oven and spun at 60 rpm for 16 hours. 
2.5.9 Staining and Scanning 
Genechip fluidic station 450 (Affymetrix) was used to wash and stain the probe 
chips. 
Wash buffers were made up the day prior to staining and scanning the chips. 
Wash buffer A was prepared as follows: 
20% SSPE   300 ml 
10% Tween   1 ml 
Water   699 ml 
Total volume  1000 ml 
 
150 ml of wash A was aliquoted into wash station bottles (one bottle per one 
Affymetrix chip). 
Wash buffer B was prepared as follows: 
MES buffer  83.2 ml 
NaCl   5.3 ml 
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10% Tween  1 ml 
Water   910.5 ml 
Total Volume 1000 ml 
 
150 ml of wash buffer B was aliquoted into wash station bottles (one bottle per 
Affymetrix chip). 
The fluidics stations were primed and for each fluidic station three bottles 
containing wash A buffer, wash B buffer and water were placed in the fluidic 
stations.  
The staining solutions to stain the chips were prepared as follows. 
Streptavidin Phycoerythrin (SAPE) solution (volumes listed are for a single 
sample, 600 μl each for the first and third stain): 
2x stain buffer 600 μl 
BSA   48 μl 
SAPE   12 μl 
Water   540 μl 
Total Volume 1200 μl 
 
Antibody solution (volumes listed are for a single sample): 
2x stain buffer 300 μl 
BSA   24 μl 
Goat IgG  6 μl 
Antibody  3.6 μl 
Water   266.4 μl 
Total Volume  600 μl 
 
The empty vials on the fluidics station were replaced with 600 μl each of SAPE 
(first and third stain) and antibody (second stain).  
The Affymetrix chips were removed from the hybridization oven and the 
hybridization mix was extracted from the chip. Each chip was inserted into a 
fluidics station where they were washed and stained, after this time the chips 
were removed and checked for air bubbles. If air bubbles were found the chips 
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were put back on the fluidic station to be re-filled with wash buffer, if no air 
bubbles were found the chips were then scanned. 
2.5.10 Scanning 
Tough-spot (Cole-Parmer) labels were used to cover the two septa on the 
affymetrix chip to prevent leakage of wash buffer. Smudges and dust were 
removed from the glass front of the chip and the chips were loaded into the chip 
carousel. The chips were scanned using GeneChip® Scanner 3000 and analysed 
using Affymetrix GeneChip Command Console software. 
2.6 PCR and SYBR green 
The primer sequences used for SYBR green are shown in Table 2.2. 
Table 2.2 Primer sequences used for RT-PCR 
 
 
Primer 
name 
 
Forward sequence 
 
Reverse sequence 
 
GAPDH 
β-actin 
Legumain 
Plexin A1 
Sema 3A 
Sema 3F 
Sema 6D 
 
TCG ACA GTC AGC CGC ATC TTC TTT 
AAT GTG GCC GAG GAC TTT GAT TGC 
CGC ACA CCA ACA CCA GCC AC 
AGG GAG AAC GGC TGC CTG GT 
TGG GGT TGC CCA GCT CCC TT 
GGA CAC AGC ATC GGC CCT CA 
GCC GTT CCA CCC ATT GCC GA 
 
ACC AAA TCC GTT GAC TCC GAC CTT 
AGG ATG GCA AGG GAC TTC CTG TAA 
AGG GGG ACG GGA GAA CTG GC 
AGC AGG GAG CGC ACG TTG TC 
TGT GCG TCT CTT TGC AGT GGG 
GAC GGG TCG TTC AGC CAC CG 
ACC ATG CCA GCT TCA GAG CCA 
 
RNA isolation was performed on samples as described in 2.5.3. 
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2.6.1 cDNA preparation 
cDNA was prepared from RNA samples according to AffinityScript™ multiple 
temperature cDNA synthesis kit. Briefly 100-500 ng of RNA, depending on 
experiment, was mixed with 3 μl random primers and RNase-free water to a 
total volume of 15.7 μl. The reaction was incubated at 650C for 5 minutes before 
being cooled to room temperature for 10 minutes to allow the primers to anneal 
to the RNA. The following components were then added to each sample for a 
total volume of 20 μl. 
2.0 μl of 10x AffinityScript RT buffer 
0.8 μl of dNTP mix 
0.5 μl of RNase Block Ribonuclease Inhibitor (40 U/μl) 
1 μl of AffinityScript Multiple Temperature Reverse Transcriptase (RT) 
A minus RT (-RT) control was also set up with each set of samples along with a 
water control. In the case of the -RT control 1 μl of RNase free water was added 
instead of the AffinityScript Multiple Temperature RT.  
The reaction was then incubated for 10 minutes at 250C to extend the primers 
prior to increasing the reaction temperature to 420C for 60 minutes for cDNA 
synthesis. The reaction was then terminated by incubating it at 700C for 15 
minutes. 
2.6.2 PCR  
2.6.3  SYBR green 
SYBR green was performed using SYBR green mastermix (Applied Biosystems). 
Prior to setting up the SYBR green the cDNA was diluted 1 in 5 using RNase-free 
water. The reaction mix was prepared as follows (volumes listed are for a single 
sample): 
Mastermix  10 μl  
Primer mix  0.8 μl 
Water   8 μl 
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Total volume  18.8 μl 
  
Each sample was measured in triplicate therefore 3 lots of reaction mix were 
prepared for each cDNA sample. For the triplicate samples 54.5 μl reaction mix 
was mixed with 6 μl cDNA and 19.8 μl of this total mixture was added to each of 
the three wells of a MicroAmp fast optical 96 well reaction plate (Applied 
Biosystems). A non template control was added to the plate where 6 μl of water 
was mixed with the 56.4 μl reaction mix and a minus RT was also included in the 
plate using the –RT control cDNA.  
Once the plate had been loaded with the cDNA samples it was covered using a 
MicroAmp optical adhesive cover (Applied Biosystems) and spun at 200 g for 5 
minutes. The plate was then transferred to an ABI 7900 H7 Fast-real-time PCR 
machine (Applied Bioststems) where it was read on the following cycle: 
Incubate 48ºC for 30 minutes 
Incubate 95ºC for 10 minutes 
40 cycles of 95ºC for 15 seconds followed by 60ºC for 1 minute 
A dissociation curve was subsequently measures on the following cycle: 
Incubate 95ºC for 15 seconds 
Incubate 60ºC for 15 seconds 
Incubate 95ºC for 15 seconds 
Using the results of this analysis, the expression of target genes relative to the 
housekeeping gene was then quantified.  
2.7 Immunohistochemical methods 
2.7.1 Antibodies 
Table 2.3 Antibody source and concentration used for IHC 
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Antibody Manufacturer Source Working concentration 
Legumain 
Plexin A1 
Prestige Antibodies 
Cell Signalling  
Rabbit 
Rabbit 
0.5 μg/ml 
1.02 μg/ml 
 
Table 2.3 shows the antibodies that were used for single immunohistochemical 
staining for light microscopy and the concentration of the antibody used. 
2.7.2 Single immunohistochemical staining 
Sections containing sections of RA synovial membrane were initially heated to 
650C for 35 minutes after which time they were de-waxed in xylene and 
rehydrated through an ethanol gradient to water/TBS Tween (TBST). To reduce 
non-specific background staining endogenous peroxidase activity was blocked 
using hydrogen peroxide (H202) and methanol. Fixation of tissue specimens forms 
cross-links that mask the antigenic sites, thereby giving weak or false negative 
staining for immunohistochemical (IHC) detection of proteins. Antigen retrieval 
using citrate buffer is designed to break the cross-links thereby unmasking the 
antigens and epitopes in the tissue. Antigen retrieval was performed in 0.01 M 
citrate buffer pH 6.0, the buffer was heated in a microwave for 5 minutes then 
the sections were added to the buffer and were heated for 8 minutes before 
being left to cool for 15 minutes. The sections were then blocked for 1 hour at 
room temperature in 2.5% serum of the species in which the secondary antibody 
was raised. The relevant primary antibody or isotype antibody was applied to the 
sections which were left overnight at 40C.  
The following day the species specific reagent from the ImmPRESS kit (Vector) 
was added to the sections for 30 minutes before being washed in TBST and 
developed with ImmPACT DAB (Vector) for up to 2 minutes until a brown 
reaction product appeared. Sections were then washed in water and 
counterstained using hematoxylin. Finally sections were dehydrated in ethanol, 
cleared in xylene to remove fats and oils and then mounted in DPX (Cellpath Ltd) 
before being imaged on a light microscope. 
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2.8 Western blotting 
2.8.1 Whole cell lysates 
CD14+ monocytes from the peripheral blood or synovial fluid of patients and 
CD14+ monocytes and M-CSF matured macrophages from normal donors were 
washed in PBS. Subsequently, 100 μl of M-PER (Thermo Scientific) with the 
addition of 1 μl Halt Protease Inhibitor Cocktail (Thermo Scientific) was added to 
the cells. The cells were solubilised for 30 minutes on ice before centrifugation 
of the lysates at 16,000 g for 15 minutes. The resulting whole cell lysate 
supernatants were removed from the cell debris pellet and were stored at -200C 
before being used for Western blot anaylsis. 
2.8.2 BCA Assay 
To determine the protein concentration of the cell lysates a BCA assay (Thermo 
Scientific) was performed. For each sample 2.5 μl was added to 72.5 μl of BCA 
reagent in triplicate on a 96 well plate and left at room temperature for 30 
minutes. A standard curve was also set up on the plate using known 
concentrations (2000 µg/ml – 25 µg/ml) of the protein bovine serum albumin 
(BSA). The plate was read on a plate reader at 502 nm. The amount of total 
protein in each sample was determined by comparing the OD value of each 
sample to a standard curve of values. 
2.8.3 SDS-PAGE gel electrophoresis 
5µg of protein from the whole cell lysates were incubated with the appropriate 
volume of 4x NuPAGE LDS sample buffer (Invitrogen) and 10 x NuPAGE reducing 
agent (Invitrogen) at 700C for 10 minutes. Samples and seeblue plus2 protein 
standard (Invitrogen) were run on NuPAGE Bis-Tris gels (4-12%) (Invitrogen) with 
NuPAGE MES running buffer (Invitrogen) at 100 V for 1 hour. The gel was then 
transferred onto a nitrocellulose membrane using the i-blot transfer system 
(Invitrogen).  
2.8.4 Western blotting 
Following transfer, nitrocellulose membranes were washed in TBS/Tween (0.5 M 
NaCl and 20 mM Tris pH 7.0 with 0.1% (v/v) Tween-20) and blocked for 1 hour in 
TBS/Tween containing 5% non-fat milk protein. Membranes were then incubated 
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with 0.2 μg/ml legumain primary antibody (R&D, AF2199) diluted in TBS/Tween 
containing 5% non-fat milk protein overnight at 4ºC. Following the incubation 
with the primary antibody the nitrocellulose membranes were washed (5 x 
5mins) with TBS/Tween and incubated in the an anti-goat HRP-conjugated 
antibody (abcam, ab6741) containing 5% non-fat milk containing protein for 1 
hour at room temperature. The membranes were then washed in TBS/Tween (5 
x 5 mins) and protein bands were visualised using the ECL detection system (GE 
Life Sciences). Nitrocellulose membranes were incubated in a mixture of equal 
volumes of ECL solution A (2.5 mM luminol, 0.4 mM p-coumaric acid and 100 mM 
Tris pH 8.5) and ECL solution B (0.002% hydrogen peroxide and 100 mM Tris pH 
8.5) for 1 minute before exposing the membranes to Kodak X-Ray film. 
Nitrocellulose membranes were then stripped and re-probed with a β-actin 
primary antibody (1/1000 dilution ab8229 Abcam). Membranes were stripped at 
room temperature for 1 hour with stripping buffer (100 mM 2-mercaptoethanol, 
2% SDS and 62.5 mM Tris pH 7). Nitrocellulose membranes were washed 
thoroughly in PBS/Tween and checked for residual signal before re-starting the 
western blotting protocol. 
2.9 Legumain activity assay 
To measure the activity of the enzyme legumain in our samples an activity assay 
was performed. The activity of legumain was measured on its ability to cleave a 
substrate Z-Ala-Ala-Asn-AMC (AnaSpec). Cleavage of this substrate releases the 
AMC (7-amino-4-methylcoumarin) flurophore which can be detected at 441 nm 
upon excitation at 342 nm. 
2.9.1 Collecting samples for activity assay 
M-CSF differentiated samples were washed in PEA prior to lysis. Patient synovial 
and blood CD14+ cells were isolated by magnetic bead separation and washed in 
PEA before lysis. All samples were lysed in lysis buffer containing 50 mM citrate, 
0.1% CHAPS (pH 5.5), 5 mM of DTT and 0.5% Triton-X 100 [342]. Cell lysates were 
collected and frozen at -700C.  
2.9.2 Setting up activity assay 
Human recombinant legumain (rhLGM) (R&D, 2199-CY-010) was used as a 
positive control and is supplied as the pro form of the enzyme. To activate the 
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rhLGM it was diluted to 100 μg/ml in activation buffer containing 50 mM sodium 
acetate and 100 mM NaCl, pH 4.0 and incubated for 2 hours at 370C. After this 
time the rhLGM was diluted to 1 ng/μl in assay buffer containing 20 mM citric 
acid, 60 mM Na2HPO4, 0.1% CHAPS (pH 5.5), 1 mM EDTA, and 1 mM DTT. 50 μl of 
the rhLGM was loaded into a well of a black welled 96 well plate. 
Cell lysate samples were freeze thawed three times before being centrifuged at 
10,000 g for 5 minutes, 50 μl of each sample was loaded into a black welled 96 
well plate. 
The substrate Z-Ala-Ala-Asn-AMC was diluted to 200 μM in assay buffer and the 
reaction was started by adding 50 μl of substrate to all wells containing sample 
and rhLGM. A blank well containing 50 μl assay buffer and 50 μl substrate was 
also put on the plate.  
The plate was read on a fluorescent plate reader programmed to take readings 
at times 0, 5, 10, 15, 20, 25, 30, 60, 90, 120, 150, 180, 210 minutes, the plate 
was incubated at 370C for the duration of the readings. 
2.10 siRNA 
N-TER Nanoparticle siRNA transfection system (Sigma) was used to knockdown 
the plexin A1 gene in M-CSF derived macrophages using 4 Flexitube plexin A1 
siRNA‘s (Qiagen). To check the transfection system was working in the 
macrophage cells an Allstars negative control with an Alexa Fluro 555 
modification (Qiagen) was used to visualise the cells after transfection. If the 
nanoparticle transfection system had worked and the siRNA negative control had 
entered the cells then the cells were seen to be fluorescing orange by light 
microscope or by FACS analysis. The Allstars negative control siRNA is a 
nonsilencing siRNA which has no known homology to any known mammalian 
gene; therefore it is used to check whether the transfection of the cells has any 
effect on the expression of the gene being investigated. 
To set up the siRNA transfection the target (plexin A1) and negative control 
(Allstars negative control) siRNA were prepared as follows: 
5 μM target/control siRNA  13 μl 
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siRNA dilution buffer  37 μl 
Total volume    50 μl 
 
The N-TER peptide was then prepared as follows (volumes listed are for each 
siRNA being tested) 
N-TER peptide    8 μl 
Water     42 μl 
Total Volume    50 μl 
 
The 50 μl of N-TER peptide was added to each 50 μl siRNA preparation and 
incubated at room temperature for 20 minutes; the concentration of siRNA at 
this point was 650 nM.  
To transfect the M-CSF differentiated macrophages the siRNA was diluted to a 
concentration of 5 – 30 nM in complete medium depending on the experiment. 
The culture medium was then removed from the macrophages and 500 μl of 
diluted siRNA was added to macrophages. The cells were incubated for 24 hours 
at 370C and after this duration the supernatants were collected for cytokine 
analysis and the cells were put in 0.5 ml trizol. Alternatively after siRNA 
treatment, the macrophages were stimulated with Tcks at 4:1 ratio or were 
stimulated with 10 ng/ml LPS for 24 hours at 370C. After this period of 
stimulation the supernatants were collected for cytokine analysis and the cells 
were put into 0.5 ml trizol.  
All 4 siRNA‘s were tested individually on the macrophages for knockdown of the 
plexin A1 gene, however in some experiments a mixture of 2 siRNA‘s were used 
to see their combined effect. In this case when preparing the siRNA 7.5 μl of 
each siRNA was added to the siRNA dilution buffer.  
2.11 Real time cell imaging 
Macrophages and T cells used for cell imaging were autoMACS purified as 
described in section 2.2.4. 
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2.11.1 Preparing macrophages for imaging 
AutoMACS purified CD14+ monocytes were cultured in 24 well plates in complete 
medium supplemented with 50 ng/ml M-CSF (Biosource) for 5 days.  To remove 
the macrophages 0.5 ml of cell dissociation solution (Sigma) was added to each 
well and the plate was placed into a 370C incubator for 10 minutes. The wells 
were then washed with PEA and scraped to remove any remaining macrophages 
still adhering to the wells. Macrophages were washed, counted and resuspended 
in complete medium at concentrations between 2x105 and 6x105 depending on 
the experiment and plated out on either a 2-well or 4-well chamberslide (VWR). 
The macrophages were left to adhere overnight in a 370C incubator.  
2.11.2 Staining macrophages for imaging 
A red fluorochrome called CMTPX (Invitrogen) was used to stain the 
macrophages, the dye was diluted to a concentration of 2.5 μM in HBSS media 
(Invitrogen) and 1 ml was added to each chamberslide well of macrophages. The 
chamberslides were placed in a 370C incubator for 20 minutes. After this time 
the media was removed from each well and 1 ml of complete medium added, 
the chamberslides were then incubated for a further 30 minutes in a 370C 
incubator to allow any excess CMTPX dye to be secreted from the cells. 
2.11.3 Staining T cells for imaging 
Depending on the experiment, either T cell purified from the blood of a healthy 
donor on the day of the imaging or Tcks that had been activated in a cytokine 
cocktail for 6 days were used. If Tcks were to be used they were washed 
thoroughly three times in PEA before being stained. The T cells/Tcks were dyed 
green with 1 ml of 10 μM CFSE (Invitrogen) which had been diluted in HBSS 
medium. The cells were incubated for 10 minutes at 370C, after this period the 
cells were washed three times in PEA to remove any excess CFSE. Tcks were 
either fixed in PBS/2% paraformaldehyde on ice for two hours, or not (as 
indicated) and the cells were added to the macrophages at a ratio of 1:1 or 4:1. 
2.11.4 Imaging cell contact on microscope 
The T cell - macrophage cell contact was left for varying amounts of time 
depending on the experiment but was usually imaged after 2 hours on a Carl 
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Zeiss Axiovert S100 inverted microscope. An automated sequence of events using 
Openlab software was setup in order to record time lapse images of the cell 
contact.  The sequence of events consisted of an image taken in green, followed 
by a brightfield image followed by a red image. This series of pictures was taken 
every 12 seconds for up to 1 hour and recorded the movement of the T 
cells/Tcks along with their interactions with the macrophages. 
2.11.5 Analysis of real time images 
Analysis of the movies produced from the time lapse images was done on 
Volocity software (PerkinElmer). Two different types of analysis were carried 
out measuring the number and duration of interactions and the co-localisation 
coefficient of interactions. 
2.12 Statistical analysis 
All microarray results were background corrected by the GC-RMA algorithm and 
analysed by paired T test or 1-way ANOVA unequal variance (Welsh ANOVA) using 
Genespring GX 11 software. In addition for specific comparisions both DAVID and 
IPA software, which use a modified version of Fisher‘s exact test, were 
employed. The remaining results are displayed as mean ± standard deviation and 
statistical analysis was done by students T test or 1-way ANOVA test, as 
indicated in figure legends, using the GraphPad Prism 4 software. A p value of < 
0.05 was considered statistically significant. 
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Chapter 3 Transcriptomic analyses of psoriatic and 
rheumatoid arthritis blood and synovial fluid CD14
+
 
cells 
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3.1 Introduction and Aims 
Rheumatoid arthritis (RA) and Psoriatic arthritis (PsA) are both chronic, 
autoimmune arthritides. The cause of neither disease is, at present, known with 
both genetic and environmental factors thought to play a role in disease 
susceptibility and progression thereafter. The synovial tissue in both RA and PsA 
is characterised by marked cellular infiltration, pronounced angiogenesis and 
increased cytokine and protease expression [132, 343]. Therapies used clinically 
in both RA and PsA induce significant improvement in disease activity status but 
many patients do not respond to existing standard of care [132], consistent with 
the heterogeneous nature of the diseases: this in turn underlines the need for 
further research and better therapies specifically targeted at patients who are 
non-responders to current treatments. 
In order to address this gap in the knowledge and understanding of RA and PsA 
many genome-wide gene expression studies have been undertaken in both 
diseases comparing the genetic profiles of patients to those of healthy controls 
in order to acquire a genetic signature unique to each disease [325-327, 329, 
330, 340, 341]. Gene expression studies have also been performed on patients 
undergoing various forms of therapy to identify discriminatory genetic markers 
which could predict the patient response to therapy [332]. Many of these genetic 
studies have been performed on peripheral blood mononuclear cells (PBMCs) or 
whole synovial tissue, which provides interesting information on the genetic 
expression status of the diseased state as a whole but cellular heterogeneity 
contained therein may be masking the contribution of individual cell types. 
Recently a small number of RA gene expression studies have specifically 
examined B cells [336], CD4+ T cells [337] and fibroblasts [334] from diseased 
patients in order to obtain an understanding of how these individual cell types 
are contributing to disease.  
There is also one microarray gene expression study that has been performed 
specifically on monocytes from RA patients, Stuhlmüller et al compared 
monocytes from the first leukapheresis pool (activated cells) and third 
leukapheresis pool (nonactivated cells) of 26 RA patients undergoing 
leukapheresis treatment to identify known and novel genes in the activated 
monocytes [338]. However, at present there are no gene expression studies 
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looking at CD14+ cells in PsA and as yet there have been no studies performed on 
both blood and synovial CD14+ monocyte/macrophage cells from RA or PsA 
patients. These cells are known to play an important role in disease progression 
as they are a major source of proinflammatory cytokines in the joint [344] and 
the number of synovial macrophages has been found to correlate with the 
degree of disease activity in RA [345]. The inflamed synovia in both RA and PsA 
have been found to contain similar numbers of macrophages upon comparison 
[243]  therefore elucidating the molecular signature of this cell type in both PsA 
and RA may lead to a better understanding of its critical role in disease activity. 
Due to the lack of transcriptome data from CD14+ cells from PsA and RA I 
therefore sought to determine the gene expression pattern of CD14+ cells from 
the matched peripheral blood and synovial fluid of RA and PsA as well as CD14+ 
cells isolated from healthy volunteer derived blood. A priori comparisons were 
set up between disease and non-diseased state (healthy versus diseased blood), 
the site of cell isolation (peripheral blood versus synovial fluid) and the two 
disease types (RA versus PsA). 
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3.2 Patients and normal donors 
Inflammatory arthritis patients attending Gartnavel General Hospital (GGH) or 
Glasgow Royal Infirmary (GRI) fulfilled the American college of Rheumatology 
criteria for RA [6], or met diagnostic criteria for PsA [346]. Information regarding 
patient characteristics is shown in Table 3.1.  
Age-matched normal donors were recruited from the Glasgow Biomedical 
Research Centre (GBRC) building and all blood samples were taken with 
informed consent. 
Table 3.1 Patient characteristics 
 
Characteristic RA patients PsA patients 
Mean age (years) 
Female:Male 
Mean Disease duration (years) 
ESR mm/hr (mean) 
CRP  (mean) 
RF positive (%) 
% of patients using DMARDS 
Anti-TNF therapy (number of patients) 
68 
5:3 
12.2 
86 
107 
87.5 
62.5 
1* 
51 
4:4 
1.8 
37 
115 
0 
37.5 
1* 
 
*Anti-TNF therapy was stopped due to patients becoming anti-TNF resistant 
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3.3 Collecting patient samples 
For the microarray study, matched synovial fluid and blood samples were 
collected from 8 RA patients and 8 PsA patients. CD14+ cells were positively 
selected from the samples using Miltenyi beads and an aliquot of cells were 
tested by FACS analysis for purity before being put into Trizol. CD14+ Miltenyi 
beads were used since the CD14 surface antigen is present on both monocytes 
and macrophages [190, 347] therefore these beads should isolate blood 
monocytes as well as the synovial fluid macrophages. Normal donors who were 
age and sex matched to patients (Table 3.2) were recruited and from these 
donors CD14+ cells were positively selected from the blood only since by 
definition no synovial compartment derived population cold be ethically derived. 
An aliquot of unactivated CD14+ cells were put into Trizol and the remainder of 
the monocytes were stimulated with M-CSF for 6 days and then cell contact 
activated (see chapter 6). Once all the samples had been collected the RNA was 
extracted from all samples at GSK Stevenage and analysed for quality. 
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Table 3.2 Patient and normal donor samples collected 
 
 
Patient 
 
Gender 
 
Age 
Age and sex 
matched normal 
donor 
PsA 1 
PsA 2 
PsA 3 
PsA 4 
PsA 5 
PsA 6 
PsA 7 
PsA 8 
RA 1 
RA 2 
RA 3 
RA 4 
RA 5 
RA 6 
RA 7 
RA 8 
Female 
Female 
Male 
Male 
Male 
Female 
Male 
Female 
Female 
Male 
Female 
Male 
Female 
Male 
Female 
Female 
53 
40 
34 
34 
80 
58 
54 
58 
71 
56 
62 
69 
78 
69 
69 
77 
Yes 
Yes 
Yes 
No 
No 
Yes 
Yes 
No 
No 
Yes 
No 
No 
No 
No 
No 
No 
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3.3.1 Purity of monocyte samples 
The CD14+ cells isolated from each patient blood and synovial fluid sample were 
analysed on a FACS Calibur to check that there were no other contaminating cell 
types that would affect the transcriptomic profile obtained. Figure 3.1 shows a 
purity check from one representative PsA patient (A) and one RA patient (B).  
3.3.2 RNA quality of patient samples 
The RNA quality of the samples was analysed on an Agilent 2100 Bioanalyser 
which is a microfluidics based platform that analyses RNA qualitatively; RNA 
samples and a standard (ladder) are loaded into wells on a specifically designed 
chip containing a fluorescent dye. The dye molecules become incorporated into 
the RNA and a voltage gradient is applied to the chip allowing the RNA to 
become separated by size. By comparing the separation of the RNA to that of 
the ladder, which contains components of known size, a standard curve of 
migration time versus fluorescence units is plotted called an electropherogram. 
Viewing the electropherogram can give an indication of the integrity of the RNA 
sample. 
Figure 3.2 (A) is an electropherogram showing an example of good quality RNA. 
It is characterised by three clear peaks, a peak for the RNA marker (1) and a 
peak for the 18 S (2) and 28 S (3) ribosomal RNA subunits. There should be a 
relatively flat baseline between the two rRNA peaks and minimal low molecular 
weight noise adjacent to the RNA marker peak. Figure 3.2 also shows the RNA 
quality from the blood and synovial fluid CD14+ cells of a representative PsA 
patient (B) and RA patient (C). All four of the samples show good quality RNA 
evident by the two clear peaks and no low molecular weight noise. After 
checking the RNA from each sample was of good quality, cDNA was generated 
from each RNA sample before being purified, fragmented and labelled. The 
labelled cDNA was then hybridised onto an Affymetrix GeneChip. 
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Figure 3.1 Purity of CD14+ cells isolated from PsA and RA patient blood and synovial fluid 
samples 
These graphs are a representative of the CD14+ cells isolated from the 8 PsA and the 8 RA 
patients that were analysed on the microarray 
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Figure 3.2 RNA quality of the CD14+ samples from two patients 
RNA was extracted and analysed for quality using an Agilent 2100 Bioanalyser. Figure (A) 
represents an example of good quality RNA. It is characterised by three clear peaks: a peak for the 
RNA marker (1) and a peak for the 18 S (2) and 28 S (3) ribosomal RNA subunits. The quality of 
representative PsA patient samples (B) and RA patient samples (C) are shown here and both 
demonstrate good quality RNA. 
 
(C) 
(B) 
PsA PB mo PsA SF mo 
(A) 
1 
2 
3 
RA PB mo RA SF mo 
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3.4 Summary of samples analysed on microarray 
The samples that were examined using the microarray GeneChips are 
summarised in Table 3.3. Eight matched PsA and RA blood and synovial fluid 
samples were obtained along with 6 age and sex matched healthy controls, 
unactivated blood CD14+ cells were not collected from one control but 
macrophage cells before and after Tck cell contact activation were collected for 
all 6 healthy controls. These latter samples will be discussed and analysed in 
chapter 6. 
Table 3.3 Summary of microarray samples 
 
Monocyte/macrophage sample analysed   Number of samples 
 
PsA PB CD14+        8 
PsA SF CD14+        8 
RA PB CD14+        8 
RA SF CD14+        8 
Healthy control PB CD14+      5 
Healthy control M-CSF activated Mø    6 
Tck cell contact activated Mø     6 
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3.5 Analysis of microarray results 
Affymetrix GeneChip microarrays are one of the most popular high-density 
oligonucleotide (oligo) gene expression arrays currently available and have been 
widely validated for the purposes of the present study – this was therefore our 
selected methodology of choice. Each gene on an Affymetrix GeneChip is 
represented by a probe set consisting of 11 pairs of 25-bp oligos covering the 
transcribed region of the gene. Each probe set pair consists of a perfect match 
(PM) and a mismatch (MM) oligonucleotide. The PM probe matches exactly the 
sequence of the gene while the MM probe differs in a single substitution in the 
central 13th base, the MM probe is designed to distinguish noise caused by non-
specific hybridisation from the actual specific hybridisation signal [348]. 
Affymetrix GeneChips have many sources of variation, for example non-
biological variation can arise due to: differences in sample preparation, unequal 
quantities of starting RNA, differences between chips or differences in 
hybridisation between chips [349], therefore pre-processing must take place to 
adjust for these sources of non-biological variation.  
Affymetrix microarrays are pre-processed in three steps: 
Background correction – this is to adjust for hybridisation effects that are not 
related to the interaction between probes and target DNA 
Normalisation – this is to remove systematic errors and bias, it is necessary as it 
allows multiple chips to be compared to each other and analysed together. It is 
performed under the assumption that all chips have approximately the same 
distribution of PM values. 
Summarisation – This is performed using the 11 individual probe intensities from 
a probe set, combined to yield a single value for each gene that best represents 
the expression level of the sample RNA transcript. 
There are many different algorithm tools that can be applied to the background 
correction step of Affymetrix data pre-processing: an appropriate choice is 
dependent upon the experimental design and dataset. Each phase will now be 
described. 
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3.5.1 Background correction of the Affymetrix chips 
At present there are several different algorithm tools that are used to 
background correct Affymetrix chips such as MAS5 [350], RMA [351], GC-RMA 
[352] and PLIER. Upon careful consideration it was decided to use GC-RMA, 
which is a modified version of RMA, as the background correction for my 
experiment design and dataset. As mentioned above each gene is represented on 
the GeneChip by 11 probe pairs made up of a MM and a PM probe, the MM probe 
is designed to distinguish noise and non-specific background signal from the 
specific hybridisation signal. However a problem arises when using MM data 
because in approximately 1/3 of probes the MM intensity levels are higher than 
the PM intensity levels. This suggests that the MM probes are detecting real 
signal. In these cases subtracting the MM signal from the PM signal results in a 
negative signal value and the loss of interesting signal value for those probes. 
Due to this problem several pre-processing algorithms were designed which only 
took into account the PM values, an example of which is RMA. RMA excludes MM 
data completely which reduces noise but also loses information therefore GC-
RMA was designed which takes into account non-specific hybridisation using the 
signal intensity of representative MM probes possessing the same GC nucleotide 
content as the PM probe of interest. 
The background correction in GC-RMA consists of three sequential steps: 
1. Optical background correction, this is an important step as the scanner 
measuring the hybridisation strength of each GeneChip will introduce 
optical noise 
2. Probe intensity adjustment through non-specific binding (NSB) using the 
optical noise adjusted representative MM probe intensities 
3. Probe intensity adjustment through gene-specific binding where the NSB 
adjusted PM intensities are corrected for the effect of PM probe affinities. 
GC-RMA is currently considered to be one of the best methods for estimating 
expression values of genes. A recent study comparing several pre-processing 
algorithms found GC-RMA to be the algorithm of choice for detecting differential 
expression of genes and also the algorithm which produced gene expression data 
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that was highly correlated to qRT-PCR validation data [353]. Hence, GC-RMA was 
chosen for pre-processing the Affymetrix GeneChips data produced in the 
current study.  
3.5.2  Signal histogram of normalised data 
Once the data normalisation had been performed and prior to formal data 
analysis, all the GeneChips must be analysed to check for outliers that may 
affect or skew the results interpretation. One method is to examine the signal 
histogram of the normalised data which plots a line for each of the GeneChips 
with the intensity of the probes contained on the chip on the x-axis and the 
frequency of the probe intensity on the y-axis. This then allows the visualisation 
of the distribution of the signal intensity to identify any outliers. Figure 3.3 
illustrates the signal histogram of all the samples that were tested, each line 
represents one GeneChip and they are coloured by condition with blue 
representing the cell contact activated macrophage samples, red the M-CSF 
treated macrophages, purple the healthy donor blood CD14+, green the patient 
blood CD14+ and gold represents the synovial fluid CD14+ cells. It can clearly 
been seen on the histogram that all the samples have a similar signal intensity 
expression apart from one sample which is a GeneChip containing a cell contact 
activated macrophage sample. The reasons for this outlying sample are unknown 
but since it is only one sample and the signal intensities of the other samples are 
relatively similar to each other it is unlikely to represent a problem with the 
hybridisation, washing or staining of the chips. As a result it is most likely to be 
due to a problem with the individual sample or the labelling of that particular 
sample. Since this sample is an outlier and may potentially skew the data 
interpretation it was removed from further data analysis. 
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Figure 3.3 Signal histogram of normalised data 
This graph represents the signal intensity of all the GeneChips that were analysed in this 
experiment. It is used to identify outliers in the samples. Each line represents one GeneChip and 
the lines are coloured according to the monocyte sample that was loaded onto each GeneChip. A 
blue line represents a cell contact activated macrophage, green is CD14
+
 cells from the patients, 
purple is healthy donor blood CD14
+
, red is M-CSF activated macrophages and gold is synovial 
fluid CD14
+
 cells.  
 
3.5.3 Principle component analysis 
Phenotypes of diseases or experimental conditions can be classified using 
Principle Components Analysis (PCA) [354]. This is an analytical method that 
identifies distinct patterns in the observed transcriptomic differences of 
samples. It transforms multidimensional data into a lower dimensional space 
using as few variables as possible. The resultant PCA graph can be used to look 
for trends in the data and also identify samples which may be outliers as samples 
clustered within the same area of the PCA graph are considered to be 
genetically similar.  
All the samples from the microarray were analysed by PCA based on conditions 
applied (Figure 3.4). Each circle on the graph represents a sample and each 
colour represents a condition. Figure (A) shows the PCA plot of all samples 
including the outlier sample that was identified in the signal histogram to 
illustrate how different the genetic profile of that sample was compared to all 
the other samples. This is visualised on the PCA plot by the one blue circle 
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representing the outlier sample being isolated on the left hand side of the graph 
while all the remaining samples are clustered on the right hand side of the 
graph. This graph provides further support for the removal of this one sample 
from the analysis as its genetic profile and signal intensity vary widely from the 
other samples. 
Figure 3.4 (B) demonstrates the PCA plot of the samples once the outlier had 
been removes. It can clearly been seen that SF CD14+ cells (gold circles) from 
both disease types cluster tightly together indicating that CD14+ cells from RA 
and PsA SF share a similar expression transcriptomic profile. This same pattern 
can also been seen for the patient blood CD14+ cells (green circles); both 
diseases have similar genetic profiles as indicated by the clustering of the green 
circles. This cluster of patient blood samples is distinct from the synovial fluid 
cluster of samples and more ‗transcriptomically similar‘ to the healthy donor 
CD14+ blood cells (purple circles) due to the healthy donor CD14+ samples being 
located in the same area of the PCA graph as the diseased blood CD14+ cells. The 
red circles and blue circles represent M-CSF activated macrophages and cell 
contact activated macrophages respectively and will be fully discussed in 
chapter 6. 
This PCA analysis helped to visualise the trends in the data and these trends 
were used to determine further comparisons to be performed. These were:  
 comparing patient blood to normal blood 
 comparing diseased blood CD14+ cells to synovial fluid CD14+ cells of both 
RA and PsA to see if there are genes that are similar in both diseases and 
conversely if each disease also has a unique distinguishing genetic subset. 
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Figure 3.4 Principle component analysis of all microarray samples 
PCA was performed on the microarray samples to try and identify trends in the data. Graph (A) 
indicates the normalised samples before the outlier was removed. The blue circle on the left hand 
side of the graph represents the outlying sample and it can been seen that all the other samples 
are clustered away from that area of the graph indicating that general genetic profile of the outlying 
sample does not match those of the remaining samples. Figure (B) shows PCA graph once the 
outlying cell contact sample had been removed. Each circle represents a sample and samples 
clustered in the same area of the graph are considered to be genetically similar. Each colour 
represents a sample condition; red is M-CSF treated macrophages, blue is cell contact activated 
macrophages, gold is synovial fluid derived CD14+ cells, green is patient blood CD14+ cells and 
purple is healthy blood CD14+ cells. 
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3.6 Comparing samples 
3.6.1 Comparison 1: Patient blood compared to normal blood 
Analysing the PCA graph indicated that the CD14+ cells from both the 8 RA and 8 
PsA patients have a similar gene expression to the 5 healthy control CD14+ cells. 
It was decided to analyse the genetic profiles of these samples further to see 
how similar they were and to determine if there were any disease-specific genes 
not detected in the healthy controls as has been found by many previous studies 
[325-327, 329, 330, 340, 341]. 
All samples were pre-processed by the GC-RMA algorithm and quality control on 
the entities was performed. To pass the quality control analysis each entity had 
to have a signal value between 20 and 100% in order to remove any background 
signal and each entity had to be expressed in all 21 samples (8 RA PB, 8 PsA PB 
and 5 healthy PB). This is due to the considerable heterogeneity in the patient 
samples with regards to treatment and disease duration; we were only 
interested in genes that had changed in all disease samples rather than genes 
that changed for example, only in response to a certain treatment type.  
41424 entities passed the quality control analysis that can be visualised as shown 
in Figure 3.5. The y value is the normalised signal intensity of the entity where 
the signal is normalised to the median value of that entity across all the 
samples. It is a visualisation tool that allows entities with very high or very low 
signal values to be visualised on the same graph. The graph indicates that whilst 
there are many entities that do not change their signal expression levels 
between non-diseased and diseased states there are some outliers that have 
varying levels of intensity in each of the three conditions.  
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Figure 3.5 Profile plot of entities that passed the quality control filter. 
Each line represents an entity and this graph shows the change in the signal intensity value of each 
entity in all healthy samples (left hand side of the graph), PsA PB samples (middle of the graph) 
and RA PB samples (right had side of the graph). The colour of the line denotes the signal intensity 
of the entity in healthy peripheral blood; blue represents a signal intensity of -6 to -1, yellow -1 to 1 
and red 1 to 6. 
3.6.1.1 Statistical analysis of healthy and diseased blood CD14+ 
cells 
During microarray data analysis, multiple testing corrections (MTC) should be 
applied where possible to decrease the number of false positives. Any statistical 
tests (e.g. T test, ANOVA) that are performed on microarray data perform one 
test per gene therefore the number of false positives increases proportionally to 
the number of tests performed. For example analysing 10000 genes with a cut-
off p value of 0.05 will mean performing 10000 individual statistical tests and as 
a result 500 genes (0.05 x 10000) are likely to appear significant by chance 
alone. The Benjamini and Hochberg (false discovery rate) MTC gives a corrected 
p value for each gene depending on the number of genes being tested [355]. 
A one-way ANOVA unequal variance (Welch ANOVA) with a Student-Newman-
Keuls (SNK) post Hoc test was used to analyse the 3 microarray conditions of 
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healthy blood, RA blood and PsA blood. A MTC was unable to be used in this 
instance as when the Benjamini and Hochberg MTC was used there were no 
significantly changed genes between the three groups. Since a p value cut off of 
0.05 was used this means that 5% of the differentially expressed genes may be 
false positives and appearing by chance alone, a way to overcome this is to look 
at the p values of each gene as the higher the p value of the gene the less 
chance of it being a false positive.  
The one-way ANOVA with a p value cut off of 0.05 gave the following results: 
494 genes significantly changed between RA and PsA PB cells 
1457 genes significantly changed between healthy blood and RA blood 
1384 genes significantly changed between healthy blood and PsA blood 
These results indicate that although the PCA graph showed all of the blood CD14+ 
samples to be genetically similar, there are groups of genes that are significantly 
changed between samples indicating that there are likely to be disease-specific 
genes being expressed.  
3.6.1.2 Fold change cut off analysis of healthy and diseased 
blood derived CD14+ cells 
Since there were many genes that had significantly changed between groups a 
fold change analysis was performed to look at differential expression. A cut off 
value of 2 was chosen, consequently if a gene had a fold change difference in 
expression between two conditions that was ≥ 2 then it would be considered 
differentially expressed. The fold change cut off gave the following results: 
43 genes changed between RA and PsA blood CD14+ cells (22 genes up-regulated 
in RA compared to PsA PB and 21 genes up-regulated in PsA compared to RA PB) 
239 genes changed between healthy blood and RA blood (158 genes up-regulated 
in RA compared to healthy PB and 81 genes down-regulated in RA compared to 
healthy PB) 
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281 genes changed between healthy blood and PsA blood (153 genes up-
regulated in PsA blood compared to healthy and 128 genes downregulated in PsA 
blood compared to healthy) 
These results demonstrate that of the 54,000 probe sets on the Affymetrix 
GeneChips there are very few of these (43 probes/genes) that are differentially 
expressed between RA blood and PsA blood. This result reinforces the PCA 
results which showed the RA and PsA blood samples to be grouped together 
therefore implying these samples were transciptionally similar. Hence from our 
data it appears that the blood monocytes from RA and PsA have similar 
transcriptomic profiles and there are very few genes that are expressed by these 
monocytes that could distinguish them as belonging to either disease. 
Nevertheless there are 43 genes that were distinguished by this analysis as being 
differentially expressed between RA and PsA PB CD14+ cells with a fold change 
difference of ≥2. Of these 43 gene hits there were only 24 individual genes that 
had changed. This is because on the affymetrix GeneChips each gene can be 
represented by more than one probe set and one gene can be appear several 
times in the differentially changed gene list, also the gene lists often contain 
transcribed loci that have no known function or gene name and therefore cannot 
be analysed further. Of the 24 genes that were differentially expressed between 
RA and PsA blood CD14+ cells 12 were upregulated in RA blood compared to PsA 
and 12 were upregulated in PsA blood compared to RA. 
Table 3.4 outlines the functions of the 12 genes upregulated in RA PB CD14+ cells 
compared to PsA PB CD14+ cells. 
Table 3.5 outlines the functions of the 12 genes upregulated in PsA PB CD14+ 
cells compared to RA PB CD14+ cells. 
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Table 3.4 A list of the 12 upregulated genes in RA PB CD14
+
 cells compared to PsA PB CD14
+
 cells  
Symbol Gene Name    Fold change upregulation  Description of Gene 
       in RA PB compared to 
PsA PB (p value) 
 
NRP1  Neuropilin 1     5.1 (5.72 X 10-5) A single pass transmembrane protein which has various ligands including 
            semaphorins and VEGF family members. They have principle functions  
in cell motility, including neural growth cone collapse mediated by 
semaphorins, and vascular and lymphatic sprouting triggered by VEGFs 
[356]. NRP-1 is the major VEGF 165 receptor in fibroblast like 
synoviocytes in RA. It is also expressed in the lining layer, endothelial 
cells and infiltrating leukocytes in RA [357]. 
 
NCAM1  Neural cell adhesion molecule 1  3.8 (0.017)  A cell surface glycoprotein which mediates homotypic and heterotypic  
           cell-cell adhesion through a homophilic binding mechanism. It is present  
           in the nervous system where it participates in neural outgrowth and cell  
           migration [358]. NCAM may also play a role in blood vessel stability as  
           NCAM deficiency results in unstable endothelial cell – pericyte  
interaction and hence vessel stability [359]. 
 
CYB5R2 Cytochrome b5 reductase 2   3.5 (0.021)  Cytochrome b5 is an electron transfer component in oxidative reactions 
such as anabolic metabolism of fats and steroids [360]. The CYB5R2 
isoform is a membrane bound form of cytochrome b5 reductase which 
partakes in fatty acid elongation and desaturation [361] and cholesterol 
biosynthesis. It may also play a role in mitochondrial respiration [362]. 
 
GPR34  G protein-coupled receptor 34  2.8 (0.048)  G protein-coupled receptors are the largest family of receptor proteins 
in mammals and are known to bind to a variety of extracellular ligands 
such as chemokines, enzymes and hormones [363]. GPR34 is highly 
abundant in mast cells where it acts as the functional receptor for 
lysophosphatidylserine which enhances mast cell degranulation [364]. 
 
HPGD  hydroxyprostaglandin dehydrogenase  2.4 (0.0062)  An enzyme responsible for the inactivation of prostaglandins and 
15-(NAD)        lipoxins by catalysing the oxidation of 15(S)-Hydroxyl group resulting 
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in metabolites with reduced biological activity [365]. It is 
downregulated in human epithelial tumours and shows tumour 
suppressor activity [366]. 
 
PKP2  Plakophilin 2     2.3 (0.046)  A protein found co-localised to desmosomes, which are adhesive  
junctions linking intermediate filament networks to sites of strong 
intercellular adhesion. These junctions provide strength to tissue 
undergoing mechanical stress such as cardiac and epidermal tissue 
[367]. Plakophilin 2 has been detected in the adherens junctions of 
cardiomyocytes [368] and can co-localise with β-catenin at adherens 
junctions in epithelial cells [369]. 
 
CA5B  carbonic anhydrase VB, mitochondrial 2.2 (0.045)  A metalloenzyme expressed in mitochondria which is involved in several  
           biosynthetic processes and plays a key role in fatty acid biosynthesis 
[370]. 
 
IL7  Interleukin 7     2.1 (0.011)  A member of the IL-2 family expressed by epithelial cells in  
lymphopoietic tissues, epithelial cells, keratinocytes, DCs and 
monocytes [371]. IL-7 plays an important role in T cell homeostasis such 
as naïve T cell survival but has also been found to induce bone loss by 
inducing osteoclast formation from human monocytes in a T cell 
dependent manner [372]. Serum levels of IL-7 are higher in RA patients 
compared to healthy controls and correlate with markers of 
inflammation [371]. IL-7+ cells correlate with the number of CD68+ cells 
in RA synovial lining and sub-lining layers and double staining 
demonstrates that CD68+ cells are a major producer of IL-7 [373]. 
 
LAMC1  Laminin, gamma 1    2.1 (0.016)  Laminins are extracellular matrix components and are a major  
constituent of basement membranes. Laminin and collagen provide the 
basic scaffold to which other basement membrane proteins, such as 
proteoglycan, integrate [374]. Laminin is also expressed in the cerebal 
cortex and laminin γ1 has been shown to play a critical role in neuronal 
morphogenesis and migration [375]. Laminin γ1 is also required for the 
deposition of matrix molecules in cardiomyocytes [376]. 
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LYCAT  Lysocardiolipin acyltransferase  2.1 (0.011)  In embryonic stem cells (ESC) differentiation lysocardiolipin  
acyltransferase plays an essential role in hematopoietic and endothelial 
lineage development [377]. It is also involved in the remodelling of the 
phospholipid cardiolipin. Cardiolipin is sensitive to oxidative damage by 
reactive oxygen species and lysocardiolipin acyltransferase plays a 
regulatory role in remodelling cardiolipin in response to stress [378]. 
 
LRP11  Low density lipoprotein receptor-related 2.1 (0.0077)  The LDL receptor related protein (LRP) is a heterodimeric endocytic 
protein 11        cell surface receptor which transports a variety of macromolecules 
into cells through a process called receptor mediated endocytosis. 
LRP11 is expressed mainly in the brain and it has been shown to play a 
role in cell-cell adhesion in neurons however it has also been shown to 
be present in vascular smooth muscle cells and can induce enhanced 
migration and invasion activities [379]. LRP11 may play a role in 
Alzheimer disease (AD) as its expression is significantly reduced in the 
brains of AD patients, in this setting LRP11 is thought to be a sorting 
protein that protects β-amyloid precursor protein (APP) processing into 
amyloid-β (Aβ) which is the peptide found accumulated within the brains 
of AD patients [380]. 
 
RNF34  Ring finger protein 34   2.0 (0.049)  Otherwise known as human ring finger homologous to inhibitor of  
apoptosis (hRFI). hRFI is an apoptosis regulator protein. Transfection of 
hRFI into HeLa cells resulted in an increase in cell survival after TNFα 
treatment [381] and transfection of hRFI into human colorectal cancer 
cells significantly inhibited death receptor mediated apoptosis with 
decreased caspase activity [382]. Thus indicating that hRFI has anti-
apoptotic activity. 
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Table 3.5 A list of the 12 upregulated genes in PsA blood CD14
+
 cells compared to RA blood CD14
+
 cells 
 
Symbol Gene Name    Fold change upregulation  Description of Gene 
       in PsA PB compared to 
RA PB (p value) 
 
GSTM2  glutathione S-transferase M2   3.0 (0.040)   Glutathione S-transferases (GSTs) are a broadly expressed family 
of enzymes which protect against endogenous oxidative stress as 
well as exogenous toxins. They detoxify a variety of electrophilic 
compounds including oxidised lipids and DNA products generated 
by reactive oxygen species damage to intracellular molecules 
[383]. Glutathione S-transferase M2 is a muscle specific enzyme. 
 
GSTM1  Gluthathione S-transferase M1  2.9 (0.035)   (See above for a description of GSTs). Allelic variant within the 
GSTM1 gene are associated with differences in detoxification 
efficiency, the GSTM1 gene has a non-functioning allele termed 
GSTM1-null. RA patients who carry this GSTM1-null polymorphism 
and are smokers are associated with worse disease severity 
[384]. A further study in a Korean population indicated that the 
GSTM1-null polymorphism is associated with increased 
susceptibility to RA [385]. 
 
PPP1R16B protein phosphatase 1,   2.9 (0.036)   Protein phosphatase 1 (PP1) is a eukaryotic serine/threonine 
regulatory (inhibitor) subunit 16B       phosphatase which regulates a large variety of cellular functions 
through the interaction of its catalytic subunit with over 50 
different regulatory subunits [386]. The PPP1R16B gene encodes 
a protein called TGF-β-inhibited membrane-associated protein 
(TIMAP). TIMAP is expressed at high levels in endothelial cells, 
phosphorylation of TIMAP controls its association with PP1 which 
in turn regulates extension of filapodia within the endothelial 
cells [387]. 
 
 
VASH1  Vasohibin 1     2.9 (0.0088)   An angiogenesis inhibitor upregulated in endothelial cells [388]. 
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Vasohibin-1 has also been detected in RA synovium in synovial 
lining cells, synovial fibroblast and endothelial cells. In vitro 
stimulation of RA synovial fibroblasts with inflammatory 
cytokines induced vasohibin-1 mRNA expression in hypoxic 
conditions [388]. 
 
CHST13 Carbohydrate (chondroitin 4)   2.8 (0.013)   Chondroitin sulfotransferases synthesize the diverse sulphated 
sulfotransferase 13         structures found in the glycosaminoglycans (GAGs) chondroitin  
sulphate [389]. As present there is no defining information on 
the specific role of carbohydrate sulfotransferase 13. 
 
FOXP1  forkhead box P1    2.7 (0.017)   A member of the FOX family of transcription factors. FOXP1 has a 
role in B cell development [390], thymocyte development [391] 
and monocyte differentiation as downregulation of FOXP1 is 
necessary for monocyte differentiation and hence macrophage 
function [392]. 
 
KLF9  Kruppel-like factor 9    2.3 (0.011)   The kruppel-like factor family are zinc finger transcription 
factors. KLF9 regulates estrogen and progesterone action by 
modulating the activity of the progesterone receptor (PGR). It 
directly interacts with PGR to mediate progesterone responsive 
genes [393] and acts as a transcriptional repressor of estrogen 
receptor signalling [394]. 
 
KIF1B  Kinesin family member 1B   2.3 (0.031)   The kinesin superfamily of proteins play a role in organelle  
transport in cells such as neurons and epithelial cells [395]. 
KIF1B is a plus end directed motor that transports synaptic 
vesicle precursors in the axon from the cell body to the synapse 
[396], it has also been shown to transport mitochondria in nerve 
cells [397]. 
 
BIN1  Bridging integrator 1    2.3 (0.035)   BIN1 contains a BAR domain that allows it to interact with  
cellular membranes and induce membrane curvature [398]. BIN1 
is a muscle specific isoform of BAR domain containing proteins. It 
is highly expressed during muscle development and helps 
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generate the membrane curvature needed to form T-tubules 
[399].  
 
MED26  Mediator complex subunit 26   2.1 (8.6 X 10-4)  Once of several subunits that comprise the Mediator complex. 
The Mediator complex forms a crucial part of the RNA 
polymerase II transcriptional machinery that is essential for the 
transcription of almost all protein coding genes [400]. 
 
ACSL3  Acyl-CoA synthetase long-chain  2.1 (0.039)   An enzyme isoform involved in lipid synthesis, fatty acid  
family member 3        catabolism and membrane remodelling [401]. 
 
EIF2AK3 Eukaryotic translation initiation factor 2.1 (0.022)   An ER transmembrane protein kinase which functions during 
2-alpha kinase 3        cellular stress as an unfolded protein response (UPR) sensor. It is  
activated by accumulated misfolded proteins in the ER and 
reduces cellular translation to allow the cell to correct for the 
misfolded proteins causing the ER stress before synthesising 
additional proteins [402]. 
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3.6.1.3 Database for annotation, visualisation and integrated 
discovery (DAVID) analysis of genes changed between 
healthy and patient CD14+ cells 
Following on from the statistical and fold change analysis of the blood CD14+ 
samples an analysis of the groups of genes which were changed between healthy 
and patient samples took place. This analysis will identify the function of the 
expressed genes and subsequently group them according to their function. This 
may be more informative rather than studying each individual gene and could 
indicate the phenotype of the diseased CD14+ cells.   
The database for annotation, visualisation and integrated discovery (DAVID) 
analysis was used to investigate the gene lists to see if there was a significant 
enrichment of group of genes required for a specific biological function. DAVID is 
a publicly available software that can systematically map a large number of 
genes to their associated biological annotation and then statistically highlight 
the most overrepresented enriched biological processes [403].   
DAVID analyses gene lists in regard to the reference background, which in this 
analysis is all of the genes expressed on the Affymetrix GeneChip. To decide the 
degree of biological enrichment within the input gene list DAVID compares it to 
the reference background for example, if 10% of the gene list are kinases versus 
1% of the genes on the Affymetrix GeneChip then kinases would be classed as 
overrepresented within the gene list. The DAVID software uses a modified 
Fisher‘s exact test to measure the gene-enrichment in the biological process 
groups and groups with a p value <0.05 were considered to be specifically 
associated with the gene list. Each gene is represented by more than one probe 
on the Affymetrix GeneChip and therefore there may be several entities in the 
gene list which correspond to the same gene, DAVID analysis takes this into 
account and will only analyse each gene once irrespective of how many times it 
appears in the gene list.  
The gene lists which were analysed using DAVID were the up- and down-
regulated genes in RA blood CD14+ compared to healthy blood CD14+ and the up-
and down-regulated genes in PsA blood CD14+ compared to healthy blood. 
Related groups of genes with a p value <0.05 were considered to be significantly 
enriched within the gene list, if there were several gene groups associated with 
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the gene list only the top 10 most significantly associated groups were analysed. 
Figure 3.6 shows the biological process gene groups which were expressed at a 
higher level in RA blood compared to healthy blood CD14+ (A) and those that 
were expressed at a lower level in RA blood (B). The upregulated groups of 
genes include genes associated with chemotaxis, which could be in preparation 
of the monocytes extravasating from the blood into the diseased joints, and 
genes associated with response to external stimulus. This latter gene group may 
be due to the proinflammatory stimuli found within the serum of arthritis 
patients but not healthy controls to which the RA blood monocytes are exposed 
[404, 405]. The downregulated groups of genes in RA PB monocytes include those 
that regulate intracellular protein complex localisation and negative regulation 
of cell migration which reinforces the results shown in graph (A) suggesting that 
RA blood monocytes are upregulating groups of genes which will enable the cell 
to migrate and respond to chemotaxis. 
Figure 3.7 indicates the biological process groups which were upregulated in PsA 
PB CD14+ compared to healthy controls (A) and downregulated in PsA PB 
compared to healthy control blood (B). The results of this analysis indicate that 
in comparison to healthy control monocytes the PsA blood monocytes have an 
increased expression of genes involved in DNA packaging, chromatin assembly 
and nucleosome assembly suggesting an overall reduction of DNA transcription 
and translation within these cells. The PsA blood monocytes are also 
upregulating genes involved in chemotaxis, which was also shown in the RA 
blood monocytes in the previous figure, and may be due to an increase in 
chemokines within the serum of PsA patients in comparison to healthy controls 
[265, 406]. The downregulated genes in the PsA blood samples are mainly 
involved in cell projection, morphogenesis, differentiation and metabolic 
processes which all involve a large amount of energy expenditure therefore the 
cells could be trying to conserve energy and resources.  
In summary, the purpose of this healthy blood and diseased blood comparison 
was to determine if there were any disease-specific genes not detected in the 
healthy controls as the PCA analysis had demonstrated that the blood CD14+ 
samples in healthy and diseased patients had similar genetic profiles. Despite 
the possibility that 5% of the genes within the gene lists generated are false 
positives due to not being able to apply a multiple testing correction (MTC) to 
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the data there were a considerable number of differentially expressed genes 
between the healthy blood samples and diseased samples. This indicates that 
there are disease specific genes being expressed in the monocytes which in the 
case of both RA and PsA included groups of genes required for chemotaxis and 
cell movement. This analysis also generated the surprising result that there are 
only 24 individual genes that are differentially expressed between RA and PsA 
blood monocytes, this would suggest that the blood monocytes are remarkably 
similar in the two forms of arthritis and may suggest that they play similar roles 
within the diseases.  
 
Figure 3.6 Up and downregulated groups of genes in RA blood compared to healthy blood 
DAVID analysis was used to discover the significantly up- and downregulated biological process 
gene groups as identified by gene ontology (GO). The 10 most significant biological process 
groups are shown which all have a p value <0.05 which is equivalent to a –log p value >1.30. 
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Figure 3.7 Up and downregulated groups of genes in PsA PB compared to healthy PB 
 DAVID analysis was used to discover the significantly up- and downregulated biological process 
gene groups as identified by gene ontology (GO). The 10 most significant biological process 
groups are shown which all have a p value <0.05 which is equivalent to a –log p value >1.30. 
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3.6.2 Comparison 2: Analysis of microarray results comparing 
psoriatic and rheumatoid patient blood CD14+ cells to 
synovial fluid CD14+ cells 
My major questions concerned changes occuring in the genetic profile as the 
CD14+ cells of PsA and RA patients move from the blood into the synovial 
compartment. The principle component analysis (PCA) plot of the RA and PsA PB 
and SF CD14+ (Figure 3.8) illustrates that there are numerous genetic differences 
between the PB and SF of both diseases indicated by the PB samples (blue and 
red circles) occupying a separate area of the PCA graph as the SF samples (green 
and purple circles). However this graph also shows that the PB CD14+ cells of 
both diseases and the SF CD14+ of the two diseases are transcriptionally similar 
to each other. This observation indicates that there are large genetic differences 
between the site from which the CD14+ were isolated (i.e. blood and synovial 
fluid) however the genetic differences between diseases at these sites  is small 
(i.e. RA and PsA SF CD14+ cells are transcriptomically similar). 
3.6.2.1 Statistical analysis of peripheral blood CD14+ compared to 
synovial fluid CD14+ 
All samples were pre-processed with the GC-RMA algorithm and quality control 
was performed on the 16 matched RA samples (8 PB and 8 SF) and then 
performed on the 16 matched PsA samples (8 PB and 8 SF). In order to pass the 
quality control filter each gene had to have a signal value between 20 and 100% 
and be expressed in all 16 samples. Again, this was selected due to the high 
heterogeneity of the 8 RA and 8 PsA patients with regard to disease duration and 
patient treatment. Ensuring that each gene was present in all of the 16 RA or 
PsA samples being tested meant that the analysis was only looking at genes 
changed in the disease condition as a whole and was not affected by an 
individual treatment type.  
Once the quality control had been performed a paired T test was undertaken for 
each disease comparing the matched PB and SF samples of each patient. The p 
value cut off was 0.05 and the Benjamini and Hochberg multiple testing 
correction was applied to the data which gives the genes a corrected p value. 
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Following this analysis there were:  
10763 significantly changed genes between RA PB CD14+ cells and RA SF CD14+ 
cells 
9533 significantly changed genes between PsA PB CD14+ cells and PsA SF CD14+ 
cells 
Figure 3.9 shows the profile plots of the significantly changed genes between RA 
PB and SF (A) and between PsA PB and SF (B). The profile plot is a visualisation 
tool similar to a heatmap to allow trends in genetic expression data to be 
identified, however its benefit over a heatmap is that it allows thousands of 
genes to be analysed simultaneously. On these graphs each line represents one 
gene and the colour of the line denotes the median GeneChip intensity value of 
that gene from the 8 blood samples; with blue signifying a low intensity value, 
yellow denotes an intermediate value and red denotes a high level of intensity. 
The profile plots indicate that there are a large number of genes in both 
diseases which are upregulated in the SF CD14+ cells compared to PB CD14+ cells; 
there are also a smaller number of genes which a downregulated in the SF cells 
compared to the PB CD14+ cells. 
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Figure 3.8 PCA analysis of PB and SF from RA and PsA patients 
PCA analysis was performed on the 32 samples to try and discover trends in the data as samples 
in the same area of the graph are considered to be genetically similar. Each circle represents an 
individual sample and all samples are colour coded per condition, red corresponds to RA PB, blue 
to PsA PB, purple to RA SF and green to PsA SF. 
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Figure 3.9 Profile plots of entities that are significantly changed between PB and SF in RA 
and PsA 
Each line on the profile plot represents one gene and the graphs indicate how the normalised 
signal intensities of the gene change between the PB samples and the SF samples. The colour of 
the line represents the median signal intensity of each gene in the PB samples. A blue line 
indicates the gene was expressed at a low level in the PB, a yellow line indicates an intermediate 
level and a red line a high level of signal intensity. 
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3.6.2.2 Fold change analysis and Ingenuity pathway analysis (IPA) 
of RA PB vs RA SF and PsA PB vs PsA SF 
The two gene lists which had been generated from the paired T test analysis 
were subjected to fold change analysis. Due to the substantial number of 
significantly expressed genes in both diseases a fold change cut off of ≥ 4 was 
applied to the data. In microarray data analysis the fold change cut off value is 
arbitrary and we were interested in genes with a high fold change difference 
between PB and SF. 
The fold change analysis gave the following results: 
 1686 genes significantly changed between RA PB and RA SF with a fold 
change ≥ 4 
 1149 genes significantly changed between PsA PB and PsA SF with a fold 
change ≥ 4 
The varying expression levels of these genes is depicted in Figure 3.10 which is a 
heatmap of all the significantly changed genes between the PB and SF samples 
of RA and PsA with a fold change cut off of 4. The heatmap displays the 
normalised signal intensity of each gene within the blood and synovial fluid 
samples of each patient. The range in colour represents the relative expression 
levels of the genes in each sample with green representing a low level of 
expression and red representing a high level of relative expression. Heatmaps 
are used as a visualisation tool and this figure is demonstrating the there appear 
to be many genes which are upregulated in the synovial fluid of the patients in 
comparison to the peripheral blood as demonstrated by the large number of 
genes which are green (low level of expression) in the peripheral blood cell but 
are red (high level of expression) in the synovial fluid cells.  
The two gene lists were then subjected to ingenuity pathway analysis (IPA) 
which may be used to analyse complicated gene sets and identify genes that are 
part of a common regulatory network. This software has advantages over DAVID 
analysis in addition to identifying the overrepresented molecular and cellular 
functions within the gene list IPA can also identify the canonical pathways as 
well as the diseases and disorders associated with the genes. IPA is similar to 
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DAVID analysis as it uses Fisher‘s exact test to determine whether an association 
of a biological process or a pathway with the dataset is due to random chance. 
The smaller the p value of the process or pathway the less likely that the 
association is random and the more significant the association, in this analysis p 
values less than 0.05 indicate a statistically significant non-random association. 
IPA determines the association of processes and pathways within the gene list by 
comparing it to a reference gene set, which in this case are all the genes 
expressed on the Affymetrix GeneChips, and calculating whether the pathways 
or processes are overrepresented in the gene list and whether this association is 
statistically significant using Fisher‘s exact test. 
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Figure 3.10 Heatmap of significantly changed genes with a fold change cut off of 4 between 
the PB and SF of PsA and RA patients 
The normalised signal intensity of each differentially expressed gene with a fold change cut off of 4 
or above is shown. The degree of colour represent the relative level of expression for each gene in 
each sample ranging from green - low relative expression, to red - high relative expression (see 
legend). It can be visualised that there are genes which are expressed at a low level in the blood 
and therefore a high level in the synovial fluid and vice versa. 
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3.6.2.3 IPA of RA blood vs RA synovial fluid CD14+ 
The 1686 differentially expressed genes between the RA PB and RA SF CD14+ 
samples with a fold change cut off of 4 were analysed using IPA. This analysis 
generated three sets of results associated with the gene lists; the top 5 
canonical pathways, the top 5 diseases and disorders and the top 5 molecular 
and cellular functions. 
Table 3.6 indicates the top 5 canonical pathways associated with the up- and 
downregulated genes observed in the RA synovial fluid samples. This analysis 
includes pathways which have previously been associated with RA such as the 
coagulation system and the role of macrophages in RA but also includes other 
pathways such as LXR/RXR activation.  
Figure 3.11 outlines the canonical pathway of LXR/RXR activation which was the 
most significant pathway associated with the RA PB vs SF gene list. All of the 
genes highlighted in the pathway are the 17 genes from the gene list associated 
with the RA comparison; all of these genes are highlighted in red which indicates 
that these genes were upregulated in the synovial fluid CD14+ cells compared to 
the PB CD14+ cells. These genes range from pro-inflammatory chemokines such 
as MCP-1 to the cholesterol efflux genes ApoE and ApoC1. The relevance of these 
genes to RA pathogenesis will be analysed in detail in the discussion section of 
this chapter. 
Table 3.7 outlines the diseases and disorders associated with the up- and down-
regulated genes expressed in RA SF CD14+ compared to RA PB CD14+. As would be 
expected all the diseases and disorders are related to or involve RA. The range 
of p values shown determines the significance of the gene list to different terms 
encompassed by the diseases and disorders. For example the term inflammatory 
disease includes more specific terms such as inflammatory disorder of the joint, 
arthritis or multiple sclerosis so depending on the association of the gene list 
with each term tested an individual p value is given. Due to the large number of 
terms that can be significant within one category a range of p values is outlined 
in the table. 
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Table 3.8 outlines the top 5 cellular functions associated with the gene list. The 
gene list comprises genes that are differentially expressed within the RA synovial 
fluid CD14+ cells and the cellular functions significantly overrepresented in this 
gene list are those which we would expect to be upregulated within the RA SF 
cells in comparison to the PB cells. Two of the cellular functions are cellular 
movement and immune cell trafficking which could be upregulated as a result of 
the CD14+ transendothelial migration from the blood vessels into the synovium 
[258, 407]. Since macrophages within the synovial compartment are known to 
participate in cellular interactions with several cell types such as fibroblasts 
[249], T cells [269, 314, 408], endothelial cells [407] and natural killer (NK) cells 
[251] it is no surprise that one of the top cellular functions associated with the 
RA SF CD14+ cells is cell-to-cell signalling and interaction. The final two cellular 
functions associated with RA SF CD14+ compared to PB cells are cellular growth 
and proliferation and cellular development which is logical due to the 
maturation that the CD14+ cells undergo into fully activated macrophages once 
they are within the synovium and exposed to the pro-inflammatory and hypoxic 
environment [409, 410]. 
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Table 3.6 The top 5 canonical pathways associated with the RA PB vs RA SF CD14+ 
comparision 
 
Canonical pathway 
p value (number of 
associated 
genes/total number 
of genes in pathway) 
 
LXR/RXR activation 
Hepatic fibrosis/ hepatic stellate cell activation 
Role of mø, fibroblasts and endothelial cells in RA 
LPS/IL-1 mediated inhibition of RXR function 
Coagulation system 
 
3.96 x 10-7 (17/86) 
2.27 x 10-5 (21/131) 
7.20 x 10-5 (36/366) 
1.07 x 10-4 (25/205) 
1.98 x 10-4 (9/37) 
 
Table 3.7 The top 5 diseases and disorders associated with the RA PB vs RA SF CD14
+
 
comparison 
 
Diseases and Disorders 
 
p value 
 
Connective Tissue Disorders  
Inflammatory Diseases 
Skeletal and Muscular Disorders 
Immunological Diseases 
Inflammatory Response 
 
4.68x10-15 – 4.77x10-4 
4.68x10-15 – 5.90 x 10-4 
4.68x10-15 – 4.77x10-4 
9.70x10-14 – 4.43x10-5 
2.79x10-13 – 7.03x10-4 
 
Table 3.8 Top 5 molecular and cellular functions associated with the RA PB vs RA SF CD14
+
 
comparison 
 
Molecular and Cellular Functions 
 
p value 
 
Cellular movement 
Cell-to-cell signalling and interaction 
Cellular growth and proliferation 
Immune cell trafficking 
Cellular development  
 
1.00x10-23 – 5.90x10-4 
1.40x10-17 – 7.03x10-4 
9.08x10-17 – 7.05x10-4 
1.72x10-15 – 1.35x10-4 
7.08x10-13 – 6.89x10-4 
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Figure 3.11 LXR/RXR activation canonical pathway associated with the RA PB vs SF 
comparison 
This diagram outlines the genes involved in LXR and RXR activation which were differentially 
expressed in the RA PB vs RA SF comparison. The genes which are coloured red are those which 
were expressed at a higher level in the RA SF cells and therefore are genes which are upregulated 
once the blood CD14
+
 cells enter the synovial environment. 
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3.6.2.4 IPA analysis of PsA blood vs PsA synovial fluid CD14+ 
The 1149 genes differentially expressed with a fold change ≥ 4 in the PsA 
synovial fluid compared to the PsA blood CD14+ were analysed using IPA. As with 
the RA blood vs synovial fluid investigation this analysis yielded three sets of 
results associated with the gene list: the top 5 canonical pathways, the top 5 
diseases and disorders and the top 5 molecular and cellular functions. 
Table 3.9 demonstrates the top 5 canonical pathways associated with the 
differentially expressed genes in the PsA SF CD14+ samples compared to the PsA 
CD14+ blood samples. Three of the pathways overlap with the results of RA SF 
associated pathways once again emphasizing the similarities between the 
synovial fluid macrophages of both RA and PsA. The PsA SF specific canonical 
pathways included the complement system and intriguingly the pathogenesis of 
multiple sclerosis. The elements of this canonical pathway along with the PsA 
genes associated with it can be visualised in Figure 3.12. This diagram 
demonstrates that the PsA SF differentially expressed genes associated with the 
pathogenesis of multiple sclerosis pathway are all chemokines and emphasises 
the overlap in inflammatory gene expression between immune mediated 
diseases. 
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Table 3.10 outlines the diseases and disorders associated with the differentially 
expressed genes in PsA SF CD14+ cells compared to PsA PB CD14+ cells. As was 
observed with the RA SF gene set in Table 3.7 all of the diseases and disorders 
associated with immunological disease and the inflammatory response. 
Table 3.11 outlines the cellular functions associated with PsA SF CD14+ cell gene 
expression. There is considerable overlap between the cellular functions 
associated with PsA SF and RA SF CD14+ cells as four of the top five functions 
associated with RA are also associated with PsA. All of the five cellular functions 
would be expected to be differentially expressed in PsA SF CD14+ cells compared 
to the matched peripheral blood cells. In PsA, monocytes are known to migrate 
from the blood into the inflamed joint [254, 411] (demonstrated by the functions 
cellular movement and immune cell trafficking) where they interact with other 
cell types and illicit an immune response [412] (demonstrated by the functions 
cell-to-cell signalling and interactions and cell mediated immune response), the 
pro-inflammatory environment also enables the differentiation of these cells 
into activated macrophages (demonstrated by the function cellular growth and 
proliferation). Hence, the cellular functions being undertaken by the PsA SF 
CD14+ cells as they move from the blood into the synovium are the functions 
needed to transform them into an activated, pro-inflammatory immune cell 
capable of sustaining the chronic inflammation seen in psoriatic arthritis. 
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Table 3.9 Canonical pathways associated with the PsA PB vs PsA SF CD14
+
 comparison 
Canonical pathway p value (number of 
associated genes/total 
genes in pathway) 
LXR/RXR activation  
Complement system 
LPS/IL-1 mediated inhibition of RXR function 
Pathogenesis of multiple sclerosis 
Hepatic fibrosis/hepatic stellate cell activation 
8.52 x 10-6 (13/86) 
7.12 x 10-5 (8/35) 
2.09 x 10-4 (20/205) 
4.50 x 10-4 (4/9) 
1.67 x 10-3 (14/131) 
 
Figure 3.12 Pathogenesis of multiple sclerosis canonical pathway associated with the PsA 
PB vs PsA SF CD14+ cell comparison. 
Component of the pathway coloured red are genes that are upregulated in the PsA SF CD14+ 
cells. Four of the nine pathway components are upregulated in PsA SF macrophages. 
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Table 3.10 Diseases and disorders associated with the PsA PB vs PsA SF CD14
+
 
comparison 
 
Diseases and Disorders 
 
p value 
 
Inflammatory Disease 
Connective Tissue Disorder 
Skeletal and Muscular Disorders 
Immunological Disease 
Inflammatory Response 
 
2.58x10-15 – 2.21x10-3 
2.76x10-15 – 2.08x10-3 
2.76x10-15 – 1.70x10-3 
6.64x10-14 – 2.08x10-3 
4.83x10-10 – 2.21x10-3 
 
Table 3.11 Molecular and cellular functions associated with the PsA PB vs PsA SF CD14
+
 
comparison 
 
Molecular and Cellular Function 
 
p value 
 
Cellular Movement 
Cell-to-cell signalling and interaction 
Cellular Growth and Proliferation 
Immune Cell Trafficking 
Cell Mediated Immune Response 
 
2.98x10-20 – 2.31x10-3 
1.51x10-16 – 2.15x10-3 
3.41x10-13 – 2.21x10-3 
1.18x10-13 – 1.14x10-3 
7.86x10-9 – 2.15x10-3 
 
164 
3.6.2.5 Depicting RA and PsA differentially expressed genes 
Analysis of the foregoing results identified the interesting observation that the 
synovial fluid CD14+ cells of both the RA and PsA patients shared substantial 
similarity in gene expression. This observation was first identified by examining 
the PCA plot (Figure 3.8) depicting the SF samples of both diseases were co-
localised indicating a similarity in the overall transcriptomes of the two diseases. 
The subsequent IPA analysis then identified that many of the same canonical 
pathways and cellular functions appeared in both diseases therefore signifying a 
similarity in gene expression. Consequently, it was decided to further analyse 
the genes that had changed in the RA and PsA PB and SF samples as we 
hypothesized that there would be a subset of genes that changed in both 
diseases as well as subsets of genes that had only changed in RA or PsA. To 
answer this hypothesis a Venn diagram was constructed (Figure 3.13) using the 
following gene lists: 
All entities (shown in blue), which is the list of genes that had a positive signal 
on the GeneChip in any of the samples. This is the starting list of genes before 
any quality control analysis has been done.  
PsA PB vs PsA SF (shown in green), these are the differentially expressed genes 
between PsA PB and PsA SF. According to a paired T test and Benjamini and 
Hochberg MTC each gene has a corrected p value ≤ 0.05. 
RA PB vs RA SF (shown in red), this list represents the differentially expressed 
genes between RA PB and RA SF. The p values were calculated in the same 
manner as those for the PsA comparsion. 
Figure 3.13 indicates the Venn diagram, analysing the results proved our 
hypothesis to be correct as the diagram produced three gene lists: 
1. Genes that are specifically changed in only the RA PB vs RA SF analysis 
(5158 genes) 
2. Genes that are specifically changed only in the PsA PB vs PsA SF analysis 
(3928 genes) 
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3. Genes that are changed in both diseases (5605 genes) 
These gene lists also demonstrate that 58% (5605 of 9533 total genes) of the PsA 
SF CD14+ differentially expressed genes and 52% (5605 of 10763 total genes) of 
the RA SF CD14+ differentially expressed genes are present in both of the 
diseases. This indicates that there is a significant and substantial amount of 
overlap between the transcriptomes of the synovial fluid CD14+ cells of the two 
diseases. 
 
 
 
Figure 3.13 Venn diagram of the differentially expressed genes between RA PB and SF and 
between PsA PB and SF 
Gene lists were applied to the Venn diagram in order to distinguish genes that were changed in 
both RA and PsA and genes that were changed in only one of the diseases. The blue circle 
represents all of the genes which were expressed on the Affymetrix GeneChips. The red circle 
represents differentially expressed genes between RA PB and RA SF which had a p value ≤ 0.05. 
The green circle represents the differentially expressed genes between the PsA PB and PsA SF 
which had a p value ≤ 0.05. The regions where these three circles overlap represent genes which 
are expressed in both RA and PsA (5605 genes), in RA only (5158 genes) and in PsA only (3928 
genes). 
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Prior to any further analysis a fold change cut off of 4 was applied to the data. 
Since the fold change cut off in microarray data analysis is arbitrary we decided 
a high fold change cut off to specifically focus on the genes that were 
differentially expressed to a large extent. The fold change cut off gave the 
following three gene lists: 
1. Up- and downregulated genes that are changed in both diseases (873 
genes) 
2. Up- and downregulated genes that are changed in the PsA PB vs PsA SF  
analysis only (154 genes) 
3. Up- and downregulated genes that are changed in the RA PB vs RA SF 
analysis only (348 genes) 
IPA analysis was subsequently performed on these three gene lists to determine 
the canonical pathways associated with both diseases and each disease 
individually. Specifically the genes that were up- and down-regulated in the 
synovial fluid compared to the peripheral blood CD14+ cells of the diseases were 
analysed to try to determine what pathways were activated within the synovial 
fluid macrophages once they were exposed to the proinflammatory environment 
of the joint. The diseases and disorders analyses in the previous IPA comparisons 
were not very informative as they highlighted that the diseases associated with 
our gene lists were related to arthritic and inflammatory disorders. Therefore in 
this IPA analysis only the canonical pathways and molecular functions associated 
with the genes lists were investigated. 
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Table 3.12 shows the canonical pathways associated with the differentially 
expressed genes that were similarly expressed in both RA and PsA synovial fluid. 
These pathways are the same as those that were identified in the IPA analysis of 
the RA PB vs SF and PsA PB vs SF comparison (Table 3.6 and Table 3.9 
respectively). Table 3.13 demonstrates the molecular and cellular functions 
associated with the gene list which was differentially expressed in both RA and 
PsA synovial macrophages. These functions have previously been identified in 
the RA PB vs SF and the PsA PB vs SF comparisons and demonstrate the shared 
macrophage functions between the two diseases. 
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Table 3.14 identified the canonical pathways that are significantly associated 
with the subset of genes which are differentially expressed specifically in the 
synovial fluid CD14+ cells of the PsA patients but not the RA patients. It outlines 
pathways that would not usually be associated with macrophages such as B cell 
development and altered B and T cell signalling in RA. Investigating the 
differentially expressed genes from the gene list which are associated with these 
pathways identifies genes that are expressed in both macrophages and B cells/T 
cells such as CD40, MHC II and TLR3. This result is highlighted in Figure 3.14 
which demonstrates that the two genes within B cell development canonical 
pathway associated with the PsA only gene list, are MHC II and CD40 which are 
two genes that are known to be expressed in both B cell and macrophages. 
Table 3.15 outlines the molecular and cellular functions associated with the 
differentially expressed genes found specifically in the PsA SF CD14+ cells 
compared to the PsA PB CD14+ cells. Two of these functions, cellular movement 
and cell-to-cell signalling and interaction, were previously associated with the 
broad PsA PB vs SF CD14+ comparison, however the other three functions which 
consist of DNA replication, cell cycle and cell death are unique to the PsA SF 
CD14+ expressed genes and demonstrate the disease specific cellular functions. 
Table 3.16 outlines the canonical pathways significantly associated with the 
subset of genes differentially expressed specifically within the RA synovial fluid 
CD14+ cells. The top two pathways were previously associated with the 
differentially expressed genes in RA PB vs SF (see Table 3.6) however this 
analysis of the unique genes expressed in RA SF cells identifies three other 
pathways involving intracellular signalling within the macrophages including 
atherosclerotic, p38 and ERK5 signalling. Figure 3.15 demonstrates the ERK5 
canonical pathway and outlines the five genes from the RA gene list which were 
associated with the pathway. In this figure, genes highlighted in green were 
expressed at a higher level in the RA PB CD14+ cells compared to the SF cells 
whereas genes highlighted in red denote the genes which were expressed at a 
higher level in the RA SF CD14+ cells compared to RA PB CD14+ cells. Table 3.17 
outlines the molecular and cellular functions associated with the gene list 
expressed by RA SF CD14+ cells only. All of these functions were previously 
associated with the broad analysis of RA PB vs SF CD14+ apart from the function 
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of cell morphology. Hence cell morphology is a disease specific function and is 
only associated with RA SF CD14+ cells. 
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Table 3.12 Canonical pathways associated with the differentially expressed genes in BOTH 
RA and PsA synovial fluid 
 
Canonical Pathways expressed in BOTH RA and 
PsA synovial fluid CD14+ 
P value (number of associated 
genes/total number of genes 
in pathway) 
LXR/RXR activation 
LPS/IL-1 mediated inhibition of RXR function 
Complement system 
Hepatic fibrosis/Hepatic stellate cell activation 
Pathogenesis of Multiple Sclerosis  
3.28x10-6 (12/76) 
7.07x10-5 (18/197) 
1.00x10-4 (7/34) 
1.52x10-3 (12/128) 
3.11x10-3 (3/9) 
 
Table 3.13 Molecular and cellular functions associated with the differentially expressed 
genes in BOTH RA and PsA synovial fluid 
 
Molecular and cellular functions associated 
with BOTH RA and PsA synovial fluid CD14+ 
P value 
Cellular movement 
Cellular growth and proliferation 
Cell-to-cell signalling and interaction 
Cellular development 
Cellular function and maintenance  
9.80x10-17 – 1.15x10-2 
3.51x10-12 – 1.15x10-2 
1.09x10-11 – 1.15x10-2 
3.96x10-7 – 1.15x10-2 
5.32x10-7 – 1.15x10-2 
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Table 3.14 Canonical pathways associated with the differentially expressed genes in PsA 
only 
 
 
Canonical pathways expressed in PsA synovial fluid 
CD14+ only 
P Value (number of 
associated genes/total 
number of genes in 
pathway) 
B cell development  
Allograft rejection signalling  
Pathogenesis of Multiple Sclerosis 
Autoimmune Thyroid disease signalling  
Altered T and B cell signalling in Rheumatoid Arthritis 
8.08x10-4 (3/30) 
1.53x10-3 (3/51) 
1.75x10-3 (2/9) 
1.79x10-3 (3/53) 
2x10-3 (4/85) 
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Figure 3.14 B cell development canonical pathway associated with the genes expressed in 
PsA synovial fluid only 
The two genes highlighted within this pathway (MHC II, CD40) are expressed in the PsA only gene 
list and are associated with this pathway. These genes are highlighted in red which indicates that 
they were upregulated in the PsA SF compared to PsA PB. 
 
Table 3.15 Molecular and cellular functions associated with the differentially expressed 
genes in PsA only 
Molecular and cellular functions associated with 
PsA synovial fluid CD14+ only 
P value 
Cellular movement  
DNA replication, recombination and repair 
Cell-to-cell signalling and interaction 
Cell cycle 
Cell death 
3.34x10-7 – 2.16x10-2 
1.08x10-5 – 1.91x10-2 
1.74x10-5 – 2.16x10-2 
2.46x10-5 – 2.16x10-2 
3.47x10-5 – 2.16x10-2 
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Table 3.16 Canonical pathways associated with the differentially expressed genes in RA 
only 
 
Canonical pathways expressed in RA synovial 
fluid CD14+ only 
p value (number of 
associated genes/total 
number of genes in 
pathway) 
Heptatic fibrosis/hepatic stellate cell activation 
Role of mø/fibroblasts and endothelial cells in RA 
Atherosclerosis signalling 
p38 MAPK signalling 
ERK5 signalling 
5.27x10-5 (9/128) 
2.19x10-4 (13/329) 
2.95x10-4 (7/107) 
1.52x10-3 (6/96) 
1.54x10-3 (5/69) 
 
174 
 
Figure 3.15 ERK5 signalling canonical pathway associated with the genes expressed in RA 
synovial fluid only 
The highlighted genes are those that were differentially expressed only in the RA PB vs RA SF 
comparison. Genes highlighted in green indicate genes which were downregulated in RA SF 
CD14
+
 cells and therefore were expressed at a higher level in RA PB CD14
+
 cells. Genes which 
are highlighted in red demonstrate genes which were expressed at a higher level in RA SF CD14
+
 
cells compared to the RA PB CD14
+
 cells. 
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Table 3.17 Molecular and cellular functions associated with the differentially expressed 
genes in RA only 
Molecular and cellular functions associated with 
RA synovial fluid CD14+ only 
P value 
Cellular movement  
Cellular growth and proliferation 
Cellular development 
Cell-to-cell signalling and interaction 
Cell morphology 
1.09x10-14 – 4.09x10-3 
3.19x10-11 – 3.75x10-3 
1.38x10-9 – 4.12x10-3 
4.87x10-9 – 3.57x10-3 
9.64x10-8 – 4.90x10-3 
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3.6.2.6 Table of genes highly upregulated in both RA and PsA SF 
samples 
The IPA analysis was very informative in defining the groups of genes and the 
pathways involved in the RA and PsA synovial CD14+ cells however we also 
wanted to study individual genes and their expression within each disease to try 
and identify novel pathways of arthritis pathogenesis. The aim of the subsequent 
analysis therefore was to locate novel genes that were increased in the CD14+ SF 
samples of both diseases. The list of genes upregulated in both RA and PsA SF 
cells compared to their matched blood cells was obtained from the Venn 
diagram analysis and analysed in order of descending fold change. Starting from 
the most highly expressed genes in both RA and PsA synovial fluid literature 
searches were performed on genes to determine their function and expression. 
Unsurprisingly, many genes had been previously associated with or found to be 
highly expressed in either RA or PsA; however some novel genes were also found. 
Table 3.18 lists several of the genes that were analysed. 
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 Table 3.18 Gene upregulated in BOTH RA and PsA synovial fluid CD14+ cells 
 
Symbol Gene Name    Fold change  Fold change   Description of Gene 
       upregulation  upregulation 
in RA SF (p value) in PsA SF (p value) 
 
SPP1  Secreted phosphoprotein 1  1762 (3.8x10-4) 484 (3.2x10-4)  An extracellular matrix glycoprotein expressed  
(osteopontin)          by many inflammatory cells. It is up-regulated  
in response to injury and inflammation  [413]. 
Thrombin cleaved OPN is found in RA SF at a 
             30 times higher concentration compared to OA 
             SF [414]. 
 
CCL18  Chemokine ligand 18   326 (6.4x10-5)  375 (2.7x10-4)  A T cell attracting chemokine expressed by 
             monocytes/macrophages and DCs [415]. Levels  
of CCL18 in RA were higher than in OA in serum, 
synovial fluid, cartilage and synovial tissue. These 
levels were positively correlated with disease activity 
and rheumatoid factor levels [416, 417]. 
 
APOCI  Apolipoprotein C-I   482 (3.3x10-4)  344 (5.4x10-4)  Apo C-I along with Apo C-II are constituents of  
high-density lipoprotein (HDL) that slows the clearance 
of triglyceride-rich lipoproteins [418]. 
 
PLTP  Phospholipid transfer protein  98 (8.9x10-4)  246 (2.7x10-4)  PLTP facilitates the transfer of phospholipids  
from triglyceride-rich lipoproteins to HDL via an enzyme 
lipoprotein lipase (LPL) [419]. PLTP may play a role in 
atherosclerosis depending on its expression. Systemic 
over-expression of PLTP is associated with increased 
atherosclerosis susceptibility [420] whereas in an LDLr-
/- mouse model, which is susceptible to atherosclerosis, 
macrophage derived PTLP was found to be 
atheroprotective [421]. 
 
178 
AXL  AXL receptor tyrosine kinase  72 (0.002)  203 (2.4x10-4)  AXL subfamily is involved in cell adhesion,  
motility, angiogenesis and signal transduction. It may 
play a role in the invasiveness of cancers [422]. 
 
FN1  Fibronectin 1    263 (8.1x10-4)  172 (5.6x10-4)  A glycoprotein that has roles in adhesion of  
multiple cell types to the extracellular matrix (ECM), 
migration, proliferation, matrix remodelling and tissue 
repair [423]. Activated T cells and macrophages 
secrete fibronectin [424] and RA SF contains 2 to 3 
times more fibronectin than RA plasma [425]. 
Fibronectin is present in the SF, synovial membrane 
and plasma of PsA patients [426-428]. 
 
LGM  Legumain    167 (1.7x10-4)  164 (2.7x10-4)  A lysomal cysteine proteinase that is specific  
for the hydrolysis of asparaginyl bonds [429]. It can 
cleave and activate MMP2 [429]; α-thymosin [430]; 
fibronectin [431] and cathepsin B, H and L [432]. It is 
over-expressed in tumour associated macrophages in 
breast cancer tumours [433]; unstable atherosclerotic 
plaque macrophages [434]; and lesional atopic 
dermatitis and psoriasis [435]. 
 
AQP3  Aquaporin 3    62 (5.5x10-4)  30 (4.4x10-4)  A small hydrophobic membrane protein  
involved in the transport of water and glycerol across 
the cell membrane [436]. AQP3 is expressed in the 
basal layer of keratinocytes mammalian skin [437, 438]. 
AQP3 has been found in OA cartilage [439] and in 
PBMCs from RA patients where it was associated with 
DAS28-CRP levels [440]. 
 
NRP1  Neuropilin 1    11 (0.002)  40 (7.0x10-4)  Single pass transmembrane glycoprotein  
involved in cell motility and whose ligands include 
semaphorins and VEGF family members [356]. 
Neuropilin 1 is the VEGF 165 receptor in fibroblast like 
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synoviocytes in RA and is also expressed on infiltrating 
leukocytes [357]. Neuropilin 1 mRNA has also been 
detected in OA but not healthy cartilage samples [441].  
 
PLXNA1 Plexin A1    26 (4.9x10-4)  27 (9.9x10-4)  Single membrane spanning proteins which,  
along with neuropilins, are receptors for semaphorins 
[442]. Plexin A1 expression is increased during M-CSF 
differentiation [443] and it is thought to be important for 
T cell – DC interactions as plexin A1 deficient DCs 
Induced 50% less T cell proliferation than control DCs 
[444]. 
 
PDPN  Podoplanin    6 (0.02)  22 (0.001)  A mucin-type transmembrane glycoprotein that  
is involved in lymphatic vessel formation. It is a specific 
marker for lymphatic endothelium and is not expressed 
in blood vessels [445]. TNFα blockade therapy 
promotes the proliferation of lymphatic vessels, the 
inflamed synovium of RA and SpA patients receiving 
TNF blockade therapy stained for podoplanin [446]. 
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Table 3.18 demonstrates the subset of genes that were explored in silico in 
depth from the list of genes upregulated in SF CD14+ cells of both diseases. They 
were analysed based on their large fold change increased in the SF; this analysis 
was set up to try and discover novel genes that as yet had not been analysed in 
the context of RA and PsA arthritis. Several novel genes were found but after 
performing comprehensive literature searches two of these genes, an enzyme 
called legumain and a surface receptor called plexin A1, appeared to be 
candidate genes which may have particular relevance to the pathogenesis of the 
synovial macrophage in both PsA and RA. It was decided to concentrate further 
research on these two genes to try and discover why they were highly 
upregulated in the SF CD14+ cells of both RA and PsA. The following two chapters 
demonstrate the experimental work performed to try and understand the role of 
these genes within the synovial environment. 
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3.7 Discussion 
Microarrays have become a standard method to investigate differential disease 
states on the basis of genome-wide expression. Previously, there have been 
numerous microarray studies analysing the two diseases RA and PsA. However, 
these studies mainly focused on the gene expression of PBMCs or whole synovial 
tissue and as yet very few studies have measured the gene expression within 
individual immune cell types. Macrophages are an essential component of the 
inflammatory cell influx into the joint, being one of the major cell types 
producing the pro-inflammatory cytokines, chemokines and extracellular matrix 
components which all contribute to the destruction and degradation of the 
arthritic joint [258]. Since very little is known about the transcriptomic profile 
of this cell type within RA or PsA we decided to microarray chip analyse several 
different samples to try and elucidate which genes were being expressed in (1) 
diseased blood monocytes compared to healthy controls, and (2) synovial fluid 
macrophages compared to blood monocytes. 
Once all the patient and normal samples had been collected, prepared and 
individually hybridized onto Affymetrix GeneChips the results were subjected to 
quality control to detect any outliers. Quality control must take place during 
microarray analysis to ensure that: i) the data is suitable to answer the 
experimenter‘s question and ii) the data is suitable for subsequent analysis 
[447]. For the current analysis quality control consisted of examining the signal 
intensity of the GeneChips on a signal histogram which resulted in the detection 
of a GeneChip which had an abnormal signal intensity. This outlier was further 
confirmed by analysing the principle component analysis (PCA) plot which graphs 
the overall transcriptomic signature of each sample. Quality control problems 
can come from several sources; for example the hybridisation step can cause 
uneven fluorescence on the chip and differences in RNA quality can produce 
variable signal intensity and reports have shown that removing outlier GeneChips 
can improve the detection of differentially expressed genes [447], therefore the 
outlier sample identified in this study was removed from further analysis. 
Once the outlier was removed a PCA plot of the samples was setup to identify 
trends in the data since samples clustered within the same area of the PCA 
graph are considered to be genetically similar [354]. This analysis identified that 
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the blood CD14+ cells from both RA and PsA were genetically similar and also the 
synovial fluid CD14+ cells from both diseases had similar genetic profiles, which 
was a surprising result as previous studies had identified differential subsets of 
macrophages in RA compared to PsA [253, 255]. On the basis of the PCA plot and 
the original hypotheses we decided to perform two main comparisons: i) the 
differentially expressed genes in the patient blood CD14+ cells compared to 
those of the healthy blood CD14+ cells, and ii) the differentially expressed genes 
in the patient synovial fluid CD14+ compared to the matched blood CD14+ cells. 
3.7.1 Comparison 1: Healthy blood versus diseased blood  
The first data comparison to take place was analysing CD14+ cells isolated from 
the blood of diseased patients and healthy controls. Previously there have been 
several microarray analyses comparing peripheral blood mononuclear cells 
(PBMCs) or peripheral blood cells (PBCs) of healthy donors to those of patients 
with rheumatic diseases such as RA, PsA and JIA [325-327, 329, 330, 340, 341]. 
These studies have been very informative in distinguishing disease specific 
expression profiles such as the microarray analysis work by van der Pouw Krann 
et al which discovered a type I IFN subpopulation of RA patients who had a 
higher expression of type I IFN specific genes and a distinct biomolecular 
phenotype compared to healthy controls [329]. Batliwalla et al performed a 
similar microarray analysis comparing the PBCs of PsA patients to those of 
healthy controls and identified specific genes that could discriminate healthy 
controls from PsA patients, which they suggested could act as diagnostic 
biomarkers for PsA [340]. Consequently, microarray analysis comparing healthy 
and diseased peripheral blood cells have provided a wealth of information for 
rheumatic disease and identified many disease specific genes and biological 
processes.  
However, this type of analysis is not without problems and several analyses have 
reported skewing of the overall data and gene expression due to differing 
numbers of cell subtypes within the whole blood. Batliwalla et al came across 
this problem when examining the gene expression profiles of PBCs from RA 
patients to those isolated from healthy controls. They found 40% of the genes 
differentially upregulated in the RA cells were classed as ―monocyte enriched‖ 
which they later discovered was due to significantly higher numbers of 
183 
monocytes in the RA patient PBCs compared to those of healthy controls [326]. 
Thus whilst microarray analysis on whole blood cells is informative, difficulties 
can arise when trying to account for differences in the number of cell subtypes 
which can cause complications when trying to compare and verify work between 
groups.  
Whole blood microarray profiling may also be masking the individual contribution 
of cell subtypes to the disease therefore microarray analysis of individual cell 
types from diseased patients may be a useful strategy in understanding the 
genetic makeup of these cells. Recently, a small number of studies have been 
performed looking at the gene expression profiles of specific cell types in RA 
such as B cells [336], CD4+ T cells [337] and fibroblasts [334]. One study 
performed by Stuhlmuller et al has also analysed the gene expression of RA 
blood monocytes isolated during the course of leukapheresis treatment [338]. 
However, at present there have been no studies analysing the blood monocytes 
of RA and PsA compared to healthy donor blood monocytes. Given the 
importance of the monocyte/macrophage in the pathogenesis of RA and PsA we 
hypothesised that analysing the gene expression profile of this cell subset in 
comparison to healthy controls may elucidate disease specific genes and also 
discriminate differences in gene expression between the two diseases. 
Peripheral blood isolated CD14+ cells were analysed from 8 RA patients, 8 PsA 
patients and 5 healthy controls. When these samples were analysed on the PCA 
plot (Figure 3.4) we discovered the intriguing result that all of the peripheral 
blood samples were clustered together indicating a similar gene expression 
profile expressed by the healthy and diseased sample conditions. Since most of 
the previous microarray experiments of healthy vs diseased PBMCs have 
demonstrated a significant difference in the genetic profiles of the two 
conditions this result may suggest that the large genetic differences seen in 
these experiments are not the result of differences in the monocytes but may be 
due to large genetic differences between other cell subtypes. 
Of the 12 genes which are upregulated in RA blood monocytes compared to PsA 
monocytes three (NCAM1, PKP2 and LAMC1) are associated with cell adhesion 
and interaction. Neural cell adhesion molecule 1 (NCAM1) otherwise known as 
CD56 is usually expressed on cytotoxic cells such as natural killer (NK) cells and 
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NK-T cells. However, a small population of CD56+ monocytes have been 
identified in healthy individuals which can present antigen and produce a variety 
of monocyte cytokines in response to LPS stimulation [448]. CD56+ NK cells are 
enriched at the inflammatory sites in RA where they have been found to interact 
with monocytes and induce TNFα expression in a cell contact dependent manner 
[251, 449]. Conversely, CD56+ CD8+ CD28- T cells displayed strong anti-
inflammatory properties in a SCID mouse chimera model of human RA by 
interacting with APCs and causing the subsequent down-regulation of CD80 and 
CD86 [450]. NCAM1 is known to mediate cell-cell adhesion and the data above 
suggests that it plays a role in cell adhesion and interaction therefore we can 
hypothesise that NCAM1 expression in RA blood monocytes may be playing a role 
in cell-cell interaction.  
PKP2 and LAMC1 are two novel genes not previously associated with RA. 
Plakophilin 2 (PKP2) is normally found co-localised with adhesive junctions in 
cardiomyocytes and epithelial cells [368, 369] therefore its possible role in RA 
blood monocytes is unclear at present. LAMC1 (laminin gamma 1) is a subunit of 
all laminin molecules which are major constituents of basement membranes and, 
along with collagen, provide the basic scaffold to which other basement 
membrane proteins, such as proteoglycan, integrate [374]. Laminins have 
structural, adhesive and cell signalling functions and are able to modulate cell 
signalling behaviour and migration by interacting with cell surface integrin 
receptors [451]. Laminin has also previously been found to affect monocyte 
phagocytosis, and play a role in monocyte migration by inhibiting their adhesion 
to basement membranes thereby assisting their migration across the membrane 
and also by inducing spontaneous migration within the cells [452-455].  LAMC1 
has previously been detected in healthy blood monocytes, which was used to 
produce the molecule laminin-8, monocyte adhesion to laminin-8 also produced 
spontaneous and chemokines-induced migration [455]. Hence, the upregulation 
of LAMC1 in RA blood monocytes could help play a role in the migration of these 
cells across the basement membrane of the blood vessels thereby assisting their 
infiltration into the joint. 
Two genes which were upregulated in RA PB compared to PsA PB have previously 
been shown to be associated with RA. These genes are NRP1 (neuropilin-1) and 
IL7 (Interleukin 7). Neuropilin-1 is a receptor for vascular endothelial growth 
185 
factor (VEGF) and is expressed in the synovium of RA patients where it was 
specifically associated with the lining layer, infiltrating leukocytes and 
endothelial cells [357]. Recent work has shown that the interaction of 
neuropilin-1 with VEGF prevented apoptosis and was therefore crucial to 
rheumatoid synovial cell survival [357]. VEGF is detected in the serum of RA 
patients [456] and has been found to correlate with the development of 
radiographic damage and CRP level [457]. Since neuropilin-1 interaction with 
VEGF has been shown to prevent apoptosis in synoviocytes we hypothesis that 
neuropilin-1 is playing the same role in the blood monocytes and the 
upregulation of NRP1 in the RA monocytes could be a mechanism to prolong their 
survival.  
IL-7 has also previously been described in RA, serum levels of the cytokine are 
higher in RA patients compared to healthy controls and correlate with markers 
of inflammation [371]. IL-7+ cells correlate with the numbers of CD68+ cells in RA 
synovial lining and double staining has demonstrated that CD68+ cells are the 
major producer of IL-7 [371]. In RA blood and synovial fluid IL-7R is primarily 
expressed on T cells, with the highest expression on CD4+ cells. Numerous 
studies have focused on the role of IL-7 in RA, synovial fluid isolated CD4+ T cells 
are hyperresponsive to IL-7 and IL-7 enhanced cell-contact dependent activation 
of T cells and macrophages resulting in TNFα production [373]. IL-7 also 
enhances IFNγ and TNFα production from T cells [458]. Hence, the RA blood 
monocytes positive for the IL7 mRNA in this present study may be a source of the 
increased RA serum IL-7 levels and due to the cytokine‘s pro-inflammatory 
properties could be contributing to increased inflammation seen in these 
patients. 
Analysing the group of 12 genes that are upregulated in PsA PB monocytes 
compared to RA PB monocytes two groups of genes emerge, genes that are 
associated with response to stress and toxins (GSTM1, GSTM2 and EIF2AK3) and 
genes involved in transcription and its initiation (FOXP1, KLF9 and MED26). 
Glutathione S-transferase M1 and M2 (GSTM1 and GSTM2 respectively) are part of 
a broadly expressed family of enzymes which catalyse the conjugation of 
glutathione and are involved in the detoxification of cytotoxic carcinogens and 
metabolites. Glutathione is an intracellular antioxidant and is a prominent 
defence against reactive oxygen species, it acts as a radical quencher in cells by 
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removing superoxide anions and hydrogen peroxide and works to maintain the 
equilibrium between free radical production and antioxidant defence thereby 
reducing oxidative stress damage [383]. Oxidative stress has previously been 
shown to be implicated in the pathogenesis of RA and PsA where an excess of 
free radicals causes oxidation and subsequent damage to cartilage, extracellular 
matrix and DNA [459] and markers of oxidation have been found in the serum 
and synovial fluid of patients [460, 461]. Hassan et al measured the level of the 
antioxidant glutathione in RA serum compared to healthy controls and found it 
to be decreased whereas the levels of the enzyme glutathione S-transferase 
(GST) were increased, which the authors suggested could be a compensatory 
mechanism in the absence of its substrate glutathione [462]. Since our data has 
shown an increase in the levels of two GST proteins, GSTM1 and GSTM2, in PsA 
blood monocytes compared to RA blood monocytes these PsA patients may also 
be increasing their levels of these enzymes to due to the increased oxidative 
stress associated with this disease and the decrease in antioxidant glutathione. 
Of interest, polymorphisms in GST genes have been associated with RA 
susceptibility, these genes include GST Theta (GSTT1), GST Pi (GSTP1) and in 
particular one of our genes of interest GST Mu (GSTM1) [385]. Some of the 
polymorphisms also show an additive effect with smoking and patients carrying 
the polymorphisms who also smoke were found to be at an increased risk of 
disease with higher disease severity [463]. Despite no susceptibility being 
reported for PsA these findings highlight the potential importance of GST 
enzymes within the pathogenesis of psoriatic arthritis. 
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) otherwise 
known as PERK is an endoplasmic reticulum (ER) transmembrane protein kinase. 
The function of the ER is to correctly fold and process proteins which are 
intended for the secretory pathway before they are transported to the Golgi 
apparatus. If the secretory demand exceeds the folding capacity of the ER, the 
accumulated mis- or unfolded proteins, often called ER stress, activates the 
unfolded protein response (UPR). The UPR aims to enhance the processing, 
assembly and transport of secretory proteins. PERK is a UPR sensor, its role is to 
reduce global translation thereby allowing the cell to correct for the impaired 
protein folding resulting from the ER stress before allowing additional secretory 
proteins to be synthesised [402]. PERK does this by phosphorylating eIF2 which 
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prevents the release of the translation factor from the ribosomal machinery and 
thus reduces translation [464]. At present there have been no studies performed 
on the role of the UPR in psoriatic arthritis, however another 
spondyloarthropathy ankylosing spondylitis (AS) has shown associations between 
the molecule HLA-B27, which is present in up to 96% of patients [465], and the 
UPR. Research into AS in HLA-B27 transgenic rats has shown that HLA-B27 has 
the propensity to mis-fold resulting in ER stress and the activation of the UPR 
[466]. Consequently, the upregulation of the UPR sensor PERK in PsA compared 
to RA blood monocytes may be an indication that the PsA monocytes are more 
exposed to mediators of ER stress such as metabolic stress or mutant/over 
expression of secreted proteins as is seen in the spondyloarthropathy AS which 
shares some clinical features with PsA. 
As mentioned above there are also a group of genes upregulated in PsA blood 
monocytes which are associated with transcription initiation namely FOXP1, 
KFL9 and MED26. Forkhead box P1 (FOXP1) is a member of the FOX family of 
transcription factors and is involved in B cell development [390], thymocyte 
development [391] and monocyte differentiation in vitro and in vivo [392, 467]. 
FOXP1 must be downregulated by the monocyte in order for it to fully 
differentiate into a macrophage, because mice which are transgenic for FOXP1 
have reduced M-CSF receptor expression, impaired migratory capacity and 
diminished macrophage function such as cytokine production [392]. Since PsA 
monocytes expressed FOXP1 as 2.7 fold change increase compared to RA 
monocytes this could suggest that at the time of the samples being taken the RA 
monocytes were more differentiated towards a macrophage phenotype 
compared to the PsA monocytes. 
Kruppel-like factor 9 (KLF9) is a member of the Kruppel-like family (KLF) of zinc 
finger transcription factors. There are 25 KLFs proteins known at present, which 
bind to GC/GT boxes found in promoter regions and enhancer/silencer regions of 
multiple chromosomal genes [468]. KLF9 has been identified as having a 
stimulatory role in neuronal cell process formation and differentiation [469] and 
endometrial cell proliferation [470]. A recent study has also shown that mice 
lacking KLF9 have disregulated intestinal crypt cell proliferation and villus cell 
migration [471]. The exact role of KLF9 within PsA blood monocytes is unclear at 
present but it could play a role in monocyte migration into the diseased joint. 
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Mediator complex subunit 26 (MED26) is one of at least 30 subunits that make up 
the mediator complex. The mediator complex is a required part of 
transcriptional activation and serves as an adaptor between the transcription 
factors bound at the regulatory elements on the DNA and both RNA polymerase II 
and the general transcription factors [472]. At present the exact role of MED26 
within the mediator complex is unknown therefore it is difficult to speculate on 
the role of MED26 on PsA blood monocytes however it could indicate an increase 
in the amount of general transcription taking place within the monocytes. 
Database for annotation, visualisation and integrated discovery (DAVID) software 
was used in this analysis to determine if there is a significant enrichment of 
different biological processes within the two remaining gene lists: (1) 
differentially expressed genes between RA PB monocytes and healthy blood 
monocytes (2) differentially expressed genes between PsA PB monocytes and 
healthy blood monocytes.  
The DAVID analysis of the genes which were expressed at a higher level in RA 
blood compared to healthy blood monocytes (Figure 3.6) demonstrated two 
distinct groups of genes, response to stimulus (indicated by the three biological 
processes response to external stimulus, response to chemical stimulus and 
response to wounding) and cellular movement (indicated by the three biological 
processes chemotaxis, taxis and locomotion). The other biological processes 
associated with this RA gene list were negative regulation of cellular process and 
positive regulation of cellular process, which both contain many of the same 
genes. Since these biological processes conflict highly with each other they were 
not analysed further.  
The RA blood monocytes may be up-regulating genes associated with response to 
stimulus function due to the pro-inflammatory stimuli present in the serum of RA 
patients which are not found in healthy controls. The three biological process 
groups: response to stimulus, response to chemical stimulus and response to 
wounding contain many of the same genes including; TSP1 (thrombospondin-1), 
SOCS3 (suppressor of cytokine signalling 3) and CLU (clusterin). Thrombospondin-
1 has previously been associated with RA [473] and a recent study indicated that 
serum thrombospondin-1 levels were increased in RA patients compared to 
healthy controls and correlated with increased serum levels of pro-inflammatory 
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cytokines [474]. This study validates the data found in this experiment which 
indicates thrombospondin-1 is expressed at a higher level in RA PB monocytes 
compared to healthy controls and is significantly associated with biological 
processes involving response to environmental stimuli. 
Another gene associated with all three response to stimuli related biological 
processes is suppressor of cytokine signalling 3 (SOCS3). The SOCS family consists 
of SOCS1–SOCS7 and cytokine-inducible SH2 (CIS) and their role is to tightly 
regulate the activity of the JAK-STAT pathway [475]. They are not constitutively 
expressed in cells but their expression is induced by a range of cytokines via 
activated STATs [476]. Once expressed they inhibit the JAK-STAT pathway by 
several mechanisms such as prevention of STAT recruitment to activated 
cytokine receptors, induction of substrate degradation and suppression of JAK 
catalytic activity [477]. SOCS3 levels are significantly higher in RA PBMCs 
compared to healthy controls, which was found to be due to the upregulation of 
SOCS3 specifically in the RA blood monocytes [478]. SOCS3 overexpression is 
effective in preventing the development of murine collagen induced arthritis 
(CIA) [479] and SOCS3 knockout mice, which have a constitutive lack of SOCS3 in 
hematopoetic and endothelial cells, developed a more severe form of acute IL-1 
dependent inflammatory arthritis [480]. Taken together these results suggest 
that SOCS3 is a critical negative regulator in inflammatory arthritis. Our data 
indicate that SOCS3 is upregulated in RA PB compared to healthy control 
monocytes which was also found by Isomaki et al [478]. This upregulation is no 
doubt caused by the increased pro-inflammatory environment to which the RA 
monocytes are exposed to within the blood and may be a regulatory mechanism 
of the cells to try and reduce the overactive inflammatory response. However, 
SOCS expression is known to alter cellular responsiveness to cytokines therefore 
up-regulation of SOCS3 may be involved in disease progression by causing 
unresponsiveness to anti-inflammatory genes.  
Clusterin (CLU) was another gene associated with the response to stimulus 
processes outlined in the DAVID analysis. It was the most differentially expressed 
genes in the RA PB vs healthy blood monocyte comparison with a fold change 
increase in RA PB of 40 it also had the second highest p value of 1.80 x10-4. Since 
a multiple testing correction was unable to be used in the analysis a high p value 
indicates that this change is more likely to be a true result and not a false 
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positive. CLU is a secreted heterodimeric protein which was initially described as 
a complement inhibitor protein, where its role is to protect cells from the 
membrane attack complex (MAC) by binding to the MAC and rendering it 
physiologically inactive [481]. It has since been found to interact with a variety 
of molecules including lipids, amyloid proteins, and Igs. However, unravelling 
the function of CLU is complicated by its ability to interact with several 
molecules and its differential expression in many diseased states such as 
neurodegenerative disease and cancer [482, 483]. Recently it became apparent 
that different functions of CLU might depend on its final maturation and 
localisation, and whilst its predominant form is a secreted 80 kDa heterodimeric 
protein (sCLU) a nuclear form of the protein (nCLU) has also been reported 
which is thought to be responsible for its functions involving NF-κB and apoptosis 
[484]. This suggests that CLU can have different functions depending on whether 
it is expressed inside or outside of the cell. 
Santilli et al reported that the intracellular level of nCLU could be essential for 
regulation of NF-κB activity through its ability to stabilise inhibitors of NF-κB 
(IκB) [485]. Consequently, Devauchelle et al further demonstrated that nCLU 
interacts with phosphorylated IκB and prevented it from being degraded by the 
E3 ubiquitin ligase βTrCP and therefore blocking NF-κB activation [486]. This 
latter study was based on the result of a previous microarray experiment which 
demonstrated significantly lower amounts of CLU in the synovial membrane of 
RA patients compared to OA [320]. Subsequently it was concluded that the lack 
of CLU within the RA synovium would result in enhanced IκB degradation and 
therefore a greater activation status of NF-κB enabling pro-inflammatory gene 
expression. This finding was also supported by their observation that siRNA 
induced knockdown of CLU in cultured fibroblast-like synoviocytes (FLS) resulted 
in increased production of IL-8 and IL-6 cytokines which are regulated by NF-κB 
[486]. 
Numerous studies have analysed the role of CLU in the apoptosis of cancer cells 
but once again the function of CLU may depend on its form and localisation. 
sCLU inhibits apoptosis in human cancer cells by interfering with Bax activation 
in mitochondria [487] however, nCLU has been found to be pro-apoptotic as 
overexpression of nCLU resulted in cell death in both the presence or absence of 
ionizing radiation [488]. It is now accepted that a shift from the cell producing 
191 
sCLU to nCLU would result in cell death as nCLU has been found to induce cell 
death in many experimental conditions [489]. 
The finding that RA blood monocytes highly upregulate CLU compared to healthy 
blood monocytes is a significant one and has not been demonstrated previously. 
Of note the same pattern of upregulated CLU expression is also seen in PsA blood 
monocytes compared to healthy controls. Many reports conclude that CLU is an 
anti-inflammatory molecule in arthritis as CLU has been found at a reduced level 
in RA synovium compared to OA synovium [320] and CLU knockout mice induced 
with the K/BN model of arthritis developed arthritis faster which also lasted for 
longer compared to the control mice [490]. Hence the reasons for the large 
upregulation of CLU in RA PB (40 fold change increase) and PsA PB (20 fold 
change increase) compared to healthy controls are unknown. Since most reports 
demonstrate that CLU is anti-inflammatory the monocytes may be upregulating 
CLU as a counteractive mechanism as a result of the pro-inflammatory 
environment. Two of the most studied functions of CLU are inhibition of the NF-
κB pathway and induction of apoptosis. However, since several of the NF-κB 
target genes, such as IL-6, are consistently upregulated in the serum of RA 
patients and there have been no reports of increased apoptosis levels in PsA or 
RA PB monocytes, to the contrary the antiapoptotic molecule Mcl-1 has been 
found to be increased in CD14+ cells isolated from RA SF [491], this may suggest 
that CLU may have a different function within arthritic blood monocytes. CLU is 
a heterogenous molecule with many differing, often conflicting, functions and 
further work into the expression of this molecule within the cells and serum of 
RA and PsA patients is necessary. 
The second group of biological processes upregulated in RA PB monocytes 
compared to healthy controls were associated with cellular movement, indicated 
by the three biological processes chemotaxis, taxis and locomotion. This group 
of biological processes in significant for the pathogenesis of RA as one of the 
earliest events in RA is the ingress of leukocytes into the inflamed synovial 
tissue. In order for the cells to enter the synovium from the blood they must 
adhere to the endothelial cells and then migrate into the interstitial matrix 
which is aided by the upregulation of chemokines and chemokines receptor on 
the leukocytes and the endothelial cells [136]. Once again due to the 
heterogeneous nature of genes and their various functions many of the same 
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genes were significantly associated with all three chemotaxis associated 
biological processes which indicate the importance of cellular movement to the 
RA PB monocytes. Some of the genes associated with these biological processes 
are LAMC1, FPR1, FPR2 and PPBP. 
Laminin gamma 1 (LAMC1) has been described earlier on in this discussion as it 
was significantly upregulated in RA PB compared to PsA PB. It is a basement 
membrane molecule and may be helping the RA monocytes migration across the 
basement membrane of the blood vessels thereby allowing their subsequent 
infiltration into the joint. The two genes formyl peptide receptor 1 (FPR1) and 
formyl peptide receptor 2 (FPR2) were also both included in the chemotaxis, 
taxis and locomotion biological process groups. The protein product of FPR1 is 
known as formyl peptide receptor (FPR) and the protein product of FPR2 is 
denoted as formyl peptide receptor-like 1 (FPRL-1) which both belong to the 
seven transmembrane domain Gi-protein-coupled receptor (GPCR) family. Two 
of the main sources of ligands for this family of receptors are bacterial [492] and 
mitochondrial proteins [493] therefore the main function of these receptors is 
thought to be to mediate trafficking of phagocytes to sites of bacterial invasion, 
tissue damage or cell necrosis, although anti-inflammatory functions of some 
ligands has also been proposed [494]. FPR and FPRL-1 are detected on 
phagocytic leukocytes especially monocytes and neutrophils and activation of 
these receptors by their agonists results in Ca2+ mobilisation and cellular 
migration [495].  
There are numerous ligands for FPR and FPRL-1 and several of them have been 
previously found in the serum and synovial fluid of RA, one such ligand is soluble 
form of the urokinase-type plasminogen activator receptor (suPAR). suPAR is a 
ligand for FPRL-1 and has been demonstrated to be released by neutrophils 
isolated from the PB and SF of RA patients. Cell lines expressing FPRL-1 migrated 
towards the supernatants harvested from RA neutrophils thereby suggesting that 
neutrophils may be involved in the recruitment of FPRL-1 expressing cells into 
the diseased synovium [496]. Consequently, the upregulation of FPR and FPRL-1 
in RA blood monocytes in comparison to healthy control blood may be due to 
pro-inflammatory environment that the RA blood monocytes are exposed to 
which has been shown to contain the ligands for these receptors. Activation of 
FPR and FPRL-1 has been demonstrated to induce monocyte migration therefore 
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the upregulation of these genes may be a mechanism to induce monocyte 
recruitment into the synovial joint. 
Pro-platelet basic protein (PPBP) otherwise known as CXCL7 is the third gene 
associated with the cell migration group of biological processes upregulated in 
RA monocytes. It is translated as a 14 kDa propeptide called PPBP or leukocyte 
derived growth factor (LDGF) which can then be cleaved into several smaller 
forms called platelet basic protein (PBP), β-thromboglobulin (β-TG) connective 
tissue activating protein-3 (CTAP-III) and neutrophil activating peptide-2 (NAP-2) 
[497]. Peptidases such as cathepsin G, are known to play a role in the post-
transcriptional modifications of PPBP [498]. The derivatives of PPBP have 
amazing functional diversity: NAP-2 is a potent neutrophil chemoattractant 
[497]; PBP and CTAP-III have antimicrobial activity and LDGF itself is a fibroblast 
mitogen [497]. PBP was originally thought to be expressed only by cells of the 
megakaryocyte lineage but it has since been shown to be expressed by 
monocytes in response to various stimuli such as exposure to microbial 
components LPS or zymosan [499]. CTAP-III has previously been found in the 
blood circulation of RA patients, deposition of CTAP-III was found in the 
synovium and is associated with a partial processing to NAP-2 isoforms [500]. It is 
difficult to speculate on the importance of the upregulation of PPBP in RA blood 
monocytes due to its ability to be cleaved into several smaller forms which all 
have differing functions especially since cathepsin G, which can cleave PPBP, is 
present in RA serum [501]. Its main function may be to act as a neutrophil 
chemoattractant however further investigations are needed. 
The biological processes downregulated in RA PB compared to healthy control PB 
monocytes display three main functions: protein complex localisation 
(demonstrated by the two biological processes cellular protein complex 
localisation and protein complex localisation), selenocysteine incorporation 
(translational readthrough and selenocysteine incorporation) and negative 
regulation of cell movement (demonstrated by the three biological processes 
negative regulation of cell migration, locomotion and cell motion). A 
downregulation in protein complex localisation was indicated by the decrease in 
expression of SMAD7 (SMAD family member 7) and TMEM48 (transmembrane 
protein 48). SMAD7 is an inhibitor of TGF-β signalling, TGF-β is a multifunctional 
cytokine which regulates cell growth, adhesion and differentiation in a variety of 
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cell types and it is also a potent immunosuppressor. Therefore the RA PB 
monocytes downregulating SMAD7, the inhibitor of TGF-β, may be an 
autoregulatory mechanism to compensate for the increased inflammatory 
processes taking place. However SMAD7 had also been demonstrated to 
negatively regulate signalling intermediaries in pro-inflammatory signalling 
pathways such as NF-κB, in this pathway SMAD7 plays a role in increasing IκB 
expression [502]. Consequently the downregulation of SMAD7 by the RA PB 
monocytes may conversely enable NF-κB signalling and increase the production 
of pro-inflammatory cytokines therefore contributing to the increased pro-
inflammatory cytokines detected within RA serum. The other gene associated 
with protein complex localisation is TMEM48 that codes for the protein 
nucleoporin NDC1. This protein is required for nuclear pore complex assembly 
which are large multiprotein complexes that span the nuclear envelope forming 
a selective channel between the cytoplasm and the nucleus. There is very little 
information regarding nucleoporin NDC1 therefore at present the relevance of 
the downregulation of this gene in RA blood monocytes is unclear. 
Selenocysteine incorporation was also process downregulated by the RA PB 
monocytes indicated by the downregulation of the genes SEPSECS (Sep (O-
phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase) and TRSPAP1 (tRNA 
selenocyteine associated protein 1). Selenocysteine incorporation it is an 
essential process required for the production of at least 25 selenoproteins. 
Selenocysteine is comprised of the trace element selenium which is an 
antioxidant, deficiency of this element results in increase reactive oxygen 
species (ROS) [503]. Selenium levels are reduced in the serum and synovial fluid 
of RA patients compared to controls and this reduced selenium is associated with 
increased risk of the disease [504]. Hence, a reduction in the selenium levels in 
the serum of the RA patients could be the reason for the downregulation of 
genes associated with selenocysteine incorporation in RA PB monocytes. Of note, 
selenium deficiency in RAW 264.7 macrophages had significantly increased 
inducible nitric oxide synthase activity (iNOS) and subsequent nitric oxide (NO) 
production after stimulation with LPS [505] therefore a reduction in selenium 
and selenocysteine incorporation in RA PB monocytes may be one mechanism 
causing the increased iNOS and NO seen in RA [506]. 
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The third group of biological processes downregulated in RA PB monocytes was 
negative regulation of cell movement which again emphasises the importance of 
the process of chemotaxis and extravasation for the diseased monocytes. The 
downregulated RA genes associated with this biological process are SMAD7, 
which has been previously discussed, and VASH1 (vasohibin 1). Vasohibin 1 is a 
negative feedback regulator of angiogenesis which was originally identified in a 
microarray analysis designed to analyse the upregulated genes induced by 
vascular endothelial growth factor (VEGF) stimulation in endothelial cells [388]. 
Subsequent immunohistochemistry analysis has identified vasohibin 1 in the 
synovium of RA patients associated with synovial lining cells, endothelial cells 
and synovial fibroblasts [507]. At present there has been no vasohibin 1 
identified specifically in monocytes therefore our observation may represents a 
novel one. Inflammatory cytokines were shown to induce vasohibin 1 expression 
in RA synovial fibroblasts [507] and its expression is thought to help co-ordinate 
the formation of blood vessels and angiogenesis in the synovium. Consequently, 
the downregulation of vasohibin 1 in RA blood monocytes could be due to it not 
being required by the blood cells and may be upregulated again once the 
monocytes enter the inflamed synovium. Analysing the RA SF macrophage 
samples (which will be discussed thoroughly in the next comparison of this 
chapter) this hypothesis is correct. The RA PB CD14+ express a low level of 
vasohibin 1 compared to healthy controls and this expression is increased by a 
fold change of 13 in the patient matched RA SF macrophages. This result 
indicates that the monocytic cells downregulate their vasohibin 1 expression 
until they migrate into the synovial fluid of RA patients where its anti-angiogenic 
properties are needed to regulate and co-ordinate the formation of blood 
vessels.  
DAVID analysis was also performed on the differentially expressed genes 
between PsA PB monocytes and healthy blood monocytes. After removal of gene 
repeats in the list and genes with no designated function the list of 154 genes 
upregulated in PsA blood monocytes was reduced to 92 and the list of 129 genes 
downregulated in PsA blood monocytes was reduced to 66 genes. The two 
biological processes associated with the 92 upregulated genes in PsA were DNA 
packaging (demonstrated by the groups nucelosome assembly, chromatin 
assembly, protein-DNA complex assembly, DNA packaging and chromatin 
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assembly and disassembly) and chemotaxis (demonstrated by the groups 
chemotaxis and taxis). Again because genes can be part of several biological 
process groups each of the six biological process groups which had the shared 
general function of DNA packaging all had the same six genes from the PsA gene 
list associated with them. These genes were HIST1H2BK (histone cluster 1, 
H2bk), TSPYL5 (TSPY-like 5), HIST1H2AC (histone cluster 1, H2ac), HIST3H2A 
(histone cluster 3, H2a), NAP1L5 (nucleosome assembly protein 1-like 5) and a 
probe on the Affymetrix GeneChip which targets six histone cluster 1 genes. 
Surprisingly there is very little to no information on the function or role of any of 
these genes particularly the histone genes. The function of NAP1L5 is also 
unknown but its shows homology to nucleosome assembly protein 1 which is 
involved in the translocation of histones from the cytoplasm into the nucleus 
[508]. Given that the role of histones is to provide a core around which DNA is 
packaged to form a nucleosome, the basic unit of chromatin, it could be 
suggested that the PsA blood monocytes upregulating genes responsible for DNA 
packaging would therefore prevent any further gene transcription. However, the 
importance of this observation cannot be fully understood until the roles of the 
upregulated genes are discovered. 
The second group of biological processes associated with the genes upregulated 
in PsA PB monocytes had the general function of chemotaxis. This result is the 
same as that seen in the upregulated genes in RA PB monocytes, and the same 
genes such as FRP1, FRP2 and PPBP are upregulated in both cell subsets. Once 
again this highlights importance of chemotaxis to the arthritic blood monocyte 
as it is via chemotaxis that the cell will move into the diseased joint. The 
increased levels of chemokines and pro-inflammatory mediators detected in the 
serum of PsA patients compared to healthy controls may be one of the triggers 
causing the upregulation of chemotaxis related genes in the PsA monocytes [406, 
509]. 
The two main biological processes associated with the downregulated genes in 
the PsA blood monocytes have the main functions of cell morphogenesis 
(demonstrated by the biological processes cell projection morphogenesis, cell 
part morphogenesis, cell morphogenesis, cell projection organisation and 
cellular component organisation) and osteoclast differentiation (demonstrated 
by the biological processes regulation of osteoclast differentiation, regulation of 
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myeloid leukocyte differentiation and positive regulation of osteoclast 
differentiation). Downregulated PsA genes associated with the cell 
morphogenesis biological processes include DYNC1I2 (dynein, cytoplasmic 1, 
intermediate chain 2) and DST (dystonin). Dynein is an energy dependent motor 
protein found to be associated with microtubules which moves cellular cargo, 
such as organelles, vesicles and RNA, towards the minus end of the 
microtubules.  DYNC1I2 is one of two intermediate chains which are involved in 
intracelluar dynein cargo transport by binding to specific cargo although the 
mechanisms of this are not fully understood [510]. Dystonin is a cytoskeletal 
interacting protein which is known to play important roles in maintaining 
cytoarchitecture integrity in skin and in the neuromuscular system, it is thought 
to act as a ―linker‖ protein linking elements of the cytoskeleton to each other or 
to subcellular components such as adhesion structures [511]. Since there are no 
reports of disregulated cytoskeletal or microtubule transport in PsA the 
importance of these downregulated genes in PsA is yet to be understood. 
Downregulated genes associated with the osteoclast differentiation include GNAS 
(GNAS complex locus) and KLF10 (Kruppel-like factor 10). GNAS codes for the 
protein Gs α-subunit (Gsα) which is a subunit of G proteins. G proteins are 
membrane associated complexes that are primarily involved in signalling at the 
plasma membrane. Gsα plays a central role in receptor mediated signal 
transduction, coupling receptor activation with the production of cAMP [512]. It 
is well known that G-protein coupled receptors play a substantial role in arthritis 
as the signal transducing receptors for many molecules such as MMPs and 
chemokines [513, 514]. However, the GNAS complex locus has recently been 
identified as an incredibly complex gene which encodes multiple gene products 
through the use of alternative promoters and first exons [515] such as extra-
large isoform Gsα, which is thought to be localised to the Golgi apparatus, and 
NESP55 amongst others [512]. Consequently, this multiple gene product 
complexity renders it impossible to try and understand the significance of the 
down-regulation of this gene in PsA blood monocytes since we do not know 
which end product of the gene the PsA and healthy monocytes are translating 
and producing. 
KLF10 otherwise known as TGFβ early gene-1 (TIEG) is a zinc finger transcription 
factor which plays an important role in mediating the TGFβ Smad signalling 
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pathway. TIEG overexpression enhances Smad 4 activity and the induction of 
TGFβ target genes [516]. Overexpression of TIEG in an epithelial cell line 
induced apoptosis [517] and reduced cell proliferation in a human osteosarcoma 
cell line which was also seen in control cells stimulated with TGFβ [518]. Hence 
the PsA monocytes may be downregulating the TIEG gene in order to avoid TGFβ 
mediated apoptosis and suppression of cellular activation and proliferation. Of 
note, this mechanism is seen in cancer cells which are known to downregulate 
their TIEG expression at the protein and mRNA level in order to avoid cell death 
and reduced proliferation [519].  
In conclusion the diseased and healthy blood comparison has been very 
informative in defining the biological functions of the groups of genes up- or 
downregulated by each monocyte subset as well and allowing the investigation 
of individual genes. The PCA analysis performed on the entire set of microarray 
samples indicated the surprising result that the peripheral blood monocytes from 
healthy donors, RA patients and PsA patients all had a very similar genetic 
profile. In addition, performing statistical and fold change analyses on the data 
did result in the identification of just 24 genes which were differentially 
expressed between the RA and PsA blood monocytes. This low result 
demonstrates that within the blood the monocyte may not a cell type 
responsible for the differing clinical features seen in both diseases since this cell 
subset is showing a similar genetic profile in both diseases. 
The 12 genes which were upregulated in RA blood compared to PsA blood 
monocytes contained a group of genes which had roles in cell adhesion and 
interaction, such as the laminin subunit LAMC1, as well as genes that had been 
previously associated with RA including the IL-7 gene. This latter result is 
encouraging as the presence of differential expression in genes previously 
associated with RA validates this dataset. The 12 genes which were upregulated 
in PsA blood compared to RA blood monocytes contained two groups of genes, 
one group had functions involved in the response to stress and toxins such as 
EIF2AK3/PERK and the other group of genes were involved in transcription and 
its initiation. It would be interesting to perform validation experiments on some 
of these genes especially those which have not been previously associated with 
monocytes in inflammatory disease. Laminin and its receptor expression has 
previously been associated with synovial fibroblasts in RA [520] but we believe 
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this is the first time the expression of a laminin subunit (LAMC1) has been found 
in RA blood monocytes and further experiments are needed in order to elucidate 
the function of LAMC1 in particular whether the monocyte is producing and 
releasing laminin molecules. The upregulated expression of EIF2AK3/PERK in PsA 
monocytes is another novel and interesting finding since this molecule is 
involved in the ER stress induced unfolded protein response (UPR). The UPR has 
not previously been implicated in the pathogenesis of PsA but has been well 
researched in another spondyloarthropathy ankylosing spondylitis (AS) [466, 521] 
which shares some clinical features with PsA. Unfortunately time restrictions 
meant that no further experimental or validation assays were able to be 
performed on these genes. 
The RA PB vs healthy PB monocyte comparison was also very revealing in 
illustrating the overall functions of the differentially expressed genes. In 
comparison to healthy blood monocytes the RA PB cells showed an upregulation 
of genes involved in response to stimulus such as CLU and genes involved in 
cellular movement such as CXCL7. These two groups of genes are not surprising 
given that it is well known that the RA serum contains many pro-inflammatory 
mediators compared to healthy control serum which will be partly responsible 
for the upregulation of the response to stimulus genes. It is also known that the 
monocyte cells in RA need to undergo chemotaxis and migration in order to 
transmigrate from the blood vessels into the synovial joint where they 
accumulate and play a role in the damage and destruction of the joint.  
The downregulated genes in RA PB had functions in complex localisation, 
selanocysteine incorporation and negative regulation of cell movement. The 
down-regulation of two genes involved in selanocysteine incorporation was 
interesting as selenium, the main component of selanocysteine, is decreased in 
the serum and synovial fluid of RA patients but also selenium deficiency has 
been shown to induce increased iNOS and subsequent nitric oxide (NO) 
production in RAW 264.7 macrophages. Therefore a lack of serum selenium may 
directly be contributing to the increased NO and NO-induced damage seen in RA. 
Down-regulation of genes associated with the negative regulation of cell 
movement also reinforces the importance of the ability of the RA monocytes to 
undergo chemotaxis and cell migration. 
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The upregulated genes in PsA blood monocytes compared to healthy blood 
monocytes had roles in DNA packaging and chemotaxis. An upregulation of genes 
associated with DNA packaging could suggest that the PsA monocytes are 
reducing their overall transcription levels by packing their DNA into nucleosomes 
and chromatin. However, since there is little to no information on any of the six 
upregulated genes associated with the DNA packaging function it is difficult to 
speculate further on the reasons for their increased expression compared to 
healthy controls. The upregulated genes associated with chemotaxis are the 
same genes upregulated in RA PB monocytes such as CXCL7, FPR1 and FPR2. The 
increased expression of these genes in PsA blood compared to healthy control 
demonstrates the importance of the arthritis specific requirement for the 
monocyte to migrate out of the blood and into the diseased joint. The 
downregulated genes in PsA monocytes identified an interesting transcription 
factor TIEG which is known to induce apoptosis; therefore the PsA monocytes 
may be down-regulating molecules like TIEG in order to maintain and prolong 
cell survival as has been seen in cancer cells. 
Due to time restrictions only 5 healthy control blood monocyte samples were 
obtained which mainly were age- and sex-matched to the PsA patients. It is 
recognised that obtaining additional healthy donor samples which were age-
matched to the RA patients would have been advantageous and allowed us to 
investigate the age specific genes that may have changed in the monocytes. 
Nevertheless, the analysis performed with the 5 healthy donors has been very 
informative in identifying the differentially regulated genes in the monocytes 
including novel genes not previously associated with inflammatory arthritis. This 
analysis has also identified that the blood monocytes in RA and PsA have very 
similar genetic profiles which was also previously unknown. 
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3.7.2 Comparison 2: RA and PsA blood versus matched synovial 
fluid 
Given the important role of synovial macrophages in the pathogenesis of both RA 
and PsA one important question to be answered by this microarray analysis was 
what changes occur in the arthritic monocyte as it exits the blood and enters the 
synovium? This is an important question as it aims to identify not only the 
monocyte differentiation markers as it changes from a monocyte into an 
inflammatory macrophage but it will also identify the inflammatory genes that 
are upregulated once the monocyte is exposed to the pro-inflammatory synovial 
environment.  
In order to answer this question paired T tests were performed between the 
matched RA blood and synovial fluid samples and a separate set of paired T tests 
were performed between the matched PsA blood and synovial fluid samples in 
order to determine the up- and down-regulated genes in the synovial 
macrophages compared to the blood monocytes. Due to the substantial amount 
of differentially expressed genes between the PB and SF of each disease (10763 
in RA and 9533 in PsA) we applied a fold change cut off of 4 to the data since 
fold change values in microarray analysis are arbitrary and we were interested in 
genes with a high fold change difference between the blood and the SF. 
Ingenuity pathway analysis (IPA) was then used to determine the canonical 
pathways and molecular functions significantly associated with the differentially 
expressed genes in the RA SF compared RA PB CD14+ cells and those significantly 
associated with the differentially expressed gene in the PsA SF compared to the 
PB CD14+.  
3.7.2.1 RA PB CD14+ versus RA SF CD14+ 
Table 3.6 shows the top 5 canonical pathways significantly associated with the 
differentially expressed genes in the RA SF macrophages compared to the RA PB 
monocytes. The most significantly associated pathway is LXR/RXR activation 
pathway. LXR is a nuclear receptor ligand-activated transcription factor, it forms 
heterodimers with RXR before binding to the DNA sequences of target genes 
[522]. Analysing the list of RA SF differentially expressed genes associated with 
this pathway demonstrates the novel finding that one of the LXR isoforms LXRα 
which has been previously been shown to be expressed in 
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monocytes/macrophages [523] is upregulated in RA SF macrophages compared to 
RA PB. Other RA SF upregulated genes associated with this pathway include the 
a range of LXR target genes such as ABCA1, ABCG1, lipoprotein lipase (LPL), 
ApoE, ApoC1 and ApoC2 which are all involved in reverse cholesterol transport 
and cholesterol efflux [524, 525]. This process ensures the efflux of cholesterol 
from peripheral cells and its transport to the liver for metabolism and biliary 
excretion hence the LXR activation pathway is considered to be central in 
maintaining cholesterol homeostasis and is considered protective against 
atheroscleosis.  
However, LXR agonism has also been considered pro-inflammatory since LPS-
stimulated human macrophages treated with two synthetic LXR agonists 
increased TNFα expression though the ability of LXRs to increase Toll-like 
receptor 4 (TLR4) expression; this agonism also increased reactive oxygen 
species generation from the macrophages [526]. LXR agonism has also been 
demonstrated by our group to exacerbate articular damage in a murine model of 
arthritis suggesting LXRs have a pro-inflammatory role in arthritis [527]. In this 
study, LXR agonism induced a dose-dependent enhancement of the prevalence, 
incidence and severity of the collagen induced arthritis (CIA) mouse model. Ex 
vivo culture of RA PB derived monocytes which were LPS stimulated and treated 
with two LXR agonists showed an increase in IL-6 and TNFα production. 
Macrophages stimulated in the in vitro inflammatory model of arthritis by direct 
cell contact with Tcks also demonstrated an increase in pro-inflammatory 
cytokine and chemokine production in response to LXR agonism. Low density 
lipoprotein (LDL) is a natural agonists for LXR activation and has been found in 
the synovial fluid of RA patients [528] therefore the up-regulation of the LXR 
pathway in RA SF macrophages compared to PB monocytes along with the 
presence of its agonist in the synovial fluid indicates that this pathway may be 
promoting articular destruction through inducing the increased production of 
pro-inflammatory cytokines and chemokines from the synovial macrophages. 
However more work on the role of LXR activation in RA SF macrophages is 
required to test this hypothesis. 
The hepatic stellate cell activation canonical pathway is the second most 
significant pathway differentially expressed in RA SF CD14+ cells. This is due to 
the overlap of several MMPs, chemokines, cytokines and growth factors that are 
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implicated in both hepatic stellate activation and synovial macrophage 
activation. For example platelet-derived growth factor alpha polypeptide 
(PDGFA) and PDGFB were both upregulated in the RA SF macrophages and these 
genes have also been implicated in hepatic stellate cell induced hepatic fibrosis 
[529, 530]. PDGF is a potent mitogen, chemoattractant and angiogenesis 
promoter [531] and the level of this growth factor is increased in RA synovial 
tissue and fluid [532, 533]. PDGF has been implicated in RA through its function 
as a growth factor for fibroblast-like synoviocytes (FLS) [532, 533]. It has 
recently been shown that in combination with TGF-β, PDGF augmented TNFα or 
IL-1β induced MMP3, IL-6, IL-8 and macrophage inflammatory protein 1 alpha 
(MIP1α) secretion by FLS suggesting PDGF induces a more pro-inflammatory, 
aggressive phenotype in the FLS in response to TNFα [534]. Consequently, the 
increased expression and possible secretion of PDGFA and PDGFB by RA SF 
macrophages may be contributing to articular damage by activating synovial FLS.  
The remaining genes differentially expressed in RA SF macrophages which were 
associated with the hepatic stellate cell activation canonical pathway consist of 
many inflammatory cytokines, chemokines and growth factors which have 
previously been connected with RA. These genes include FN1 (fibronectin) which 
is detected in the synovial fluid of RA and can induce MMP expression from 
fibroblasts [425]; the gelatinases MMP2 and MM9 (matrix metalloproteinase 2 and 
9) which are both upregulated in the synovium of RA patients [535] and their 
levels are associated with increased joint erosions [536]; CCL2 (monocyte 
chemoattractant protein 1, MCP1) is also increased in the synovium and is a 
potent chemoattractant for immune cells [537]; and CSF1 (macrophage colony 
stimulation factor, M-CSF). M-CSF is a growth factor which controls the 
proliferation, survival and differentiation of mononuclear phagocytes, it is 
normally expressed by the tissue environment however macrophages can also 
produce and secrete M-CSF if the tissue cells are unable to supply large amounts 
of the growth factor [538]. In conclusion, the association of the hepatic stellate 
cell activation pathway with the genes differentially expressed in the RA SF 
macrophages compared to RA PB monocytes has highlighted the upregulation of 
several important inflammatory genes discussed above. However not only do the 
SF macrophages up-regulate genes which will contribute to the pro-inflammatory 
environment but they also demonstrate increased expression of the macrophage 
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differentiation and survival factor M-CSF which could help differentiate 
monocytes infiltrating into the joint into pro-inflammatory macrophages.  
The third canonical pathway is defined as the role of macrophages, fibroblasts 
and endothelial cells in RA. The association of this canonical pathway validates 
the genes that are differentially expressed by the RA SF macrophages as many of 
these genes are known to be expressed in the RA synovium. This pathway 
contains many of the upregulated genes which were associated with the hepatic 
stellate cell activation pathway such as fibronectin, MMP2, MMP9 and the two 
PDGFs as well as other genes such as TRAF5 (TNF receptor-associated factor 5), 
WNT5A (wingless type MMTV integration site family member 5A) and FZD7 
(frizzled homolg 7). 
TRAFs are cytoplasmic adaptor proteins for the TNF/IL-1/TLR receptor 
superfamily, they are responsible for transducing extracellular signals from cell 
surface receptors and activating intracellular signalling cascades such as the NF-
κB and the JNK signalling pathways [539]. The RA SF macrophages demonstrated 
a 5 fold increase in TRAF5 expression compared to matched blood monocytes 
and interestingly a SNP upstream of TRAF5 has been identified as an RA 
susceptibility gene [540]. TRAF5 interacts with lymphotoxin β receptor (LTβR) 
and CD40 and has shown functional redundancy with TRAF2 [541].  Both TRAF2 
and TRAF5 can mediate TNF-induced NF-κB activation and protection from cell 
death [539]. Hence, an upregulation of TRAF5 in the RA SF macrophage may 
imply that it plays a proinflammatory role such as increased cellular activation 
and transcription of other proinflammatory cytokines. However, a recent study 
into the role of macrophage TRAF5 in atherosclerosis found it to be anti-
inflammatory as murine monocytes deficient for TRAF5 demonstrated an 
upregulation of cell adhesion molecules implicated in cell adhesion and rolling 
and also enhanced migration and chemokine production [542]. Since macrophage 
TRAF5 has not been examined in RA at present further studies are required to 
distinguish whether TRAF5 plays a pro- or anti-inflammatory role in this disease. 
WNT5A was also upregulated in the RA SF macrophages compared to the blood 
monocytes, Wnt-5a is one of 19 Wnt proteins which are a family of secreted 
lipid-modified glycoproteins that display a highly regulated pattern of expression 
and have distinct roles during development and tissue homeostasis. The 
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importance of Wnt-5a in various developmental pathways is demonstrated in 
Wnt-5a knockout mice which die at birth and display many defective features 
such as facial abnormalities, truncated bodies and shortened limbs [543]. Wnt 
signalling pathways are activated by the binding of secreted Wnt to the cystolic 
domain of a family of transmembrane receptors called the Frizzled receptor 
proteins (Fz) [544]. The binding of Wnts to their receptors determines the type 
of downstream signalling pathway either canonical, which involves the 
transcriptional activation of β-catenin, or non-canonical which does not involve 
β-catenin. Wnt-5a is classed as a non-canoical Wnt which are generally 
considered to control morphogenic movement. In RA Wnt-5a has been shown to 
be upregulated in synovial fibroblasts where it binds to frizzled 5 (Fz5), and the 
downregulation of Wnt-5A or Fz5 both resulted in inhibition of synovial fibroblast 
activation [545]. 
Wnt-5a has also been demonstrated to be upregulated in human macrophages 
stimulated with bacterial pathogens in vitro as it was demonstrated that 
activation of TLR4 signalling cascade induced Wnt-5a expression. These 
macrophages also expressed Fz5 and it was demonstrated that Wnt-5a and Fz5 
regulated the microbially induced IL-12 release from these cells [546]. Wnt-5a 
has been demonstrated to be expressed in macrophages of murine and human 
atherosclerotic plaques associated with TLR4 [547] and has also been 
demonstrated to be critical for invasion and MMP7 and TNFα release from 
tumour associated macrophages which were found to be positive for Wnt-5a 
[548]. Consequently the upregulation of Wnt-5a in the RA SF macrophages may 
be as a result of increased TLR4 signalling since TLR4 ligands are present in the 
RA synovium [549]. Both synovial fibroblasts and macrophages have been 
demonstrated to express a Wnt-5a receptor Fz5 therefore the secretion of Wnt-
5a by synovial macrophages could be acting in an autocrine or paracrine manner 
by stimulating surrounding cells. This activation by Wnt-5a could cause 
inflammatory cytokine and proteinase secretion by synovial fibroblasts or 
macrophages thereby contributing to the synovial joint damage. 
FZD7 (frizzled homolog 7) was another gene upregulated by the RA SF 
macrophages which was associated with role of macrophages and fibroblasts in 
RA canonical pathway. As mentioned above frizzled molecules are the cell 
surface receptors for Wnt proteins and the subsequent binding of these two 
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molecules activates the Wnt signalling pathways. Frizzled 7 (Fz7) has previously 
been detected in RA synovial tissue [550] and a recent paper has demonstrated 
the Fz7 can associate with Ror2 to form a receptor complex to mediate Wnt-5a 
signalling and activation of the JNK signalling pathway [551]. Put together this 
novel data demonstrates the upregulation of a Wnt protein (Wnt-5a) and part of 
its receptor complex (Fz7) specifically in RA synovial macrophages, further work 
is required to elucidate the importance of these molecules in RA pathogenesis 
however they could play a role in the invasive potential, inflammatory mediator 
secretion and sustained activation of these cells. 
The differentially associated genes with the role of macrophages and fibroblasts 
in RA canonical pathway was also associated with genes that were 
downregulated in RA SF macrophages compared to their matched PB monocytes. 
Two of these downregulated RA SF macrophage genes were TLR5 and TLR7. The 
activation of TLRs by pathogen-associated molecular patterns (PAMPs) alters the 
host to presence of infection and triggers a variety of defense mechanisms, such 
as the production of pro-inflammatory cytokines and chemokines, depending on 
the receptor and cell type. Several TLRs have been detected in RA synovium as 
well as candidate endogenous TLR ligands [552] therefore the perpetual 
activation of TLR signalling has been identified as a potential mechanism for the 
maintenance of the chronic inflammation seen in RA. TLR5 has not previously 
been identified in the synovium of RA however stimulation of FLS from RA and 
JIA patients with the TLR5 ligand flagellin did induce IL-6, MMP1 and MMP3 
production suggesting that these FLS expressed TLR5 [553]. 
TLR7 has been demonstrated to be expressed within the RA synovium [554]. 
However, when DCs isolated from RA patients were stimulated with TLR7 ligands 
the level of cytokine production was similar between DCs from RA and those 
from healthy patients. This was in marked contrast to TLR2 or TLR4 stimulation 
which induces a much higher production of inflammatory mediators for RA DCs 
compared to healthy controls [554]. This result suggests that TLR7 may not as 
essential to the perpetuation of arthritis as TLR2 and TLR4, which is further 
verified by the observation that TLR2 and TLR4 deficient mice do not develop 
serum transfer or streptococcal cell wall-induced arthritis [555, 556]. 
Consequently, the downregulation of TLR5 and TLR7 by the RA SF macrophages 
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may be due to these receptors not being as vital in the pathogenesis of RA as 
some of the other Toll-like receptor members such as TLR2/TLR4. 
The LPS/IL-1 mediated inhibition of RXR was the fourth most significant 
canonical pathway associated with the RA SF differentially expressed genes. The 
associated genes include many of the same genes which were included in the 
LXR activation pathway such as APOC1, APOC2 and APOE. All three of these 
apolipoprotein molecules are constituents of the anti-inflammatory and athero-
protective high density lipoprotein (HDL) [418]. ApoE and another apolipoprotein 
ApoA1 have been detected at an increased level in the synovial fluid of RA 
patients compared to serum levels and total cholesterol was also at an increased 
level in the synovial fluid [557]. Accumulation of HDL particles in the inflamed 
joint has anti-inflammatory effects since HDL can block the pro-inflammatory 
cytokine production from monocytes induced by T cell contact through binding 
to the T cell surface activating factors [558]. However, it has also been proposed 
that the accumulation of HDL within the synovium of RA patients and thereby 
reducing the amount of circulating HDL may contribute to the increased 
cardiovascular risk seen in these patients [559]. Consequently, the upregulation 
of these genes in the RA SF macrophages as well as the lipid transporter ABCA1 
needed to assemble the HDL particles may be as a result of the activation of the 
LXR/RXR pathway, as indicated by the canonical pathway analysis, or it may be 
as a result of the macrophage trying to dampen down the immune response by 
producing anti-inflammatory HDL particles which will inhibit the local production 
of inflammatory cytokines.  
The presence of the LPS/IL-1 mediated inhibition of RXR canonical pathway also 
indicates that the LPS pathway may play a role in the RA SF CD14+. LPS is one of 
the ligands for TLR4 which is a protein expressed on the surface of immune cells 
such as monocytes and its activation triggers signalling pathways which in turn 
lead to the induction of inflammatory cytokines such as TNF-α [560]. TLR4 has 
been detected in the RA synovium [549] and a TLR4 agonist has shown 
therapeutic effect in two murine models of arthritis [561] indicating that it may 
play a role in pathogenesis. Therefore the association of this canonical pathway 
with RA SF CD14+ is unsurprising since many TLR4 agonists such as hyaluronan, 
fibrinogen and heat shock proteins have been detected in the RA synovium. 
208 
The coagulation system is the fifth canonical pathway that is significantly 
associated with the differentially expressed genes in the RA SF CD14+ cells due 
to the upregulation of genes such as coagulation factors and plasminogen 
activators such as UPA (plasminogen activator, urokinase). UPA can convert 
plasminogen into the less specific plasmin which has various substrates including 
fibrin, cytokines and proMMPs, and also has a role in matrix degradation [562]. It 
has been demonstrated that systemic inflammation in arthritis can activate the 
coagulation cascade [563]. Levels of UPA are increased in RA [564] and induction 
of CIA in UPA-/- mice resulted in a mild disease indicating a pro-inflammatory 
role for UPA in RA [565]. Therefore these results indicate that RA synovial fluid 
macrophages are expressing genes which are contributing to the increased 
coagulation cascade seen in RA as well as the increased matrix degradation and 
inflammation.  
The diseases and disorders associated with the differentially expressed genes in 
RA SF macrophages compared to their matched PB monocytes are all related to 
rheumatoid arthritis such as inflammatory disease and skeletal and muscular 
disorders. The presence of these diseases significantly associated with the 
differentially expressed gene list validates this dataset as they are all related to 
our disease of interest. 
The top 5 cellular functions significantly overrepresented in the RA SF gene list 
comprise functions which we would expect to upregulated in the monocytes 
once they move from the blood into the synovium. This is exemplified by two of 
the cellular functions being cellular movement and immune cell trafficking 
which would be expected to be upregulated as a result of the CD14+ 
transendothelial migration from the blood vessels into the synovium [258, 407]. 
Transendothelial migration is the mechanism via which leukocytes infiltrate into 
the RA joint and several adhesion molecules which assist in this process have 
been identified in RA [179]. Another cellular functions significantly associated 
with the up- and down-regulated genes in the RA SF gene list was cell-to-cell 
signalling and interaction which is unsurprising since it has been well 
documented that macrophages within the synovial compartment are known to 
participate in cellular interactions with several cell types such as fibroblasts 
[249], T cells [269, 314, 408], endothelial cells [407] and natural killer (NK) cells 
[251]. The final two cellular functions associated with RA SF CD14+ compared to 
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PB cells are cellular growth and proliferation and cellular development which is 
logical due to the maturation that the CD14+ cells undergo into fully activated 
macrophages once they are within the synovium and exposed to the pro-
inflammatory and hypoxic environment [409, 410]. An upregulation of genes such 
as CSF1 (M-CSF) which was previously discussed will be contributing to the 
maturation of the blood monocytes into synovial macrophages. 
In conclusion the RA PB versus RA SF analysis to determine the effect of the 
migration of the monocytes from the blood into the synovial fluid has been very 
informative. The IPA analysis demonstrated the association of the differentially 
expressed genes with several pathways such as the LXR/RXR activation pathway. 
This pathway could be contributing towards an anti-inflammatory effect, though 
the production of HDL, or a pro-inflammatory effect since research by our group 
has demonstrated LXR activation is pro-inflammatory in a murine arthritis model 
[527]. Further analysis of the IPA canonical pathways also demonstrated the 
upregulation of novel receptor ligand complexes in the RA SF macrophages such 
as Fz7 and Wnt-5a which warrant further investigation. The cellular and 
molecular functions associated with the RA SF gene list consisted of cellular 
migration, cell-to-cell interaction and cellular development. This result 
demonstrates that once the RA PB monocytes migrate into the synovial 
compartment they are expressing transcripts of genes involved in cellular 
interactions, which are know to promote the production of pro-inflammatory 
mediators, and also genes associated with monocyte maturation into a fully 
functional synovial macrophage. 
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3.7.2.2 PsA PB CD14+ versus PsA SF CD14+ 
The IPA analysis of the differentially expressed genes in the PsA SF CD14+ cells 
compared to the PB CD14+ cells resulted in remarkably similar results to those 
obtained from the IPA analysis of the RA SF gene list. Three of the five 
significantly associated canonical pathways were the same pathways found 
associated with RA SF macrophages: LXR/RXR activation, LPS/IL-1 mediated 
inhibition of RXR function and hepatic stellate cell activation. Many of the 
individual genes associated with these pathways were the same in the PsA and 
RA gene lists indicating similarities between the two types of arthritic synovial 
macrophages. LXR activation has not previously been demonstrated to be 
associated with PsA therefore this finding is a novel one. The LXR activation 
pathway could be playing one of two roles; it could be an anti-inflammatory 
pathway in PsA by producing components of HDL which prevents cytokine 
secretion from monocytes [558] or it is more likely to be playing a pro-
inflammatory role in PsA. As discussed in the previous section LXR agonism in 
LPS-stimulated monocytes resulted in increased TNFα production and LXR 
agonism also exacerbates a murine model of arthritis possibly through the 
increased cytokine and chemokine production [526, 527]. A natural agonist of 
the LXR activation pathway is LDL, which has been detected in the plasma of PsA 
patients therefore indicating a mechanism for the LXR activation [566]. The 
association of the LPS/IL-1 mediated inhibition of RXR pathway with the 
differentially expressed PsA SF macrophage genes is due to the upregulation of 
the same apoplipoproteins and lipid transporter genes which were upregulated 
in the RA SF macrophages including APOE, APOC1, APOC2, ABCA1 and ABCG1. As 
discussed for the RA SF CD14+ cells the upregulation of these genes would result 
in an increase in HDL which prevents monocyte cytokine secretion and therefore 
mediate an anti-inflammatory effect from the PsA SF macrophage. 
The association of the hepatic stellate cell activation canonical pathway with 
the PsA gene list is due the upregulation of growth factors, MMPs and 
chemokines which are also involved in hepatic stellate cell activation. It includes 
genes which have been previously associated with PsA such as MMP2, MMP9 
[567], fibronectin [426] and CCL2 [509] but also novel genes such as SMAD7 and 
TGFB2 (transforming growth factor beta 2). TGFβ exists in three isoforms TGFβ1, 
TGFβ2 and TGFβ3, it is a multifunctional cytokine which regulates cell growth, 
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adhesion and differentiation in a variety of cell types, it is a potent 
immunosuppressor but also helps to drive the differentiation of Th17 which can 
promote inflammation and augment autoimmune conditions [568]. Of note there 
are increased levels of circulating Th17 cells in the blood of PsA patients [569]. 
TGFβ has not previously been associated with PsA but one of its isoforms TGFβ1 
is present in the epidermis and serum of psoriasis patients and correlates with 
the psoriasis area and severity index (PASI), although the same study found no 
correlation between PASI and our TGF isoform of interest TGFβ2 [570]. 
Overexpression studies of TGFβ1 in keratinocytes of mice induces a psoriasis-like 
skin inflammation suggesting TGFβ is pro-inflammatory [571] however the 
mechanisms for this are not understood. In addition to an upregulation of 
TGFβ2, the PsA SF macrophages also upregulated SMAD7 which paradoxically is a 
negative regulator of TGFβ2 [572]. SMAD7 had also been demonstrated to 
negatively regulate signalling intermediaries in pro-inflammatory signalling 
pathways such as NF-κB, in this pathway SMAD7 plays a role in increasing IκB 
expression [502]. Therefore the upregulation of SMAD7 in the PsA macrophages 
may be as an auto-regulatory anti-inflammatory mechanism in order to decrease 
the amount of NF-κB pro-inflammatory gene transcription. TGFβ2 and SMAD7 
expression have not been analysed in PsA previously therefore our observation is 
an interesting one. It is difficult to determine the overall net effect of the 
upregulation of the potential pro- and anti-inflammatory molecule TGFβ2 along 
with its intracellular inhibitor SMAD7 therefore further expressional and 
functional studies would be required. 
The two canonical pathways which are specifically associated with the PsA SF 
macrophage differentially expressed gene list are pathogenesis of multiple 
sclerosis and the complement system. Numerous studies have implicated the 
complement system within rheumatoid arthritis; elevated levels of complement 
activation products have been detected within RA synovial fluid [573] and 
several animals models have provided evidence for the involvement of 
complement in arthritis such as C5-/- and C3-/- mice being resistant to CIA [574, 
575]. In comparison there are very few studies implicating the complement 
system in PsA, one study has found the presence of terminal complement 
complex in PsA serum [576] and another study indicated that erythrocytes from 
psoriatic patients had reduced expression of surface CD59 compared to healthy 
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controls and it was hypothesised that this may be an indicator of low tissue CD59 
expression [577]. CD59 (protectin) is an inhibitor of the membrane attack 
complex (MAC) therefore a reduction in its expression could result in the 
perpetual activation of the complement system and increased lysis of 
erythrocytes and synovial cells through the MAC. Contrary to this observation the 
data generated by our microarray indicates that the PsA SF actually have an 
increased level of CD59 expression compared to PB monocytes which may due to 
the macrophage trying to regulate the amount of complement activation taking 
place in order to prevent perpetual activation. Brought together these data 
suggest that the complement system may be involved in PsA as well as RA and 
the synovial macrophage could be a key cell type producing complement system 
components. 
The pathogenesis of multiple sclerosis canonical pathway is significantly 
associated with the differentially expressed genes in PsA SF CD14+ due to four 
chemokines which play a role in this small nine component pathway being 
present in the gene list (see Figure 3.12). The four chemokines involved in this 
pathway are CCL4, CCR5, CXCL9 and CXCL11. CCL4 otherwise known as 
macrophage-inflammatory protein-1 beta (MIP-1β) is produced by activated 
macrophages [578]. CCL4 has been identified as one of the chemokines 
significantly upregulated in the serum of PsA patients compared to healthy 
controls and it is significantly associated with cellular synovial tissue markers in 
PsA [237]. Studies performed in RA have demonstrated that mediators found 
within RA synovial fluid, such as osteopontin, can induce CCL4 production from 
monocytes [241] and there is also evidence that the interaction between CCL4 
and its receptor CCR5 plays a crucial role for trafficking Th1 and other immune 
cells into the RA joint [235, 579]. Apart from the identification of CCL4 within 
PsA serum and synovial fluid there is little known about the role of CCL4 within 
PsA; however it could be hypothesised that this chemokine plays a similar role in 
inflammatory cell recruitment that has been described for RA. 
CCR5 otherwise known as CC-CKR5 is a receptor found on macrophages and T 
cells which binds RANTES, MIP-1α and MIP-1β (CCL4) with high affinity [580]. As 
has been illustrated above it has been implicated in Th1 cell trafficking into the 
RA joint and its expression has been determined within the RA synovial tissue 
and on synovial fluid monocytes and T cells [581]. At present there is no 
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evidence for the presence of CCR5 within the PsA synovial compartment apart 
from the data presented here, however since its high affinity ligand CCL4 has 
been demonstrated to be present in the synovial fluid we can hypothesise that 
CCR5 is also present also and contributing to the inflammatory cell influx into 
the diseased joint. 
The third gene upregulated in PsA SF CD14+ cells and associated with pathogensis 
of MS pathway was CXCL9 otherwise known as monokine induced by IFN-γ (Mig). 
CXCL9 is produced by activated monocytes [582] and mRNA levels of this 
chemokines have previously been detected in the synovium of PsA [238] where it 
is thought to help regulate the influx of inflammatory cells. CXCL11 otherwise 
known as IFN-inducible T-cell alpha chemoattractant (I-TAC) was the fourth 
chemokine upregulated in PsA SF CD14+ cells, this chemokines is upregulated by 
LPS stimulated macrophages [583] and had been detected in PsA synovial fluid 
[584]. Consequently, from this result it is not assumed that the pathogenesis of 
multiple sclerosis (MS) plays a role in PsA only that several of the chemokines 
which are involved in the pathogenesis of MS are also upregulated in PsA synovial 
fluid macrophages. 
The diseases and disorders correlated with the PsA SF macrophage differentially 
expressed genes are the same as those found associated with the RA SF 
macrophage genes and are all related to arthritic disease such as inflammatory 
diseases and inflammatory response. Again the significant association of these 
disorders with the gene list validates our PsA dataset. 
The molecular and cellular functions associated with the up- and down-regulated 
PsA SF macrophages are highly similar to those correlated with the RA SF 
macrophage genes as 4 of the 5 associated functions are the same in RA and PsA. 
This data further substantiates the finding that the RA and PsA macrophages 
have very similar genetic profiles and upregulate analogous genes once the 
monocytes migrate out of the blood and into the synovial fluid. The molecular 
and cellular functions which were significantly associated with the PsA genes 
included cell movement and immune cell trafficking which will be due to the 
presence of up- and downregulated genes involved in transendothelial migration 
and movement of the cells into the synovial joint. The synovium of PsA patients 
is characterised by an inflammatory cell influx [7] and monocytes isolated from 
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PsA patients have been demonstrated to interact with cultured endothelial cells 
whilst down-regulating adhesion molecules which is thought to aid in their 
migration [411]. PBMCs from PsA patients are also have a significant increase in 
their adhesion to endothelial cells compared to healthy PBMCs [585] and the 
level of chemokines is significantly increased in the serum and synovium of PsA 
patients [259, 406, 509]. These data emphasize the importance of 
transendothelial migration in the pathogenesis of PsA and also emphasises why 
the PsA SF have a significant change in their migratory associated genes 
compared to PB monocytes. 
Another molecular and cellular function associated with the PsA SF macrophage 
expressed genes was cell-to-cell signalling and interaction. In comparison to RA 
there have been only two studies into the role of macrophage direct cell contact 
in PsA. These studies demonstrated that direct cell contact between PsA 
monocytes and NK cells was able to differentiate the monocytes into DCs [586] 
and direct interaction of PsA monocytes with endothelial cells aided in their 
transendothelial migration [411]. Despite the lack of information regarding the 
role of direct macrophage cell contact in PsA, due to the close proximity of 
macrophages to other immune cells in the synovium [124] we can hypothesise 
that direct cell interaction is one method through which macrophages exert 
their pro-inflammatory potential as has been extensively demonstrated in RA. 
The two other molecular and cellular functions associated with the PsA SF 
macrophage gene list are cellular growth and proliferation and cell mediated 
immune response. A reason for genes associated with both of these functions 
being differentially expressed in the synovial macrophages could be due the pro-
inflammatory environment into which the cells migrate. Previous studies have 
demonstrated the PsA synovium to be a hypoxic environment [587] containing 
many cytokines, chemokines and inflammatory mediators [237, 259] which would 
in turn cause the monocytes to differentiate into macrophages and illicit an 
immune response. 
In summary the PsA PB versus PsA SF microarray comparison to establish the 
effect of the PB monocyte migration into the synovium has identified the 
activation of novel pathways in the macrophages such as LXR/RXR activation as 
well as the identification of novel genes which have not previously been 
associated with PsA such as TGFβ2 and its inhibitor SMAD7. Nevertheless, the 
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most interesting observation to come out of this analysis is the similarity 
between the transcriptomes of the RA and PsA synovial macrophages which is 
investigated further in the following comparison. 
3.7.2.3 Identification of genes expressed in: both RA and PsA 
synovial fluid macrophages, only in RA macrophages or 
only in PsA macrophages  
The similarity between the transcriptomes of the RA and PsA samples first 
became apparent during the PCA comparison which indicated that the synovial 
fluid samples of both PsA and RA were clustered in the same area of the graph 
indicating that these samples had similar genetic expression. Investigating the 
two diseases individually during IPA analysis then demonstrated that the synovial 
macrophages in both RA and PsA shared many of the same canonical pathways 
and molecular functions. These results let us to hypothesise that the synovial 
fluid macrophages of PsA and RA shared many of the same genes. To investigate 
this hypothesis the differentially expressed genes from both disease PB versus SF 
comparison were subjected to a Venn diagram comparison to determine genes 
which were expressed in both diseases and also genes which were specific to the 
synovial fluid macrophages of each disease. 
Interestingly the Venn diagram demonstrated that 58% of the PsA differentially 
expressed genes and 52% of the RA differentially expressed genes were present 
in both diseases indicating that just under half of the genes expressed in the RA 
or PsA synovial fluid cell were disease specific. This result is in contrast to those 
of Dominique Baeten and his group who have previously described a differential 
macrophage phenotype in SpA (including PsA) compared to RA patients through 
revealing an increased number of CD163+ cells in the synovium of SpA patients 
[255] and demonstrating that the synovial fluid of SpA but not RA was able to 
polarise blood monocytes to express CD163 [253]. CD163 is a cell surface 
glycoprotein which is classed as a marker of alternatively activated macrophages 
(M2), M2 macrophages have been implicated in tissue remodelling and immune 
regulation and are in stark contrast to classically activated macrophages (M1) 
which are thought to be the main source of pro-inflammatory cytokines which 
are associated with tissue damage [185]. Consequently, Baeten et al suggest that 
the macrophage phenotype in RA and SpA are significantly different due to the 
presence of different markers of macrophage polarisation and the ability of the 
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diseased synovial fluid to induce these macrophage phenotypes. Our venn 
diagram data illustrates that in contrast to results of Baeten et al the genetic 
profile and therefore the phenotype of both RA and PsA macrophages are very 
similar and over 50% of the genes expressed by each diseased macrophage are 
shared between the diseases. This observation is further exemplified by 
analysing for the presence of genes associated with M1 and M2 phenotypes in the 
macrophage gene lists from both diseases. As although CD163 is not present in 
either the PsA or RA SF macrophages, possibly due to the strict inclusion criteria 
for the microarray analysis, other markers of M2 phenotype such as the mannose 
receptor (MRC1 and MRC2) and macrophage scavenger receptor (CD204) are 
upregulated by a similar fold change in both RA and PsA. MRC1 has a fold change 
(FC) increase of 73 in PsA and 61 in RA, MRC2 (FC 32 PsA, 32 RA) and CD204 (FC 
10 PsA, 8 RA). However, analysis of markers of M1 polarisation demonstrates 
that these markers are also upregulated to similar levels of magnitude in both 
RA and PsA SF macrophages such as CD86 (FC 11 PsA, 15 RA) and MHC class II 
molecules HLA-DOA (FC 7 PsA, 4 RA). Our results would suggest that rather than 
the RA and PsA SF macrophages being two separate phenotypes, as implicated by 
work of Beaten et al, they are both similar cell types and at the RNA transcript 
level appear to have no preferential expression of an M1 or M2 phenotype. This 
could be an indication of the high level of plasticity of macrophage cells and 
their ability to constantly change their phenotype in response to their 
environment. Despite there being very little differences in the expression of 
several M1 and M2 macrophage markers the results of the venn diagram did also 
demonstrate that both the RA and PsA have a subset of genes that were disease 
specific which could account for some of the differences in seen in the 
pathogenesis and cytokine profiles of the two diseases.  
The results of the Venn diagram were saved as three individual datasets; i) genes 
which were differentially expressed in both diseases, ii) genes which were 
expressed only in PsA and iii) genes which were expressed only in RA. These 
gene lists were then analysed by IPA to identify the canonical pathways and the 
molecular and cellular functions which were significantly associated with them. 
The canonical pathways associated with the gene list expressed by both PsA and 
RA consisted of pathways which had already been discovered from the previous 
IPA analyses of RA PB vs RA SF and PsA PB vs PsA SF. These five pathways were: 
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LXR activation which has been previously been described as being a potential 
pathogenic pathway in RA [527] but as yet no association has been demonstrated 
for PsA; LPS/IL-1 inhibition of RXR function is also associated with the gene list 
due to an upregulation of HDL constituents in both RA and PsA macrophages, the 
significance of this pathway is not fully understood but since HDL had been 
demonstrated to prevent monocytes from releasing pro-inflammatory mediators 
[315, 558] this pathway may be an anti-inflammatory mechanism through which 
the macrophages counter-balance their disproportionate pro-inflammatory 
response. The complement system was the third pathway associated with the 
genes expressed in both diseases, complement components have been detected 
in the serum and synovial fluid of RA and PsA patients [573, 576] and several 
animals models have already provided evidence for the involvement of 
complement in arthritis such as C5-/- and C3-/- mice being resistant to CIA [574, 
575]. Therefore the combination of this data with our microarray data indicate 
that synovial macrophages may be a specific cell type in both RA and PsA to be 
involved in the activation of the complement pathway. 
The hepatic stellate cell activation was the fourth associated canonical pathway, 
as described previously the presence of this pathway is due to the occurrence of 
pro-inflammatory chemokines, cytokines and growth factors that are expressed 
in both hepatic stellate cells and synovial macrophages during cellular 
activation. The final canonical pathway was the pathogenesis of multiple 
sclerosis, the association of this pathway to the gene list is due to the presence 
of three chemokines which play a role in both multiple sclerosis as well as RA 
and PsA pathogenesis. The three chemokines were CCL4 (MIP-1β) and its 
receptor CCR5 which are both associated with macrophages and play a role in 
trafficking immune cells into the arthritic joint [235, 579], and CXCL11 which 
has been previously detected in RA synovium [588] and PsA synovial fluid [584]. 
The molecular and cellular functions associated with the gene list expressed in 
both RA and PsA SF CD14+ cells had all previously been associated with the SF 
macrophages such as cell-to-cell signalling and interaction, cellular development 
and cellular movement. The one function which had not previously been 
correlated to the SF macrophages was cellular function and maintenance which 
may be due to genes associated with cellular homeostasis being expressed by the 
RA and PsA macrophages. 
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The canonical pathways associated with the genes specifically expressed in PsA 
SF macrophages were: B cell development, pathogenesis of multiple sclerosis, 
autoimmune thyroid disease signalling, altered T and B cell signalling in 
rheumatoid arthritis, and allograph rejection signalling. The pathogenesis of 
multiple sclerosis was previously associated with the PsA PB vs SF comparison 
but the four other canonical pathways are unique to the PsA SF macrophage 
gene list. All four of these novel canonical pathways appear to be specifically T 
and B cell related, however they are associated with the PsA SF specific gene list 
due to the presence of three genes within the gene list. These genes are CD40, 
HLA-DQA1 and HLA-DOA which were all upregulated in PsA SF macrophages 
compared to PB monocytes and these genes are found in all four canonical 
pathways. 
CD40 is a cell surface receptor found on macrophages/monocytes, B cells and 
myeloid DCs and it is activated by ligation with CD154 found on CD4+ T cells, 
platelets, mast cells and basophils [589]. Ligation of CD40 on monocytes and 
macrophages results in the induction of pro-inflammatory cytokine and 
chemokine synthesis such as IL-1α, TNFα, IL-6, IL-8, CCL2 and CCL4 [589]. CD40 
ligation on monocytes or macrophages also upregulates the expression of MHC 
class II and co-stimulatory molecules CD80 and CD86, as well as CD40 itself 
[590]. CD40 has previously been demonstrated to play a role in arthritis as 
blockade of the CD40:CD154 interaction inhibited the onset of collagen induced 
arthritis (CIA) [591]. Once again, in comparison to RA there have been few 
studies analysing the role of CD40 in PsA. However, soluble CD40 ligand (sCD40L) 
is present in the serum of PsA patients [592] and interestingly Stoeckman et al 
discovered that CD40 and its signalling intermediates were downregulated in PsA 
PBMCs compared to healthy controls which they suggested could be due to the 
migration of CD40-expressing cells out of the blood and into the synovium. Our 
data agrees with this hypothesis as we demonstrate that in comparison to PsA PB 
CD14+ cells there is an upregulation of CD40 gene expression in PsA SF CD14+ 
cells. The presence of CD40 on PsA synovial macrophages will be contributing to 
the inflammatory milieu within the synovium through its ligation with CD154 
present on the synovial T cells and sCD40L present within PsA patients. 
The remaining two genes associated with the four canonical pathways specific to 
the PsA macrophage differentially expressed genes are HLA-DQA1 and HLA-DOA. 
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Human leukocyte antigen (HLA) is coded for by the major histocompatibility 
complex (MHC) gene region and HLA molecules are critical for distinguishing self 
from non-self. Cell-surface HLA molecules function to present processed 
antigenic peptide, which is held within a groove in the HLA molecule, to T cell 
receptor molecules expressed on the surface of T cells. HLA class II DR, DQ and 
DP molecules are found on B cells and professional antigen presenting cells and 
present processed peptides derived from exogenous antigens to CD4+ T cells 
[593]. An increased expression of HLA genes within the PsA SF macrophage could 
indicate an increase in the amount of antigen presentation taking place within 
the synovium and is also a marker of increased cellular activation. HLA-DQA1 
alleles have been associated with susceptibility to a wide variety of 
inflammatory conditions such as multiple sclerosis [594] and coeliac disease 
[595]. The expression of this molecule has also been upregulated in 
oligoarticular JIA [596] and different alleles have been demonstrated to be a risk 
factor for susceptibility to RA [597] and susceptibility to psoriasis [598]. These 
results indicate that HLA-DQA1 has a role in immune disease and arthritis 
pathogenesis and despite there being no direct link to PsA increased levels of 
HLA-DQA1 in PsA macrophages may be playing a role in disease susceptibility and 
antigen presentation. The other gene associated with the PsA specific canonical 
pathways is HLA-DOA which is another HLA molecule involved in antigen 
presentation and is upregulated at the RNA and protein level in monocytes 
treated with GM-CSF [599]. A single nucleotide polymorphism (SNP) in HLA-DOA 
which is significantly associated with RA susceptibility has recently been 
identified [600] again emphasising the importance of antigen presentation in the 
pathogenesis of arthritic disease. 
The cellular and molecular functions specifically associated with PsA SF 
macrophages included two functions, cellular movement and cell-to-cell 
signalling and interaction, which have been previously discussed. However, the 
other three pathways: DNA replication, recombination and repair; cell cycle and 
cell death represent functions which are specific to PsA SF macrophages. Despite 
there being no direct link of DNA replication, recombination and repair to PsA 
pathogenesis this molecular function is associated with the PsA macrophages due 
to an increase in the expression of genes such as TOP2A (topoisomerase (DNA) II 
alpha 170kDa). TOP2A is an enzyme which transiently breaks and rejoins double 
220 
stranded DNA in order to resolve topological problems which arise as a result of 
supercoiling or knotting which can occur naturally in the DNA [601]. 
The molecular function of cell cycle is associated with the PsA gene list due to 
the upregulation of genes such as TOP2A (described above) and CDK1 (cyclin-
dependent kinase 1) which regulates cell division and controls cell-cycle 
transitions by associating with different cell-cycle stage specific cyclins [602]. 
The association of the cell death function with the PsA gene list is due to the 
differential expression of apoptosis related genes including the down-regulation 
of clusterin (CLU) in SF macrophages. Clusterin was discussed previously in this 
chapter as a protein which was highly upregulated in RA PB monocytes compared 
to healthy controls. Clusterin‘s cellular functions are context dependent and 
nuclear associated clusterin (nCLU) is a pro-apoptotic factor [489]. Hence the 
down-regulation of this gene within the SF macrophages may be a mechanism 
through which these cells evade apoptosis. This data demonstrates that as well 
as the proinflammatory pathways which are being upregulated in the synovial 
macrophages, as demonstrates by the pathways correlated with the genes 
expressed in both RA and PsA SF macrophages, the PsA macrophages are also up-
regulating cellular functions associated with the maintenance of homeostasis 
such as cell cycle and DNA replication as well as pro-survival factors.  
The canonical pathways associated with the gene list expressed specifically in RA 
SF macrophages compared to the PB monocytes consisted of two pathways, 
hepatic stellate cell activation and the role of macrophages, endothelial cells 
and fibroblasts in RA, which were previously associated with the primary RA PB 
vs RA SF comparison. This is due to the differential expression of genes such as 
CSF1 (M-CSF) and VEGFA which play a role in these pathways and the 
pathogenesis of RA. However, the IPA analysis of the genes expressed only in RA 
SF macrophages also revealed three RA specific pathways: atherosclerosis 
signalling, ERK5 signalling and p38 MAPK signalling. The presence of the 
atherosclerosis signalling pathway within the IPA analysis of the RA SF specific 
genes is interesting as inflammatory pathways have been implicated in both 
atherosclerosis and RA and this result emphasises the overlap in immune 
disregulation which exists in both diseases. RA patients also have a 30-60% higher 
risk of cardiovascular events compared to osteoarthritis patients or patients 
without arthritis [603]. This phenomenon is thought to be due to RA patients 
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being exposed to chronic inflammation which is known to be a driver of 
atherosclerosis. 
One of the RA SF macrophage genes correlated to this atherosclerosis signalling 
pathway was TNFRSF12A (tumour necrosis factor receptor superfamily, member 
12A) which codes for the TWEAK (TNF-like weak inducer of apoptosis) receptor 
otherwise known as fibroblast growth factor inducible 14 (Fn14). TWEAK has 
been demonstrated to induce proliferation as well as cell adhesion molecule and 
cytokine expression in human umbilical vein endothelial cells (HUVECs) [604] and 
has also been implicated in angiogenesis in vivo. Recently, studies using an anti-
human Fn14 monoclonal antibody have demonstrated that TWEAK-induced 
proliferation and migration is solely mediated by its Fn14 receptor [604]. The 
TWEAK/Fn14 interaction has been implicated in the pathogenesis of arthritis as 
serum levels of TWEAK were elevated in murine CIA and neutralising TWEAK in 
this model significantly reduced the clinical severity, paw swelling and 
infiltration of inflammatory cells [605, 606]. Recently, Fn14 has been detected 
in the RA synovium and on synovial fibroblasts where its ligation with TWEAK 
induced the production of pro-inflammatory cytokines and the expression of 
intracellular adhesion molecule (ICAM-1) [607]. This pro-inflammatory cytokine 
release has since been demonstrated to be mediated through the activation of 
the NF-κB pathway [608]. Fn14 is detected within the synovium of both RA and 
PsA where it has been demonstrated to be specifically expressed on 
macrophages and fibroblasts [609] and its ligand TWEAK is present in the serum 
of RA patients and correlates with disease activity [610]. Consequently, the 
upregulation of the Fn14 gene TNFRSF12A by the RA SF macrophages in our study 
demonstrates a mechanism through which these macrophages can contribute to 
the inflammatory environment in RA synovium. The TWEAK/Fn14 has been shown 
to play a role in the pathogenesis of atherosclerosis and cardiac dysfunction due 
to its ability to induce angiogenesis, exacerbate vascular damage and mediate 
lipid uptake by macrophages [611-613] and therefore may be a pathway causing 
the increased risk of cardiovascular events seen in RA. 
The remaining two canonical pathways associated with the RA specific gene list 
were ERK5 signalling pathway and p38 MAPK pathway, both of these pathways 
are members of the MAPK signalling family and their association with RA SF 
macrophages is due to the up- and down-regulation of genes coding for signalling 
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intermediates and transcription factors involved in these pathways. ERK5 
signalling pathway has not previously been associated with RA pathogenesis but 
some of its signalling components which were differentially expressed in the RA 
SF macrophages have been demonstrated to play a role. For example, FOSL1 is 
upregulated in the RA SF macrophages and this gene codes for the Fra-1 protein 
which dimerises with c-Jun to form the AP-1 transcription factor. AP-1 has been 
demonstrated to be constitutively active in rheumatoid synovium [614] and 
treatment of rheumatoid synoviocytes with TNFα and IL-1β induced the nuclear 
translocation of Fra-1 and induction of AP-1 transcription [615]. Consequently, 
despite no evidence for the ERK5 pathway being implicated in RA the 
components of this pathway have been demonstrated to play a role in the 
pathogenic phenotype of synovial cells.  
The p38 MAPK pathway is also correlated to the RA SF macrophages which is due 
to the upregulation of genes coding for IL-1 receptor type I, IL-1 receptor type II, 
IL-1 receptor-associated kinase 2 (IRAK2) and the anti-inflammatory molecule IL-
1 receptor antagonist. The ligation of  IL-1α or IL-1β to the IL-1 receptor type I 
on the cell surface activates IRAK and commences the activation of the p38 
MAPK signalling pathway and the subsequent translation of genes coding for pro-
inflammatory mediators such as IL-6, IL-8, CCL2 (MCP-1), IL-1α and IL-1β [616]. 
Interestingly the RA SF macrophages have also upregulated levels of IL-1 
receptor antagonist (IL-RA) and the decoy receptor IL-1 receptor II (IL-1R2) 
which are inducible negative regulators of IL-1 signalling and can terminate or 
limit IL-1 effects. Hence the RA SF macrophages are not only up-regulating 
activator components of the p38 MAPK pathway but also negative regulators of 
this pathway, the net effect of this gene expression is not known since IL-1RA 
binds IL-1R1 with a similar specificity and affinity as IL-1α and IL-1β [616]. Of 
interest, a recombinant version of human IL-1RA designated anakinra is used as a 
therapy for RA demonstrating the significant anti-inflammatory properties of IL-
1RA [266]. 
The molecular and cellular functions of the RA SF specific gene list highlight the 
same group of functions which were associated with the previous RA PB vs RA SF 
comparison such as cellular movement, cell-to-cell signalling and cellular 
growth. As discussed previously the differential expression of genes associated 
with these functions demonstrates the increased cellular migration undertaken 
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by the macrophages as well as the physiological growth and development which 
the PB monocytes undergo to mature into the synovial macrophages.  
In summary, the analysis of the genes similarly expressed in both RA and PsA SF 
macrophages as well as the genes expressed specifically in PsA SF macrophages 
or RA SF macrophages has been crucial in defining groups of genes specifically 
expressed in each disease. The Venn diagram analysis also revealed the 
significant similarity in gene expression in both RA and PsA macrophages 
compared to their matched disease blood monocytes with over 50% of the genes 
being shared in each disease. 
Apart from the identification of the shared expression of the LXR activation 
pathway which was an interesting finding this analysis unfortunately did not 
reveal any novel genes which change in expression as the RA monocytes move 
from the blood into the synovial fluid. For that reason it was decided to analyse 
the differentially expressed genes that changed in both RA and PsA SF 
macrophages to try and detect novel genes that had not previously been 
associated with arthritis. This was in the hope of finding novel pathways 
regulating the pathogenesis of the arthritic synovial macrophage. The genes 
which had been upregulated in the synovial macrophages compared to the blood 
monocytes were analysed starting with those that had the largest fold change 
difference. Analysing the genes using this method unsurprisingly resulted in the 
identification of genes coding for molecules which have previously been 
associated with arthritis such as FN1 (fibronectin), SPP1 (osteopontin) and 
CCL18. However, through this analysis we also discovered two novel genes; LGM 
which codes for the enzyme legumain and PLXA1 which codes for the cell surface 
receptor plexin A1. These two candidate genes were subsequently validated and 
further analysis was performed to determine their function within the arthritic 
synovium. These results are discussed in full detail in the following chapters. 
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Chapter 4 Investigation into the expression and 
function of the novel gene plexin A1 in rheumatoid 
and psoriatic arthritis patients  
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4.1 Introduction  
Plexin A1 is one of the genes found to be upregulated in RA and PsA SF CD14+ 
cells in the preceding microarray experiment; it has not been previously 
associated with arthritis and is one of the two genes that I selected for intensive 
investigation in the context of rheumatoid and psoriatic arthritis pathogenesis. 
Plexins are a homogenous family of proteins, which when first identified were 
shown to be neuronal cell surface molecules with a function in cell adhesion 
[442]. They are grouped into four categories (A-D) based on their overall 
homology, there are 4 type-A, three type-B, one type-C and one type D found in 
vertebrates and two plexins found in invertebrates (A and B) [617].  
Plexins are the receptors for semaphorins, which are both secreted and 
membrane associated proteins named for their properties which are analogous 
to the system of flags and lights used in rail and maritime communication for the 
direction of movement. Semaphorins were originally characterised in the 
developing nervous system as chemorepellent molecules which acted to initiate 
axonal collapse in areas where they were found in high concentration, thus 
resulting in axonal guidance [618, 619]. However, more recently they have been 
shown to have diverse functions in several physiological processes such as 
angiogenesis [620], tumor metastasis [621, 622], osteoclastogenesis [623] and 
immune regulation [624]. More than 20 types of semaphorins have been 
identified and are grouped into eight classes on the basis of their structural 
elements and amino acid sequence similarity [619]. The semaphorins found in 
invertebrates are grouped into classes 1 and 2, classes 3-7 are vertebrate 
semaphorins and the final group, group V, are viral semaphorins. Proteins in the 
semaphorin classes 1, 4, 5, 6 and 7 are membrane associated whereas those in 
classes 2, 3 and the viral semaphorins are secreted [617]. All semaphorins 
contain a conserved ~500 amino acid extracellular domain termed a sema 
(semaphorin) domain and a class specific C terminus. 
Plexins are single membrane spanning proteins that have an extracellular domain 
consisting of a ~500 amino acid sema domain, that is conserved among all 
semaphorin family members, followed by a cysteine-rich motif and several 
glycine-proline rich motifs [442]. Most plexin-semaphorin interactions are 
mediated through the sema domains of both proteins except for class 3 
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semaphorins, which, with the exception of sema 3E, bind to neuropillin-1 or 
neuropilin-2 along with plexin in a co-receptor complex [625-627]. Neuropilins 
have a very short cytoplasmic domain that cannot transduce intracellular signals, 
therefore the plexin receptor must act as the signal transducing components of 
the semaphorin-neuropilin-plexin complex [628]. Plexin A family members are 
the main receptors for the secreted class 3 semaphorins as shown in Figure 4.1, 
semaphorin 3A will only bind neuropilin-1 (NRP-1) in the plexin-neuropilin 
receptor complex whereas semaphorin 3C and 3F bind both NRP-1 and NRP-2 
[443]. 
 
Figure 4.1 Semaphorin ligands for type A plexin family members 
There are four members of the plexin A family which interact primarily with two classes of 
semaphorins, class 3 and class 6. Both plexins and semaphorins are characterised by a sema 
domain shown in red for the plexins and blue for the semaphorins. Arrows indicate binding 
interactions detected between semaphorins and plexins. Labels on the arrows indicate which 
specific semaphorins have been shown to interact with which plexin [443, 444, 617, 629-632]. Blue 
labels of semaphorin names indicate the necessity for neuropilin-1 (dark blue) or neuropilin-
1/neuropilin-2 (green). 
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Plexin A1 is the only receptor in the type A family of plexins that interacts with 
two different classes of semaphorins, class 3 and class 6 (Figure 4.1). It is our 
gene of interest based on the results of the microarray and it is one of the 
semaphorin receptors whose function has been widely investigated. It is known 
to be expressed in the heart, liver, brain, kidney, spleen and lung of 4 week old 
mice [623] and is specifically expressed on plasmacytoid DCs [633], mature 
dendritic cells [444] and at low levels on T and B cells [623]. Recently plexin A1 
has also been shown to increase in expression during M-CSF differentiation of 
human monocytes into macrophages [443], the same group also showed LPS 
stimulation suppressed plexin A1 expression in macrophages. Toyofuku et al first 
identified semaphorin 6D (sema 6D) as one of plexin A1‘s ligands during chick 
cardiac development. Plexin A1 was found to form site specific receptor 
complex with vascular endothelial receptor type 2 (VEGFR2) in the conotruncal 
segment or with Off-track in the ventricle segment. These specific complexes 
bound to sema 6D and were responsible for its specific effects in these regions 
[631]. It is thought that semaphorin binding relieves plexin autoinhibition, as 
plexin A1 lacking its sema domain is constitutively active [634]. 
Plexin A1 has been previously shown to play a role in axonal guidance in the 
developing nervous system by acting as a co-receptor with neuropilin-1 to bind 
sema 3A resulting in a chemorepulsive signal [635]. It also has a role in 
chemotaxis of carcinoma cells as expression of constitutively active plexin A1 in 
breast carcinoma cells impaired their ability to chemotax [636]. However, the 
first report of plexin A1 in immune cell function came as a result of a microarray 
that identified plexin A1 as a gene down regulated in CIITA-deficient DCs to 5% 
of that found in wild type cells [444]. CIITA (class II transactivator) is a 
transcription factor that controls MHC class II expression [637], it functions as a 
transcriptional scaffold to coordinate NF-Y and RFX5 transcription factors in 
binding the conserved promoter regions found in MHC class II promoters. The 
same group found plexin A1 to be highly expressed in mature DCs from wild type 
mice and it was established that depletion of plexin A1 in mature DCs by RNA 
interference led to a 50% reduction in T cell stimulation in vitro and in vivo 
indicating that plexin A1 expression is important for T cell-DC interactions. This 
reduced proliferation could not be attributed to decreased antigen processing, 
MHC expression or peptide loading; however a suggested function for plexin A1 
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on the DCs was to serve as a co-stimulatory marker that binds its partner ligand 
on the T cells therefore enhancing the T cell-DC interaction.  
A further study, [623], into plexin A1‘s role in immune responses found that 
plexin A1-/- DCs had an impaired ability to stimulate antigen-specific T cells as 
they had reduced proliferative responses and cytokine production, consistent 
with the previous work performed by Wong et al. The plexin A1-/- mice had 
reduced cellularity in their long bones compared to wild type litter mates and it 
was revealed that plexin A1 deficiency resulted in increased bone mass and the 
development of osteopetrosis. It was also shown that plexin A1-/- mice had 
decreased osteoclast numbers, lower osteoclast surface to bone ratio and 
reduced osteoclast bone turnover therefore implicating a role for plexin A1 in 
bone homeostasis. This group had previously identified sema 6D as the ligand for 
plexin A1 in chick cardiac development [631] and found sema 6D to be highly 
expressed in T cells, therefore they incubated DCs with soluble recombinant 
sema 6D and showed that it induced IL-12 production and upregulation of MHC 
class II suggesting that sema 6D is the ligand for plexin A1 in T cell- DC cellular 
interactions. Sema 6D was also found to be expressed on osteoclasts and soluble 
recombinant sema 6D promoted osteoclast differentiation again suggesting that 
sema 6D is the ligand for plexin A1 in bone homeostasis. To try and further 
understand the plexin receptor complex, the group screened molecules 
associated with plexin A1 in DCs and osteoclasts and identified TREM-2. Previous 
studies have indicated that TREM-2 forms a receptor complex with DAP12, an 
ITAM-bearing activating adaptor protein, through a positively charged amino acid 
in its transmembrane domain [638]. Several experiments using RNA interference 
and DAP12-/- cells suggested that plexin A1, DAP-12 and TREM-2 are the sema 6D 
functional receptor components on DCs and osteoclasts [623]. Interestingly, 
genetic mutations in TREM-2 or DAP12 result in a bone fracture syndrome called 
Nasu-Hakola disease further underscoring the importance of the association of 
plexin A1 with DAP12 and TREM-2 in bone homology [639]. 
Further studies into the localisation of plexin A1 in DCs found it to be associated 
with the DC-T cell immune synapse in approximately 70% of T cell- DC cellular 
conjugates where it was found to regulate actin polarisation in the DCs via 
activation of the small GTPase Rho [640]. Plexin A1 has also been found to 
associate with DAP12 and another TREM family member found specifically on 
229 
pDCs designated PDC-TREM. Sema 6D binding to the plexin A1-DAP12-PDC-TREM 
complex on pDCs induced the production of type I IFN [633]. 
Plexin A1 has recently been shown to play a crucial role in allowing murine DCs 
to enter the lymphatic system and track to the lymph node. This migration is 
dependent on the presence of semaphorin 3A (sema 3A), one of plexin A1‘s 
ligands, in the lymphatic system. Sema 3A is thought to promote DC 
transmigration by inducing actomyosin contraction, which allows the cells to 
pass through constricted areas, by regulating myosin II activity and 
phosphorylation. This was demonstrated by treating the DCs with the myosin II 
inhibitor blebbistatin or the Rho kinase ROCK inhibitor Y-27632 which abolished 
sema 3A induced transmigration across lymphatic endothelial cell monolayers 
[632]. 
Due to the identification of a novel gene, plexin A1, expressed in RA and PsA SF 
CD14+ cells, and its plausible biologic profile, I therefore sought to validate this 
expression by RT-PCR in the microarray samples and samples from other 
patients. I then sought to identify its potential function in macrophage cells by 
siRNA and to investigate the expression of its semaphorin ligands on stimulated 
T cells and synovial membrane. 
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4.2 Validation of plexin A1 in microarray samples 
Plexin A1 was one of the genes identified when the group of genes upregulated 
in both RA and PsA SF were analysed. It had a fold change increase from the PB 
to the SF of 26 in RA patients and 27 in PsA patients. Figure 4.2 (A) demonstrates 
the raw fluorescent data signals of plexin A1 obtained from the Affymetrix 
GeneChips. The PB samples from both disease groups have very low levels of 
signal intensity indicating that these samples had low levels of plexin A1 mRNA. 
In contrast the patient synovial fluid samples have much higher levels of signal 
intensity and therefore contained higher levels of plexin A1 mRNA. The reason 
for the variable levels of the mRNA expression may be due to different disease 
duration in the patients or differences in disease therapy. To verify and validate 
this expression qRT-PCR was used to analyse the expression of plexin A1 in the 8 
RA and 8 PsA matched PB and SF CD14+ samples. All of the samples were able to 
be analysed apart from one RA PB sample which consistently produced unusual 
results which could not be included in the analysis. This may have been due to a 
problem with the RNA sample therefore that PB sample and its matched SF were 
not analysed. Figure 4.2 (B) shows the results of qRT-PCR, the fold change values 
were calculated by comparing the level of plexin A1 expression in the synovial 
fluid compared to the PB. Each circle represents one patient and the line is the 
mean fold change, the RA samples had a mean fold change increase of 8 from 
the PB to the SF and the PsA samples had a mean fold change increase of 13.  
The results demonstrate that there was an increase in plexin A1 expression in all 
of the synovial fluid samples compared to their matched peripheral blood 
samples which agree with the results obtained from the microarray.  
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Figure 4.2 Plexin A1 expression in microarray samples 
(A) Demonstrates the raw signal intensities of the plexin A1 gene locus on the Affymetrix 
GeneChips. Each circle represents one patient sample which was hybridised to one genechip and 
the line represents the mean signal intensity. Plexin A1 mRNA levels were then measured in the 
RA and PsA paired PB and SF microarray samples by qRT-PCR. (B) The fold change of plexin 
expression in the SF samples was normalised to the matched patient PB sample, each circle 
represents one patient and the line the mean fold change  
 
4.3 Expression of plexin A1 in other patient samples 
Once the expression of plexin A1 had been validated in the microarray patient 
samples we then analysed the expression of plexin A1 in CD14+ of other arthritic 
patients to check that the increase in plexin A1 expression was generalizable. 
Figure 4.3 shows the results of this analysis, graph (A) indicated all the CD14+ 
cells that were obtained and tested for relative expression plexin A1 which was 
normalised to the housekeeping gene GAPDH. PsA SF cells have varying 
PsA PB PsA SF RA PB RA SF
0
50
100
150
200
250
300
350
400
450
500
550
Monocyte type
A
ff
ym
e
tr
ix
 s
ig
n
a
l
RA patients PsA patients
0
5
10
15
20
25
30
35
40
45
50
55
pl
ex
in
 A
1 
fo
ld
 c
ha
ng
e 
fr
om
 P
B
 t
o 
S
F
(A) 
(B) 
232 
expressions of plexin A1 depending on the individual patient but the mean 
relative expression is higher than the mean relative expression of the PsA PB 
samples. The RA SF samples also have variable amount of plexin A1 but the mean 
expression is similar to that seen in PsA SF.  An inflammatory polyarthritis and a 
juvenile idiopathic arthritis (JIA) SF sample were also obtained for this analysis 
and both samples contain plexin A1 RNA, unfortunately no matched peripheral 
blood CD14+ cells were acquired for either patient so we cannot determine 
whether the plexin A1 expression increases in the SF cells compared to the PB 
cells as is seen with RA and PsA patients. However, matched PB and SF CD14+ 
cells from a patient with osteoarthritis (OA) were also analysed and shows that, 
as with the RA and PsA from the microarray, plexin A1 expression is higher in the 
SF compared to the PB. This indicates that expression of plexin A1 on CD14+ cells 
is not confined to PsA and RA SF and could also be expressed in other arthritic 
diseases. These analyses should however be considered anecdotal and are 
included here for completeness at this stage. Five of the PsA patients analysed 
had matched SF and PB CD14+ cells therefore the fold change increase of plexin 
A1 from the PB samples to the SF samples was determined (graph B). In 
summary, these data indicate that in the majority, but not all, PsA patients 
plexin A1 RNA levels are higher in the SF compared to the PB CD14+ cells as was 
seen in the microarray experiment. 
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Figure 4.3 Plexin A1 expression in CD14
+
 cells from arthritic patients 
To verify the microarray results plexin A1 RNA levels were measured in CD14
+
 cells from several 
other arthritic patients (A). Five of the PsA patients analysed in (A) had matched PB and SF 
samples therefore the fold change increase of plexin A1 expression from the PB sample to the SF 
sample was measured for each of these patients and is shown in (B) each square represents one 
patient. Lines on each graph indicate the mean. 
(A) 
(B) 
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4.4 Immunohistochemistry of plexin A1 
Once plexin A1 expression had been validated as being present in the microarray 
samples and other patient samples by RT-PCR, immunohistochemistry (IHC) was 
used to investigate the presence of plexin A1 protein in RA synovial membrane 
tissue. Five RA membranes stained positively for plexin A1; Figure 4.4 shows the 
pattern of staining seen in a representative membrane. Panel (B) shows an area 
of the membrane at x10 magnification on the left and x40 magnification on the 
right. The synovial membrane can be seen to be positively stained (indicated by 
brown staining) around vascular structures and within cells in the area 
surrounding the vasculature possibly indicative of infiltrating cells (indicated by 
black arrows). Panel (C) indicates two more images taken from the same 
membrane and again demonstrates that the areas staining positively for plexin 
A1 are those surrounding blood vessels and in cells around vasculature area but 
there are also cells within the synovial membrane structure that have stained for 
plexin A1. The staining appears to be present in both the cytoplasm and the 
nucleus of the cells. The positive staining surrounding the vasculature could be 
indicative of endothelial cells but the identity of the positive cells within the 
membrane require double staining of plexin A1 and other cellular markers. Such 
experiments would be the focus of future analysis in order to confirm the extent 
of plexin A1 expression. 
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Figure 4.4 Plexin A1 staining in RA synovial membrane 
Five RA synovial membrane tissues were stained for the presence of plexin A1. This figure 
indicates the staining pattern seen in one of these membranes. Panel (A) indicates the isotype 
control at x 10 and x 40 magnification. Panel (B) and (C) show the positive plexin A1 staining 
(shown in brown) of two areas within the membrane (arrows identify infiltrating cells), the staining is 
shown at x 10 magnification on the left and x 40 magnification on the right. 
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4.5 siRNA knockdown of plexin A1 in M-CSF derived 
macrophages 
I next decided to establish the role of plexin A1 in macrophage biology using RNA 
interference (RNAi). RNAi is a pathway in eukaryotic cells by which sequence 
specific small interfering RNA (siRNA) is able to find and cleave complementary 
mRNA [641]. An enzyme known as Dicer can cleave double stranded RNA into 
siRNA fragments [642]. Once siRNA is present in the cell it is incorporated into a 
protein complex called the RNA induced silencing complex (RISC) [643] where 
argonaute-2 unwinds the siRNA. The activated RISC complex containing the 
antisense strand of siRNA will then find and degrade mRNA that is 
complementary to this strand resulting in specific gene silencing. Synthetic 
siRNA specific to a gene can be directly introduced into a cell allowing gene 
silencing of almost any mammalian gene thereby allowing analysis of specific 
gene function.  
So far most experimental work on plexin A1 has looked at plexin A1 expression 
and function in DCs, since our results showed that plexin A1 is upregulated in 
monocytes/macrophages in the arthritic synovial fluid we wanted to determine 
the role of plexin A1 in this cell type with the use of siRNA. M-CSF differentiated 
macrophages were used to work up the siRNA experiments as these are a 
relatively accessible cell source compared to the limited number of synovial 
fluid patient samples we obtain in the lab. 
4.5.1 Expression of plexin A1 in macrophages after 6 days of M-
CSF differentiation 
A preliminary experiment before starting the siRNA knockdown of plexin A1 was 
to first determine that macrophages expressed plexin A1 mRNA. A previous study 
had demonstrated that plexin A1 was upregulated in macrophages differentiated 
in M-CSF for 2 days [443]. In our experimental setup monocytes were 
differentiated with 50 ng/ml M-CSF for 6 days and analysed at day 0 and 6 for 
plexin A1 expression. Figure 4.5 shows the fold change in plexin A1 expression in 
day 6 differentiated macrophages compared to day 0. Once the presence of 
plexin A1 had been determined in these cells we could then set up the siRNA 
experiments. 
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Figure 4.5 Plexin A1 in M-CSF differentiated macrophages  
Monocytes were differentiated with 50 ng/ml M-CSF for 6 days. Fold change in plexin A1 mRNA 
expression was measured by qPCR. 
4.5.2 Transfection efficiency of N-TER reagent 
An N-TER nanoparticle transfection system was used to knockdown the plexin A1 
gene. In this transfection system the N-TER peptide binds siRNA non-covalently 
forming a nanoparticle. The nanoparticle then interacts with the lipids on the 
surface of the plasma membrane thus allowing the nanoparticle to diffuse across 
the cell membrane and delivering the siRNA to the cytoplasm.  
To test the efficiency of this transfection system a negative control siRNA with 
an Alexa Fluro 555 modification was used. The negative control siRNA will not 
knockdown any genes in the cell since it is a non-silencing siRNA with no known 
homology to any known mammalian gene. Since it is modified with a fluorescent 
tag it can be used to measure the transfection efficiency of the N-TER peptide as 
any cell that has been successfully transfected will fluoresce. To determine the 
concentration at which the N-TER peptide worked most effectively, cells were 
transfected with the negative control siRNA and analysed on a fluorescent 
microscope and by FACS.  
4.5.2.1 Inverted microscope images 
Day 6 M-CSF differentiated macrophages were transfected with varying 
concentrations of negative control siRNA for 24 hours in the presence or absence 
of fetal calf serum (FCS) as FCS can sometimes affect siRNA transfection. The 
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cells were then imaged on a fluorescent inverted microscope as seen in Figure 
4.6. In the cells transfected in medium plus FCS all concentrations of siRNA have 
resulted in positively transfected cells as shown by the orange fluorescence. 
However, the cells did not transfect as well at the 5 nM concentration of siRNA 
indicated by the less intense fluorescent staining of those macrophages. A 
similar staining pattern can be seen in the cells which were transfected without 
serum in the medium as all the concentrations of siRNA show positive 
transfection and fluorescent cells but some cells in the 10 nM and 5 nM 
concentrations are not stained as brightly as the cells in the 30 nM and 20 nM 
concentrations. The cells that were incubated without serum contained lots of 
cellular debris as can be seen in the 30 nM image indicating that this could be 
detrimental to the cells. Therefore, siRNA transfection was performed in the 
presence of FCS. 
 
 
Figure 4.6 siRNA transfection efficiency by imaging fluorescence on the microscope 
Macrophages were treated with M-CSF for 6 days and transfected with varying concentrations (30 - 
5 nM) of negative control siRNA for 24 hours in the presence or absence of fetal calf serum (FCS). 
The negative control siRNA has a fluorescent tag therefore cells that been successfully transfected 
cells will fluoresce. 
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4.5.2.2 FACS plots 
To quantify the amount of positive transfection with the N-TER transfection 
system macrophages were treated with the negative control siRNA for 24 hours 
in serum-containing media, the cells were then collected and analysed on the 
FACS for Alexa Fluro-555 fluorescence compared to untransfected cells. Figure 
4.7 shows the results of this FACS analysis and demonstrates that at least 93% of 
macrophages were positive for negative control siRNA in all of the 
concentrations tested. This indicates that the N-TER transfection system allows 
siRNA to successfully enter the macrophage cells even at 5 nM 
concentration.
 
Figure 4.7 FACS analysis siRNA transfected macrophages 
Monocytes were differentiated with M-CSF for 6 days and transfected with varying concentrations 
of a fluorescent tagged negative control siRNA for 24 hours in complete medium. Cells were then 
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collected and analysed by FACS for fluorescence which was indicative of positive siRNA 
transfection. 
4.5.3 Testing siRNA 1-4 at 3 concentrations 
Once the transfection system had been validated in macrophage cells the plexin 
A1 siRNA was tested in the macrophage cells to see if it changed the expression 
of plexin A1. The plexin A1 siRNA received from Qiagen consisted of four 
individual siRNA‘s designated 1-4. Each individual siRNA was tested on the 
macrophages at three concentrations 10, 20 and 30 nM. It was decided not to 
test the siRNA at 5 nM as from the fluorescent microscope experiment the 
macrophages did not appear to be as intensely stained at the 5 nM concentration 
as they did at the other concentrations. 
4.5.3.1 PLX1- 4 at 30, 20, 10 nM 
Macrophages were M-CSF treated for 6 days and then treated with negative 
control siRNA (designated control) and the four plexin siRNA (designated PLX 1-
4) at 10, 20 and 30 nM concentrations for 24 hours. After this time the cells were 
collected and put into trizol and the qRT-PCR was performed on the samples to 
determine whether the siRNA had decreased the amount of plexin A1 siRNA 
being expressed by the cells. Since the negative control siRNA is a non-silencing 
siRNA it should not affect the amount of plexin A1 expression and therefore the 
plexin A1 mRNA levels in the samples treated with siRNA PLX 1-4 were compared 
back to the negative control siRNA to look for a relative increase or decrease in 
expression. Figure 4.8 shows the results of this experiment; graph (A) 
demonstrates the expression of plexin A1 as a result of siRNA treatment. The 
values of the negative control siRNA are 1 and the line drawn on the graph is set 
at 1. It can be seen that at 30 nM concentration PLX 1, -2 and -3 siRNAs are 
causing an increase in Plexin A1 expression rather than knocking it down and at 
the 10 nM concentration PLX 2 and 3 siRNA are also causing an increase in plexin 
A1 expression in the cells compared to the control. 
 Figure 4.8 (B) shows the percentage inhibition of plexin A1 as a result of adding 
the 4 different siRNAs. The percentage inhibition was calculated relative to the 
negative control and a negative value indicates an increase in plexin A1 
expression whereas a positive value indicates a decrease in plexin A1 expression. 
At the 30 nM concentration PLX 1, PLX 2 and PLX 3 siRNA induced an increase in 
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plexin A1 expression of 89, 83 and 84% respectively. Also at the 10 nM 
concentration PLX 2 and PLX 3 siRNA increased the amount of plexin A1 mRNA by 
100 and 67% respectively. The reason for these siRNAs increasing the amount of 
expression is unknown. A recent study has shown when an siRNA sequence is 
complementary to the promoter region of a gene it can increase transcription of 
that gene [644]. However, the siRNAs used in this study are unlikely to target 
the promoter region of plexin A1 as the phenomenon of the PLX siRNA inducing 
expression of plexin A1 does not occur at all of the concentrations tested and 
only occurs at 30 nM and 10 nM concentrations.  
Due to the PLX 2 and PLX 3 siRNA producing an increase in plexin A1 levels at 30 
and 10 nM concentrations they were omitted from further experiments. PLX 1 
siRNA induced an increase of plexin A1 at the 30 nM concentration but otherwise 
induced a high amount (75%) of inhibition at the 20 nM concentration and also 
decreased plexin A1 levels at the 10 nM concentration. PLX 4 siRNA was the only 
siRNA to consistently decrease the level of plexin A1 mRNA. Consequently only 
PLX 1 and 4 were used in additional experiments. 
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Figure 4.8 Testing siRNA PLX 1-4 in M-CSF differentiated macrophages 
M-CSF differentiated macrophages were treated with 4 siRNAs PLX 1-4 and a negative control 
siRNA that should not affect the expression of plexin A1 at 3 different concentrations 10, 20 and 30 
nM for 24 hours. Using qRT-PCR the amount of expression of plexin A1 in the cells relative to the 
negative control, which is set at 1, was determined in graph (A). The line on the graph is set at 1 
therefore any bars above the line are showing an increase in plexin A1 expression and any lines 
below are a decrease in plexin A1 expression. The percentage inhibition of plexin A1 was also 
determined for this experiment as can be seen in graph (B). Positive values for the percentage 
inhibition indicate that there was a decease in plexin A1 expression compared to the negative 
control. 
4.5.3.2 PLX 1 and 4 at 30, 20, 10 nM 
To check the level of plexin A1 inhibition by the two siRNAs PLX 1 and PLX 4, M-
CSF derived macrophages were treated with 10, 20 and 30 nM siRNA for 24 
hours. Figure 4.9 (A) indicates that both PLX 1 and PLX 4 decreased the amount 
of plexin A1 mRNA expression in the macrophages compared to the negative 
control in all of the three conditions. The percentage inhibition of plexin A1, 
graph (B), ranged from 14% to 54%. The concentration at which the percentage 
inhibition was greatest was 20 nM, at this concentration PLX 1 and PLX 4 induced 
49 and 54% inhibition respectively compared to the negative control. Hence the 
20 nM concentration of PLX 1 and PLX 4 was used in the further experiments, a 
mixture of both siRNAs was also used to determine if combining the two siRNAs 
results in a greater amount of gene silencing. 
(A) 
(B) 
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Figure 4.9 Testing PLX 1 and PLX 4 siRNA in macrophages 
PLX 1 and PLX 4 siRNA were tested again to ensure that they were decreasing the amount of 
plexin A1 expression in M-CSF derived macrophages. The relative expression compared to the 
negative control is shown (A) as well as the percentage inhibition of plexin A1 expression (B). 
 
4.5.4 Effect of plexin A1 knockdown in M-CSF derived 
macrophages stimulated with LPS or Tck 
I next examined the effect of plexin A1 knockdown on macrophage activation. 
M-CSF derived macrophages were treated with 20 nM PLX 1, PLX 4 and PLX 1 + 
PLX 4 for 24 hours, the transfection media was then removed and the cells were 
either left unstimulated or stimulated with 10 ng/ml LPS or Tcks at a ratio of 4:1 
for 24 hours. The supernatants were then removed for cytokine analysis and the 
cells were analysed by qRT-PCR. This experiment was repeated three times and 
the following results are a representative example of the results achieved. 
(A) 
(B) 
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4.5.4.1 qRT-PCR data 
Prior to analysing the TNF ELISA data it was necessary to check that the plexin 
A1 expression had decreased as a result of treating the cells with siRNA. Figure 
4.10 shows the relative expression of plexin A1 in the macrophage samples 
relative to the negative control. In the unstimulated macrophages which were 
incubated with media after the siRNA treatment there is a decrease in the 
amount of plexin A1 being expressed by the cells which were treated with PLX 1 
siRNA. The amount of plexin A1 expression in macrophages treated with PLX 4 
siRNA is also decreased compared to control but the siRNA treatment producing 
the highest amount of gene silencing is the combined treatment of PLX 1+4. This 
same pattern is seen with the macrophages which were stimulated with LPS, 
where the greatest level of gene silencing is seen when the combination of 
PLX1+4 were used. The percentage inhibition of plexin A1 in the macrophages 
treated with PLX 1+4 siRNA was 43% and 55% for the macrophage samples which 
were subsequently incubated with media or LPS respectively. Despite this being 
a large percentage inhibition in the context of the experiment it indicates that 
there is still over 50% or just under 50% of the total amount of plexin A1 being 
expressed in the macrophages, which will therefore bias the results when trying 
to determine effect of silencing the plexin A1 gene in macrophages. It also 
indicates that there is a discrepancy of over 10% in the amount of gene 
knockdown obtained each time the macrophages are treated with PLX siRNA; 
this variability will also bias the results of the siRNA experiment. 
In Figure 4.10 the results from the macrophages which were subsequently 
stimulated with Tcks in a cell contact (c.c) indicate that there was very little 
gene silencing of plexin A1 in these cells since the level of plexin A1 relative 
expression in the cells treated with siRNA is similar to the level of plexin A1 in 
the cells treated with the negative control siRNA. This may be due to 
contaminating Tcks in the sample with the macrophages as although every effort 
was made to remove the Tcks before putting the cells in trizol some may have 
remained. T cells have been shown to express plexin A1 [623] and the presence 
of contaminating Tcks in the macrophage sample could have diluted out the 
effect of the siRNA gene silencing therefore producing the result of little or no 
plexin A1 gene knockdown in these samples. 
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Once the result of 43% and 55% gene knockdown in the macrophage samples had 
been determined, the pro-inflammatory output from these stimulated 
macrophages could be analysed. 
 
Figure 4.10 RT-PCR of plexin A1 knockdown in activated macrophages 
PLX 1, 4 or 1+4 siRNA were used to silence the plexin A1 gene in macrophages that were 
subsequently stimulated with LPS or Tcks. 
4.5.4.2 TNFα ELISA data 
To establish whether the plexin A1 knockdown had any effect on the pro-
inflammatory output of the macrophages stimulated with LPS or Tcks a TNFα 
ELISA was performed on the cell supernatants. Figure 4.11 shows the results of 
the ELISA, while there were small amounts of TNFα produced by the 
macrophages incubated for 24 hours in media alone the stimulated macrophages 
both produced elevated quantities of TNFα. The LPS stimulated macrophages 
produced less TNFα in the samples which had been treated with PLX siRNA 
compared to the samples which had been treated with the negative control 
siRNA. The lowest amount of TNFα produced is from the macrophage sample 
that was treated with PLX 4 which from the previous figure induced 31% 
inhibition of plexin A1 therefore inhibiting a relatively small percentage of 
plexin A1 in macrophages may be enough to change its pro-inflammatory profile. 
This decrease in TNFα using PLX 4 siRNA compared to the negative control 
sample is statistically significant using a 1 way ANOVA and a Turky‘s multiple 
comparison test. 
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The Tck cell contact activated macrophages do not appear to have changed their 
proinflammatory output as a result of siRNA silencing of plexin A1 since the 
amount of TNF produced by the cells treated with PLX siRNA is not significantly 
different to the TNF production from the negative control treated macrophages. 
This could indicate that plexin A1 may not be involved in the cellular cross talk 
between macrophages and T cells however plexin A1 was not fully silenced with 
the PLX siRNA and it is possible that in order to elucidate the role plexin A1 
plays in the cellular contact between macrophages and T cells the plexin A1 
gene must be fully knocked down. 
Figure 4.11 TNFα ELISA of siRNA treated macrophages 
A TNFα ELISA was performed on macrophages that had been treated with various siRNAs before 
being incubated with media alone, 10 ng/ml LPS or Tcks (c.c). Error bars are mean ±SEM. This is 
a representative of three individual experiments. Using a 1 way ANOVA with Tukey’s multiple 
comparison test on the LPS treated group there is a statistically significant difference between the 
–ve control LPS group and the PLX 4 LPS group in addition to a statistically significant difference 
between –ve control LPS and PLX1+4 LPS group (p<0.05). 
 
4.6  Investigation into the expression of the Plexin A1 
ligand semaphorin 6D on T cells 
Plexin A1 is known to have several semaphorin ligands including semaphorin 6D. 
In the context of the immune system semaphorin 6D is the most well studied 
plexin A1 ligand to date and several studies have indicated that plexin A1 
expressed on DCs may interact with T cells expressing semaphorin 6D [623]. A 
recent study investigated the regulation of semaphorin 6D expression on T cells 
and found that in vitro activation of murine CD4+ T cells using plate-bound anti-
CD3 and anti–CD28 antibody increased mRNA levels of sema 6D by 24 hours and 
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after 5 days induced 71% surface expression of sema 6D compared to control 
during the late phase of activation [645].  
Since plexin A1 is upregulated in RA and PsA synovial fluid CD14+ cells and 
macrophages are known to interact with T cells in the arthritic joint [408] we 
hypothesised that semaphorin 6D, one of plexin A1‘s specific ligands, is 
expressed on arthritic T cells and is one of the receptor-ligand interactions 
taking place within the synovium of diseased patients. It was decided to first 
test for the presence of sema 6D on cytokine activated T cells (Tcks) since these 
are an in vitro model of activated synovial T cells [298, 309]. As a positive 
control human T cells were also activated with anti-CD3 and anti-CD28 
antibodies as a previous study had shown 71% of murine cells stimulated in this 
manner were found to express semaphorin 6D after 5 days [645]. 
4.6.1 Semaphorin 6D FACS analysis 
T cells were isolated from normal donors and stimulated for 6 days with a 
cytokine cocktail to produce Tcks or CD3/CD28 microbeads to produce activated 
T cells. T cells were analysed for semaphorin 6D expression at day 0 
(unactivated T cells), day 3 and day 6. Since the semaphorin 6D antibody was 
unconjugated a secondary APC antibody was incubated with the cells to detect 
whether sema 6D had bound to the cells. As a control, an irrelevant antibody 
(CD68) that should not have bound to the T cells was incubated with the cells 
before adding the secondary antibody in order to detect any non-specific 
staining of the secondary antibody. 
4.6.1.1 Semaphorin 6D expression on CD3/CD28 stimulated T   
cells 
Figure 4.12 demonstrates representative results of the FACS staining for the T 
cells stimulated for 0, 3 and 6 day with anti-CD3, anti-CD28 microbeads. Isotype 
control is shown as the grey histogram, semaphorin 6D surface and intracellular 
staining is shown in blue on the left hand histograms. Irrelevant antibody 
staining is shown in red on the right hand panel of histograms. 
Unstimulated T cells on day 0 appear to have approximately 3.5% semaphorin 6D 
surface staining however upon comparison to the irrelevant antibody, which has 
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3.16% positive staining, it appears  that the majority of the staining seen at day 
0 is non-specific secondary antibody staining. The same pattern is seen at day 3 
where there is 3.5% positive surface staining from the irrelevant antibody which 
indicates that the 4.39% positive semaphorin 6D staining is unlikely to be a valid 
observation. The same observation is seen within the day 6 activated T cells.. 
The intracellular staining at day 6 is also negative for both semaphorin 6D and 
irrelevant antibody. However, the intracellular staining in the T cells at day 3 
appears to show a small increase in semaphorin 6D expression compared to 
isotype control as 9% of cells are positive for semaphorin 6D. The irrelevant 
antibody staining at this timepoint is 1.9% indicating that the semaphorin 6D 
expression could be valid observation. 
Consequently, day 3 intracellular staining is the only timepoint which shows 
expression of semaphorin 6D, the intracellular levels are negative at day 6 and 
there is no surface expression of semaphorin 6D at any of the three timepoints 
examined. These observations conflict with the results shown by O‘Connor et al 
[645] who demonstrated that over 70% of murine CD4+ T cells express 
semaphorin 6D on the surface after 5 days of stimulation with anti-CD3 and anti–
CD28 antibodies. 
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Figure 4.12 Surface and intracellular semaphorin 6D staining of CD3/CD28 stimulated T cells 
T cells were analysed at day 0, day 3 and day 6 after stimulation for surface and intracellular 
staining of semaphorin 6D (blue lines). The semaphorin 6D was not a directly conjugated FACS 
antibody therefore a secondary APC conjugated antibody was incubated with the cells after 
semaphorin 6D staining to detect the presence of the surface ligand. As a control an irrelevant 
antibody (CD68) was incubated with the cells before adding the secondary antibody in order to 
check for non-specific staining of the secondary antibody (red lines). Isotype control is shown as 
the grey histograms. The surface staining is a representative of n=6 experiments and the 
intracellular staining is a representative of n=2 experiments. 
4.6.1.2 Semaphorin 6D expression in cytokine stimulated T cell 
(Tcks) 
Tcks were also analysed for semaphorin 6D expression after 0, 3 and 6 days of 
activation (Figure 4.13). Semaphorin 6D staining is shown by the blue lines on 
the left hand panel of histograms and irrelevant antibody staining is shown by 
the red lines on the right hand panel of histograms. Since the same unactivated 
T cells were used as a control for both CD3/CD28 and Tck activated T cells 
before the cells were activated with either stimulus, day 0 T cells show the 
same results as in the previous figure. There is no surface semaphorin 6D 
expression due to a similar percentage of positive staining for the irrelevant 
antibody, indicating that the secondary antibody is binding non-specifically. 
There was no induction of surface semaphorin 6D expression after 3 and 6 days 
of cytokine activation (2.1% and 2.5% positive respectively) considering that the 
250 
secondary antibody was also positive (0.68% and 1.7% respectively) indicating 
non-specific staining. There was also no intracellular semaphorin 6D expression 
at day 6 since the percentage of positive cells for semaphorin 6D and irrelevant 
antibody were almost identical (3.93% and 3.75%). However, as was seen with 
the CD3/CD28 activated T cells the intracellular expression of semaphorin 6D in 
Tcks was increased at day 3, 17.1% of Tcks were positive for semaphorin 6D. The 
irrelevant antibody had a considerably lower expression at this timepoint (3.97%) 
suggesting that the semaphorin 6D staining was specific. 
As was seen with the CD3/CD28 activated T cells semaphorin 6D is only 
expressed in Tcks intracellularly after 3 days of activation but is not expressed 
on the surface of the cells during the 6 days of activation.  
 
Figure 4.13 Surface and intracellular semaphorin 6D staining of Tcks 
T cells were analysed at day 0, 3 and 6 after cytokine stimulation for surface and intracellular 
expression of semaphorin 6D (blue lines). Since the semaphorin 6D was not a conjugated FACS 
antibody a secondary APC conjugated antibody was incubated with the cells after semaphorin 6D 
staining to detect the presence of the ligand. As a control an irrelevant antibody (CD68) was 
incubated with the cells before adding the secondary antibody in order to check for non-specific 
staining of the secondary antibody (red lines). Isotype control is shown as the grey histograms. The 
surface staining is a representative of n=6 experiments and the intracellular staining is a 
representative of n=2 experiments. 
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4.6.2  Investigation into the level of semaphorin 6D mRNA in T 
cell samples 
Due to problems with repeated non-specific staining of the secondary antibody 
during the FACS analysis we therefore went on to analyse the levels of 
semaphorin 6D mRNA in cytokine- and CD3/CD28-activated T cells. A PCR was 
set up with these samples and no detectable bands could be observed (data not 
shown) therefore to verify this result the samples were analysed by qRT-PCR. 
4.6.2.1 qRT-PCR of T cell samples 
T cells were isolated from 2 donors and activated with cytokines or CD3/CD28 
for 6 days. CD3+ cells were also isolated from 3 PsA synovial fluids. The relative 
expression of semaphorin 6D compared to the GADPH of each sample is shown in 
graph (A) of Figure 4.14. All Tck and CD3/CD28 samples have very low relative 
expression values indicating that semaphorin 6D is almost certainly not being 
expressed. The Tck day 6 sample of one of the donors has a much higher relative 
expression compared to all of the other samples which could suggest semaphorin 
6D mRNA is being expressed. The three PsA synovial fluid CD3+ samples have 
varying levels of semaphorin 6D relative expression but the levels are still 
relatively low, again indicating that semaphorin 6D is unlikely to be expressed in 
these cells.  
The fold change of semaphorin 6D expression in the Tck and CD3/CD28 activated 
cells can be determined by comparing the semaphorin 6D expression of the 
activated samples to that of the corresponding inactivated day 0 T cell sample. 
Graph (B) of Figure 4.14 illustrates the fold change in semaphorin 6D in the 
activated T cell samples compared to inactivated T cells. The Tcks and 
CD3/CD28 T cells activated after 3 days in both donors demonstrated a decrease 
in the amount of semaphorin 6D compared to inactivated T cells. The day 6 Tcks 
and CD3/CD28 T cells had a decrease in the amount of semaphorin 6D (fold 
change of -141 and -28 respectively) in donor 1 and a slight increase in donor 2 
(fold change 11 and 1.9 respectively).  
The combined FACS and qRT-PCR data suggest that in the activated T cells there 
are donor specific variances in the mRNA level of semaphorin 6D, however these 
expression levels are very low and on the whole demonstrate a decrease in the 
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amount of semaphorin 6D mRNA compared to inactivated T cells. The levels of 
semaphorin 6D expression within CD3+ cells from PsA synovial fluid are also very 
low. Semaphorin 6D protein appears to be transiently expressed within the T cell 
during activation. Plexin A1 is a receptor for semaphorin 6D and can only form 
an interaction if its ligand is present on the cell surface. During the FACS 
analysis surface semaphorin 6D could not be detected in the Tck samples that 
have been previously demonstrated to be an in vitro model of synovial T cells 
[298, 309]. This data combined with the very low levels of semaphorin 6D mRNA 
in the CD3+ synovial fluid samples suggests that T cells within the arthritic joint 
may not be the source of plexin A1‘s ligand semaphorin 6D. 
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Figure 4.14 qRT-PCR of semaphorin 6D expression in T cell samples and patient CD3
+
 
samples 
T cells from two donors were stimulated for 3 and 6 days with cytokines (Tcks) or CD3/CD28 
microbeads. These activated T cells and inactivated T cell were then analysed for semaphorin 6D 
expression by qRT-PCR. T cells were also isolated from 3 PsA synovial fluids and analysed for 
semaphorin 6D. Graph (A) shows the relative expression of semaphorin 6D compared to the 
GAPDH levels in each sample. Graph (B) shows the fold change in expression in the Tck or 
CD3/CD28 activated T cells compared to the inactivated T cells (T cells d=0). 
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4.7 Investigation into the expression of other plexin A1 
ligands semaphorin 3A, 3F, 6D on RA synovial 
membrane 
The previous results suggested that semaphorin 6D is unlikely to be expressed on 
the T cells in the arthritic joint therefore it was decided to analyse the synovial 
membrane of RA patients for semaphorin 6D. If the membrane was positive for 
semaphorin 6D expression, this would imply that plexin A1‘s ligand is being 
expressed by other cell types rather than T cells. 
Plexin A1 is also known to interact with class 3 semaphorins namely semaphorin 
3A and semaphorin 3F [617]. As mentioned in the introduction class 3 
semaphorins will only bind plexin A1 if neuropilin is present as a co-receptor, 
semaphorin 3A will specifically bind neuropilin-1 (NRP-1) and semaphorin 3F will 
bind NRP-1 and NRP-2 [443]. Analysing the microarray data (presented in chapter 
4) for genes that are upregulated in addition to plexin A1 in the RA and PsA SF 
CD14+ cells reveals that these cells have upregulated NRP-1 with a fold change 
increase of 40 in PsA SF and 11 in RA SF and NRP-2 with a fold change increase of 
24 in PsA SF and 31 in RA SF. Since these cells had upregulated plexin A1 and the 
two co-receptors needed for semaphorin 3A and 3F signalling it was possible that 
plexin A1 could be binding to either of these ligands hence the presence of 
semaphorin 3A and 3F were also analysed in the RA synovial membrane. 
4.7.1 qRT-PCR on RA synovial membrane 
SYBR green analysis was performed on 10 RA synovial membranes to investigate 
the presence of three plexin A1 ligands. The results are shown in Figure 4.15 and 
indicate that all three semaphorins are expressed in the RA membranes however 
semaphorin 3A has the greatest relative expression in the samples compared to 
its housekeeping gene. Semaphorin 6D is also expressed in the RA membranes 
indicating that although we could not detect it on T cells it may be present on 
other cell types within the membrane. Consequently the level of these 
semaphorins on another cell type known to be present in the RA synovium was 
investigated. 
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Figure 4.15 Semaphorin 3A, 3F, 6D expression in RA synovial membrane 
qRT-PCR was used to determine the relative expression of 3 of plexin A1’s ligands in 10 RA 
synovial membranes. Each dot represents one patient sample and the line indicates the mean 
expression. 
4.7.2 SYBR green of RA synovial fibroblasts 
Given that it had been determined that three of the plexin A1 ligands were 
expressed in the RA synovial membrane it was hypothesised that fibroblasts may 
be a cell type expressing these semaphorins since macrophages and fibroblasts 
are known to interact in the inflamed synovial joint [646]. Consequently, the 
relative expression of semaphorin 3A, 3F and 6D compared to GAPDH was 
determined for RA synovial fibroblasts from 5 patients. Figure 4.16 outlines the 
results and reveals that semaphorin 3F was the most highly expressed 
semaphorin and all five samples expressed it at a similar level. Semaphorin 3A 
was also expressed but the levels varied between samples with 3 samples having 
a high level of expression comparable to semaphorin 3F samples whereas the 
remaining 2 samples having a low level of expression. The five RA fibroblast 
samples expressed semaphorin 6D but at a lower level compared to the other 
semaphorin‘s examined. The overall expression of the three semaphorin 
molecules is very low with all of the relative expression values being lower than 
0.02. Further analysis with more samples would need to be performed to 
determine whether synovial fibroblasts could be expressing the plexin A1 
ligands.  
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Figure 4.16 Semaphorin 3A, 3F and 6D expression in RA synovial fibroblasts 
Synovial fibroblasts from 5 RA patients were analysed for semaphorin (sema) 3A, 3F and 6D. qRT-
PCR was used to determine the relative expression of the semaphorins which were then 
normalised to GAPDH levels of each sample. The line represents the mean value. 
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4.8 Discussion 
Plexin A1 is a semaphorin receptor known to participate in axonal guidance 
[635], chick cardiac development [631], bone homeostasis [623], T cell-DC 
interactions [444, 623] and DC trafficking to the lymph node [632]. Plexin A1 had 
been previously shown to be expressed on human M-CSF differentiated 
macrophages [443] but has not been shown to be present or play a role in PsA or 
RA. After discovering plexin A1 to be a highly upregulated gene in RA and PsA 
CD14+ cells, showing a fold change increase of 26 and 27 respectively, we were 
interested in its previously identified role in T cell-DC interactions. In this 
setting plexin A1 is expressed on the DCs and is thought to act as a co-
stimulatory marker for a T cell ligand because plexin A1-/- DCs have a reduced 
ability to stimulate T cells [623] and plexin A1 has been shown to be localised at 
the T cell-DC interface [640]. Since macrophages have been demonstrated to 
interact with many cellular subtypes within the synovium of arthritis patients 
[249, 408, 646] we hypothesized that the increased levels of plexin A1 on 
synovial fluid CD14+ cells may play a role in enhancing cellular interactions 
within the diseased joint. In order to investigate this hypothesis we needed to 
demonstrate that plexin A1 was present within the synovial fluid cells and the 
synovium of arthritis patients, determine which plexin A1 ligands were present 
within the joint and investigate the effects of silencing plexin A1 on the pro-
inflammatory cytokine level obtained from activated macrophages. 
Plexin A1 was expressed at the mRNA level in all of the CD14+ cells isolated from 
the synovial fluid of RA and PsA examined which included the samples that had 
been analysed on the microarray and other patient samples. Plexin A1 mRNA was 
also detected in the CD14+ synovial fluid cells of a JIA, an inflammatory 
polyarthritis and an OA patient indicating that this cell surface molecule may 
also be playing a role in other arthritic diseases, although more patients would 
have to be analysed to verify this. In the patients where a matched synovial fluid 
and blood sample were available the mRNA level of plexin A1 was consistently 
increased in the synovial fluid CD14+ cells compared to the blood CD14+ cells 
verifying the microarray results and suggesting the pro-inflammatory 
environment within the diseased joint causes the CD14+ cells to upregulate 
plexin A1 once they exit the blood and enter the synovium. 
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We observed the presence of plexin A1 in five RA synovial membranes where it 
was mainly located in cells outlining vascular structures, possibly indicative of 
endothelial cells, and within cells surrounding the vasculature structures which 
could represent cells infiltrating into the membrane via the blood vessels. 
However, due to a lack of PsA synovial membrane this disease was unable to be 
analysed for plexin A1 staining.  
Plexin A1 is a receptor molecule for semaphorin ligands and previous work has 
indicated that the specific ligands which interact with plexin A1 are semaphorin 
3A, 3F and 6D [624]. The main focus of research involving plexin A1‘s role in the 
immune response has been its interaction with semaphorin 6D on T cells [623, 
640]. O‘Connor et al demonstrated that CD3/CD28 activation of murine CD4+ 
cells induced the surface expression of semaphorin 6D [645] therefore we 
investigated whether an in vitro system of cytokine activation previously shown 
to induce a T cell phenotype similar to that of synovial T cells [298, 309] could 
induce the expression of semaphorin 6D. The interaction of macrophages and T 
cells in the arthritic joint has been well documented [314, 408] therefore a 
plexin A1 – semaphorin 6D receptor ligand complex could be one of the 
interactions taking place. We observed no surface semaphorin 6D expression on 
the cytokine activated or CD3/CD28 activated T cells and no mRNA expression of 
semaphorin 6D in these cells or synovial fluid CD3+ T cells. The lack of surface 
semaphorin 6D on CD3/CD28 activated T cells conflicted with the results of the 
O‘Connor paper  which demonstrated CD3/CD28 antibody stimulation induced 
semaphorin 6D expression in 70% of T cells after 5 day [645]. However, this 
discrepancy may be explained by a species specific response as the O‘Connor 
paper analysed murine T cells whereas we investigated semaphorin 6D in human 
T cells.  
Despite semaphorin 6D being undetected in cytokine activated and synovial T 
cells there was a possibility that semaphorin 6D was being expressed in the 
synovium on other cell types. There was also the prospect of the macrophage 
plexin A1 interacting with one of its other ligands in the synovium such as 
semaphorin 3A or 3F. However, both of these semaphorins only interact with 
plexin A1 in the presence of neuropilin-1 or -2 acting as a co-receptor [647]. 
Analysis of the microarray study data indicated that compared to blood CD14+ 
cells RA and PsA SF CD14+ had increased levels of neuropilin-1 and -2 as well as 
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plexin A1 indicating that binding of semaphorin 3A or 3F would be possible in 
these synovial macrophages. We observed that 10 RA synovial membranes 
expressed semaphorin 3A mRNA at a higher level than that of semaphorin 3F or 
6D and so it appeared that semaphorin 3A could be the main receptor for plexin 
A1 in the synovial compartment. To try and elucidate which cell type expressed 
the plexin A1 ligands we investigated five RA synovial fibroblasts samples since 
synovial macrophages have been demonstrated to interact with synovial 
fibroblasts [249]. In these cells semaphorin 3F mRNA was expressed at a higher 
level compared to semaphorin 3A and 6D. However, the relative expression of 
these semaphorins were very low and further studies to analyse protein levels of 
expression should be conducted before a definitive conclusion can be made 
about the presence of semaphorins on synovial cell types. 
Despite being unable to define which cells were expressing the plexin A1 ligands 
we had shown that these ligands were present in the synovium of RA patients 
and therefore could hypothesize that the upregulation of plexin A1 in synovial 
macrophages was significant and may be playing a role in the progression of 
disease in RA and PsA. To try and elucidate the function of plexin A1, small 
interfering (siRNA) was used to silence the plexin A1 gene in M-CSF derived 
macrophages which had been shown to upregulate plexin A1 mRNA during their 
differentiation. The transfection efficiency was over 90% indicating that the 
siRNA was effectively entering the cells using the nanoparticle transfection 
system. Unexpectedly, two of the four siRNA induced an increase in plexin A1 
expression rather than knocking it down. siRNA‘s are known to have off-target 
effects as a result of a lack of specificity and can therefore silence other genes 
within the cell if the siRNA imperfectly pairs with sequence motifs residing in 
the 3‘ UTR of cellular mRNA [648]. There has been one report of siRNA 
treatment resulting in the upregulation of mRNA within cells. This was thought 
to be due to competition between the transfected siRNA and the cell‘s own 
endogenous miRNA. Hence the mRNAs targeted by the endogenous miRNA are 
not degraded and the cell demonstrates an upreglulation of these mRNA‘s [649]. 
However, despite this report of upregulation of mRNA levels occurring as a result 
of siRNA treatment there has been no report of upregulation of the siRNA target 
gene which is what occurred during the plexin A1 knockdown experiments. The 
reason for the observed upregulation of plexin A1 mRNA is unknown but could 
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have been due to badly designed siRNA which did not target the plexin A1 mRNA 
for degradation. As a result the two PLX siRNA which demonstrated increased 
plexin A1 expression were not used in further experiments. 
The TNFα cytokine profile of siRNA treated macrophages subsequently 
stimulated with 10 ng/ml of LPS or cell contact activated with Tcks for 24 hours 
were analysed. It was thought that these two treatments may mimic the pro-
inflammatory environment to which synovial macrophages may be exposed as 
TLR signalling may play a role in arthritis [650] and cellular contact with 
activated T cells is known to take place within the joint.  
In the experiment shown, treating macrophages with 20 nM PLX 1+PLX 4 resulted 
in a 43% inhibition of plexin A1 in the cells which were subsequently cultured 
with media alone and 55% inhibition in the macrophages which were 
subsequently stimulated with LPS. This discrepancy of over 10% in the amount 
gene silencing demonstrated the large variability of the siRNA treatment which 
was seen throughout all three siRNA experiments. The small amount of gene 
silencing also indicated that potentially there could be as much as 50% of the 
total amount of plexin A1 mRNA still present in the macrophage cells before 
activation which could therefore bias the results of the cytokine analysis. In the 
siRNA treated macrophages which were activated with Tcks there appeared to 
be little to no gene silencing with the maximal amount of inhibition being 10% 
with PLX 4 treatment. This observation could be the result of contaminating Tcks 
remaining in the culture wells as T cells have been shown to express plexin A1 
[623]. Consequently, contaminating T cells in the macrophage sample may have 
diluted out any effect of the siRNA treatment which resulted in the appearance 
of no plexin A1 knockdown. Due to this discrepancy we must assume that the 
level of gene silencing in the Tck-stimulated was at a similar level to the gene 
silencing seen in the other macrophage samples i.e. around 43 – 55% inhibition. 
The subsequent TNFα analysis of the macrophage samples demonstrated that the 
cytokine level did not change in the macrophages incubated in media alone, 
indicating that the siRNA treatment did not adversely activate the macrophages. 
The LPS stimulated macrophages produced less TNFα in the samples which had 
been treated with siRNA compared to the negative control. The sample 
producing the lowest amount of TNFα was the sample which had a 31% 
261 
knockdown of the plexin A1 gene suggesting that even a small decrease in the 
amount of plexin A1 may be enough to change the pro-inflammatory cytokine 
profile of the macrophage. This result would imply that plexin A1 is playing a 
pro-inflammatory role within the macrophage as a decrease in plexin A1 
expression causes less TNFα to be released by the cell as a result of TLR4 
stimulation. This observation is in contrast to that of Ji et al [443] who 
previously demonstrated that LPS stimulation of human monocytes alongside M-
CSF stimulation for 24 hours resulted in the inhibition of plexin A1 mRNA 
expression. The inconsistency could be due to the stage of monocyte activation 
as the Ji et al paper investigated day 0 monocytes which were M-CSF and LPS 
stimulated at the same time for 24 hours while our investigation analysed the 
effect of plexin A1 silencing in macrophages that had been treated with M-CSF 
for 6 days and therefore would have a more activated phenotype. It must also be 
noted that the plexin A1 inhibition in the macrophages of this experiment was 
55% therefore there is still 45% of the total plexin A1 mRNA level being 
expressed within these cells. Subsequently, it is difficult to draw definitive 
conclusions about the role of plexin A1 with regards to TLR-4 stimulation until 
complete knockdown of the plexin A1 gene is established. 
The TNFα levels measured in the siRNA treated macrophage activated with Tcks 
did not appear to have changed significantly in comparison to siRNA negative 
control macrophages. This result could indicate plexin A1 on the macrophages is 
not involved in the cellular cross talk which occurs between Tcks and 
macrophages since its knockdown did not affect the pro-inflammatory output of 
the macrophages. This conclusion is supported by our  finding that semaphorin 
6D, one of plexin A1‘s most studied ligands, is not present on Tcks or synovial 
CD3+ cells at the surface protein or mRNA level. However, as with the siRNA-
treated LPS stimulated macrophages it is difficult to draw conclusions about the 
role of plexin A1 within the macrophage - Tck cell contact when the plexin A1 
gene is incompletely silenced. The true function of plexin A1 may only become 
apparent once macrophage cells with 100% knockdown of plexin A1 are studied. 
In conclusion, the plexin A1 investigation has demonstrated that plexin A1 mRNA 
is highly upregulated in synovial fluid macrophage cells of PsA and RA and is also 
upregulated in synovial CD14+ cells of other arthritic conditions such as OA, JIA 
and inflammatory polyarthritis. It is present within the synovial membrane of all 
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5 RA patients examined although double staining is necessary to determine if the 
plexin A1 positive cells are predominantly macrophages. One of plexin A1‘s 
ligands semaphorin 6D could not be measured on cytokine activated T cells 
(Tcks) or CD3/CD28 activated T cells as had been previously described [645] and 
its mRNA levels could not be determined in the above cell types or synovial fluid 
CD3+ cells suggesting that macrophage plexin A1 was not interacting with T cells 
in the synovium. However, another of plexin A1‘s ligands, semaphorin 3A, was 
found to be highly expressed at the mRNA level in 10 RA synovial membranes 
indicating that this could be plexin A1‘s main ligand within the arthritic joint. At 
present the cell type expressing this semaphorin has not been discovered and 
analysis of RA synovial fibroblasts indicated that they expressed low levels of 
semaphorin. Investigation into the function of plexin A1 using siRNA has hinted 
at a possible pro-inflammatory role in macrophages as LPS induced TNFα 
secretion decreased in siRNA treated cells. However further investigations are 
needed to fully confirm this observation. 
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Chapter 5 Investigation into the expression and 
function of the novel gene legumain in rheumatoid 
and psoriatic arthritis patients 
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5.1 Introduction 
The second ‗novel articular‘ gene to be discovered during the analysis of the 
upregulated genes in RA and PsA SF CD14+ cells was legumain. Legumain, 
otherwise known as asparagine endopeptidase (AEP), is a lysosomal cysteine 
protease that specifically cleaves protein substrates on the C-terminal side of 
asparagine [651]. The mammalian form was cloned and sequenced in 1997 [651] 
after being described in leguminous plants [652] and the blood fluke Schistosoma 
mansoni [653]. There are four families of cysteine endopeptidases found in 
mammals, the most numerous of those belong to the papain family (C1), which 
are predominantly lysosomal enzymes and include cathepsin S, L, F, B, K and C 
[654]. These enzymes are responsible for proteolysis in the lysosomal/endosomal 
system and can also be secreted to act extracellularly. The other families of 
cysteine endopeptidases consist of calpain (family C2), caspase and legumain 
(family C13) [655]. 
Legumain is produced as an inactive zymogen that requires proteolytic cleavage 
to gain activity. Legumain activates itself autocatalytically which requires the 
sequential cleavage of a C-terminal 110-residue propeptide and then a shorter 
N-terminal 8-residue propeptide, this activation is pH dependent occurring 
optimally between pH 4.0-4.5 [656]. Initial studies of legumain found it to have 
the highest activity in the kidney of rat, rabbit and pig [651]. However, further 
studies of mouse legumain found it be expressed in all samples examined 
including placenta, spleen, kidney, heart, lung, liver, testis and thymus but the 
active legumain was particularly abundant in the kidney and placenta [657]. 
Legumain deficient mice have enlarged proximal renal tubule cells suggesting 
that material to be degraded is accumulating in the lysosomes; previous 
hypotheses proposed that legumain has a role in the biosynthesis of lysosomal 
enzymes [432]. Legumain has since been shown to be ubiquitously expressed in a 
large panel of human tissue at mRNA level [435] and is constitutively expressed 
in most cells types including macrophages and DCs [658]. 
Legumain is known to cleave and activate several substrates such as MMP-2 
[429]; fibronectin [431]; α-thymosin [430]; cathepsin B, H and L [432]; TLR9 in 
DCs [658] and it also processes microbial tetanus toxin antigen [659]. Due to this 
wide variety of substrates, the functional role of legumain is cell and tissue 
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context dependent. Manoury et al [659] first described a role for legumain as the 
enzyme which processes microbial tetanus toxin antigen (TTCF) for antigen 
presentation; legumain was isolated from disrupted lysosomes of the human B 
cell line EDR and exposed to TTCF in vitro. Peptide inhibitors to legumain slowed 
TTCF presentation to T cells while pre-processing of the peptide with legumain 
accelerated its presentation. The same group later showed that T cell responses 
to TTCF were still mounted in legumain-deficient mice but the in vivo kinetics of 
TTCF presentation was slower. Boosting legumain levels in the primary APCs 
accelerated TTCF processing and presentation in vitro indicating that legumain 
is the most efficient protease for TTCF processing but in its absence other 
enzymes can substitute to enable a slower immune response [660]. Recently, 
Sepulveda et al [658] showed that legumain plays a role in the processing of 
TLR9 in DCs as legumain deficiency resulted in decreased secretion of 
proinflammatory cytokines in response to umCpG DNA. They also showed that 
transfection of TLR9 deficient DCs with a mutant TLR9 lacking a legumain 
cleavage site did not restore TLR9 signalling, suggesting that TLR9 is a direct 
substrate for legumain.  
As well as its roles in antigen processing and TLR9 cleavage, legumain has also 
been shown to directly degrade fibronectin in vitro and in cultured mouse renal 
proximal tubular cells [431]. The processing of fibronectin was abrogated by 
chloroquine, an inhibitor of lysosomal degradation, and was enhanced by the 
overexpression of legumain revealing that fibronectin degradation occurs in the 
presence of legumain in the lysosomes of renal proximal tubular cells. Similarly, 
legumain-deficient mice exhibit renal injury induced protein accumulation of 
fibronectin and enhanced renal interstitial fibrosis which led to the hypothesis 
that renal proximal tubular cells take up and degrade fibronectin intracellularly 
thereby linking legumain to extracellular matrix remodelling. Legumain may also 
play an indirect role in matrix remodelling as it can cleave pro-MMP-2 into active 
MMP-2 [429]. MMP-2 is known to degrade the extracellular matrix due its wide 
variety of substrates including fibronectin, several MMPs and collagen types 
[661]. 
Despite playing an important role in extracellular matrix turnover and antigen 
processing legumain is also linked to various pathological conditions such as 
cancer, atherosclerosis and skin barrier function. Legumain was first 
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demonstrated to be involved in cancer when Liu et al showed that it was 
overexpressed in a panel of human solid tumours including breast, colon, lung, 
prostate and ovarian carcinoma [662]. The same study used fluorescent 
microscopy in tumour cells to show legumain expression associated with 
intracellular membranous vesicles, consistent with its function as a lysosomal 
protease, as well as on the cell surface and in membranous vesicles 
concentrated at the invadopodia of the tumour cell. HEK 293 cells stably 
expressing legumain were found to have increased migration and invasion in 
vitro and legumain expression was correlated with tumour invasion and 
metastasis in vivo [662]. Legumain was also found to be expressed specifically in 
tissue sections of a mouse tumour line CT26 where it was detected in vascular 
endothelial cells, macrophages and in the extracellular matrix associated with 
collagen I [663]. Cystatin E/M is a cysteine protease inhibitor and its relationship 
with legumain was investigated in human melanoma, legumain was expressed 
and active in most of the cell lines but was absent or at low levels in cell lines 
secreting cystatin E/M. When melanoma lines lacking cystatin E/M secretion 
were transfected with a plasmid containing full length cystatin E/M their 
intracellular legumain activity was inhibited, suggesting that it regulates 
legumain activity and hence its invasive potential [664]. 
Legumain was first associated with atherosclerosis when a microarray study 
comparing stable and unstable atherosclerotic plaques found legumain to be one 
of the genes upregulated in the unstable areas of plaques [434]. The same group 
demonstrated legumain mRNA to be co-localised with CD68 macrophages in the 
shoulder region of the plaque by in situ hybridisation and IHC. Another group 
followed on from this initial observation by using a microarray to study the aorta 
of aging Apolipoprotein E deficient mice with developed atherosclerosis, they 
found that legumain mRNA expression increased with the development of 
atherosclerosis while its expression remained at low unchanged levels in aged 
matched C57BL/6 control mice [665]. In both Apolipoprotein E deficient mouse 
arteries and human advanced atherosclerotic plaques legumain was 
predominantly expressed in macrophages. It was also shown to induce 
chemotaxis of primary human monocytes and human umbilical vein endothelial 
cells (HUVECs). The macrophage-specific expression of legumain in vivo as well 
as the ability of legumain to induce chemotaxis of cells in vitro suggests 
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legumain could play a functional role in atherogenesis. It has also subsequently 
been shown that human unstable plaques express twice the amount of legumain 
as stable plaques [666]. 
Cystatin C and cystatin E/M both bind to legumain with high affinity in vitro 
thereby inhibiting its activation [667]. Since cystatin E/M plays a regulatory role 
in epidermal differentiation, misregulation of this pathway leads to abnormal 
stratum corneum and hair follicle formation as well as severe disturbances of 
skin barrier formation [668]. Legumain is found in the epidermis and hair 
follicles of wild type and Cystatin E/M null mice (ichq mouse) but active 
legumain is only found in the epidermis of the ichq mouse suggesting that a role 
for cystatin E/M in vivo is to regulate legumain activity [669]. Regulation of 
legumain activity is important as it cleaves and activates cathepsin L which in 
turn activates transglutaminase 3 (TGM3). Active TGM3 was detected in skin 
extracts of cystatin E/M null mice at a time where skin lesions developed and 
caused abnormal cornification [669], therefore unrestricted legumain activation 
could play a role in irregular skin barrier formation. Ichq mice are a model of the 
human disorder type 2 harlequin ichthyosis which is a severe type of skin disease 
and as yet the presence of legumain in this disorder has not been determined. 
However, legumain mRNA has been detected in atopic dermatitis and psoriasis 
suggesting it may be contributing to the abnormal skin barrier seen in these 
conditions [435]. 
Since legumain was expressed at high levels in the SF of RA and PsA in my 
microarray samples and it is has been demonstrated to cleave and activate 
several substrates found in the arthritic joint, such as fibronectin [425-428], 
MMP-2 [670] and cathepsin B and L [671-673], it was decided to analyse legumain 
and its expression and activity in RA and PsA samples.  
Due to identification of a novel gene legumain which was highly upregulated in 
RA and PsA CD14+ SF cells I therefore sought to validate this expression in the 
microarray samples and samples from other patients. I also sought to determine 
the level of protein expression of legumain in the synovial membrane of 
diseased patients and in the CD14+ cells of diseased patients by IHC and western 
blot. Once the presence of legumain had been verified I sought to determine 
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whether the legumain that was present was active and still able to cleave 
substrates. 
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5.2 Validation of legumain expression in microarray 
samples 
Legumain had a fold change increase from PB CD14+ samples to the matched SF 
CD14+ samples of 167 in RA and 164 in PsA. However, since microarray results 
require validation and verification by an alternative and complementary gene 
expression profiling method qRT-PCR was used to determine  the expression of 
legumain in the 8 RA and 8 PsA pairs of samples that had been used for the 
microarray study. Figure 5.1 (A) shows the raw data signals of legumain on the 
affymetrix GeneChips for each patient sample. The signal values of legumain in 
the synovial fluid of both sets are considerably higher than those of the blood 
samples however the signal intensity varies between the synovial fluid samples 
of each patient indicating that the levels of legumain in the synovial fluid CD14+ 
cells are not consistent possibly due to differences in disease duration and 
treatment type of the patients. 
To validate these results qRT-PCR was used to determine the fold change in 
legumain expression in the SF samples compared to the PB samples. One RA 
patient was unable to be analysed due to a problem with the peripheral blood 
sample, as repeated measurements gave unusual results which could not be 
analysed. This could have been due to a problem with the RNA for that sample 
therefore the matched PB and SF samples from that particular patient were not 
analysed. Figure 5.1 (B) shows the results of the qRT-PCR and clearly 
demonstrates that legumain expression increases from the PB to the SF of each 
patient which reflects the results obtained from the microarray.  
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Figure 5.1 Legumain expression in microarray samples 
(A) Demonstrates the raw signal intensities of the legumain gene locus on the Affymetrix 
GeneChips. Each circle represents one patient sample and the line represents the mean signal 
intensity. Legumain mRNA levels were then measured in the RA and PsA paired PB and SF 
microarray samples by qRT-PCR. (B) The fold change of legumain expression in the SF samples 
was normalised to the matched patient PB sample, each circle represents one patient and the line 
the mean fold change. 
5.3 Expression of legumain in other patient samples 
Once it had been verified that legumain was expressed in the samples used in 
the microarray we then analysed legumain expression in more patient samples to 
check that increased legumain expression in the SF of RA and PsA occurred in 
other patients and not just the 16 who were examined on the microarray. Figure 
5.2 shows the legumain expression in all of the CD14+ samples tested. In graph A 
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it can been seen that there are varying levels of legumain in the PsA CD14+ SF 
samples but the mean level of expression is higher than that seen in PsA PB 
CD14+. Five of these PsA patients tested had matched PB and SF CD14+ cells and 
therefore the fold change increase in legumain expression from the PB to the SF 
was able to be measured as seen in Figure 5.2 (B). As was observed in the 
microarray samples some of the patients had a substantial fold change 
differences but the mean fold change difference in legumain expression was 133 
which is similar to the mean fold difference of 138 seen from the microarray 
samples. We were unable to obtain matched PB samples for the RA patients 
analysed however, in part (A) of Figure 5.2 the RA SF CD14+ and PsA SF CD14+ 
samples both have a similar mean relative expression of legumain which concurs 
with the results observed in the microarray samples. 
Graph (A) of Figure 5.2 also demonstrates the other arthritic patient samples 
from which we obtained CD14+ cells to analyse for legumain expression. The 
inflammatory arthritis and JIA CD14+ samples both appear to have lower levels of 
legumain expression compared to the RA and PsA SF samples however legumain 
is present in the samples. Unfortunately we were not able to obtain PB CD14+ 
samples from each patient to distinguish whether the legumain expression level 
increased from PB to SF CD14+ as has been seen with the RA and PsA patients. 
Matched OA PB and SF CD14+ cells from the same patient were measured for 
legumain expression and as with the RA and PsA microarray samples the level of 
mRNA expression increased from the PB to the SF. These data demonstrate that 
legumain is not specific to RA and PsA but is also expressed in other arthritic 
diseases. 
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Figure 5.2 Legumain expression in CD14
+
 cells from arthritic patients 
Legumain RNA expression was measured in the CD14+ cells from the PB or SF of arthritic 
patients. (A) Expression was measured relative to GAPDH. Five of the PsA patients had matched 
PB and SF samples, in these patients the fold change increase of legumain expression was 
measured and plotted in graph (B). 
(A) 
(B) 
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5.4 Immunohistochemistry 
Next immunohistochemistry (IHC) was performed to detect the enzyme in RA 
synovial membrane. The antibody staining was first optimised on tonsil sections 
before the RA synovial membranes were stained for legumain (data not shown). 
Five individual RA membranes were stained and they all displayed specific 
positive staining of legumain. Figure 5.3 shows representative staining from one 
of the RA synovial membranes. The x10 and x40 magnification isotype controls 
are shown in panel (A). Positive legumain staining at x10 and x40 magnification 
from two different areas of the same RA synovial membrane are shown in panel 
(B) and (C). The isotype controls show no non-specific staining indicating the 
antibody is specific for legumain. In panel (B) legumain staining is seen to be 
constitutively expressed throughout the membrane and analysing the x40 
magnification the staining is cytoplasmic with no nuclear staining and within 
some cells the staining is granular indicative of lysosomal staining.  
Panel (C) shows staining from the same tissue and demonstrates that positive 
legumain staining is seen on the edge of the membrane where it is contained 
within the cytoplasm of cells. Positive staining can also been seen in cells within 
follicular regions of the tissue (indicated by arrows). The staining appears to be 
present in macrophage-like cells but this cannot be verified until the membrane 
is double stained for legumain and CD68. 
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Figure 5.3 Immunohistochemistry staining of legumain in RA synovial membrane 
Five individual membranes were stained for legumain; this figure shows the results from one 
membrane that represents the staining pattern of legumain seen in the membranes. The isotype 
controls are shown in (A) at the x10 and x40 magnification. Images (B) and (C) define the positive 
legumain staining (shown in brown) seen in the RA membrane. Arrows in panel C denote positive 
follicular staining. The x10 magnification is shown on the left and the x40 magnification of an area 
of the x10 image defined by the box is shown on the right. 
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5.5 Western blot for legumain  
Since we had determined that legumain RNA was expressed in synovial CD14+ 
cells and IHC had indicated that legumain was present in RA synovial membrane 
we wanted to determine if arthritic synovial CD14+ cells were expressing the 
legumain enzyme at the protein level. Legumain has already been demonstrated 
to be upregulated in M-CSF macrophages [665, 674] therefore M-CSF treated 
macrophages were also analysed as a positive control. 
5.5.1 Legumain in M-CSF derived macrophages by RT-PCR 
To determine whether the presence of legumain increased as a result of M-CSF 
treatment, day 6 M-CSF treated macrophages from 5 individual donors were 
analysed by RT-PCR. As can be seen from Figure 5.4, M-CSF treatment induced 
legumain mRNA production in all 5 donors. The fold change difference between 
untreated monocytes and treated macrophages is donor dependent and varies 
between the lowest fold change of 26 and the highest fold change of 3567. 
 
Figure 5.4 Legumain expression in M-CSF treated macrophages for 6 days 
Monocytes were obtained from 5 healthy donors and treated with M-CSF for 6 days. Monocyte 
samples were taken at day 0 and compared to the M-CSF treated macrophages for legumain 
expression by RT-PCR. The graph shows the relative fold change in legumain expression from day 
0 monocytes to day 6 treated macrophages. 
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5.5.2 Legumain in M-CSF macrophages by western blot 
Once we had shown that legumain is present in M-CSF derived macrophages at 
the mRNA level we next wanted to verify expression at the protein level. 
Monocytes were isolated from three individual donors and analysed at day 0, 3 
and 6 days after M-CSF treatment for legumain and also for β-actin as a loading 
control (Figure 5.5). As described in the introduction legumain can exist in two 
forms, a pro form and an active form, to convert to the active form legumain 
must autocatalytically cleave itself in a pH dependent process [656]. In Figure 
5.5 the upper panel indicates the presence or absence of legumain in each 
sample. There appears to be no legumain in any of the day 0 - monocyte samples 
however day 3 M-CSF treated monocytes exhibit two bands representing pro-
legumain at 52 kDa and active legumain at 36 kDa. At day 6 in all three donors 
the amount of pro-legumain is reduced as well as the amount of active 
legumain. The lower panel of Figure 5.5 demonstrates the β-actin loading 
control of each macrophage sample. Despite the samples being analysed by BCA 
for protein concentration and 5 μg of protein being loaded to each well, the β-
actin blot indicates that the amount of protein loaded into each well varies due 
to the different intensity of the β-actin band in each sample. Also, there appears 
to be very little sample in day 0 monocytes of donor 1 due to a lack of a band for 
the β-actin control. However, regardless of the loading control we have 
demonstrated that macrophages express the pro- and active form of legumain 
when induced via M-CSF differentiation of monocytes. 
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Figure 5.5 Legumain western blot of M-CSF treated macrophages 
Three donors were analysed after day 0, 3 and 6 of M-CSF treatment for the presence of legumain 
(top blot) or β-actin as a loading control (bottom blot). Both pro- and active legumain were present 
at day 3 in all three donors whereas by day 6 the pro-legumain levels had decreased. 
5.5.3 Legumain in patient CD14+ samples by western blot 
We next wished to detect legumain by western blotting in RA synovial CD14 
cells.  The western blot assay had already been optimised for the detection of 
legumain using M-CSF derived macrophages as a control. CD14+ cells were 
isolated from five individual RA bloods, one PsA blood, two PsA synovial fluids 
and one RA synovial fluid and run on a western blot to detect legumain and the 
loading control β-actin.  
The upper panel in Figure 5.6 illustrates the presence of active legumain in 4 of 
the 5 RA bloods and in the PsA blood CD14+ cells which was not seen in the CD14+ 
cells at day 0 of the normal donors in Figure 5.5. Large amounts of pro- and 
active legumain were present in both of the PsA synovial fluid macrophage 
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samples however, there does not appear to be any legumain in the RA synovial 
fluid CD14+ cells. The lower panel of Figure 5.6 demonstrates the β-actin loading 
control of the samples as observed in the M-CSF macrophage western blot 
despite 5 μg of protein being added to each well there appears to be varying 
levels of protein in each well as indicated by the difference in intensity of the β-
actin bands. Also the two samples which appeared to contain no legumain in the 
upper panel, the RA PB sample and the RA SF sample, do not have a β-actin band 
suggesting that not enough of sample was loaded into these wells. These 
samples would have to be repeated to determine if they do contain the enzyme 
legumain. We have therefore demonstrated that active legumain is present in 
the peripheral blood CD14+ cells of arthritic patients which was not seen in 
normal donors day 0 CD14+ cells (Figure 5.5). We have also demonstrated that 
pro- and active legumain is expressed in the PsA synovial fluid CD14+ cells.  
 
Figure 5.6 Legumain western blot of patient CD14
+
 cells 
CD14
+
 cells from five RA bloods, one PsA blood, two PsA synovial fluids and one RA synovial fluid 
were analysed by western blot for the presence of legumain (upper panel) and β-actin control 
(lower panel). 
5.6 Legumain activity assay 
Legumain is a lysosomal enzyme that in its active form specifically cleaves 
protein substrates after an asparagine residue [651], despite showing that M-CSF 
derived macrophages and synovial fluid derived CD14+ cell express the active 
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form of legumain it was necessary to establish that this enzyme was still 
physiologically active and could still cleave its substrates. A legumain activity 
assay was therefore employed which uses a substrate Z-Ala-Ala-Asn-AMC. 
Incubating active legumain with this substrate results in its cleavage after the 
asparagine residue (Asn) thereby releasing the AMC (7-amino-4-methylcoumarin) 
flurophore. The amount of flurophore released can be detected on a 
luminescence reader.  
To determine the presence of active legumain in M-CSF derived macrophages 
and patient derived CD14+ samples, cells were resuspended in lysis buffer and 
then freeze thawed three times to disrupt the lysosomes where legumain is 
thought to reside [432]. 
5.6.1 Legumain activity assay of M-CSF derived macrophages 
Given that large amounts of the active form of legumain were visualised in the 
M-CSF derived macrophages by western blot it was decided to analyse these 
samples to determine if the legumain in these samples was physiologically active 
and still able to cleave its substrate. Clerin et al [665] previously demonstrated 
that legumain is more active and can cleave its substrate in day 3 M-CSF 
differentiated macrophages compared to monocytes however a timecourse of 
day 0, 3 and 6 activated macrophages has not been reported to my knowledge. 
Day 0, 3 and 6 M-CSF treated macrophages from two donors were analysed using 
the activity assay; the same number of cells (1 x 106) were examined per 
condition. Recombinant human (rh) legumain was also analysed on the assay as a 
positive control. Figure 5.7 illustrates the results of the activity assay; the rh 
legumain (black line) shows an increase in fluorescence units (FU) over time 
indicating that the legumain is active. The two donors tested are shown by the 
red line for donor 1 and blue line for donor 2 with the triangle symbol indicating 
day 0 monocytes, the square symbol indicating macrophages treated with M-CSF 
for 3 days and the diamond symbol indicates day 6 M-CSF treated macrophages. 
In both donors a similar pattern in legumain activity can be observed. The day 0 
monocytes have little or no legumain activity for the duration of the assay as the 
FU detected were less than the background fluorescence of the assay. This 
corroborates the legumain western blot of M-CSF macrophages (Figure 5.5) as 
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there was no legumain detected in the day 0 monocytes. The fluorescence units 
of day 3 M-CSF activated macrophages in both donors is high and increases over 
time to a maximum of 670 FU and 592 FU in donors 1 and 2 respectively 
indicating a high level of legumain activity. This discrepancy in the amount of 
legumain activity in these samples despite having the same number of 
macrophages may be due to donor specific variability or it is possible that the 
macrophages from donor 1 contain more legumain. 
In both day 6 activated macrophage samples the amount of fluorescence and 
therefore legumain activity is lower compared to the day 3 activated 
macrophages. The FU from donor one decreases by almost two thirds from 670 
to 177 FU at the 210 minute timepoint and the FU from donor two decreases 
from 592 to 346. This indicates that there could be less legumain present in 
these cells and therefore legumain may undergo a cyclic form of expression with 
no active legumain present in day 0 monocytes, a high level of activity and 
expression in 3 day differentiated macrophages which then decreases to a lower 
level at day 6. This observation agrees with the western blot of the M-CSF 
differentiated macrophages as there was a greater amount of active legumain 
expressed in the day 3 macrophages compared to the day 6 macrophages. 
Overall it has been demonstrated that legumain is expressed at varying levels in 
M-CSF activated macrophages depending on the duration of activation, this 
legumain is the active form of the enzyme and as a result is able to fulfil its 
physiological role and cleave its endogenous substrate.  
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Figure 5.7 Legumain activity assay in M-CSF derived macrophages 
M-CSF activated macrophages for 0, 3 and 6 days from two separate donors were analysed using 
a legumain activity assay to determine whether the legumain detected in these samples was active 
could cleave a substrate. Once the substrate is cleaved it releases a fluorophore which can be 
detected on a luminescence plate reader. The assay is incubated at 37ºC for 3.5 hours and the 
amount of fluorescence (measured in fluorescent units) is measured at set time points. Human 
recombinant legumain was used as a positive control and is indicated by the black line. Cells from 
donor 1 are shown by the red line and cells from donor 2 are shown by the blue line with the 
triangle symbol indicating day 0 monocytes, square symbol indicating M-CSF treated macrophages 
for 3 days and diamond symbol indicating M-CSF macrophages treated for 6 days. Each donor 
sample contained 1 x 10
6
 cells. 
5.6.2 Legumain activity assay of patient CD14+ samples 
Once we had determined that legumain was present and active in the M-CSF 
macrophage samples we then went on to establish whether the large amounts of 
legumain present in the CD14+ patient samples as seen on the western blot was 
active and able to cleave its substrate. Two RA synovial fluid samples, one with 
a matched blood, were obtained and CD14+ cells were isolated from each. Due 
to differences in the amount of synovial fluid obtained and donor variation there 
were slight differences in the total number of cells, analysed, RA patient 1 had 
7.2 x 105 SF CD14+ cells whereas RA patient 2 had 8.8 x 105 SF CD14+ cells. 
The results for the patient legumain activity assay are shown in Figure 5.8. As in 
the previous experiment rh legumain was used as a positive control. Despite 
having the lowest total cell number RA patient 1 SF (red line) exhibited the 
largest amount of legumain activity shown by the steady increase over time of 
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FU up to a maximum of 830 FU. However, the PB sample (red line) from the 
same patient contained a much lower amount of legumain; the fluorescence 
level of this sample was very low and did not increase above the background 
level of fluorescence indicated by the negative FU values. Nevertheless, it 
appears that this sample did contain a small amount of legumain as the FU can 
be seen to slowly increase towards the baseline which would suggest that 
legumain is present but there is not enough enzyme to create a strong 
fluorescent signal. This same pattern of activity can be visualised in the patient 
2 RA SF sample (blue line) where the fluorescence unit increase from -30 to -1 
FU over the duration of the assay indicating that active legumain is present in 
this sample but in small amounts. 
Synovial fluid from several patients including six RA, six PsA, one OA, one JIA 
and one inflammatory polyarthritis were analysed using the activity assay to 
investigate whether these samples contained active legumain that may have 
been excreted from the synovial cells. However, no activity was determined for 
any of the samples (data not shown). 
 
Figure 5.8 Legumain activity assay in CD14
+
 patient samples 
CD14
+
 cells isolated from patient blood or synovial fluid samples were analysed using a legumain 
activity assay to determine whether the legumain that was present in these cells was active and 
able to cleave a fluorescent substrate. The assay is incubated at 37ºC and the amount of 
fluorescence measured in fluorescence units (FU) is quantified at set time points. Human 
recombinant legumain (black line) was also assayed as a positive control. RA patient 1 is shown in 
red with the upwards facing triangle indicating blood CD14
+
 cells and the downwards facing triangle 
indicating synovial fluid CD14
+
 cells. RA patient 2 is shown by the blue line indicating synovial fluid 
CD14
+
 cells. 
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5.7  Analysing legumain expression under normoxic 
and hypoxic conditions 
Once we had established that legumain was present in RA synovial fluid 
macrophages and was physiologically active we decided to try and determine 
what potential factors could be inducing legumain expression. To do this we 
cultured healthy donor M-CSF differentiated macrophages in complete media or 
in complete media supplemented with 10% RA or PsA synovial fluid for 24 hours 
under normoxic (24% oxygen) or hypoxic (1% oxygen) conditions. This was in 
order to represent the conditions that the arthritic macrophages may be exposed 
to once they exit blood and enter the synovial compartment. The synovium has 
been shown to be a hypoxic environment [409] and the synovial fluid of arthritic 
patients contains many cytokines, chemokines, antibodies and extracellular 
matrix proteins [410, 537] which could interact with and induce differential gene 
expression in the macrophages. Therefore, we hypothesized that exposing 
macrophages to patient synovial fluid under hypoxic conditions may induce the 
expression of legumain within these cells. Three RA and three PsA synovial fluids 
were tested on the macrophages and the experiment was repeated three times. 
Figure 5.9 shows the fold change in legumain mRNA expression relative to the 
macrophage in complete media alone control. Graph (A) demonstrates those 
cells which were incubated with the six synovial fluids for 24 hours under 
normoxic conditions. The fold change in legumain expression increases with 2 of 
the RA synovial fluids but the addition of RA SF 2 seems to decrease the amount 
of legumain expression resulting in a negative fold change. In contrast, only one 
PsA SF appeared to increase the amount of legumain expression under normoxic 
conditions while PsA SF 1 and PsA SF 3 decreased the amount of legumain 
expression.  
On the other hand, culturing macrophages with synovial fluid under hypoxic 
condition increased legumain expression in all synovial fluid conditions relative 
to the macrophages incubated with media alone. The hypoxic conditions are 
shown in graph (B) of Figure 5.9; the three RA synovial fluids and three PsA 
synovial fluids all induced an increase in legumain expression compared to 
control indicated by the positive fold change values.  
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These results suggest that the combination of both synovial fluid and hypoxia are 
needed in order to induce legumain expression in macrophages. As the addition 
of synovial fluid under normoxic conditions induces both up and down regulation 
of legumain expression compared to control whilst the macrophages cultured 
under hypoxic conditions show an increase in legumain expression with all of the 
six synovial fluids examined. 
 
Figure 5.9 Legumain expression in the presence of synovial fluid under hypoxic and 
normoxic conditions 
M-CSF differentiated macrophages were cultured individually with three different RA synovial fluids 
or three PsA synovial fluids for 24 hours under normoxic (24% oxygen) (A) or hypoxic (1% oxygen) 
(B) conditions. The fold change in legumain expression is shown relative to the mo alone control for 
either the hypoxic or normoxic condition. This is a representative of three independent 
experiments.  
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5.8  Discussion 
The second gene identified from the microarray experiment as being highly 
expressed in both RA and PsA synovial macrophages was the enzyme legumain. It 
is an enzyme that specifically cleaves its substrates after an asparagine residue 
and has a role in the cleavage and activation of several substrates as well as in 
the processing of microbial antigen for MHC II presentation [659]. Legumain is 
known to be disregulated in several inflammatory conditions and diseased states 
such as breast cancer where it is specifically overexpressed on tumour 
associated macrophages [433]; atherosclerosis where it is upregulated in 
macrophages in unstable areas of plaques [434] and in inflamed skin where it is 
highly upregulated in lesional atopic dermatitis and psoriasis compared to 
normal skin [435].  
Legumain has not been previously associated with inflammatory arthritis 
however several of its substrates that it can cleave and activate are present 
within the synovium of arthritis patients. These substrates include fibronectin 
[431] a glycoprotein that has been found in the synovia of RA and PsA patients 
[426] whose cleaved fragments acquire catalytic activities which can stimulate 
cartilage chrondrolysis [675]; legumain can activate gelatinase A (MMP2) [429] 
which has been found a higher levels in RA patient blood compared to controls 
[670] and is also upregulated in the RA and PsA SF CD14+ cells in my microarray 
experiment (see chapter 3). Legumain has also been demonstrated to cleave 
several cathepsins including cathepsin B and L which are upregulated in RA 
synovial fluid [671]. Since active fibronectin, gelatinase A, cathepsin B and L are 
all known to degrade collagen and other components of the extracellular matrix 
we hypothesised that legumain is upregulated by synovial fluid macrophages as a 
result of the pro-inflammatory environment to function as an extracellular 
matrix degradation enzyme and therefore may be contributing to the cartilage 
and bone degradation that is often seen in these two diseases.  
These are the first data to investigate legumain expression in RA and PsA and 
using qRT-PCR we observed that all of the RA and PsA synovial fluid samples 
analysed were expressing legumain at varying levels and the amount of synovial 
fluid CD14+ legumain was always elevated in comparison to the CD14+ blood 
cells. We also demonstrated that legumain was expressed in the synovial fluid 
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CD14+ cells of an OA patient, a JIA patient and an inflammatory polyarthritis 
patient indicating that this enzyme was not exclusively expressed in RA and PsA 
and appeared to be a marker of other arthritic synovial macrophages. Research 
into the control of mRNA expression has uncovered small non-coding RNAs 
termed microRNAs (miRNA) that target and degrade mRNA thereby suppressing 
proteins synthesis [676] therefore observing mRNA expression of a gene such as 
legumain does not imply that it will be expressed at the protein level. 
Consequently, further studies took place to investigate the expression of 
legumain. Immunohistochemistry revealed a novel observation that legumain 
was consitutively expressed in five RA synovial membranes. At a higher 
magnification legumain was observed specifically in the cytoplasm of the cells in 
a granular pattern which is indicative of its role as a lysomomal enzyme [432] 
and cell surface staining was also observed. Legumain has previously been shown 
to be expressed on the cell surface and along the invadapodia of invading 
tumour cells where it correlated with increased tumour invasion and metastasis 
[662]. Further double staining of legumain and the plasma membrane would 
need to be carried out to verify legumain cell surface expression on synovial 
arthritic cells but a role for this surface expression could be to help invading 
synovial cells to further degrade the cartilage and extracellular matrix. Positive 
staining was also observed within follicular regions of the membrane and within 
cells on the outside edge of the synovium. We propose that the legumain 
positive cells on the outside of the membrane are well positioned to uptake 
substrates from the synovial fluid, such as fibronectin, in order to cleave them 
intracellularly. To establish whether this synovial legumain was present mainly 
in macrophages double staining would need to be performed but time 
restrictions meant this could not be performed. 
It had been observed that synovial fluid CD14+ macrophages expressed legumain 
at the mRNA level and arthritic synovial membrane expressed legumain at the 
protein level therefore we wanted to determine whether synovial fluid 
macrophages expressed legumain at the protein level by western blot. Legumain 
has been previously shown to be upregulated in M-CSF differentiated 
macrophages [665, 674] therefore these cells were used as a positive control for 
the western blot. We confirmed that M-CSF differentiated monocytes had 
increased legumain mRNA expression, the fold change increase in legumain 
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ranged from 26 to 3573 indicative of donor specific variability. A western blot 
was performed on 3 donors consisting of monocyte samples which were treated 
for 0, 3 and 6 days with M-CSF. We observed no legumain in the day 0 CD14+ 
monocytes but pro- and active legumain were visible at day 3 and 6 of all three 
donors analysed. There appeared to be more active legumain in all of the day 3 
samples but it is difficult to remark on levels of the enzyme since the β-actin 
loading control was not consistent among all samples despite the same amount 
of protein (5 μg) being loaded onto the assay. Repetition of these experiments 
would be helpful to formally define this issue – time precluded this analysis. 
Once we had validated the western blot assay, we analysed CD14+ cells from the 
blood and synovial fluid of RA and PsA patients. There has been no previous work 
illustrating legumain‘s presence in PB monocytes, however it has been 
demonstrated that other cysteine proteases are upregulated in monocytes in 
response to pro-inflammatory cytokines [677, 678]. The serum of PsA and RA 
patients is known to contain pro-inflammatory cytokines, growth factors, MMPs 
and adhesion molecules [679-681] which could be inducing active legumain in 
diseased blood monocytes, a phenomenon that is not seen in healthy donor 
blood monocytes. The two PsA synovial fluid CD14+ samples tested on the 
western blot were positive for high levels of pro- and active legumain but the RA 
SF CD14+ tested did not develop any protein bands. This result indicates that the 
legumain positive cells detected by IHC in the synovium are likely to be 
macrophages however the possibility that other cells express legumain cannot be 
discounted. The two RA PB and SF samples which did not develop a legumain 
band were also negative for a β-actin loading control band indicating either a 
problem with the samples or that perhaps not enough sample was loaded onto 
the western blot. Further analysis of the presence of legumain within RA SF 
CD14+ samples would be useful to verify that these cells express legumain at the 
protein level but time restrictions meant this was not possible.  
An activity assay was set-up to determine if the legumain protein detected in 
the samples was active. Clerin et al [665] had previously demonstrated that 
monocytes treated with M-CSF for 3 days contained physiologically active 
legumain however a timecourse of M-CSF treated monocytes had not been 
examined. The results of the western blot were replicated in the activity assay 
as day 0 monocytes showed no activity on the assay and no protein on the 
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western blot. Day 3 activated monocytes had high levels of active legumain 
which decreased in the day 6 activated macrophages. These observations 
demonstrate that legumain may undergo a cyclic form of expression with no 
active legumain present in day 0 monocytes, a high level of activity and 
expression in 3 day differentiated macrophages which then decreases to a lower 
level at day 6. At present there have been no other reports of legumain 
undergoing cyclic expression dependent on macrophage maturation as all other 
studies have analysed legumain levels at one timepoint. Further studies are 
required to understand the significance of this observation. 
Patient derived CD14+ cells were analysed on the activity assay to ascertain 
whether these cells contained physiologically active legumain. We examined 
matched RA PB and SF CD14+ samples and a RA SF CD14+ sample due to the 
variation in isolated cell numbers in patient samples the number of cells 
analysed in each sample was slightly different. Nevertheless, the SF patient 
sample containing the least number of cells had the highest amount of active 
legumain illustrating that individual macrophage cells may contain varying levels 
of legumain. The matched PB sample from this patient showed a low level of 
active legumain as did the other RA SF sample analysed again indicating that the 
level of legumain varies between patients. It would be interesting to determine 
if treatment type or disease duration was a factor determining how much active 
legumain was present within the synovial macrophages of arthritic patients. 
Unfortunately we did not receive any PsA patient samples to assay and time 
restrictions meant we could not continue collecting samples. 
The inflammatory synovium is known to be a hypoxic environment [409] and the 
synovial fluid of RA patients contains many cytokines, chemokines, antibodies 
and extracellular matrix proteins [410, 537, 682-685] which could interact with 
and induce differential gene expression in the cells entering the synovium. 
Establishing what factors could be causing the upregulation of active legumain in 
macrophages once they have transmigrated from the blood system into the 
diseased joint is vital in understanding legumain‘s role in disease pathology. 
Proinflammatory cytokines have been previously shown to induce expression of 
other cysteine proteases in monocytes [677, 678] therefore we hypothesised that 
the proinflammatory mediators and environmental stresses within the synovial 
environment may be inducing the large upregulation of legumain once the 
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macrophages entered the synovial compartment. To address this question we 
differentiated healthy monocytes with M-CSF for 6 days and cultured them in the 
presence of three RA synovial fluids and three PsA synovial fluids for 24 hours in 
hypoxic or normoxic conditions. We observed that under normoxic conditions 
macrophages had increased legumain mRNA expression when incubated with two 
of the three RA synovial fluids and one of the three PsA synovial fluids compared 
to macrophages incubated alone. However, under hypoxic conditions legumain 
mRNA expression increased in all of the macrophages incubated with the six 
synovial fluids indicating that a combination of the hypoxic environment with 
the proinflammatory mediators contained within the synovial fluid is necessary 
to induce upregulation of legumain. 
In summary, legumain is an enzyme which plays a physiological role in the 
biosynthesis of lysosomal enzymes in the proximal tubule cells of the kidney 
[431] and is expressed in macrophages and DCs where it is thought to play a role 
in cleaving peptides for antigen presentation [658, 659]. However it has now 
become apparent that legumain is involved in many inflammatory diseases and 
conditions including arthritis. We propose that legumain is a marker for cell 
activation demonstrated by its upregulation in macrophages but it is also an 
inflammatory enzyme induced and deregulated during inflammation. The 
perpetual inflammation that occurs during arthritis causes the upregulation of 
this enzyme. Legumain is induced in the arthritic blood monocytes by the pro-
inflammatory mediators contained within the serum and is also induced within 
the synovial fluid macrophages by the hypoxic inflammatory milieu found within 
the joint. Once upregulated within the synovial macrophages legumain is 
expressed on the cell surface and may be assisting the cells to invade and 
degrade the surrounding joint cartilage and extracellular matrix. Pro- legumain 
has recently been found to be excreted from macrophages and has been shown 
to induce chemotaxis of primary monocytes [665], therefore if the legumain 
positive macrophages visualised within the synovium were also excreting 
legumain this could be playing a role in increasing the number of infiltrating 
monocytes into the arthritic joint.  
Legumain is also expressed within the lysosomal compartment of the cells where 
it may cleave and active glycoproteins such as fibronectin either being produced 
by the cell or which have been taken up by the cell. One of legumain‘s primary 
290 
roles during homeostasis is to cleave microbial antigen for MHC II presentation 
and to activate several cathepsins which are also involved in antigen 
presentation [432, 686]. T cells specific to autoantigens such as collagen type II 
have been found within the arthritic joint [687] therefore an increase of 
legumain within synovial macrophages may play a role in the presentation of 
autoantigens to these T cells thereby aiding the perpetuation inflammation and 
destruction seen in RA and PsA. Figure 5.10 summaries these findings. 
 
 
Figure 5.10 Overview of legumain's expression and proposed role in arthritis 
A summary of legumain’s expression in patient blood monocytes and synovial fluid macrophages, 
the factors that could be inducing its expression and its proposed role in the synovium. 
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Chapter 6 Microarray analysis of cell contact 
activated macrophages 
292 
6.1 Introduction 
One critical mechanism whereby macrophages are thought exert their 
proinflammatory potential in the synovium is by direct cell-cell interaction with 
T cells. We and other groups have investigated this interaction in an in vitro 
model system of inflammatory arthritis. In order to set up this model monocytes 
and T cells are isolated from normal donors before activating T cells with a 
cytokine cocktail (IL-2, IL-6, TNFα) and maturing the monocytes into 
macrophages with M-CSF for 6 days each.  After this time the two cells types are 
put into direct contact for a period of 24 hours after which the supernatants are 
collected and analysed for cytokine release. Several groups have investigated 
this in vitro system and found it to be a robust model of inflammatory arthritis 
since both cytokine activated T cells (Tcks) and RA synovial T cells can induce 
production of TNFα and several CC and CXC chemokines in resting M-CSF treated 
macrophages in a cell contact dependent manner [269, 298, 308]. Also Brennan 
et al found that after 8 days of stimulation Tcks acquire an activated phenotype 
resembling RA synovial T cells, such as upregulation of adhesion molecules and 
activation markers. Neutralising these markers in both T cell types abolished the 
cell contact dependent TNFα production from resting macrophages [309]. 
However, apart from cytokine and chemokine production little is known about 
the effects of Tck direct cellular contact activation on the macrophages. 
Due to the lack of transcriptomic information of the cell contact activated 
macrophages it was decided to collect normal donor samples, which were age 
and sex matched to the RA and PsA patient samples collected for the 
microarray, and activate these using the cell contact model of inflammatory 
arthritis. These macrophages were then analysed on the microarray and the 
results were compared to the synovial CD14+ cell samples to determine how 
similar these Tck activated macrophages were to the synovial macrophages. The 
results should inform us how comparable the macrophages from the in vitro 
model of inflammatory arthritis are to synovial macrophages from RA and PsA 
patients. 
6.2 Patients and normal donors 
As described previously, inflammatory arthritis patients attending Gartnavel 
General Hospital (GGH) or Glasgow Royal Infirmary (GRI) fulfilled the American 
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college of Rheumatology criteria for RA [6], or met diagnostic criteria for PsA 
[346].  
Age-matched normal donors were recruited from the Glasgow Biomedical 
Research Centre (GBRC) building and all blood samples were taken with 
informed consent. 
6.3 Separating macrophages from the cell contact 
In order to analyse the transcriptomic profile of the activated macrophages after 
they had been in contact with the Tcks we had to first gain a pure population of 
macrophages that did not have any contaminating Tcks which would affect the 
results of the microarray. 
6.3.1 Live cell contact 
The in vitro cell contact model of inflammatory arthritis can be set up in a 
number of ways including using T cell membranes [294], fixed Tcks or live Tcks 
to activate the macrophages. For the microarray experiment we wanted to 
compare cell contact activated macrophages with patient derived SF CD14+ cells 
and therefore decided to set up the cell contact experiment with live Tcks. This 
would allow us to see the effects of direct cellular contact along with the 
soluble mediators that the Tcks released upon the activation of macrophages. 
The cell contact was set up at a ratio of 4 Tcks to 1 macrophage for 24 hours, 
the cells were separated by washing off the non-adherent Tcks (Tck fraction) 
and scraping the adherent macrophages from the wells (macrophage fraction). 
However, when the two cell fractions were analysed on the FACS for cell purity 
(Figure 6.1) the macrophage fraction (A) was 91% positive for CD3 cells and had 
no CD14 positive cells but a very small percentage (3.7%) of CD3 negative cells. 
This experiment was repeated n=5 times with the same or similar results 
occurring each time. The same experiment was set up with fixed Tcks as it was 
thought that fixed cells may be less likely to stick to the macrophages, however 
we obtained similar Tck contamination in the macrophage fraction in these 
experiments (data not shown). 
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Figure 6.1 Separation of cells from a live cell contact 
Cells were separated by washing the non-adherent Tcks from the wells designated Tck fraction (B) 
and scraping the adherent macrophages from the wells designated macrophage fraction (A). This 
is a representative FACS plot from n=5 experiments 
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6.3.2 FACS ARIA sorting of macrophages 
Due to the problem of being unable to fully separate the macrophages from the 
Tcks using the method of washing and scraping the wells, it was decided to try 
and separate the two cell fractions from the cell contact using the FACS ARIA.  
The Tcks were stained with carboxyfluorescein succinimidyl ester (CFSE) and 
fixed before being put into cell contact with the macrophages. After incubating 
the cell contact all the cells were collected and put through the FACS ARIA 
machine, separating the cells based on FITC-positive cells (Tcks) and FITC-
negative cells (presumably macrophages). Figure 6.2 shows the plots from one 
FACS ARIA experiment; figure A shows all the cells that were isolated from the 
cell contact experiment and the histogram shows the counts of cells that were 
FITC positive and FITC negative. On the histogram the gates p1 and p2 indicate 
the gates that were used to differentiate and collect FITC-negative (macrophage 
cells) and FITC-positive (Tck cells) respectively. The two gates did not overlap 
and a substantial gap was left between them, cells included in this area were 
not collected as it was important for the purpose of the microarray to be able to 
collect a pure population of macrophages with no contaminating Tcks. Figure B 
and C show the plots and histograms of the two separated cell fractions, Tcks 
and macrophages respectively. The cells collected in the Tck fraction (B) were 
all FITC-positive, as indicated by the histogram, and the forward and side scatter 
plot indicates the cells collected in this fraction are of the correct size and 
granularity for activated T lymphocytes. As expected all cells collected in the 
macrophage fraction (C) were FITC-negative and on the forward and side scatter 
plots show the cellular size and granularity of macrophage like cells. However, it 
must be noted from panel (C) that a large proportion of the events on the 
forward side scatter graph are in the bottom left hand corner which is indicative 
of cellular debris. This debris may be as a result of the removal of the 
macrophages from the culture wells after cell contact activation and the 
presence of this debris may ultimately affect the purity of the macrophages used 
for the microarray.  
Subsequently an aliquot of the FACS ARIA separated cells was used for cytospins 
which were stained with RAPI-DIFF reagents to check for cell purity and 
morphology. As can been seen in figure (D) the cells from the macrophage 
fraction had the correct shape and morphology of macrophage cells with no 
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visible contaminating Tck cells whereas the cells from the Tck fraction (E) were 
the morphology and size of T lymphocytes. 
It was decided therefore that using the FACS ARIA to gain a pure population of 
cell contact activated macrophages was the optimal method of separation for 
the normal donor samples that would be age and sex matched to the patient 
samples.  
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Figure 6.2 Separating the macrophages and Tcks from cell contact using the FACS ARIA 
The FACS ARIA was used to separate fixed CFSE stained Tcks from the macrophages after cell 
contact. (A) All cells from the cell contact experiment showing the forward and side scatter plot of 
the cells and the histogram plot with the gates used to separate the cells, gate p1 (FITC negative 
cells) and gate p2 (FITC positive cells). (B) Tck cell fraction after separation and (C) macrophage 
cell fraction. An aliquot of the two cell fractions from the macrophage fraction (D) and the Tck 
fraction (E) was stained with RAPI-DIFF to check for cell morphology. 
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6.4 Analysing cell contact RNA yield and quality 
Microarray experiments demand a high quality of RNA in order for correct 
interpretation of results and the amount of RNA obtained from the cells should 
be consistent between samples. Therefore before the cell contact activated 
cells are analysed on a microarray the RNA quality and yield from the 
macrophage cells must be examined (described in detail in chapter 3). 
 
6.4.1  Cell contact activated macrophages have variable RNA 
quality after 24 hours 
Fixing the Tcks before putting them into cell contact was found to help recover 
a more pure population of macrophages after FACS ARIA separation thus it was 
decided that fixed Tcks should be used in all cell contact experiments. Three 
independent macrophage – Tck cell contact experiments were set up at a 4:1 
ratio of fixed Tcks to macrophages, after 24 hours the Tcks and macrophages 
were separated and both cell types were put into Trizol reagent. The RNA was 
isolated from the cells and the quality was analysed on an Agilent 2100 
Bioanalyser. The principles of the agilent 2100 bioanalyser are described in 
section 3.3.2 of chapter 3, but briefly this equipment is used to ascertain the 
quality of the RNA and allows the user to obtain a plot indicating the RNA 
integrity. Figure 6.3 (A) shows an example of good quality RNA. It is 
characterised by three clear peaks, a peak for the RNA marker (1) and a peak for 
the 18 S (2) and 28 S (3) ribosomal RNA subunits. There should be a relatively 
flat baseline between the two rRNA peaks and minimal low molecular weight 
noise adjacent to the RNA marker peak. 
Figure 6.3 (B) shows the electropherogram of the three fixed Tck and 
macrophage samples after 24 hours of cell contact. The Tcks in all three 
experiments had degraded RNA indicated by the low molecular weight noise and 
the absence of 18 S and 28 S peaks. The degraded RNA for the Tcks was thought 
to be a consequence of fixing the Tcks with paraformaldehyde. However, the 
RNA from the macrophages was of poor quality in two of the three experiments. 
The macrophage RNA from experiment 2 shows good quality RNA with two sharp 
rRNA peaks and no low molecular weight noise but the RNA from experiment 1 
and 3 is of poor integrity with the complete absence of rRNA peaks. Due to the 
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large variability in quality of the macrophages RNA it was decided that a 
timepoint cell contact should be set up to try and discover why the macrophage 
RNA is degraded after 24 hours of cell contact. 
 
Figure 6.3 RNA integrity of macrophages and Tcks after 24 hours of cell contact 
An Agilent 2100 Bioanalyser was used to analyse the quality of the RNA from 3 macrophage and 3 
Tck samples after 24 hours of cell contact. (A) an example of good quality RNA (B) the agilent 
profile electropherograms of the three cell contact experiments. 
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6.4.2 Cell contact activated macrophage RNA quality over time  
A timecourse cell contact was set up three times and the macrophages were 
activated with Tcks for between 1 and 48 hours. Figure 6.4 shows the results of 
one timecourse experiment and consist of RNA electropherograms for the fixed 
Tcks, unactivated macrophages (Mø) and macrophages that have been cell 
contact activated for varying amounts of time. The fixed Tck RNA is once again 
badly degraded due to the paraformaldehye fixation process. The RNA from the 
macrophages that had not been cell contact activated (Mø) was of good integrity 
as indicated by the two sharp rRNA peaks and the absence of low molecular 
weight noise. The RNA from the macrophages that had been in cell contact for 1 
hour up until 8 hours is also of good quality showing similar electropherogram 
plots to the one for the inactivated macrophages. With the exception of 28 hr 
cell contact activated macrophages (t=28hrs) the plots for RNA isolated from 
macrophages after 8 hours of cell contact all showed blank electrophreogram 
plots, apart from the RNA marker peak, indicating that the RNA was either 
degraded or in such low concentration that the Agilent machine could not detect 
it. t=28 hrs RNA was the only exception to this observation as that sample was of 
high quality with no degradation. 
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Figure 6.4 Macrophage RNA quality after different durations of cell contact 
Macrophages were exposed to direct cellular contact with fixed Tcks for between 1 and 48 hours. 
The Tcks were removed from the macrophages and the quality of the Tck and macrophage RNA 
were analysed on an Agilent 2100 Bioanalyser 
 
6.4.3 RNA yield decreases after prolonged cell contact activation 
The total amount of RNA that was being recovered from the macrophages during 
the timecourse cell contact experiments was also investigated and measured on 
a nanodrop. Figure 6.5 shows a representative experiment from the three 
experiments that were set up, for comparison the amount of RNA from the fixed 
Tcks and macrophages alone (t=0) was also measured. It can be seen that 
compared to the unstimulated macrophages, designated t=0, the total amount of 
RNA decreases with increasing duration of cell contact activation. This trend 
continues until 26 hours of cell contact where the total amount of RNA increases 
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from 202 ng at cell contact t=26 hrs to 608 ng at cell contact t=28 hrs, however 
after this one timepoint cell contact the amount of RNA recovered from the 
sample decreases to 252 ng at t=48hrs. This trend of decreasing total yield of 
RNA from cell contact activated macrophages compared to the unstimulated 
macrophages was seen in the two other timecourse experiments set up (data not 
shown). Based upon the preceding results it was decided to analyse macrophages 
which had been cell contact activated for 2 hours on the microarray as well as 
unactivated macrophages from the same donor. The reasons for this were due to 
the large variability in the yield and quality of macrophage RNA after 8 hours 
and also because we were interesting in the early response genes that changed 
in a macrophage after Tck contact. 
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Figure 6.5 Total RNA yield from macrophages after increasing duration of cell contact 
activation by Tcks 
A fixed 4:1 cell contact between Tcks and macrophages was set up for varying amounts of time 
between 1 and 48 hours. Each cell contact was set up in an individual well of a culture plate. After 
the specified time the macrophages and Tcks were separated and the macrophages placed into 
Trizol reagent. RNA was extracted from all samples and the total yield measured. RNA was also 
extracted from Tcks (fixed Tcks) and macrophages alone (t=0). This graph is a representative of 
n=3 experiments. 
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6.5 Collecting patient samples 
Normal donors who were age and sex matched to patients (Table 3.2) were 
recruited and from these donors CD14+ cells were positively selected from the 
blood. An aliquot of unactivated CD14+ cells were put into trizol and the rest of 
the cells were differentiated with M-CSF for 6 days. After this duration the 
macrophages were cell contact activated for 2 hours with fixed Tcks that had 
been obtained from the same donor. The cell contact activated macrophages 
were isolated using the FACS ARIA and put into trizol as well as unactivated M-
CSF derived macrophages from the same donor. Once all the samples had been 
collected the RNA was extracted from all samples at GSK Stevenage and 
analysed for quality. The samples which were analysed by the microarray are 
summarised in table 3.3 of chapter 3. Six age and sex matched healthy controls 
were recruited and macrophage cells before and after Tck cell contact activated 
were collected from all of these controls. 
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Patient Gender Age Age and sex matched 
normal donor 
PsA 1 
PsA 2 
PsA 3 
PsA 4 
PsA 5 
PsA 6 
PsA 7 
PsA 8 
RA 1 
RA 2 
RA 3 
RA 4 
RA 5 
RA 6 
RA 7 
RA 8 
Female 
Female 
Male 
Male 
Male 
Female 
Male 
Female 
Female 
Male 
Female 
Male 
Female 
Male 
Female 
Female 
53 
40 
34 
34 
80 
58 
54 
58 
71 
56 
62 
69 
78 
69 
69 
77 
Yes 
Yes 
Yes 
Yes 
No 
Yes 
No 
No 
No 
Yes 
No 
No 
No 
No 
No 
No 
Table 6.1 Patient and normal donor samples collected 
 
6.6 Microarray analysis 
6.6.1 Signal histogram of normalised data 
The signal histogram of all the samples which were analysed by the microarray is 
shown in figure 3.3 of chapter 3. Upon inspection of the histogram it was 
discovered that one of the cell contact activated samples was an outlier as it 
clearly had a distinct signal intensity compared to the other samples which were 
analysed. The reasons for this sample being an outlier are unknown but since the 
other samples have similar signal intensities it is most likely to be due to a 
problem with the individual sample or the labelling of that particular sample. 
Due to this sample being an outlier it may potentially skew the data 
interpretation and therefore was removed from further data analysis. 
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6.6.2 Principle component analysis 
The PCA plot shown in Figure 6.6 has previously been shown in chapter 3 but it is 
represented in this chapter to demonstrate the outlier cell contact activated 
macrophage sample indicated by the blue circle on the left hand side of the 
graph in (A). Once this sample had been removed the PCA analysis graph was 
analysed to look for trends in the data since samples represented in the same 
area of the graph are considered to be genetically similar. Each circle on the 
graph represents a sample and each colour represents a condition.  
Figure 6.6 (B) demonstrates the PCA plot of the samples once the cell contact 
outlier sample had been removed. This plot demonstrates that the cell contact 
activated macrophages (blue circles) are genetically distinct from the M-CSF 
activated macrophages (red circles) indicating that transcriptional changes take 
place once the macrophages are put into cell contact with Tcks for 2 hours. 
However, it can also been seen that the cell contact activated samples (blue 
circles) appear to be genetically distinct from the synovial fluid activated 
macrophage samples (yellow circles) which could argue against the cell contact 
macrophages not having a similar genetic profile to the synovial fluid. This will 
be explored further in the following sections. 
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Figure 6.6 Principle component analysis of all microarray samples 
PCA was performed on the microarray samples to try and identify trends in the data. Graph (A) 
indicates the normalised samples before the outlier was removed. The blue circle on the left hand 
side of the graph represents the outlying sample and it can been seen that it is distinct from all the 
other samples indicating that its genetic profile is dissimilar to that of the remaining microarray 
samples. Figure (B) shows PCA graph once the outlying cell contact sample had been removed. 
Each circle represents a sample and samples clustered in the same area of the graph are 
considered to be genetically similar. Each colour represents a sample condition; red is M-CSF 
treated macrophages, blue is cell contact activated macrophages, gold is synovial fluid derived 
CD14+ cells, green is patient blood CD14+ cells and purple is healthy blood CD14+ cells. This 
graph was previously shown in chapter 3. 
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6.7 Cell contact activated macrophages compared to 
synovial fluid activated macrophages 
Cell contact dependent activation of macrophages by synovial T cells has 
previously been shown to play a role in arthritis and as a result an in vitro model 
of inflammatory arthritis has been developed by our group and others to mimic 
the cellular interactions taking place within the diseased joint. Investigations 
into the proinflammatory cytokines and chemokines released by the 
macrophages as a result of T cell interactions have taken place [269, 298, 308] 
as well as analysing the activated T cells [309]. One study by Gruaz et al [315] 
has also analysed the genetic profile of the macrophages after being stimulated 
by the isolated membranes of the human T cell line HUT-78. However there has 
been no comparative analysis of the in vitro cell contact stimulated 
macrophages and macrophages isolated from the arthritic joint.  
The cell contact activated macrophages were stimulated with fixed cytokine 
activated T cells (Tcks) for 2 hours as we were interested in the early response 
genes that were differentially expressed in the macrophages. Previous analyses 
indicated that one of the cell contact activated macrophage samples was an 
outlier due to its abnormal signal intensity. Therefore this sample and its 
matched unactivated macrophage sample was removed from further analysis.  
6.7.1.1 Statistical analysis of genes and elucidating similarly 
expressed genes between conditions using a Venn 
diagram 
All samples were pre-processed using the GC-RMA algorithm and quality control 
was performed on the three macrophage conditions i.e. cell contact, RA or PsA. 
In order to pass the quality control filter each gene had to have a signal value 
between 20 and 100% and be expressed in all of the samples of each condition. 
To establish the presence of differentially expressed genes in the three 
activated macrophage conditions paired T Tests were first performed with a p 
value cut off of 0.05 followed by the Benjamini and Hochberg multiple testing 
correction (MTC). However an MTC was unable to be used in the cell contact 
comparison as there were no significantly changed genes between the 
unactivated macrophages and cell contact activated macrophages. Since a p 
value cut off of 0.05 was used this means that 5% of the differentially expressed 
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genes may be false positives and appearing by chance alone, a way to overcome 
this is to look at the p values of each gene as the higher the p value of the gene 
the less chance of it being a false positive. This statistical analysis gave the 
following results:  
 Unactivated M-CSF macrophages vs cell contact activated macrophages 
(n=5 matched samples) 3902 significantly expressed gene entities 
 RA PB vs RA SF (n=8 matched samples) 10879 significantly expressed gene 
entities 
 PsA PB vs PsA SF (n=8 matched samples) 7401 significantly expressed gene 
entities 
The up- and downregulated genes with a p value <0.05 from each of the three 
comparisons were then inputted into a Venn diagram to distinguish if there were 
similar genes being expressed by the activated macrophages conditions. 
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Figure 6.7 Venn diagram of the significantly differentially expressed genes within the cell 
contact activated macrophages, RA synovial fluid macrophages and PsA synovial fluid 
macrophages 
Paired T Tests were performed between the unactivated and cell contact activated macrophages, 
RA blood and RA synovial fluid macrophages and between PsA blood and PsA synovial fluid 
macrophages. The up and downregulated genes in the activated macrophage samples were then 
put into a Venn diagram, blue represents the differentially expressed genes in the RA condition, 
green represents the PsA condition and red represents the cell contact activated macrophages. 
The genes that were expressed by cell contact macrophage samples and PsA or RA or by all three 
conditions were analysed further. 
Figure 6.7 shows differentially expressed genes in all three conditions, blue 
represents the significantly expressed genes between RA PB and RA SF CD14+ 
samples, green represents the significantly changed genes between PsA PB and 
PsA SF while red represents the significantly expressed genes between 
unactivated M-CSF macrophages and cell contact activated macrophages. 
Analysing the Venn diagram it can be seen that there are three groups of genes 
being expressed in cell contact activated and synovial fluid macrophages: 
 Genes expressed in all conditions (cell contact, RA SF and PsA SF 
macrophages). 590 genes 
 Genes expressed in cell contact macrophages and PsA SF macrophages. 
221 genes 
 Genes expressed in cell contact macrophages and RA SF macrophages. 664 
genes 
310 
The Venn diagram also indicates that only a small proportion of the genes 
expressed by the RA or the PsA synovial fluid are expressed within the cell 
contact activated macrophages. 10% (811 of 7401 genes) of PsA genes and 11% 
(1254 of 10879) of RA genes are expressed in the cell contact activated 
macrophages. 
The three gene groups listed above were then subjected to fold change analysis 
where the cut off threshold was set at a fold change ≥ 2. This analysis gave the 
following results: 
 149 genes expressed in all three conditions (c.c, RA SF, PsA SF) 
 40 genes expressed in both cell contact macrophages and PsA SF 
 146 genes expressed in both cell contact macrophages and RA SF  
Since the basis of this investigation was to determine how similar the cell 
contact activated macrophages were to the synovial fluid macrophages, the gene 
lists generated from the fold change analysis were scrutinised further to only 
include genes that were up or downregulated in both the cell contact samples 
and the synovial fluid samples. This is due to the discovery that many genes 
were being expressed in different directions, for example a gene that was 
upregulated in the cell contact activated samples was downregulated in the 
synovial fluid samples. As a result the number of similar genes from cell contact 
and synovial fluid macrophages decreased further: 
 110 genes expressed in all three conditions (72 downregulated genes and 
38 upregulated genes) 
 18 genes expressed in cell contact macrophages and PsA SF (6 
downregulated genes and 12 upregulated genes) 
 128 genes expressed in cell contact macrophages and RA SF (88 
downregulated genes and 40 upregulated genes) 
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6.7.1.2 DAVID analysis of the differentially expressed genes in 
cell contact activated macrophages and synovial fluid 
macrophages 
DAVID software was used to analyse the up- and downregulated genes that were 
changed in the cell contact macrophages and the synovial fluid macrophages to 
determine the overall biological functions of these genes. DAVID analysis did not 
find any significantly overrepresented processes within the gene list expressed in 
both the cell contact and PsA SF macrophage samples, which was likely to be 
due to the small number of genes within the list. Figure 6.8 demonstrates the 
top ten overrepresented biological processes associated with the upregulated 
genes found in all 3 macrophage conditions (A) and the downregulated genes 
found in all 3 macrophage conditions (B). The results of this analysis indicate 
that the macrophage samples are upregulating genes associated with immune 
response and response to stimulus and stress. The same macrophage samples are 
also downregulating genes associated with intracellular signalling cascade and 
regulation of myeloid cell differentiation. Figure 6.9 shows the biological 
processes associated with the upregulated genes found in both the cell contact 
and RA SF macrophages conditions (A) and the biological processes associated 
with the downregulated genes in both the cell contact and RA SF macrophage 
conditions (B). The upregulated genes are involved in processes such as 
intracellular signal transduction and phosphorylation. The downregulated genes 
are involved in processes such as cellular metabolism and T cell differentiation. 
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Figure 6.8 Up- and downregulated biological processes in cell contact, RA SF and PsA SF 
macrophages 
DAVID software was used to analyse the genes which were differentially expressed in all three 
macrophage conditions to determine overrepresented biological processes associated with the 
genes. The top ten significantly overrepresented processes are shown here with a p value <0.05 
which is equivalent to a –log p value > 1.30 
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Figure 6.9 Up- and downregulated biological processes in cell contact and RA SF 
macrophages 
DAVID software was used to analyse the genes which were differentially expressed in cell contact 
and RA SF macrophage conditions to determine overrepresented biological processes associated 
with the genes. The top significantly overrepresented processes are shown here with a p value 
<0.05 which is equivalent to a –log p value > 1.30 
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6.8  Discussion 
The in vitro model of inflammatory arthritis consists of direct cell contact 
activating M-CSF differentiated macrophages with cytokine activated T cells. 
Microarray analysis of one cell type requires a pure cell population as 
contaminating cells would have an effect on the genetic profiles obtained. 
Therefore we devised a method of isolating the activated macrophages from the 
T cells by CFSE staining the T cells and using the FACS ARIA to separate the cells 
based on their fluorescence. This method ensured that no antibody or CFSE 
staining of the macrophages took place as any manipulation of these cells may 
have altered their genetic profile. However, the FACS ARIA plots indicated that a 
large amount of cellular debris had been collected in the macrophage cell 
fraction which may have ultimately affected the macrophage purity and 
subsequently the transcriptomic profile of the cell contact activated 
macrophages. 
A 2 hour timepoint was demonstrated to be the appropriate duration of cell 
contact activation for the macrophages due to variability in the quality and yield 
of RNA after this time. It is difficult to fully explain these variable findings. 
However, the low quality RNA in the cell contact activated macrophages, as 
visualised by the empty electropherogram plots seen after t = 8hours in Figure 
6.4, may be due to very low amounts of RNA being run through the Agilent 
Bioanalyser The sequential decrease in the yield of macrophage RNA over the 
duration of the cell contact activation was also an unusual finding but may be 
due to increased apoptosis and cell loss which would therefore decrease the 
yield of RNA from the cells. As a result of these findings, we decided to analyse 
the macrophages after they had been cell contact activated for 2 hours, it was 
also decided that this timepoint was more appropriate for analysing the early 
response genes that would be differentially expressed within the macrophages. 
Crucially however this may not represent the gene profile present in a 
chronically activated macrophage derived from within the synovial compartment 
and in this sense the outcome was perhaps predictable. 
After completion of the microarray experiment and removal of the outlier cell 
contact macrophage sample from further analysis a PCA plot of the samples was 
setup to identify trends in the data since samples clustered within the same area 
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of the PCA graph are considered to be genetically similar [354]. This analysis 
identified that the M-CSF differentiated macrophages were genetically distinct 
from the Tck activated macrophages which suggests that being in cell contact 
with the Tcks for 2 hours induced a transcriptional change in the macrophages. 
However, the PCA analysis also demonstrated that the cell contact macrophages 
were genetically distinct from the synovial fluid macrophages. 
Previous work has demonstrated that the cytokine activated T cells (Tcks) used 
in this in vitro system are similar to RA synovial T cells, as they up-regulate the 
same cell surface activation markers and adhesion molecules and also induce the 
production of various cytokines and chemokines from macrophages in a cell 
contact dependent manner [298, 308, 309]. Recently, a microarray analysis of 
monocytes activated for 24 hours by PMA and PHA stimulated T cell membrane 
fragments was performed by Gruaz et al who analysed the anti-inflammatory 
effects of high-density lipoproteins (HDL) on the transcriptome of the activated 
monocytes. They discovered that 666 probe sets were altered in the activated 
monocytes compared to unactivated monocytes indicating that T cell contact 
activation of monocytes does have an effect on the transcriptome of the cells 
[315]. Hence, for our study it was hypothesised that cell contact activation of 
macrophages by fixed Tcks for 2 hours should indicate the early response genes 
upregulated by the macrophages. Given that the Tcks have been demonstrated 
to be similar to synovial T cells, the genes upregulated in these macrophages 
should be similar to those expressed in the synovial fluid CD14+ cells. 
The three macrophage conditions of cell contact, PsA synovial fluid and RA 
synovial fluid were compared to their matched unactivated or baseline samples, 
which in this comparison were unactivated M-CSF macrophages, RA PB CD14+ 
cells and PsA CD14+ cells. After determining the differentially up- and down-
regulated genes in these activated conditions a Venn diagram was used to 
discover if any genes overlapped with those of the other conditions. The initial 
results of the Venn diagram were disappointing as it demonstrated that only 10% 
of the total significantly expressed genes in the PsA SF condition and 11% of the 
total expressed genes in the RA SF condition were expressed in the cell contact 
macrophages indicating that these conditions were not significantly similar. A 2-
fold change analysis was subsequently performed on the gene lists which were 
then examined further to ensure that they were all differentially expressed in 
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the same direction. For example, if a gene was differentially expressed in both 
the cell contact activated and PsA synovial fluid conditions it had to be either 
up-regulated or down-regulated in both conditions but could not be up-regulated 
in one condition and down-regulated in the other since we were investigating 
the similarities between the conditions. This resulted in further decreasing the 
size of the gene lists and of the 54,675 probe sets on the Affymetrix GeneChips 
less than 130 were expressed in each of the three gene lists of i) expressed in 
cell contact, RA SF and PsA SF conditions, ii) expressed in cell contact and RA 
SF, iii) expressed in cell contact and PsA SF. 
DAVID analysis was performed on the up- and down-regulated genes in each of 
the three comparisons to determine the biological function of the similarly 
expressed genes. DAVID analysis of the genes present in all conditions indicated 
that all three macrophage types were up-regulating genes involved in response 
to stimuli. In the cell contact macrophages this would be as a result of Tck 
contact and in the synovial fluid macrophages this would be as a result of direct 
cell contact as well as the pro-inflammatory environment. All three cell 
conditions are also up-regulating genes associated with the immune response 
and its regulation, this would be expected in the synovial fluid macrophages 
since it has been well documented that the cellular influx into the joint is 
exposed to many pro-inflammatory mediators [537, 682-685] which would result 
in the up-regulation of these genes. However, it is reassuring to observe that the 
cell contact activated macrophages also up-regulate genes involved in immune 
system regulation since these cells are used as an in vitro model of arthritis. 
This also reflects the observations seen in the Gruaz et al microarray analysis of 
monocytes activated with PMA and PHA stimulated T cells which demonstrated 
an up-regulation of cytokines and mediators involved in the immune system 
[315]. The biological processes of the down-regulated genes in all three 
conditions include intracellular signalling cascade, RNA polymerase II 
transcription, and regulation of myeloid cell differentiation suggesting that the 
macrophages could be trying to regulate the increased transcription and 
signalling observed in cell contact activated and synovial cells as a result of 
extracellular stimuli. 
DAVID analysis of the genes up- and down-regulated in the cell contact 
macrophages and the RA synovial fluid macrophages demonstrated that the up-
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regulated genes were involved in processes such as signal transduction and 
intracellular signalling cascade. Signal transduction pathways provide an 
intracellular mechanism by which cells can respond and adapt to their 
environment. Proinflammatory stimuli found within the synovial environment 
can activate signalling cascades within a cell to alter gene transcription and 
protein expression. Several signal transduction pathways have been implicated in 
RA such as mitogen-activated protein kinase (MAPK) and NF-κB as well as the 
transcription factors janus kinase (JAK) and signal transducer and activator of 
transcription (STAT) [688, 689]. Signal transduction pathways, specifically NF-κB 
but not PI-3 kinase, have also previously been shown to play a role in the 
production and secretion of pro-inflammatory cytokines within the cell contact 
activated macrophages [298]. The results from this DAVID analysis highlight the 
importance of signal transduction and intracellular signalling in allowing the 
synovial macrophage to contribute to the pro-inflammatory milieu found in the 
synovium and also emphasises the ability of the cell contact model of arthritis to 
replicate this biological process found in the synovial macrophage.  
The biological processes of the down-regulated genes in RA synovial fluid and 
cell contact activated macrophages were metabolic process, T cell 
differentiation and regulation of IFN-α production. IFN-α is a proinflammatory 
cytokine that is present within the synovial fluid of RA patients and the 
macrophage cells may be down-regulating genes associated with its production 
as an anti-inflammatory regulatory mechanism [690]. The T cell differentiation 
process is a misleading title as two of the three genes associated with this 
function (the transcription factor Ikaros and the phosphatase PTPN22/Lyp) have 
been demonstrated to be expressed in macrophages as well as T cells [691, 692] 
and the third gene, ZNF278, a zinc finger repressor of gene expression has not 
been previously demonstrated to be present in T cells. This result highlights the 
point that the genes associated with each biological process may need to be 
analysed further to understand why the process is associated with the gene list 
since genes can appear in several biological process pathways and each gene can 
be expressed by more than one cell type.  
DAVID analysis could not be performed on the shared PsA synovial fluid and cell 
contact activated macrophages due to the small number of genes within this 
gene list. However, analysis of the gene list demonstrates that both PsA 
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macrophages and cell contact activated macrophages are upregulating 
inflammatory genes such as the cytokine TNFα which has a pronounced role in 
the pathogenesis of arthritis. These two macrophage types are also upregulating 
genes such as NRP2 (neuropilin 2) which is a surface receptor originally 
identified as a factor involved in nerve fibre repulsion during neuronal growth 
[693]. Neuropilin 2 positive nerve fibres have been detected in the synovium of 
rheumatoid arthritis patients and soluble neuropilin 2 has also been detected in 
the synovial fluid of these patients where it was hypothesised to aggrevate the 
loss of sympathetic nerve fibres which is observed in RA [694]. Consequently 
despite the low numbers of genes that are the same in the PsA and cell contact 
macrophages, the genes that are shared between the subgroups are of an 
inflammatory phenotype and have been demonstrated to be involved in the 
destructive phenotype of arthritis. 
The common genes between all three conditions and between cell contact 
activated macrophages and RA synovial fluid macrophages were revealed to 
share biological processes such as immune system regulation, which 
demonstrates that after just 2 hours the Tck contact activation is eliciting an 
immune response in the M-CSF macrophages similar to that seen in synovial fluid 
derived macrophages. Nevertheless, this study has also demonstrated that of all 
the genes differentially expressed between RA PB and RA SF CD14+ and between 
PsA PB and PsA SF CD14+ only 11% and 10%, respectively, of those genes are also 
differentially expressed between the M-CSF and cell contact activated 
macrophages. This result would indicate that the cell contact model of 
inflammatory arthritis may not be a suitable in vitro model for arthritis since the 
cell contact activation does not appear to effectively replicate the same level of 
transcriptional expression within the M-CSF macrophage compared to a synovial 
fluid macrophage isolated from a patient. 
Nonetheless, there are several possible reasons for this discrepancy. Firstly, the 
FACS ARIA separation suggested that a large proportion of collected events for 
the macrophage cell fraction was celluar debris which may have been created 
during the removal of the macrophages from the culture wells after cell contact 
activation. The presence of this debris would affect the overall purity of the 
macrophage cells and may have contained cellular components and nuclear 
material which could have affected the transcriptomic measurement and 
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analysis. In addition,  due to time restrictions only 6 normal donors were able to 
be recruited for the cell contact activation samples and since one of these 
samples was the outlier identified at the start of the microarray analysis its 
removal meant that only 5 matched cell contact samples were compared to 8 
matched RA and 8 matched PsA samples. Therefore the full spectrum of the cell 
contact transcriptome may not have been analysed. The cell contact donors 
were also only age and sex matched to the PsA patients who had a smaller mean 
age compared to the RA patients. Many papers have described the effect of 
aging on epigenetics such as altered DNA methylation and histone modification 
which in turn impact on chromatin folding [695], women are also more 
predisposed to rheumatic diseases due to hormonal as well as genetic 
differences between males and females [696]. Hence not including age and sex 
matched donors to the RA patients may have automatically discarded genes 
associated with these two factors.  
As noted at the outset of my discussion, the final and most important variable 
which may have affected the gene expression of the cell contact activated 
macrophages was the duration of activation. During the cell contact model the 
macrophages are usually stimulated for 24 hours with the Tcks before analysis, 
however due to our interest in the early response genes expressed in the 
macrophages and the variability in the macrophage quality and yield it was 
decided to analyse the cells after a shorter duration. Consequently trying to 
compare macrophages which have been activated for 2 hours to macrophages 
from the synovial fluid which have been activated for an unknown duration 
presents problems. A recent paper which analysed the stability and temporal 
changes in inflammatory gene expression in TNFα stimulated murine fibroblasts 
found three groups of mRNA expression: group 1 genes had a peak mRNA 
expression at 0.5 hours after stimulation but their expression was unstable and it 
fell to baseline after 1 hour; group 2 genes had a peak expression at 2 hours 
however upon the removal of the TNFα stimulus their expression fell to baseline; 
group 3 genes had peak expression 12 hours after the stimulus, these genes were 
transcribed at a slow rate but the resulting mRNA was very stable [697].  
Subsequently if the same pattern of mRNA expression was occurring within the 
cell contact activated macrophages then analysing these cells after 2 hours 
would only detect the group 2 genes as mRNA from the group 1 genes would 
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probably already be in the process of degradation and the group 3 genes would 
not be expressed at a detectable level. 
In summary, despite the cell contact activated macrophages only sharing 10-11% 
of the genes expressed in RA or PsA synovial fluid macrophages those genes 
involve a high proportion of immune system regulation genes indicating that this 
system is upregulating the types of genes thought to be involved in the perpetual 
immune activation seen in macrophages of the arthritic joint. However, to fully 
elucidate the appropriateness of this cell contact system as a model of 
inflammatory arthritis an extended microarray experiment would have to be set 
up in which each RA and PsA patient had an age- and sex-matched donor for the 
cell contact activation and particular care was taken when isolating the 
macrophage cells from the cell contact to ensure a high cell purity. The cell 
contact activated cells would ideally be activated over a timecourse of 1-24 
hours to determine the different groups of genes being expressed within these 
cells over time.  
 
321 
Chapter 7 Validation of an in vitro live cell imaging 
system 
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7.1 Introduction 
The macrophage – T cell co-culture experiment is a well established in vitro 
model of inflammatory arthritis. The method of cytokine activation of the T cells 
for this in vitro model confers a pro-inflammatory synovial phenotype which can 
induce the release of several cytokines and chemokine from the macrophages via 
direct cellular contact as has previously demonstrated by the vast amount of 
research performed by our group and several others [298, 308, 309, 408]. Whilst 
we have obtained a wealth of information regarding several aspects of the in 
vitro model such as the signalling pathways involved in the cytokine and 
chemokine release from the macrophages as well as the adhesion molecules 
upregulated by the cytokine activation of the T cells, there are still important 
facets of this model which have not been explored. One important question 
which we addressed in the previous chapter is how similar is the transcriptome 
of the Tck cell contact activated macrophage compared to the synovial 
macrophage. However, another important aspect of the cell contact model is 
determining how the macrophages and Tcks in this model interact and how long 
these interactions last for; this information can be determined using in vitro live 
cell imaging.  
Live cell imaging is a widely used technique which has become more sensitive 
and efficient in recent years with the introduction of new imaging techniques 
and machines such as two-photon laser scanning microscopy. A large amount of 
the current work using live cell imaging has focused on the in vivo interactions 
between DCs and T cells within the lymph node [698]. These studies have been 
very informative in determining the behaviour of the T cell – DC interactions 
during antigen presentation. Such studies have revealed that when T cells are 
moving around the lymph node they follow a chaotic trajectory with random 
movements and are not directed by chemotatic gradients over large distances as 
was previously thought [699]. Live cell imaging has also demonstrated that T cell 
may make several contacts of a short duration with antigen loaded DCs before 
forming a stable cell-cell immunological synapse contact with one DC. The use of 
live cell imaging has made it possible to visualise the movement of the T cells 
towards the DCs during antigen presentation and several papers have proposed 
models for the type of movements and behaviours observed by the T cells before 
they form stable, long-lived interactions such as ―drive by‖ which is a situation 
323 
where the T cell will have a short interaction with the DC but will then move 
away from the DC and carry on migrating [700]. 
Despite the wealth of knowledge about the interactions of T cells and DCs 
gained from live cell imaging there has been far fewer investigation into the 
interactions between T cells and macrophages either in vivo or in vitro. One 
study performed by Underhill et al imaged such interactions using OVA specific 
murine T cells containing a reporter construct which caused the cell to express 
green fluorescent protein (GFP) upon productive engagement with OVA 
presenting macrophages. Using in vitro live cell imaging this group demonstrated 
that 90% of the T cells appeared to move around the surface of individual 
macrophages and 50% of T cells migrated from one macrophage to another 
during 3 hours of time lapse imaging. Underhill et al also determined that the T 
cell — macrophage interactions had to be sustained for 2 hours for the T cell to 
become fully activated and express GFP however due to the behaviour of the T 
cells this activation may be the summing up of multiple activatory signals during 
the numerous interactions with the macrophages [701]. This study was analysing 
the T cell — macrophage interactions in the presence of antigen and at present 
there are no studies analysing such in vitro interactions in an antigen 
independent environment. 
Histological analysis of the inflamed synovium has shown that macrophages are 
found in close contact with T cells [286] indicating that direct cell contact may 
be a mechanism causing the production of pro-inflammatory cytokines. 
Subsequent studies using the in vitro cell contact model have demonstrated this 
observation to be correct since the incubation of synovial-like Tcks with 
macrophages induces the production of pro-inflammatory cytokines and 
chemokines as well as anti-inflammatory cytokines such as IL-10 [269, 308]. 
Despite the large amount of experimental work on the cell contact model of 
arthritis there are still gaps in our knowledge regarding the mechanisms of the 
cell—cell interactions and the behaviour of the cells during the co-culture. 
Therefore we set out to use an inverted microscope to image these antigen 
independent interactions in real time. We aimed to determine the number and 
duration of Tck—macrophage interactions and the overall area of these 
interactions. Different variables such as using inactivated T cells or fixed Tcks 
were analysed to visualise their effects on the interaction measurements. Once 
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the behaviour and movement of the cells during the cell contact model have 
been fully understood, the live cell in vitro imaging system could then be used 
to analyse the impact that blocking molecules or proteins may have on the Tck—
macrophage interaction. It was our intention to bring this imaging system 
together with the preceding microarray data to visualise the effect of altering 
key genes, which had identified as being differentially expressed in the synovial 
macrophages, on the cellular interactions taking place and also whether this 
may be affecting the cytokine/chemokine profile of the cell contact. 
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7.2 Real-time imaging 
Figure 7.1 demonstrates the experimental set up to allow real time imaging of 
the cell contact events. The conditions being compared may differ from those in 
the figure however the general experimental set up was the same. Macrophages 
were isolated from a healthy donor and stimulated for 5 days with M-CSF before 
being stained with the red fluorescent dye CMTPX and plated out onto a 
specialised imaging culture chamber for 24 hours to allow the cells to adhere. T 
cells isolated from the same donor which were treated under differing conditions 
were stained with the green fluorescent dye CFSE and cultured with the 
macrophages. The cultures were incubated for 2 or 24 hours (as indicated in the 
text) and then imaged on an inverted microscope. Each condition was imaged for 
varying lengths of time therefore each co-culture set up was often staggered for 
each condition to maintain a constant incubation time before being imaged.  
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Figure 7.1 Outline of in vitro real time imaging experimental setup 
An example of the experimental set up for real time imaging demonstrating how a comparative 
analysis between a macrophage (Mø) and Tck culture compared to a macrophage and 
unstimulated T cell culture would be set up. For this experiment macrophages and T cells are 
isolated from the donor, T cells are stimulated for 6 day with cytokines to generate cytokine 
activated T cells (Tcks) and the monocytes are stimulated for 5 days with M-CSF before being 
stained red with a CMTPX dye and plated out onto two imaging chamber for 24 hours to allow them 
to adhere to the chamber. On day 6 T cells are isolated from the same donor and stained green 
with CFSE and the Tcks are also stained green. Each of the two T cell conditions are then 
incubated with macrophages and the two cell contacts are incubated for a specified duration before 
being imaged on the microscope. 
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7.2.1 Imaging on the microscope 
Once the cell contact experiments had been cultured for the specified duration 
the co-cultures were imaged on an inverted microscope which had a heated 
stage to maintain the cultures at 37ºC. For each imaging condition three movies 
were taken of three separate areas of the co-culture chamber. Once the area to 
be visualised had been chosen the microscope was set up to take three images 
every 12 seconds. The three images consisted of a green fluorescent image, a 
brightfield image and a red fluorescent image as shown in Figure 7.2. The 
brightfield image was taken to ensure that the camera remained aligned while 
the green and red fluorescent images were merged to obtain a single timepoint 
image. When all of the merged imaged were played in sequence they produced a 
real time movie of the in vitro cell contact model of inflammatory arthritis. 
  
Figure 7.2 Example of the images taken by the inverted microscope for the real time imaging 
During the real time imaging the inverted microscope takes three consecutive images. An image of 
the green fluorescence, a brightfield image and an image in red fluorescence (top three images of 
panel). The red and the green fluorescent images are then merged to make the single timepoint 
image (bottom image of panel). The brightfield image is not used in the final timepoint image but is 
taken to ensure that the microscope remains aligned.  
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7.2.2  Quantitative measurements of imaging 
Once generated, the real-time images and movies were analysed to determine if 
there is a difference in the interactions between experimental conditions. 
Volocity is specific imaging software which allows factors such as the number 
and duration of T cell-macrophage interactions to be examined as well as the 
colocalization coefficient between the two cell types.  
7.2.2.1 Number and duration of interactions 
The number and duration of each macrophage-T cell interaction during the 
course of the real time movies were calculated using the Volocity software. This 
software has specific functions that can detect red fluorescence (representing 
the macrophage cells) and green fluorescence (representing the T cells) and 
then determine where these two fluorescence signals intersect i.e. where the 
two cell types are interacting. The software measures the interactions taking 
place in the field of view for the first time frame of the movie and then 
calculates how long these interactions last for the duration of the imaging. It 
also measures any new interactions and their duration taking place during the 
co-culture therefore enabling the user to determine exactly how many 
interactions took place between the two cell types and how long these 
interactions last for. The basis for how the software identifies these cell-cell 
interactions is shown in Figure 7.3. 
7.2.2.2 Colocalization coefficient 
The Volocity software can also be used to measure the colocalization coefficient 
of the macrophage-T cell interactions. In the context of digital fluorescence 
imaging, colocalization can be described as the detection of signal at the same 
pixel localisation in each of two channels. The two channels are made up of 
images of two different fluorochromes taken from the same sample area. The 
Volocity software therefore detects how many yellow pixels are in each time 
frame image as the yellow pixels are representing the position where the two 
fluorescent colours (green and red) are overlapping and hence where the two 
different cell types are interacting. The colocalization coefficient therefore 
analyses the area of interaction between the two cell types, it has an advantage 
over the number and duration analysis as statistical analyses can be made on the 
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colocalization coefficient values between two different experimental conditions 
to determine if there is a significant difference between the areas of 
colocalization. In summary there are two different methods of analysis for the 
real time movies generated of the in vitro model of inflammatory arthritis. They 
are both constructive methods of analysis and enable the amount and duration 
of interactions as well as the overall areas of interactions to be measured. 
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Figure 7.3  Volocity software method for determining the macrophage-T cell interactions 
Each macrophage-T cell culture movie is made up of individual frames taken by the microscope 
which, when played in sequence, produces the real time movie. To determine the number and 
duration of interactions taking place during each movie Volocity begins by analyses the first time 
frame of the movie. In this image Volocity identifies objects which are fluorescing green (T cells) 
and identifies objects which are fluorescing red (macrophages). It highlights each new object it 
identifies in a different colour. The software then identifies the areas of intersection between the red 
and green objects and each area is classed as an interaction between the two cell types. The 
software will then track these interactions and any new interactions which form during the movie 
and determine how long each interaction lasted for. The cartoons on the right hand side of the 
figure depict how the software views the cells and locates the areas of interaction. 
331 
7.3 Comparison of cytokine activated T cells to 
unstimulated T cells 
In the cell contact model of inflammatory arthritis the T cells are stimulated 
with a specific cytokine cocktail for 6 days, this stimulation induces an activated 
T cell (Tck) phenotype which resembles T cells isolated from an RA synovial 
joint. Not only do these Tcks express a similar cell surface ligand and activatory 
marker phenotype as the synovial T cells they also induce a similar pro-
inflammatory cytokine and chemokine profile in macrophages by direct cell 
contact [269, 298, 308, 309]. To establish whether the cytokine activation of the 
T cells induced more interactions with the macrophages or a larger area of 
interactions a comparative analysis of Tcks and inactivated T cells took place.  
Figure 7.4 is a representative of three independent experiments performed. 
Since each co-culture condition was imaged three times in separate areas of the 
culture chamber panel, Figure 7.4 (A) shows individual time frames of a 
representative movie for each culture condition taken at t=0, t=60 seconds and 
t=120 seconds for the macrophage—T cell co-culture (top panel) and the 
macrophage—Tck co-culture (bottom panel). The white arrows on the 
macrophage—Tck co-culture images indicate Tck cell movement during the 
course of the movie. Upon comparison of the two sets of images it can be seen 
that many Tcks are clustered around the macrophages which is not visualised in 
the non activated T cells images. Consequently, the cytokine stimulation of the 
T cells would appear to induce a higher rate of clustering and interaction with 
the macrophages compared to T cells from the same donor which have not been 
stimulated.  
This pattern of interaction can also been seen in the two real time movies 
represented by the panel of images in part (A) of Figure 7.4. The supplementary 
file designated movie 1 demonstrates the inactive T cell — macrophage 
interactions. It can be seen that there is little T cell movement within the field 
of view. There are also only a small number of interactions taking place between 
the T cells and the macrophages which appear to be stable. The movie for the 
Tck—macrophage co-culture is supplementary file movie 2 and from this short 
movie it can be seen that the majority of interactions are stable long-lived 
interactions where many Tcks have clustered around one macrophage indicating 
332 
their increased activation status compared to the inactivate T cells. There are 
only a small number of Tcks which have not formed stable interactions moving 
though the field of view therefore it is difficult to comment on the migration 
pattern of the Tcks. It is likely that in the 24 hours prior to the imaging of the 
co-culture the majority of the Tcks have already formed and established stable 
interactions with the macrophages therefore a shorter imaging timepoint may be 
necessary in order to visualise the how the Tcks migrate and behave. I note also 
that the experiment is not performed under formal flow conditions which might 
alter the adhesive activities of cells. 
Volocity analysis was used to analyse the movies in order to determine the 
number and duration of interactions which are shown in Figure 7.4 (B). These 
graphs show the number of interactions on the y axis and the duration of 
interactions in time frames on the x axis. One time frame is equivalent to a 
duration of 12 seconds since this is the unit of time between each image being 
taken on the microscope. The graphs represent the average number and duration 
of interactions throughout the three movies taken of each co-culture condition. 
The graph on the left hand side demonstrates that the Tcks (red line) have more 
sustained interactions with the macrophages. These interaction last for a longer 
duration which is identified by the peak of interactions just before time frame 
200 and at time frame 250 which is not seen in the T cell co-culture (black line). 
Due to the difficulty in visualising the difference in the number of short duration 
interactions between the two co-culture conditions all interactions which lasted 
up to 10 minutes, equivalent to 50 time frames, were plotted on a separate 
graph (demonstrated by the right hand side graph). Analysing this graph 
illustrates that as well as having more sustained interactions with the 
macrophages the Tcks also have a higher number of shorter duration 
macrophage interactions compared to the T cells. This can be most easily seen 
at time frames 5 to 10 where the Tcks consistently exhibit a higher number of 
interactions compared to the T cells. Volocity analysis of the colocalization 
coefficient in Figure 7.4 (C) reveals that the average area of interaction was 
significantly higher in the three movies of the Tck co-culture compared to the 
three movies of the T cell co-culture (p<0.0001). 
Hence these results demonstrate that cytokine activation of the T cells does 
induce more interactions with the macrophages, these interactions are more 
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sustained and have a significantly larger area. However, analysis of the movies 
demonstrates that there is little Tck movement towards the macrophages as 
most of the Tcks have migrated towards and maintained their interactions with 
the macrophages in the 24 hour period prior to microscope imaging. Since we 
are also interested in visualising how the Tcks migrate towards and interact with 
the macrophages it was decided to analyse the co-culture experiments after a 
shorter 2 hour duration of incubation.  
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Figure 7.4 Imaging Tcks or non-activated T cells incubated with macrophages for 24 hours 
The two co-culture experiments were analysed after 24 hours of incubation, three fields of view 
were imaged from each condition. Figure (A) shows single images from the real time movie taken 
at t=0, t=60 seconds and t=120 seconds from the cell contact containing macrophages and non 
activated T cells (top panel) and the cell contact containing macrophages and Tcks (bottom panel). 
The white arrows on the bottom panel of images indicate Tck cell movement during the course of 
the imaging. These images are a representative of the three movies which were taken of each 
condition. Figure (B) indicates the number and duration of macrophage-T cell interactions 
throughout the course of the movies. The duration of interactions is represented in time frames 
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where one time frame is equivalent to 12 seconds. The data points represent the average value 
taken from the three movies of the macrophage-T cell co-culture (black line) and the macrophage-
Tck co-culture (red line). The graph on the left indicates all the interactions which occur for the 
duration of the movies. Since the number of short interactions is difficult to visualise on this graph 
the short duration interactions lasting no longer than 10 minutes (50 time frames) have been 
plotted on the right hand side graph. Figure (C) demonstrates the average colocalization coefficient 
of the two co-cultures (mean plus standard deviation). Colocalization coefficient is a measure of the 
area of interaction between the macrophages and T cells and this result demonstrates that there is 
a significantly higher amount of interaction taking place in the Tck co-culture compared to the T cell 
co-culture (p<0.0001). 
 
7.3.1  Comparison of Tcks and T cells after 2 hours of co-culture 
with macrophages 
I next examined cellular contacts between macrophages and T cells/Tcks after a 
2 hour duration of incubation. Since we also planned to use this model system to 
analyse the effect of different proteins/molecules identified from the 
microarray on this inflammatory model of arthritis, analysing the co-culture 
system after 2 hours would also allow us to identify early effects of targeting or 
manipulating these proteins.  
Figure 7.5 is a representative of three independent experiments that measured 
the interactions between macrophages and non-activated T cells or Tcks after 2 
hours of co-culture. Figure (A) is displaying screen shots taken from the movie of 
the macrophages incubated with non-activated T cells (upper panel) or 
incubated with Tcks (lower panel). Examination of the two image panels 
revealed that even after 2 hours of incubation the macrophages and T cells are 
already in contact with one another. This demonstrates that the T cells require 
only a short duration of time in which to establish their interactions with the 
macrophages. Upon comparison of the two panels of screenshots, the 
macrophage-Tck co-culture appear to have substantial clustering of the T cells 
around the macrophages compared to the non-activated T cell –macrophage co-
culture. This clustering of the Tcks around the macrophages is not distributed 
evenly throughout the field of view and is localised to a subgroup of 
macrophages. The reason for this is unclear at present but it may be due to an 
increased activation of the macrophage subset causing increased expression of 
cell surface activatory markers or increased chemokine or cytokine expression 
from these cells which could be causing the Tcks to cluster around them. 
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The representative movie for the macrophage—T cell 2 hour co-culture is 
designated movie 3 in the supplementary files. Upon observing this real time 
movie it is clear, especially at the start of the movie, that all of the T cells are 
moving in the same direction and they all change their direction of movement at 
the same time. This would indicate that rather than undergoing independent 
random movement the T cells are all moving throughout the field of view as a 
result of an external variable which could possibly be the external airflow. 
Despite this variable, several of the inactive T cells have formed stable contacts 
with the macrophages indicating that the two cell types can establish stable 
interactions after just 2 hours of co-culture. Analysing the migrating T cells in 
the movie demonstrates that these T cells appear to only briefly interact with 
the macrophages before moving away. These short interactions may be due to 
the T cells being inactivate and therefore are not expressing the high level of 
adhesion molecules needed to form strong interactions upon the first encounter 
of the macrophages. In addition the external air flow could be playing a role in 
moving the T cells away from the macrophages before the establishment of the 
stable interactions. This is in contrast to the small number of stable interactions 
which have formed between the two cell types which may have formed during 
the 2 hour co-culture in a 37ºC incubator without the influence of external air 
flow. 
The representative movie for the macrophage—Tck 2 hour co-culture is 
designated movie 4 in the supplementary files. Analysis of this movie indicates 
that the Tcks have formed stable interactions emphasising the observation that 
the Tcks only need a few hours to form stable cell contacts with the 
macrophages. In the middle of the field of view in the movie there is a 
macrophage dense region around which many Tcks have clustered. This 
clustering of T cells was not seen in the inactive T cell movie indicating that the 
Tcks have a greater capacity for macrophage cell contact. As was visualised in 
the previous movie, the external air flow appears to be influencing the 
movement of the Tcks as all of the Tcks are moving in the same direction though 
the field of view, making it difficult to distinguish the migration pattern of the 
Tcks. However, although their movement appears to be influenced by the air 
flow the Tcks are demonstrating more short duration interactions with the 
macrophages compared to the inactive T cells. This observation is not due to the 
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selection of the field of view as three areas were selected at random for this 
analysis and the same pattern of airflow was visualised in all three fields of 
view. In addition, the Tcks appear to interact for longer with the macrophages 
before moving away in comparison to the inactive T cells which appear to only 
interact briefly. 
Panel (B) of Figure 7.5 is showing the number and duration of interactions 
occurring between the macrophages and the non-activated T cell or the Tcks. 
The left hand graph indicates the average number and duration of the 
macrophage-T cell interaction which took place during the two conditions. The 
interactions between the macrophages and Tcks are indicated by the red line 
and the interactions between the macrophages and the non-activated T cells are 
indicated by the black line. On the left hand graph it is difficult to visualise the 
number of interactions lasting for a short duration however both the Tcks and 
the non-activated T cells appear to have a similar number of interactions lasting 
for the maximal duration of 265 time frames (53 minutes). Due to the difficulty 
in viewing the number of interactions lasting for a short duration, this data was 
re-graphed specifically analysing interactions which lasted for up to 10 minutes 
in duration. This graph can be seen on the right hand side of panel (B) and 
demonstrates that the Tcks (red line) had an increased number of short 
interactions with the macrophages compared to the non-activated T cells (black 
line). Volocity analysis of the area of interaction (colocalization coefficient) 
within each of the movies was also calculated and the results are shown in panel 
(C). The colocalization coefficient is significantly higher (p<0.0001) when the 
Tcks are co-cultured with the macrophages compared to the non-activated T 
cells indicating a higher area of interaction. These results correspond with those 
that were observed during comparison of the images in panel (A) and 
supplementary movies 3 and 4 where it was observed that more Tcks appeared 
to be in contact and clustered around the macrophages compared to the non-
activated T cells.  
In summary, this 2 hour imaging condition has verified the results of the 
Tck/non-activated T cell imaging performed after 24 hours of co-culture as it 
has demonstrated at this timepoint that cytokine activated T cells have a higher 
number of interactions with the macrophages and these interactions have a 
larger area. The results of the 2 hour co-culture imaging also inform us that the 
338 
T cells interact with the macrophages after a relatively short duration of 
incubation and it is not necessary to incubate the co-culture for 24 hours before 
imaging. Performing imaging after such a short incubation has its advantages as 
the initial movement and interactions of the T cells with the macrophages can 
be visualised along with the early effects of adding inhibitory molecules or 
targeting specific genes within the co-culture system. 
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Figure 7.5 Imaging Tcks or non-activated T cells incubated with macrophages for 2 hours  
The two co-culture experiments were analysed after 2 hours of incubation. Figure (A) shows single 
images from the real time movie taken at t=0, t=60 seconds and t=120 seconds from the cell 
contact containing macrophages and non activated T cells (top panel) and the cell contact 
containing macrophages and Tcks (bottom panel). Figure (B) indicates the number and duration of 
macrophage-T cell interactions throughout the course of the movies. The data points represent the 
values taken from the macrophage-T cell co-culture (black line) and the macrophage-Tck co-
culture (red line). The graph on the left indicates all the interactions which occur during the movies. 
Since the number of short interactions is difficult to visualise on this graph the short duration 
interactions lasting for up to 10 minutes (50 time frames) have been plotted on the right hand side 
graph. Figure (C) demonstrates the average colocalization coefficient of the two co-cultures. 
Colocalization coefficient is a measure of the area of interaction between the macrophages and T 
cells and this result demonstrates that there is a significantly higher amount of interaction taking 
place in the Tck co-culture compared to the T cell co-culture (p<0.0001). 
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7.4 Comparison of fixed and live Tcks after 2 hours co-
culture with macrophages 
Once it had been established that the Tcks, which have a phenotype similar to 
RA synovial T cells, have more interactions compared to non-activated T cells we 
decided to develop and validate the in vitro imaging system further by 
comparing fixed Tcks to live Tcks. We hypothesised that the live Tcks would be 
able to actively migrate towards the macrophages and therefore would have a 
larger number of interactions with the macrophages compared to fixed Tcks. 
Figure 7.6 is a representative of five experiments which took place to image the 
fixed and live Tck co-culture conditions with live macrophages. For the fixation 
process 2% paraformaldehyde was used which fixes the cells through cross linking 
the proteins. Consequently, the fixed Tcks will still have the cell surface 
markers and adhesion molecules needed to interact with the macrophages but 
they will not be able to actively migrate or chemotax towards the macrophages 
or produce cytokines or chemokines which could activate the macrophages. 
Panel (A) of Figure 7.6 is showing the screen shots from one of the three fields 
of view taken for each imaging condition for this experiment. The screen shots 
are taken at 0, 60 and 120 seconds after the commencement of imaging. 
Comparison of the two sets of screenshots demonstrates that there are very few 
interactions taking place between the macrophages and fixed Tcks however the 
live Tcks have clustered around the macrophages and are interacting with them. 
This can also be visualised in the real time movies taken of these conditions. 
Supplementary file movie 5 is the representative field of view taken of the fixed 
Tcks—macrophages after 2 hours of co-culture. Upon analysis of this movie it is 
clear that there are very few interactions taking place between the fixed Tcks 
and the macrophages. Furthermore, there appears to be a very small number of 
stable interactions between the fixed Tcks and the macrophages, the Tcks which 
are moving around the field of view are seen to very briefly interact with the 
macrophages before moving away. The supplementary file movie 6 represents 
the live Tcks from the same donor imaged after 2 hours of co-culture. This movie 
demonstrates that the live Tcks are highly activated and have clustered around 
and acquired stable interactions with the macrophages. Some of the Tcks are 
interacting with two macrophages at the same time and can be visualised 
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spreading over the surface of the macrophage in order to increase the area of 
interaction. The external air flow does not appear to be playing a large role in 
the movement of the live Tcks as was seen in previous movies. In addition, it can 
also be visualised that once a Tck becomes within close proximity of a 
macrophage it is more likely to interact with the macrophage rather than 
migrate past it which is what is observed in the fixed Tck movie. 
Part (B) of Figure 7.6 reveals the average number and duration of interactions 
that took place throughout the imaging conditions. Each condition was imaged 
three times therefore the points on this graph represent the mean number and 
duration of interactions which took place. These results demonstrate that the 
live Tcks (red line) had substantially more interactions than the fixed Tcks; the 
difference was so striking there was no need to display the interactions lasting 
for up to 10 minutes in duration as was done in the previous figures. The graph 
also demonstrates that the live cells not only had numerous short interactions 
with the macrophages but also had interactions lasting for a long duration which 
is demonstrated by the peak of interactions at approximately 130 time frames. 
Panel (C) of Figure 7.6 demonstrates that the mean area of interaction between 
the macrophages and the Tcks was significantly higher (p<0.0001) in the live cell 
co-culture compared to the fixed cell co-culture. These results along with the 
preceding ones verify our hypothesis that the live Tcks would have more 
interactions with the macrophages compared to the fixed Tcks. Whilst this result 
was not surprising since fixed Tcks are unable to migrate, this condition was an 
important one to set up as it ensured that our in vitro system was functional and 
that our methods of analysis were accurate and reliable. 
Unfortunately time restrictions meant that no further experiments using our 
validated in vitro real time imaging system could be performed and therefore 
the imaging method could not be used for its intended purpose of imaging the 
effect of blocking proteins discovered during the microarray analysis to be 
upregulated in the synovial fluid macrophages. If time had permitted we would 
have imaged the cell contact after siRNA treating the macrophages to 
knockdown plexin A1 production. Plexin A1 is a gene which was highly 
upregulated in our RA and PsA synovial fluid microarray samples compared to 
their matched blood samples, it is a surface receptor for semaphorin ligands and 
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has been demonstrated to have a role in immune regulation and axonal guidance 
[444, 618]. Hence imaging the effect of siRNA knockdown of plexin A1 could 
have demonstrated if it played a role in Tck—macrophage interaction and 
whether silencing plexin A1 in the macrophage had an impact on the number, 
duration or area of cellular interactions. 
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Figure 7.6 Imaging fixed or live Tcks incubated with macrophages for 2 hours 
The two co-culture experiments were analysed after 2 hours of incubation. Figure (A) shows single 
images from the real time movie taken at t=0, t=60 seconds and t=120 seconds from the cell 
contact containing macrophages and fixed Tcks (top panel) and the cell contact containing 
macrophages and live Tcks (bottom panel). These images are a representative of the three movies 
which were taken of each condition. Figure (B) indicates the number and duration of macrophage-T 
cell interactions throughout the course of the movies. The data points represent the average value 
taken from the three movies of the macrophage- fixed Tck co-culture (black line) and the 
macrophage-live Tck co-culture (red line). Figure (C) demonstrates the average colocalization 
coefficient of the two co-cultures (mean plus standard deviation). Colocalization coefficient is a 
measure of the area of interaction between the macrophages and T cells and this result 
demonstrates that there is a significantly higher amount of interaction taking place in the live Tck 
co-culture compared to the fixed Tck co-culture (p<0.0001). 
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7.5 Discussion 
This project has demonstrated the validation work required to verify an in vitro 
imaging model of inflammatory arthritis, and we have illustrated the effects of 
changes to the model through fixing the Tcks or by adding unstimulated T cells 
to the culture. In addition, this work has allowed the visualisation of the 
dynamic nature of the interactions between the cytokine activated Tcks and 
macrophages. The inflammatory cell contact model has previously been 
demonstrated to be a robust model of arthritis since the cytokine activation of 
the T cells induces a phenotype similar to T cells found in the RA synovium [269, 
298, 308, 309]. However, previous work has only analysed the 
cytokine/chemokine profiles of the macrophage—Tck co-culture, the activatory 
markers present on the Tcks or the inflammatory signalling pathways which are 
activated in the macrophage as a result of co-culture. Hence, we set out to 
visualise and measure the interactions that take place within this co-culture 
model with the eventual aim of imaging the effect of blocking specific proteins 
shown to be upregulated in the synovial macrophage by combining this work with 
the microarray results of the preceding chapters.  
The first set of experiments which were performed compared the interactions 
between a macrophage—Tck to a macrophage —T cell co-culture that had been 
incubated for the standard duration of 24 hours. The results of these 
experiments revealed that on average the Tcks engaged in a higher number of 
interactions with macrophages compared to the unstimulated donor matched T 
cells. These Tck interactions also lasted for a longer duration and had a 
significantly higher surface area compared to the T cell interactions. Recently, 
Brennan et al showed that the cytokine activation of T cells results in the 
upregulation of T cell activation markers such as CD25, CD69 and HLA-DR as well 
as adhesion molecules such as L-selectin, integrin β-1 (CD29), integrin β-2 (CD18) 
and CD49d an integrin alpha subunit that in combination with CD29 make up the 
integrin very late antigen-4 (VLA-4) [309]. These adhesion molecules are known 
to interact with receptors which are present on the surface of macrophages, 
such as VCAM-1 which interacts with Tck VLA-4 and ICAM-1 which interacts with 
Tcks CD18. Consequently, the observations of increased interactions between 
Tcks and macrophages with a higher surface area compared to those between 
inactivated T cells and macrophages is unsurprising since the Tcks have 
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previously been shown to express adhesion molecules which will aid in their 
establishment and maintenance of interactions with the macrophages. Analysis 
of the numerous movies taken of the two co-culture conditions demonstrated 
that while many stable interactions had formed between the Tcks/T cells and 
the macrophages there were very few Tcks or T cells which were actively 
migrating or moving throughout the field of view. This result indicated that most 
of the Tcks/T cells had already established and maintained their stable 
interactions with the macrophages in the 24 hours prior to the commencement 
of the real time imaging. 
Since part of this investigation was to visualise the movement of the T cells 
within the cell contact system and visualise the establishment of these 
interactions it was decided to analyse the co-culture system after a shorter 
duration of incubation. An incubation period of 2 hours was decided upon before 
the commencement of the real time imaging. This short incubation period should 
allow the T cell movement to be observed and the establishment of short and 
stable interactions as a previous study analysing murine T cell macrophage 
interactions demonstrated that the T cells move from one macrophage to 
another after 2 hours of real time imaging [701]. In addition, using a 2 hour 
incubation period before imaging the co-culture would coordinate well with 
using this in vitro imaging system alongside the microarray results to visualise 
the function of particular genes. The microarray analysis took place after 2 
hours of co-culture to analyse the early response genes that are changed in the 
macrophages therefore imaging this co-culture system after 2 hours will allow 
the visualisation of the effect these early response genes have on the 
interactions between the Tcks and macrophages. 
Imaging the Tck—macrophage co-culture in comparison to the T cell—
macrophage co-culture after 2 hours of incubation correlated well with the 
previous analyses of the co-culture after 24 hours. The number of short duration 
interactions and the colocalization coefficient was higher in the Tck co-culture 
compared to the T cell co-culture however both co-culture systems had a similar 
average number of long-duration stable interactions. Hence not only are the 
Tcks having more short duration interactions with the macrophages but the area 
of these interactions is also significantly larger, this observation may be caused 
by the increased expression of adhesion molecules on the surface of the Tcks 
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after cytokine activation as previously described [309]. Analysis of the movies 
from these co-culture experiments unfortunately did not reveal a large amount 
of information regarding the independent movement of the T cells/Tcks due to 
external factors influencing their movement. In each movie the Tcks/T cells can 
be observed to all move in a single direction before changing their direction of 
movement simultaneously which leads to the conclusion that external air flow 
may be causing the movement of the T cells. 
Despite the external air flow, which was not consistent throughout the 
experiements, patterns of interaction can still be noted from these movies. 
During the numerous Tck—macrophage co-cultures which were set up the Tcks 
were seen to cluster around specific macrophages and were not evenly 
distributed throughout the field of view. Studies analysing murine T cell—DC 
interactions in the absence of antigen have demonstrated that the rate of 
contacts is not solely the result of random collision events. Chemokines, such as 
CCL3 and CCL4, produced at the site of T cell-DC conjugates increases the 
chance of migrating CCR5-expressing CD8+ T cells to contact DCs by a factor of 2 
to 4 [702]. In addition in vitro observations have revealed that T cell movement 
and behaviour can be influenced by the presence of surface bound chemokines 
on the DC. Friedman et al demonstrated that when T cells encounter APCs which 
have been pulsed with CCR7 ligands in the absence of antigen they remain 
attached to the APCs for several minutes by a uropodal tether. It was also 
demonstrated that this attachment was reduced by 62% in the presence of a 
blocking antibody to ICAM-1 [703]. In the human in vitro model of inflammatory 
arthritis Tcks have been demonstrated to express the chemokine receptor CCR5 
and to a lesser extent CCR7 [309] therefore the movement and cellular 
interaction of these Tcks could be influenced by the expression of chemokines 
from the macrophages. Since the CCR5 ligands CCL3 and CCL4, otherwise known 
as MIP-1α and MIP-1β, are expressed by activated macrophages [578] the 
clustering of Tcks around certain macrophages may the result of these subsets of 
macrophages expressing a higher level of chemokine ligands which causes the 
specific migration and interaction of Tcks to these cells. Once these Tcks are in 
close contact with the macrophages their cellular contacts and maintenance of 
stable interactions will be mediated by adhesion molecules previously associated 
with Tcks and macrophages such as L-selectin and ICAM-1. There is no clustering 
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pattern of inactive T cells around the macrophages seen in the T cell movies 
which is most likely due to the lack of chemokine receptors expressed on the T 
cells that ensures these T cells are not moving by a chemotactic gradient 
towards the macrophages and only interact with the macrophages by random 
chance. 
In conclusion imaging the co-culture after 2 hours of incubation rather than 24 
hours showed a similar pattern of colocalization coefficient but the advantage of 
imaging after such a short incubation allows the movement and brief 
interactions of the Tcks/T cells with the macrophages to be observed whereas 
the was very little T cell movement when the co-culture was analysed after 24 
hours. However, it must be noted that the Tck/T cell movement may not be 
entirely random during the real time imaging as the behaviour and motion of 
these cells may be influenced by the external air flow outside of the imaging 
chamber. 
Once it had been established that the Tcks, which have a phenotype similar to 
RA synovial T cells, partake in more cellular interactions with the macrophages 
compared to non-activated T cells it was decided to validate the in vitro imaging 
system further by comparing fixed Tcks to live Tcks after 2 hours of co-culture. 
Fixation of the Tcks before incubating them with the macrophages results in T 
cells which express all the surface bound chemokine receptors or adhesion 
molecules which are known to be upregulated on Tcks [309] but are unable to 
actively migrate towards the macrophages. Analysis of the graphs in Figure 7.6 
which represent one of five experiments clearly indicates that live Tcks have 
more interactions with the macrophages compared to fixed Tcks and these 
interactions last for a longer duration and have a significantly higher surface 
area. These results validated our hypothesis that the live Tcks are able to move 
towards the macrophages and respond to the chemokines and adhesion 
molecules present on the surface of the macrophages. Analysis of the 
representative movies demonstrated that fixed Tcks do form stable interactions 
with the macrophages, since these cells cannot actively migrate towards the 
macrophages this would indicate that these interactions are the result of random 
movement of the fixed Tcks possibly influenced by the external air flow aiding 
the cells in their movement. Combining these results would indicate that the 
formation of stable interactions between Tcks and macrophages are the result of 
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random movement as well as chemotaxis through the production of chemokines 
from the macrophages. Analysis of the fixed and live Tck co-cultures enabled the 
validation of the in vitro imaging system and ensured that this inflammatory 
arthritis model produced reliable and reproducible results. 
This imaging system had provided us with interesting results regarding the 
movement and interaction of cells within the cell contact model of arthritis but 
there are several areas of improvement for future experiments. One such area 
would be to reduce the influence of the external airflow on the T cell movement 
through the use of a heated chamber which surrounds the in vitro system. This 
modification would subsequently allow the observation of the independent T cell 
movement and migration rather than the cell movement being influenced by the 
air flow. The use of z stacks to take images at different focal depths of the field 
of view should also be considered as this would enable a 3D image of the cells 
within the field of view to be acquired. The z stack information would reveal the 
3D area of interaction between the Tcks and macrophages, which would be more 
informative than the current 2D area measured in the preceding experiments. 
Such z stack information would also enable a more accurate colocalization 
coefficient to be measured between the Tcks and the macrophages. Also the use 
of a 3D collagen matrix would make the movement of the cells more 
physiological and would be representative of the environment within the 
synovial joint. Several experiments were set up using a collage matrix (data not 
shown) but the inability to focus on the cells made it impossible to image their 
interaction. However, such imaging capacity is available using a confocal 
microscope which is more advanced than the inverted microscope used for the 
current study. In summary, the use of a collagen matrix in addition to measuring 
z stacks on more advanced confocal microscope would greatly enhance the 
amount of information gained from this in vitro imaging system.  
In addition, time restrictions meant that this imaging model could not be used 
for its intended purpose of imaging the effect of blocking genes identified from 
the microarray analysis performed in this project (see chapter 4) to ascertain 
whether the interactions between the macrophages and synovial-like Tcks were 
affected. For example imaging the effect of silencing the plexin A1 gene would 
be of interest as these experiments may determine whether this cell surface 
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associated protein, which was found to be highly upregulated in RA and PsA 
synovial macrophages, has a role in the synovial T cell—macrophage interaction. 
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Chapter 8: General Discussion 
At the outset of my studies many microarray investigations had been performed 
to analyse the trancriptomic signature of RA and PsA either by whole blood or 
whole tissue profiling [318-320, 325-327, 329, 330, 340, 341] but very few had 
analysed the individual cell subsets which drive the pathogenesis of disease. I 
therefore sought to determine the expressed genetic profiles of matched blood 
and synovial fluid CD14+ monocytes and macrophages from RA and PsA patients 
to determine how the macrophages change their transcriptome once they 
migrate from the blood into the inflamed synovial joint. I also sought to compare 
these profiles to those of healthy blood CD14+ monocytes and to cell-contact 
activated macrophages, representing an in vitro model of inflammatory arthritis. 
Analysis of the microarray data comparing i) healthy blood, ii) RA blood and iii) 
PsA blood CD14+ cells revealed the unexpected result that the overall genetic 
profiles of these three monocyte types were remarkably similar and there were 
very few genes that could distinguish one monocyte subset from another. This 
result was in contrast to previous microarray analyses which have found a 
distinct disease signature in RA and PsA blood compared to healthy control blood 
[326, 329, 330, 340, 341]. The discrepancy between microarray results may be 
due to differences in sample numbers as my study only included 5 healthy donors 
and were age- and sex-matched to the PsA patients only. Despite this, my results 
suggested that the monocytes within RA and PsA are not responsible for the gene 
expression differences seen in other PBMC microarray studies between healthy 
and arthritic patients indicating that other cells within the peripheral blood may 
be causing the diseased genetic signature. Numerous microarray studies have 
proposed the use of genetic data from patient PBMCs to discover molecular 
discriminators indicating a response to treatment or disease progression. 
However, since my data suggest that the RA and PsA blood monocytes do not 
have a differentiating disease signature compared to healthy controls it may not 
be appropriate to use this cell subset as a marker of disease or treatment 
response. 
Comparison of matched blood and synovial fluid CD14+ cells from the RA and PsA 
patients also revealed some novel findings. Unsurprisingly, the synovial fluid 
genetic signature was vastly different to that of the matched blood samples 
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therefore demonstrating that the monocytes only develop a disease specific 
signature once they exit the blood and enter the diseased joint. In addition, 
upon comparison of the differentially expressed genes it was discovered that 
over 50% of the expressed genes in the synovial fluid CD14+ cells compared to 
the blood cells were the same in both RA and PsA. This result was unexpected 
given previous analyses by Baeten et al who suggested that the macrophages in 
SpA and RA were different since they found SpA (including PsA) macrophages 
expressed higher levels of markers of alternative activation compared to RA 
macrophages [255] and SpA synovial fluid but not RA was able to polarise blood 
monocytes to express the alternative activation marker CD163 [253]. However, 
analysis of the genetic transcriptome generated by my study demonstrated a 
similar level of alternative activation markers, such as CD204 or mannose 
receptor, expressed in the PsA CD14+ and RA CD14+ SF cells. Indeed, I also found 
similar levels of classical activation markers such as CD86 expressed in both RA 
and PsA SF cells demonstrating that within this study the RA and PsA 
macrophages do not have a preferential activation phenotype which contradicts 
the previous findings. The reasons for this may be due to the Baeten et al study 
analysing the effects of SF on healthy blood monocytes rather than analysing the 
diseased macrophages isolated from the source of inflammation as was 
performed in our study as the effect of the cell-cell contact that takes place 
within the synovium in addition to the SF environment may play a role in the 
expression of activation markers and macrophage polarization. However, further 
studies on the phenotype of the macrophages and protein expression of 
activation markers are required to test this hypothesis.  
Due to the same genes being differentially expressed in the RA and PsA SF 
macrophages compared to their matched blood monocytes many of the same 
canonical pathways were significantly associated with these genes lists. 
Interestingly, the top pathway was LXR activation which has previously been 
associated with RA but is a novel finding for PsA. Work performed by our 
research group prior to this observation had demonstrated that LXR agonism 
exacerbated articular damage in CIA a murine model of arthritis. In addition, ex 
vivo culture of RA PB derived monocytes which were LPS stimulated and treated 
with two LXR agonists showed an increase in IL-6 and TNFα production, 
suggesting LXRs have a pro-inflammatory role in arthritis [527]. However in the 
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present investigation several of the RA and PsA SF macrophage genes associated 
with this LXR canonical pathway are constituents of the anti-inflammatory 
lipoptotein HDL. HDL has been previously shown to mediate anti-inflammatory 
effects within RA since HDL can block the pro-inflammatory cytokine production 
from monocytes induced by T cell contact through binding to the T cell surface 
activating factors [558]. Consequently, the net inflammatory effect of the 
upregulated LXR pathway in the RA and PsA SF macrophages is yet to be defined 
and should be the focus of further investigations. 
Analysis of the highly upregulated genes in both of the RA and PsA SF 
macrophage subsets compared to the PB monocytes resulted in the identification 
of two novels genes that had not been previously associated with arthritis. One 
of these genes was legumain which is a lysosomal cysteine protease that 
specifically cleaves protein substrates such as MMP2, cathepsins and fibronectin 
[429, 431] which are all found within the synovium of arthritis patients. My work 
revealed that legumain was found at the mRNA and protein level in RA and PsA 
SF CD14+ cells and was physiologically active; in addition M-CSF matured 
macrophages could be induced to express legumain when cultured in RA or PsA 
SF under hypoxic conditions. Therefore, I hypothesise that legumain is highly 
upregulated by macrophages once they enter the hypoxic pro-inflammatory 
environment of the synovium and is required by the cell to activate 
glycoproteins or enzymes being produced or taken up by the cell which therefore 
contribute to the destructive inflammation seen in the synovium. Legumain was 
also seen to be expressed on the cell surface of the synovial macrophages and 
has also been shown to be excreted from cells [665] and therefore could be 
activating destructive enzymes such as MMPs within the synovial fluid milieu. 
Plexin A1 was the second novel gene discovered by the microarray analysis to be 
highly upregulated in the RA and PsA SF macrophages compared to the blood 
monocytes. Plexin A1 is a cell surface receptor which binds to semaphorin 
ligands and has previously been shown to be important for T cell-DC interactions 
and subsequent T cell activation [444, 623]. Due to the large body of literature 
describing macrophage interactions with other cell types in the arthritic 
synovium causing subsequent activation and pro-inflammatory mediator release I 
hypothesised that plexin A1 expression on the synovial macrophages may be 
playing a role in the cellular contacts taking place between these and other 
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synovial cells. In our study, plexin A1 was shown to be expressed at the protein 
and RNA level and knocking down the gene using siRNA demonstrated that it may 
be playing a potential pro-inflammatory role. Nevertheless our studies were 
hampered by the inability to discover the presence of the most widely know 
plexin A1 ligand, semaphorin 6D, on activated or synovial T cells despite it 
previously being detected on activated murine T cells [645]. However, plexin A1 
is known to have several semaphorin ligands and whilst our initial studies 
suggested these may be expressed at the RNA level in synovial membrane and 
synovial fibroblasts more investigation is required to elucidate what role plexin 
A1 and its ligands could be playing in arthritic disease. 
Analysis of the expressed genetic signature of the Tck activated macrophages, 
(postulated to represent an in vitro model of inflammatory arthritis [298, 309, 
314]), in comparison to synovial fluid derived macrophages demonstrated that 
only 10% of the expressed genes in the cell contact activated macrophages were 
expressed in RA or PsA synovial fluid macrophages. This would imply that this in 
vitro system may not be a suitable model of arthritis; however my analysis was 
confounded by several variables particularly the duration of macrophage 
activation by the Tcks which was restricted to 2 hours. Therefore further 
investigation especially involving a more extensive timecourse of macrophage 
activation is required to fully elucidate the relevance of this in vitro model to an 
in vivo disease process. 
The real time imaging performed on the in vitro cell contact model of arthritis 
provided some interesting observations on the variables influencing the 
interactions between the T cells and macrophages. It was discovered that the 
number of individual interactions between the macrophages and T cells was high 
at 2 hours of co-culture due to the Tcks moving around the field of view and 
interacting with several macrophages. This observation may help to explain why 
there were so few genes in the 2 hour cell contact activated macrophages that 
were shared with the SF macrophages as stable interactions with the Tcks, which 
would activate the macrophages, were not fully formed after 2 hours of co-
culture. Unfortunately time restrictions meant that this imaging system could 
not be used for its intended purpose which was imaging the effect of blocking 
genes identified in the microarray analysis. These experiments may have allowed 
us to visualise whether these genes, i.e. plexin A1, played a role in the 
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interaction of macrophages with other cell types such as the synovial T cell like 
Tck. 
While this new evidence of the genetic signatures of RA and PsA synovial fluid 
macrophages has been informative, several avenues of investigation remain to 
be explored. Future studies must identify the role of plexin A1 within the 
synovial fluid macrophages and the semaphorin ligand it is potentially 
interacting with. In addition, understanding the consequences of high levels of 
active legumain within the RA and PsA synovium through the use of legumain 
knockout mice and further functional analyses is of paramount importance as it 
represents an entirely novel enzyme with arthritic disease relevant functions. 
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